NZ791470A - Beta-lactamase inhibitor compounds - Google Patents
Beta-lactamase inhibitor compoundsInfo
- Publication number
- NZ791470A NZ791470A NZ791470A NZ79147017A NZ791470A NZ 791470 A NZ791470 A NZ 791470A NZ 791470 A NZ791470 A NZ 791470A NZ 79147017 A NZ79147017 A NZ 79147017A NZ 791470 A NZ791470 A NZ 791470A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- mmol
- alkoxy
- compound
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 346
- 239000003781 beta lactamase inhibitor Substances 0.000 title abstract description 22
- 239000011780 sodium chloride Substances 0.000 claims abstract description 111
- 150000003839 salts Chemical class 0.000 claims abstract description 108
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims abstract description 43
- 239000002132 β-lactam antibiotic Substances 0.000 claims abstract description 43
- 206010060945 Bacterial infection Diseases 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims description 182
- 239000000203 mixture Substances 0.000 claims description 170
- -1 -OH Chemical group 0.000 claims description 114
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 63
- 125000000623 heterocyclic group Chemical group 0.000 claims description 63
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 59
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 51
- 229910052739 hydrogen Inorganic materials 0.000 claims description 51
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 45
- 125000005843 halogen group Chemical group 0.000 claims description 43
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 41
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 34
- 125000001153 fluoro group Chemical group F* 0.000 claims description 33
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 32
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 31
- 150000002431 hydrogen Chemical group 0.000 claims description 29
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 22
- 150000002500 ions Chemical class 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- 125000001188 haloalkyl group Chemical group 0.000 claims description 16
- 206010046577 Urinary tract infection Diseases 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 13
- 230000001580 bacterial Effects 0.000 claims description 13
- 125000000018 nitroso group Chemical group N(=O)* 0.000 claims description 13
- 239000007800 oxidant agent Substances 0.000 claims description 13
- 230000001590 oxidative Effects 0.000 claims description 13
- 230000001154 acute Effects 0.000 claims description 11
- 201000005661 acute cystitis Diseases 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims description 9
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 206010035664 Pneumonia Diseases 0.000 claims description 8
- 210000003491 Skin Anatomy 0.000 claims description 8
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 7
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 206010056519 Abdominal infection Diseases 0.000 claims description 6
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 claims description 6
- 229960004797 cefpodoxime proxetil Drugs 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims description 5
- 206010069918 Bacterial prostatitis Diseases 0.000 claims description 5
- 206010023424 Kidney infection Diseases 0.000 claims description 5
- 206010024971 Lower respiratory tract infection Diseases 0.000 claims description 5
- 206010062255 Soft tissue infection Diseases 0.000 claims description 5
- 201000001178 bacterial pneumonia Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000006242 amine protecting group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010024774 Localised infection Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 abstract description 43
- 229940040975 systemic penicillins Beta-lactamase inhibitors Drugs 0.000 abstract description 13
- 229940079593 drugs Drugs 0.000 abstract description 9
- 239000000543 intermediate Substances 0.000 description 464
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 343
- 239000000243 solution Substances 0.000 description 216
- 239000007787 solid Substances 0.000 description 164
- 229910001868 water Inorganic materials 0.000 description 164
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 146
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 136
- 235000019439 ethyl acetate Nutrition 0.000 description 128
- 239000011541 reaction mixture Substances 0.000 description 125
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 124
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 104
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 100
- 238000006243 chemical reaction Methods 0.000 description 95
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 80
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 72
- 239000008079 hexane Substances 0.000 description 68
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 68
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 64
- 239000002253 acid Substances 0.000 description 59
- 239000012267 brine Substances 0.000 description 56
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 54
- 235000019341 magnesium sulphate Nutrition 0.000 description 54
- 239000000047 product Substances 0.000 description 54
- 238000010898 silica gel chromatography Methods 0.000 description 54
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 53
- 239000003921 oil Substances 0.000 description 51
- 235000019198 oils Nutrition 0.000 description 51
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 50
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 49
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 49
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 48
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 48
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 46
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 43
- 238000005160 1H NMR spectroscopy Methods 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 38
- 239000006260 foam Substances 0.000 description 35
- 102000006635 beta-Lactamases Human genes 0.000 description 30
- 108020004256 beta-Lactamases Proteins 0.000 description 30
- 239000003242 anti bacterial agent Substances 0.000 description 29
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 29
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 27
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
- 239000000706 filtrate Substances 0.000 description 26
- 238000004108 freeze drying Methods 0.000 description 26
- 239000010410 layer Substances 0.000 description 26
- XIXADJRWDQXREU-UHFFFAOYSA-M Lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 25
- 239000012230 colorless oil Substances 0.000 description 25
- 239000000651 prodrug Substances 0.000 description 25
- 229940002612 prodrugs Drugs 0.000 description 25
- 239000000741 silica gel Substances 0.000 description 25
- 229910002027 silica gel Inorganic materials 0.000 description 25
- 229910000027 potassium carbonate Inorganic materials 0.000 description 24
- 235000015320 potassium carbonate Nutrition 0.000 description 24
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 24
- OXBLHERUFWYNTN-UHFFFAOYSA-M Copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 23
- 238000007792 addition Methods 0.000 description 23
- 239000012044 organic layer Substances 0.000 description 23
- ULNDTPIRBQGESN-GSVOUGTGSA-N ethyl (2S)-2-bromo-2-fluoroacetate Chemical compound CCOC(=O)[C@@H](F)Br ULNDTPIRBQGESN-GSVOUGTGSA-N 0.000 description 22
- 101710028591 sam1 Proteins 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 150000002148 esters Chemical group 0.000 description 21
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 20
- 239000001184 potassium carbonate Substances 0.000 description 20
- 238000003756 stirring Methods 0.000 description 20
- 239000000725 suspension Substances 0.000 description 20
- HXJUTPCZVOIRIF-UHFFFAOYSA-N Sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 19
- 238000004128 high performance liquid chromatography Methods 0.000 description 19
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 19
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 19
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- 229910003002 lithium salt Inorganic materials 0.000 description 18
- 159000000002 lithium salts Chemical class 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 17
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- 229910052799 carbon Inorganic materials 0.000 description 17
- 239000012043 crude product Substances 0.000 description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- JFPVXVDWJQMJEE-IZRZKJBUSA-N (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 16
- 229960001668 Cefuroxime Drugs 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 235000012970 cakes Nutrition 0.000 description 15
- KMIPKYQIOVAHOP-YLGJWRNMSA-N Cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 description 14
- WYUSVOMTXWRGEK-HBWVYFAYSA-N Cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 14
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 14
- 229960004069 cefditoren Drugs 0.000 description 14
- 229960005090 cefpodoxime Drugs 0.000 description 14
- 239000003208 petroleum Substances 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 238000004007 reversed phase HPLC Methods 0.000 description 13
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 229960002129 CEFIXIME Drugs 0.000 description 11
- OKBVVJOGVLARMR-QSWIMTSFSA-N Cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 11
- 239000012298 atmosphere Substances 0.000 description 11
- 230000003115 biocidal Effects 0.000 description 11
- 239000003054 catalyst Substances 0.000 description 11
- ULNDTPIRBQGESN-UHFFFAOYSA-N ethyl 2-bromo-2-fluoroacetate Chemical compound CCOC(=O)C(F)Br ULNDTPIRBQGESN-UHFFFAOYSA-N 0.000 description 11
- 238000003818 flash chromatography Methods 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
- FPPNZSSZRUTDAP-UWFZAAFLSA-N Carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 10
- 229960003669 Carbenicillin Drugs 0.000 description 10
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N Cefalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 10
- 229940106164 Cephalexin Drugs 0.000 description 10
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 10
- 229960000723 ampicillin Drugs 0.000 description 10
- 229960003525 cefalexin Drugs 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 10
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6R,7R)-7-[[(2R)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 9
- 239000010752 BS 2869 Class D Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 9
- NBFNMSULHIODTC-CYJZLJNKSA-N Cefadroxil Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 9
- 229960004841 Cefadroxil Drugs 0.000 description 9
- 235000019502 Orange oil Nutrition 0.000 description 9
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 9
- 229960002580 cefprozil Drugs 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 9
- 239000010502 orange oil Substances 0.000 description 9
- 230000001717 pathogenic Effects 0.000 description 9
- 244000052769 pathogens Species 0.000 description 9
- 108091000057 penicillin binding proteins Proteins 0.000 description 9
- 239000012268 protein inhibitor Substances 0.000 description 9
- 229940121649 protein inhibitors Drugs 0.000 description 9
- 230000002829 reduced Effects 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- 230000002194 synthesizing Effects 0.000 description 9
- GPYKKBAAPVOCIW-HSASPSRMSA-N (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 GPYKKBAAPVOCIW-HSASPSRMSA-N 0.000 description 8
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 8
- MQLRYUCJDNBWMV-GHXIOONMSA-N Cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- HGGAKXAHAYOLDJ-FHZUQPTBSA-N Faropenem Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 HGGAKXAHAYOLDJ-FHZUQPTBSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 8
- 229960003022 amoxicillin Drugs 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229960004041 cefetamet Drugs 0.000 description 8
- 229960000379 faropenem Drugs 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 229960001977 loracarbef Drugs 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- FCYUPOCBNOAMHF-VGMFFHCQSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1.C[C@H](N)C1=CC=CC=C1 FCYUPOCBNOAMHF-VGMFFHCQSA-N 0.000 description 7
- ICTXGKNZADORBH-SFOWXEAESA-N (2R)-2-bromo-2-fluoroacetic acid Chemical compound OC(=O)[C@H](F)Br ICTXGKNZADORBH-SFOWXEAESA-N 0.000 description 7
- GXXLUDOKHXEFBQ-YJFSRANCSA-N (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)SC(C1)CN1C1=NCCS1 GXXLUDOKHXEFBQ-YJFSRANCSA-N 0.000 description 7
- RTXOFQZKPXMALH-GHXIOONMSA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(N-hydroxyimino)acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 7
- VVSASNKOFCZVES-UHFFFAOYSA-N 1,3-dimethyl-1,3-diazinane-2,4,6-trione Chemical compound CN1C(=O)CC(=O)N(C)C1=O VVSASNKOFCZVES-UHFFFAOYSA-N 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- VAMSVIZLXJOLHZ-QWFSEIHXSA-N 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(3S)-2,2-dimethyl-4-oxo-1-sulfooxyazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetic acid Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 VAMSVIZLXJOLHZ-QWFSEIHXSA-N 0.000 description 7
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N Ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 7
- NUJOXMJBOLGQSY-UHFFFAOYSA-N Manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 7
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 7
- 229940035295 Ting Drugs 0.000 description 7
- 125000004429 atoms Chemical group 0.000 description 7
- 235000020127 ayran Nutrition 0.000 description 7
- 229960003719 cefdinir Drugs 0.000 description 7
- 229960004086 ceftibuten Drugs 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000000875 corresponding Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000008234 soft water Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 229950010206 tigemonam Drugs 0.000 description 7
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 6
- VNDYJBBGRKZCSX-UHFFFAOYSA-L Zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 6
- ILVNXEDSGXLYHO-MNOVXSKESA-N [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)O)C Chemical compound [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)O)C ILVNXEDSGXLYHO-MNOVXSKESA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 6
- 150000003857 carboxamides Chemical class 0.000 description 6
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 230000000474 nursing Effects 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Substances SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
- ICTXGKNZADORBH-UHFFFAOYSA-M 2-bromo-2-fluoroacetate Chemical class [O-]C(=O)C(F)Br ICTXGKNZADORBH-UHFFFAOYSA-M 0.000 description 5
- ICTXGKNZADORBH-UHFFFAOYSA-N 2-bromo-2-fluoroacetic acid Chemical compound OC(=O)C(F)Br ICTXGKNZADORBH-UHFFFAOYSA-N 0.000 description 5
- 229960000583 Acetic Acid Drugs 0.000 description 5
- HBJXCJGYADJSFE-VQVTYTSYSA-N CC1=C[C@@H]2CN([C@@H]1C(N)=O)C(=O)N2O[C@H](F)C(O)=O Chemical compound CC1=C[C@@H]2CN([C@@H]1C(N)=O)C(=O)N2O[C@H](F)C(O)=O HBJXCJGYADJSFE-VQVTYTSYSA-N 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 150000002923 oximes Chemical class 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- 125000003373 pyrazinyl group Chemical group 0.000 description 5
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- KEJCWVGMRLCZQQ-DJMWJSSGSA-N 1-acetyloxyethyl (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2E)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)/C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-DJMWJSSGSA-N 0.000 description 4
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 4
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 4
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 4
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- VYLVYHXQOHJDJL-UHFFFAOYSA-K Cerium(III) chloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N Dess–Martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- 206010060803 Diabetic foot infection Diseases 0.000 description 4
- FAMRKDQNMBBFBR-BQYQJAHWSA-N Diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N Diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 4
- 241000229754 Iva xanthiifolia Species 0.000 description 4
- 229910000949 MnO2 Inorganic materials 0.000 description 4
- MSXVEPNJUHWQHW-UHFFFAOYSA-N Tert-Amyl alcohol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 4
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 4
- UCPYLLCMEDAXFR-UHFFFAOYSA-N Triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive Effects 0.000 description 4
- 239000003570 air Substances 0.000 description 4
- 230000000844 anti-bacterial Effects 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- 229960002620 cefuroxime axetil Drugs 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 229940079866 intestinal antibiotics Drugs 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 4
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-Crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 3
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 3
- LCFNIMWVJDLNSM-UHFFFAOYSA-N 2-nitro-N-prop-2-enoxybenzenesulfonamide Chemical compound [O-][N+](=O)C1=CC=CC=C1S(=O)(=O)NOCC=C LCFNIMWVJDLNSM-UHFFFAOYSA-N 0.000 description 3
- YHPMRWZVIQTSFZ-UHFFFAOYSA-N 3,5-difluoro-2-(2-fluorophenyl)pyridine Chemical compound FC1=CC(F)=CN=C1C1=CC=CC=C1F YHPMRWZVIQTSFZ-UHFFFAOYSA-N 0.000 description 3
- 238000006596 Alder-ene reaction Methods 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- 241000587112 Enterobacteriaceae sp. Species 0.000 description 3
- 240000002283 Eucalyptus alba Species 0.000 description 3
- 240000000437 Eucalyptus leucoxylon Species 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- SAGCLBGWUIMZAG-RITPCOANSA-N ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)N)C Chemical compound ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)N)C SAGCLBGWUIMZAG-RITPCOANSA-N 0.000 description 3
- 102100013574 POU2F1 Human genes 0.000 description 3
- 101710006192 POU2F1 Proteins 0.000 description 3
- 108010013639 Peptidoglycan Proteins 0.000 description 3
- CZDYPVPMEAXLPK-UHFFFAOYSA-N Tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000001640 fractional crystallisation Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 101700050775 oct-1 Proteins 0.000 description 3
- YCTDZYMMFQCTEO-UHFFFAOYSA-N oct-3-ene Chemical compound CCCCC=CCC YCTDZYMMFQCTEO-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 150000003952 β-lactams Chemical class 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- BTANRVKWQNVYAZ-SCSAIBSYSA-N (2R)-butan-2-ol Chemical compound CC[C@@H](C)O BTANRVKWQNVYAZ-SCSAIBSYSA-N 0.000 description 2
- BAYAKMPRFGNNFW-UHFFFAOYSA-N 2,4-dimethylpentan-3-ol Chemical compound CC(C)C(O)C(C)C BAYAKMPRFGNNFW-UHFFFAOYSA-N 0.000 description 2
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-Toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 229940072107 Ascorbate Drugs 0.000 description 2
- 229950003588 Axetil Drugs 0.000 description 2
- 102100015747 BPI Human genes 0.000 description 2
- 101700014079 BPI Proteins 0.000 description 2
- OUTIPNCLVICETC-UHFFFAOYSA-N BrC(C(=O)OC(C(C)C)C(C)C)(F)F Chemical compound BrC(C(=O)OC(C(C)C)C(C)C)(F)F OUTIPNCLVICETC-UHFFFAOYSA-N 0.000 description 2
- AEIDTMOTHWKBSU-UHFFFAOYSA-N BrC(C(=O)OC(C)C)F Chemical compound BrC(C(=O)OC(C)C)F AEIDTMOTHWKBSU-UHFFFAOYSA-N 0.000 description 2
- 206010006451 Bronchitis Diseases 0.000 description 2
- YSHOWEKUVWPFNR-UHFFFAOYSA-N Burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 2
- ZBVVRIAMQNZAEH-JKWIPACXSA-N C(Cl([2H])([2H])([2H])([2H])([2H])[2H])([ClH][2H])(Cl)[2H] Chemical compound C(Cl([2H])([2H])([2H])([2H])([2H])[2H])([ClH][2H])(Cl)[2H] ZBVVRIAMQNZAEH-JKWIPACXSA-N 0.000 description 2
- LWSSLQNFGPDQMP-JHJVBQTASA-N CCOC(=O)[C@H](F)ON1[C@H]2CN([C@H](CNC(=O)OC(C)(C)C)C(C)=C2)C1=O Chemical compound CCOC(=O)[C@H](F)ON1[C@H]2CN([C@H](CNC(=O)OC(C)(C)C)C(C)=C2)C1=O LWSSLQNFGPDQMP-JHJVBQTASA-N 0.000 description 2
- 101710025995 CLINT1 Proteins 0.000 description 2
- 229940041011 Carbapenems Drugs 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M Copper(I) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N Copper(I) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L Copper(II) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N Coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 2
- YFAGHNZHGGCZAX-JKIFEVAISA-N Dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 2
- 238000005698 Diels-Alder reaction Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 240000001414 Eucalyptus viminalis Species 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 101700009858 HEX1 Proteins 0.000 description 2
- 101700075495 HEXA Proteins 0.000 description 2
- 229960002182 IMIPENEM Drugs 0.000 description 2
- GSOSVVULSKVSLQ-JJVRHELESA-N Imipenem Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- 229940041033 Macrolides Drugs 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N Meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-Methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- WOOWBQQQJXZGIE-UHFFFAOYSA-N N-ethyl-N-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- KJXSXETVMIHLNQ-UHFFFAOYSA-N NOCCS(=O)(=O)N Chemical compound NOCCS(=O)(=O)N KJXSXETVMIHLNQ-UHFFFAOYSA-N 0.000 description 2
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N Nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N Oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010057190 Respiratory tract infection Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- PQDJYEQOELDLCP-UHFFFAOYSA-N Trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N Trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
- HHNLJRLNDSEYOX-UHFFFAOYSA-M [Br-].CC=C[Mg+] Chemical compound [Br-].CC=C[Mg+] HHNLJRLNDSEYOX-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 125000000746 allylic group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Inorganic materials [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229910000423 chromium oxide Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- XGECURGNFFGHOR-UONOGXRCSA-O cyclohexyloxy-[[(2S,5R)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dihydrofuran-2-yl]methoxy]-oxophosphanium Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO[P+](=O)OC2CCCCC2)O1 XGECURGNFFGHOR-UONOGXRCSA-O 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229960001585 dicloxacillin Drugs 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-M fluoroacetate Chemical compound [O-]C(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-M 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011984 grubbs catalyst Substances 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960002260 meropenem Drugs 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N n-pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 229960000515 nafcillin Drugs 0.000 description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 229960001019 oxacillin Drugs 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 150000003385 sodium Chemical class 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atoms Chemical group 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- WTDSBZCGBQDOHM-OAHLLOKOSA-N tert-butyl (2S)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-methyl-5-oxo-2,6-dihydropyridine-1-carboxylate Chemical compound CC1=CC(=O)CN(C(=O)OC(C)(C)C)[C@@H]1CO[Si](C)(C)C(C)(C)C WTDSBZCGBQDOHM-OAHLLOKOSA-N 0.000 description 2
- HSFSKUHPZHQHLR-LSDHHAIUSA-N tert-butyl (3S,6S)-6-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-hydroxy-5-methyl-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound CC1=C[C@H](O)CN(C(=O)OC(C)(C)C)[C@@H]1CO[Si](C)(C)C(C)(C)C HSFSKUHPZHQHLR-LSDHHAIUSA-N 0.000 description 2
- RXTKSYUIDWDWTH-UHFFFAOYSA-N tert-butyl N-(aminomethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCN RXTKSYUIDWDWTH-UHFFFAOYSA-N 0.000 description 2
- RSBIYGOMSUNKJS-HNNXBMFYSA-N tert-butyl N-[(2S)-1-[tert-butyl(dimethyl)silyl]oxybut-3-en-2-yl]-N-[2-[methoxy(methyl)amino]-2-oxoethyl]carbamate Chemical compound CON(C)C(=O)CN(C(=O)OC(C)(C)C)[C@@H](C=C)CO[Si](C)(C)C(C)(C)C RSBIYGOMSUNKJS-HNNXBMFYSA-N 0.000 description 2
- KAJZZLBZXOBEMD-UHFFFAOYSA-N tert-butyl N-chlorosulfonylcarbamate Chemical compound CC(C)(C)OC(=O)NS(Cl)(=O)=O KAJZZLBZXOBEMD-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 235000019529 tetraterpenoid Nutrition 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229940102001 zinc bromide Drugs 0.000 description 2
- AAWZDTNXLSGCEK-WYWMIBKRSA-M (-)-quinate Chemical compound O[C@@H]1C[C@](O)(C([O-])=O)C[C@@H](O)[C@H]1O AAWZDTNXLSGCEK-WYWMIBKRSA-M 0.000 description 1
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1R,2R)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 1
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- UPAQXOVSXSXSBN-GFCCVEGCSA-N (2S)-1-[tert-butyl(dimethyl)silyl]oxy-3-cyclopropylbut-3-en-2-amine Chemical compound CC(C)(C)[Si](C)(C)OC[C@@H](N)C(=C)C1CC1 UPAQXOVSXSXSBN-GFCCVEGCSA-N 0.000 description 1
- SOKFJPGUYADDIL-VIFPVBQESA-N (2S)-1-[tert-butyl(dimethyl)silyl]oxybut-3-en-2-amine Chemical compound CC(C)(C)[Si](C)(C)OC[C@@H](N)C=C SOKFJPGUYADDIL-VIFPVBQESA-N 0.000 description 1
- ICTXGKNZADORBH-PVQJCKRUSA-N (2S)-2-bromo-2-fluoroacetic acid Chemical compound OC(=O)[C@@H](F)Br ICTXGKNZADORBH-PVQJCKRUSA-N 0.000 description 1
- QJVHTELASVOWBE-AGNWQMPPSA-N (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 description 1
- HDZPXWOWOIXDEC-UHFFFAOYSA-N (3-methyl-2-oxobut-3-enyl) carbamate Chemical compound CC(=C)C(=O)COC(N)=O HDZPXWOWOIXDEC-UHFFFAOYSA-N 0.000 description 1
- KEDAXBWZURNCHS-GPODMPQUSA-N (4R,5S,6S)-3-[(3S,5S)-5-[(3S)-3-[[2-(diaminomethylideneamino)acetyl]amino]pyrrolidine-1-carbonyl]-1-methylpyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound O=C([C@@H]1C[C@@H](CN1C)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)N1CC[C@H](NC(=O)CN=C(N)N)C1 KEDAXBWZURNCHS-GPODMPQUSA-N 0.000 description 1
- UHIWBQIWXWWDKT-MRVPVSSYSA-N (4S)-4-hydroxy-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide Chemical compound O=S1(=O)N(CCCOC)C[C@@H](O)C2=C1SC(S(N)(=O)=O)=C2 UHIWBQIWXWWDKT-MRVPVSSYSA-N 0.000 description 1
- LZKPUSJSJVEXAW-WDXSGGTDSA-N (4S,5R,6S)-3-[7-[1-(2-amino-2-oxoethyl)pyridin-1-ium-3-carbonyl]imidazo[5,1-b][1,3]thiazol-2-yl]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C([O-])=O)=O)[C@H](O)C)C(SC1=2)=CN1C=NC=2C(=O)C1=CC=C[N+](CC(N)=O)=C1 LZKPUSJSJVEXAW-WDXSGGTDSA-N 0.000 description 1
- FLSUCZWOEMTFAQ-PRBGKLEPSA-N (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(1R,3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CC[S@@](=O)C1 FLSUCZWOEMTFAQ-PRBGKLEPSA-N 0.000 description 1
- HOBJEFOCIRXQKH-BYPYZUCNSA-N (5S)-5-(hydroxymethyl)pyrrolidin-2-one Chemical compound OC[C@@H]1CCC(=O)N1 HOBJEFOCIRXQKH-BYPYZUCNSA-N 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- DKOQGJHPHLTOJR-PUIFZAHNSA-N (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-PUIFZAHNSA-N 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-L (E)-4-hydroxy-2-oxido-4-oxobut-2-enoate Chemical compound OC(=O)\C=C(\[O-])C([O-])=O UWYVPFMHMJIBHE-OWOJBTEDSA-L 0.000 description 1
- CRPTXKKKIGGDBX-UHFFFAOYSA-N (Z)-but-2-ene Chemical group [CH2]C=CC CRPTXKKKIGGDBX-UHFFFAOYSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- ITZHHMQIKLMWIN-UHFFFAOYSA-N 1,3$l^{2}-thiazolidine Chemical group C1CSC[N]1 ITZHHMQIKLMWIN-UHFFFAOYSA-N 0.000 description 1
- ZRPFJAPZDXQHSM-UHFFFAOYSA-L 1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazole;dichloro-[(2-propan-2-yloxyphenyl)methylidene]ruthenium Chemical compound CC(C)OC1=CC=CC=C1C=[Ru](Cl)(Cl)=C1N(C=2C(=CC(C)=CC=2C)C)CCN1C1=C(C)C=C(C)C=C1C ZRPFJAPZDXQHSM-UHFFFAOYSA-L 0.000 description 1
- FPEBOWFSDGQHSP-KTZMUZOWSA-N 1-(4-amino-1,2,5-oxadiazol-3-yl)-5-(4,5-dihydro-1,3-thiazol-2-ylsulfanylmethyl)-N-[(E)-[4-methoxy-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]phenyl]methylideneamino]triazole-4-carboxamide Chemical compound C1=C(CSC=2SC(C)=NN=2)C(OC)=CC=C1\C=N\NC(=O)C=1N=NN(C=2C(=NON=2)N)C=1CSC1=NCCS1 FPEBOWFSDGQHSP-KTZMUZOWSA-N 0.000 description 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N 1-Hexanol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- CQMJEZQEVXQEJB-UHFFFAOYSA-N 1-hydroxy-1,3-dioxobenziodoxole Chemical compound C1=CC=C2I(O)(=O)OC(=O)C2=C1 CQMJEZQEVXQEJB-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- DCGGMHIZEAHUJL-UHFFFAOYSA-N 1-methyl-1,3-diazinane-2,4,6-trione Chemical compound CN1C(=O)CC(=O)NC1=O DCGGMHIZEAHUJL-UHFFFAOYSA-N 0.000 description 1
- HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N 2-Butanol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- KZRDDIMEUPJTAW-UHFFFAOYSA-N 2-N-Carboxamidonormianserin Chemical compound C1C2=CC=CC=C2N2CCN(C(=O)N)CC2C2=CC=CC=C21 KZRDDIMEUPJTAW-UHFFFAOYSA-N 0.000 description 1
- BTZKCSHCFFBUJO-ZDUSSCGKSA-N 2-[(2S)-1-[tert-butyl(dimethyl)silyl]oxybut-3-en-2-yl]isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N([C@@H](C=C)CO[Si](C)(C)C(C)(C)C)C(=O)C2=C1 BTZKCSHCFFBUJO-ZDUSSCGKSA-N 0.000 description 1
- XWARCKJYBAUGMZ-QMMMGPOBSA-N 2-[(2S)-1-hydroxybut-3-en-2-yl]isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N([C@@H](C=C)CO)C(=O)C2=C1 XWARCKJYBAUGMZ-QMMMGPOBSA-N 0.000 description 1
- XFKYKTBPRBZDFG-UHFFFAOYSA-N 2-aminoacetonitrile;hydrochloride Chemical compound Cl.NCC#N XFKYKTBPRBZDFG-UHFFFAOYSA-N 0.000 description 1
- GKJMVMJIDBDPDZ-UHFFFAOYSA-N 2-bromo-N-methoxy-N-methylacetamide Chemical compound CON(C)C(=O)CBr GKJMVMJIDBDPDZ-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- YAQLSKVCTLCIIE-UHFFFAOYSA-M 2-bromobutanoate Chemical compound CCC(Br)C([O-])=O YAQLSKVCTLCIIE-UHFFFAOYSA-M 0.000 description 1
- GAWAYYRQGQZKCR-UHFFFAOYSA-M 2-chloropropanoate Chemical compound CC(Cl)C([O-])=O GAWAYYRQGQZKCR-UHFFFAOYSA-M 0.000 description 1
- MOKRDWKSHLLYKM-UHFFFAOYSA-N 2-hydrazinyl-2-oxoacetamide Chemical compound NNC(=O)C(N)=O MOKRDWKSHLLYKM-UHFFFAOYSA-N 0.000 description 1
- BLGJHQMNSBYLEZ-UHFFFAOYSA-N 2-hydroxyethanesulfonamide Chemical compound NS(=O)(=O)CCO BLGJHQMNSBYLEZ-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- GNDKYAWHEKZHPJ-UHFFFAOYSA-N 2-nitrobenzenesulfonimidic acid Chemical compound NS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O GNDKYAWHEKZHPJ-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 101710017909 24 Proteins 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- AQIXEPGDORPWBJ-UHFFFAOYSA-N 3-Pentanol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 1
- 125000000981 3-amino-3-oxopropyl group Chemical group [H]C([*])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- SNGRYJSFEVUFBF-UHFFFAOYSA-N 3-aminopropane-1-sulfonamide Chemical compound NCCCS(N)(=O)=O SNGRYJSFEVUFBF-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
- DMAYBPBPEUFIHJ-UHFFFAOYSA-N 4-bromobut-1-ene Chemical compound BrCCC=C DMAYBPBPEUFIHJ-UHFFFAOYSA-N 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- UJOOMSDQMTXWAE-UHFFFAOYSA-N 5-(aminooxymethyl)pyrrolidin-2-one Chemical compound NOCC1CCC(=O)N1 UJOOMSDQMTXWAE-UHFFFAOYSA-N 0.000 description 1
- 101710037290 A674R Proteins 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- XXROGKLTLUQVRX-UHFFFAOYSA-N Allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N Allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 229940009444 Amphotericin Drugs 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N Azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 229960003623 Azlocillin Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N Aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 Aztreonam Drugs 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N BINAP Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960002699 Bacampicillin Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N Barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 241000219430 Betula pendula Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OHXKKLBEAYCMIL-UHFFFAOYSA-N BrC(C(=O)OC(C(C)C)C(C)C)F Chemical compound BrC(C(=O)OC(C(C)C)C(C)C)F OHXKKLBEAYCMIL-UHFFFAOYSA-N 0.000 description 1
- LILOUEUQYUKZJM-UHFFFAOYSA-N BrC(C(=O)OC(CC)CC)F Chemical compound BrC(C(=O)OC(CC)CC)F LILOUEUQYUKZJM-UHFFFAOYSA-N 0.000 description 1
- SCPUUWXQWJSKHU-UHFFFAOYSA-N BrC(C(=O)OC1CCOCC1)F Chemical compound BrC(C(=O)OC1CCOCC1)F SCPUUWXQWJSKHU-UHFFFAOYSA-N 0.000 description 1
- LQSGFCLRVSHCFU-UHFFFAOYSA-N BrC(C(=O)OCCOC)F Chemical compound BrC(C(=O)OCCOC)F LQSGFCLRVSHCFU-UHFFFAOYSA-N 0.000 description 1
- USEGWGFGZVWYOI-ROLXFIACSA-N BrC(C(=O)O[C@@H](C)CC)F Chemical compound BrC(C(=O)O[C@@H](C)CC)F USEGWGFGZVWYOI-ROLXFIACSA-N 0.000 description 1
- WLBFGGXFXHZDCN-REOHCLBHSA-N Br[C@H](C(=O)OC)F Chemical compound Br[C@H](C(=O)OC)F WLBFGGXFXHZDCN-REOHCLBHSA-N 0.000 description 1
- MMYMLMVOYRVHKM-QMMMGPOBSA-N Br[C@H](C(=O)OCC1=CC=CC=C1)F Chemical compound Br[C@H](C(=O)OCC1=CC=CC=C1)F MMYMLMVOYRVHKM-QMMMGPOBSA-N 0.000 description 1
- XNXWPDYAHKZTIR-BYPYZUCNSA-N Br[C@H](C(=O)OCCC)F Chemical compound Br[C@H](C(=O)OCCC)F XNXWPDYAHKZTIR-BYPYZUCNSA-N 0.000 description 1
- QLRPOQVAUCFORT-YFKPBYRVSA-N Br[C@H](C(=O)OCCCC)F Chemical compound Br[C@H](C(=O)OCCCC)F QLRPOQVAUCFORT-YFKPBYRVSA-N 0.000 description 1
- BSSSVGWPHAMMOD-LURJTMIESA-N Br[C@H](C(=O)OCCCCC)F Chemical compound Br[C@H](C(=O)OCCCCC)F BSSSVGWPHAMMOD-LURJTMIESA-N 0.000 description 1
- WQMFBRJXRIVEHF-ZETCQYMHSA-N Br[C@H](C(=O)OCCCCCC)F Chemical compound Br[C@H](C(=O)OCCCCCC)F WQMFBRJXRIVEHF-ZETCQYMHSA-N 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- WZMJFNQWBNUQCP-KGLIPLIRSA-N C(C)(=O)NCNC(=O)[C@H]1N2C(N([C@H](C=C1C)C2)O[Si](C)(C)C(C)(C)C)=O Chemical compound C(C)(=O)NCNC(=O)[C@H]1N2C(N([C@H](C=C1C)C2)O[Si](C)(C)C(C)(C)C)=O WZMJFNQWBNUQCP-KGLIPLIRSA-N 0.000 description 1
- SJURCIWIZZIIDD-ISJQUSKDSA-N C(Cl([2H])([2H])([2H])[2H])(Cl)(Cl)[2H] Chemical compound C(Cl([2H])([2H])([2H])[2H])(Cl)(Cl)[2H] SJURCIWIZZIIDD-ISJQUSKDSA-N 0.000 description 1
- SHQROYWDBBWZCW-BDAKNGLRSA-N CC(=O)NCNC(=O)[C@H]1N2C[C@@H](C=C1C)N(O)C2=O Chemical compound CC(=O)NCNC(=O)[C@H]1N2C[C@@H](C=C1C)N(O)C2=O SHQROYWDBBWZCW-BDAKNGLRSA-N 0.000 description 1
- MGOVTWLZQOXRDP-UHFFFAOYSA-N CC(C)(C)OC(=O)NCNS(=O)(=O)NC(=O)OC(C)(C)C Chemical compound CC(C)(C)OC(=O)NCNS(=O)(=O)NC(=O)OC(C)(C)C MGOVTWLZQOXRDP-UHFFFAOYSA-N 0.000 description 1
- HFTSMHTWUFCYMJ-YIOMYIDASA-N CC1=C(COC(=O)N2CC[C@H](C2)N2CC\C(=C/C3=C(N4[C@H](SC3)[C@H](NC(=O)C(=N/O)\C3=NSC(N)=N3)C4=O)C(O)=O)C2=O)OC(=O)O1 Chemical compound CC1=C(COC(=O)N2CC[C@H](C2)N2CC\C(=C/C3=C(N4[C@H](SC3)[C@H](NC(=O)C(=N/O)\C3=NSC(N)=N3)C4=O)C(O)=O)C2=O)OC(=O)O1 HFTSMHTWUFCYMJ-YIOMYIDASA-N 0.000 description 1
- ISLYPKVVRAAIQA-YWTFCRFGSA-N CC1=C[C@@H]2CN([C@@H]1C(=O)NCCC1CCC(=O)N1)C(=O)N2O Chemical compound CC1=C[C@@H]2CN([C@@H]1C(=O)NCCC1CCC(=O)N1)C(=O)N2O ISLYPKVVRAAIQA-YWTFCRFGSA-N 0.000 description 1
- JIHDHPVKXRKAFX-SFYZADRCSA-N CC1=C[C@@H]2CN([C@@H]1C(=O)NCCNS(N)(=O)=O)C(=O)N2O Chemical compound CC1=C[C@@H]2CN([C@@H]1C(=O)NCCNS(N)(=O)=O)C(=O)N2O JIHDHPVKXRKAFX-SFYZADRCSA-N 0.000 description 1
- CEVMHRKJTINVBA-SFYZADRCSA-N CC1=C[C@@H]2CN([C@@H]1C(=O)NCCS(N)(=O)=O)C(=O)N2O Chemical compound CC1=C[C@@H]2CN([C@@H]1C(=O)NCCS(N)(=O)=O)C(=O)N2O CEVMHRKJTINVBA-SFYZADRCSA-N 0.000 description 1
- YNPPYUPSPAGMSG-SCZZXKLOSA-N CC1=C[C@@H]2CN([C@@H]1C(=O)NCc1ncco1)C(=O)N2O Chemical compound CC1=C[C@@H]2CN([C@@H]1C(=O)NCc1ncco1)C(=O)N2O YNPPYUPSPAGMSG-SCZZXKLOSA-N 0.000 description 1
- DHLHEKUSPGMZIY-AGIUHOORSA-N CC1=C[C@@H]2CN([C@@H]1C(=O)NOC[C@@H]1CC(F)(F)CN1C(=O)OC(C)(C)C)C(=O)N2O Chemical compound CC1=C[C@@H]2CN([C@@H]1C(=O)NOC[C@@H]1CC(F)(F)CN1C(=O)OC(C)(C)C)C(=O)N2O DHLHEKUSPGMZIY-AGIUHOORSA-N 0.000 description 1
- KMUITFHVANBUJM-NXEZZACHSA-N CC1=C[C@@H]2CN([C@@H]1CNC(=O)OC(C)(C)C)C(=O)N2O Chemical compound CC1=C[C@@H]2CN([C@@H]1CNC(=O)OC(C)(C)C)C(=O)N2O KMUITFHVANBUJM-NXEZZACHSA-N 0.000 description 1
- NHCGBXGSGNHZFN-GMTAPVOTSA-N CC1=C[C@@H]2CN([C@@H]1CNC(=O)OC(C)(C)C)C(=O)N2O[C@@H](F)C(O)=O Chemical compound CC1=C[C@@H]2CN([C@@H]1CNC(=O)OC(C)(C)C)C(=O)N2O[C@@H](F)C(O)=O NHCGBXGSGNHZFN-GMTAPVOTSA-N 0.000 description 1
- RETFRDUILHMREW-UHFFFAOYSA-N CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 Chemical class CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 RETFRDUILHMREW-UHFFFAOYSA-N 0.000 description 1
- HZKUYLIAYLIBQY-AMIUJLCOSA-N CCOC(=O)C(F)ON1[C@H]2CN([C@H](C(=O)NCc3cnccn3)C(C)=C2)C1=O Chemical compound CCOC(=O)C(F)ON1[C@H]2CN([C@H](C(=O)NCc3cnccn3)C(C)=C2)C1=O HZKUYLIAYLIBQY-AMIUJLCOSA-N 0.000 description 1
- XWWDFJPVQRREEB-WGTSGOJVSA-N CCOC(=O)C(F)ON1[C@H]2CN([C@H](C(N)=O)C(C)=C2)C1=O Chemical compound CCOC(=O)C(F)ON1[C@H]2CN([C@H](C(N)=O)C(C)=C2)C1=O XWWDFJPVQRREEB-WGTSGOJVSA-N 0.000 description 1
- YCICLSTXFPYTGB-WGTSGOJVSA-N CCOC(=O)C(F)ON1[C@H]2CN([C@H](c3nnc(o3)C(N)=O)C(C)=C2)C1=O Chemical compound CCOC(=O)C(F)ON1[C@H]2CN([C@H](c3nnc(o3)C(N)=O)C(C)=C2)C1=O YCICLSTXFPYTGB-WGTSGOJVSA-N 0.000 description 1
- HBTJAJKQYCWDLS-CIUDSAMLSA-N CCOC(=O)[C@@H](F)ON1[C@H]2CN([C@@H](C=C2C)C(N)=O)C1=O Chemical compound CCOC(=O)[C@@H](F)ON1[C@H]2CN([C@@H](C=C2C)C(N)=O)C1=O HBTJAJKQYCWDLS-CIUDSAMLSA-N 0.000 description 1
- UWHWQYAAFVGBER-MIMYLULJSA-N CCOC(=O)[C@@H](F)ON1[C@H]2CN([C@H](C(N)=O)C(=C2)C2CC2)C1=O Chemical compound CCOC(=O)[C@@H](F)ON1[C@H]2CN([C@H](C(N)=O)C(=C2)C2CC2)C1=O UWHWQYAAFVGBER-MIMYLULJSA-N 0.000 description 1
- GPBVKAYHIGDKPM-FXUDXRNXSA-N CCOC(=O)[C@H](F)ON1[C@H]2CN([C@H](C(=O)NOC[C@@H]3CC(F)(F)CN3C(=O)OC(C)(C)C)C(C)=C2)C1=O Chemical compound CCOC(=O)[C@H](F)ON1[C@H]2CN([C@H](C(=O)NOC[C@@H]3CC(F)(F)CN3C(=O)OC(C)(C)C)C(C)=C2)C1=O GPBVKAYHIGDKPM-FXUDXRNXSA-N 0.000 description 1
- SDLCZFKFRRNRFW-VVLHAWIVSA-N CCOC(=O)[C@H](F)ON1[C@H]2CN([C@H](C(=O)NOC[C@@H]3CCCN3C(=O)OC(C)(C)C)C(C)=C2)C1=O Chemical compound CCOC(=O)[C@H](F)ON1[C@H]2CN([C@H](C(=O)NOC[C@@H]3CCCN3C(=O)OC(C)(C)C)C(C)=C2)C1=O SDLCZFKFRRNRFW-VVLHAWIVSA-N 0.000 description 1
- JALKIGXFIQHCTR-JDUUOCRZSA-N CC[C@H](C)OC(=O)C(F)ON1[C@H]2CN([C@H](C(N)=O)C(C)=C2)C1=O Chemical compound CC[C@H](C)OC(=O)C(F)ON1[C@H]2CN([C@H](C(N)=O)C(C)=C2)C1=O JALKIGXFIQHCTR-JDUUOCRZSA-N 0.000 description 1
- 101700067048 CDC13 Proteins 0.000 description 1
- 229960000466 CEFPIROME Drugs 0.000 description 1
- NEETVBHJPJIRDA-OLZOCXBDSA-N COC(=O)[C@H]1N(C[C@@H](C=C1C)N(O)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C Chemical compound COC(=O)[C@H]1N(C[C@@H](C=C1C)N(O)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C NEETVBHJPJIRDA-OLZOCXBDSA-N 0.000 description 1
- RJOWOPYNJRBJPC-GOSISDBHSA-N CON(C)C(=O)CN([C@H](CO[Si](C)(C)C(C)(C)C)C(=C)C1CC1)C(=O)OC(C)(C)C Chemical compound CON(C)C(=O)CN([C@H](CO[Si](C)(C)C(C)(C)C)C(=C)C1CC1)C(=O)OC(C)(C)C RJOWOPYNJRBJPC-GOSISDBHSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 229960005361 Cefaclor Drugs 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N Cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N Cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960003012 Cefamandole Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N Cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 Cefazolin Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N Cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N Cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960004261 Cefotaxime Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N Cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960005495 Cefotetan Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N Cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960002682 Cefoxitin Drugs 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N Cefradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 229960002588 Cefradine Drugs 0.000 description 1
- 229960000484 Ceftazidime Drugs 0.000 description 1
- 229960004755 Ceftriaxone Drugs 0.000 description 1
- 229940106195 Cephalothin Drugs 0.000 description 1
- 229940106192 Cephradine Drugs 0.000 description 1
- 206010008326 Cervicitis gonococcal Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N Chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 241000588917 Citrobacter koseri Species 0.000 description 1
- 229960003324 Clavulanic Acid Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N Cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M Copper(I) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- WCASXYBKJHWFMY-NSCUHMNNSA-N Crotyl alcohol Chemical compound C\C=C\CO WCASXYBKJHWFMY-NSCUHMNNSA-N 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N DAPTOMYCIN Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N DCM Dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 229960005484 Daptomycin Drugs 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 230000035695 Efflux Effects 0.000 description 1
- 206010014665 Endocarditis Diseases 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 229910015400 FeC13 Inorganic materials 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229960004273 Floxacillin Drugs 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N Glyoxalate, Glyoxylate Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 229910004003 H5IO6 Inorganic materials 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N Isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 241000588749 Klebsiella oxytoca Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 229940045505 Klebsiella pneumoniae Drugs 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N Linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 108010004718 Lipoglycopeptides Proteins 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium Ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N MeCN acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N MeOH methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229960003194 Meglumine Drugs 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 229940041009 Monobactams Drugs 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N Monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N N,N-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- ZEICLMMMMGQHIK-BWVDBABLSA-N NC(=O)[C@H]1N2C[C@@H](C=C1C1CC1)N(O[C@@H](F)C(O)=O)C2=O Chemical compound NC(=O)[C@H]1N2C[C@@H](C=C1C1CC1)N(O[C@@H](F)C(O)=O)C2=O ZEICLMMMMGQHIK-BWVDBABLSA-N 0.000 description 1
- 240000007639 Nepenthes mirabilis Species 0.000 description 1
- 208000004235 Neutropenia Diseases 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N Nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- XRNYCPOLQBIMBI-QMMMGPOBSA-N O=C1CC[C@@H](CON2C(=O)C3=C(C=CC=C3)C2=O)N1 Chemical compound O=C1CC[C@@H](CON2C(=O)C3=C(C=CC=C3)C2=O)N1 XRNYCPOLQBIMBI-QMMMGPOBSA-N 0.000 description 1
- IFDNUNUJXJNYGW-QMMMGPOBSA-N O=C1CC[C@H](N1)CCNC(OC(C)(C)C)=O Chemical compound O=C1CC[C@H](N1)CCNC(OC(C)(C)C)=O IFDNUNUJXJNYGW-QMMMGPOBSA-N 0.000 description 1
- RNPLINJVUILJEN-UHFFFAOYSA-N O=C1N(C(C2=CC=CC=C12)=O)OCCS(=O)(=O)N Chemical compound O=C1N(C(C2=CC=CC=C12)=O)OCCS(=O)(=O)N RNPLINJVUILJEN-UHFFFAOYSA-N 0.000 description 1
- XRJDSJGGJMFDOO-NSHDSACASA-N O=C1N(C(C2=CC=CC=C12)=O)OC[C@H]1N(CC(C1)(F)F)C(=O)OC(C)(C)C Chemical compound O=C1N(C(C2=CC=CC=C12)=O)OC[C@H]1N(CC(C1)(F)F)C(=O)OC(C)(C)C XRJDSJGGJMFDOO-NSHDSACASA-N 0.000 description 1
- JAAMQGNBUGANJD-VIFPVBQESA-M O=C1N(C(C2=CC=CC=C12)=O)OC[C@H]1N(CCC1)C(=O)[O-] Chemical compound O=C1N(C(C2=CC=CC=C12)=O)OC[C@H]1N(CCC1)C(=O)[O-] JAAMQGNBUGANJD-VIFPVBQESA-M 0.000 description 1
- WKMCWVQOPMCTKT-FJXQXJEOSA-N OC(=O)C(F)Br.C[C@H](N)c1ccccc1 Chemical compound OC(=O)C(F)Br.C[C@H](N)c1ccccc1 WKMCWVQOPMCTKT-FJXQXJEOSA-N 0.000 description 1
- HBXKZXFCZLNEKF-UHFFFAOYSA-N OC(=O)C(O)=O.CNc1cnccn1 Chemical compound OC(=O)C(O)=O.CNc1cnccn1 HBXKZXFCZLNEKF-UHFFFAOYSA-N 0.000 description 1
- BUICZRYXWLTJFC-BYPYZUCNSA-N OC[C@H]1C(C=CN1)=O Chemical compound OC[C@H]1C(C=CN1)=O BUICZRYXWLTJFC-BYPYZUCNSA-N 0.000 description 1
- SLYCYWCVSGPDFR-UHFFFAOYSA-N Octadecyltrimethoxysilane Chemical compound CCCCCCCCCCCCCCCCCC[Si](OC)(OC)OC SLYCYWCVSGPDFR-UHFFFAOYSA-N 0.000 description 1
- 101710027499 Os03g0268000 Proteins 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940056367 Penicillin V Drugs 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N Phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N Phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N Piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M Potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229950000033 Proxetil Drugs 0.000 description 1
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 108020004753 RAN Proteins 0.000 description 1
- 101710028343 RARS Proteins 0.000 description 1
- 101710019471 RARS1 Proteins 0.000 description 1
- 102100004755 RARS1 Human genes 0.000 description 1
- 239000005092 Ruthenium Substances 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 206010040490 Sexually transmitted disease Diseases 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- 206010040872 Skin infection Diseases 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M Sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 229940076185 Staphylococcus aureus Drugs 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229940041030 Streptogramins Drugs 0.000 description 1
- 108010034396 Streptogramins Proteins 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N Sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 229950000153 Sulopenem Drugs 0.000 description 1
- 208000006379 Syphilis Diseases 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 101700026084 THY1 Proteins 0.000 description 1
- BSUXZTMOMIFYBF-FFWSUHOLSA-N Tabtoxinine β-lactam Chemical compound OC(=O)[C@@H](N)CC[C@]1(O)CNC1=O BSUXZTMOMIFYBF-FFWSUHOLSA-N 0.000 description 1
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N Tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 1
- BVCKFLJARNKCSS-DWPRYXJFSA-N Temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229940040944 Tetracyclines Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N Ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 Ticarcillin Drugs 0.000 description 1
- 229950003816 Tomopenem Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N Triphenylphosphine oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 208000000143 Urethritis Diseases 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 Vancomycin Drugs 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- FIAINKIUSZGVGX-DKWTVANSSA-N [(2S)-1-amino-1-oxopropan-2-yl]azanium;chloride Chemical compound Cl.C[C@H](N)C(N)=O FIAINKIUSZGVGX-DKWTVANSSA-N 0.000 description 1
- AMZNHHZJURKRFX-JTQLQIEISA-N [(2S)-5-oxopyrrolidin-2-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@H]1NC(=O)CC1 AMZNHHZJURKRFX-JTQLQIEISA-N 0.000 description 1
- KLFSEZJCLYBFKQ-WXYNYTDUSA-N [(3S)-3-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1,5-dihydroxy-4-oxopyridin-2-yl)methoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCC1=CC(=O)C(O)=CN1O KLFSEZJCLYBFKQ-WXYNYTDUSA-N 0.000 description 1
- IXSKGWZJVNAIOD-NSCUHMNNSA-N [(E)-but-2-enyl]boronic acid Chemical compound C\C=C\CB(O)O IXSKGWZJVNAIOD-NSCUHMNNSA-N 0.000 description 1
- LFTYALBVGVNGLI-UHFFFAOYSA-M [Br-].CC([Mg+])=C Chemical compound [Br-].CC([Mg+])=C LFTYALBVGVNGLI-UHFFFAOYSA-M 0.000 description 1
- PNXFDIDWKILRDT-LPZNKSAJSA-M [Li+].C(C)(C)(C)OC(=O)NCC1=CC=C(C=C1)NC(=O)[C@H]1N2C(N([C@H](C=C1C)C2)O[C@@H](C(=O)[O-])F)=O Chemical compound [Li+].C(C)(C)(C)OC(=O)NCC1=CC=C(C=C1)NC(=O)[C@H]1N2C(N([C@H](C=C1C)C2)O[C@@H](C(=O)[O-])F)=O PNXFDIDWKILRDT-LPZNKSAJSA-M 0.000 description 1
- QQGWBRJQPRTJDA-UHFFFAOYSA-N [Li].CC(O)=O Chemical compound [Li].CC(O)=O QQGWBRJQPRTJDA-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- DZJUVZSVYPJQAQ-PIJUOVFKSA-N [Si](C)(C)(C(C)(C)C)ON1C2C=C([C@H](N(C1=O)C2)C#N)C Chemical compound [Si](C)(C)(C(C)(C)C)ON1C2C=C([C@H](N(C1=O)C2)C#N)C DZJUVZSVYPJQAQ-PIJUOVFKSA-N 0.000 description 1
- JEXZJCPBEOLNJL-MNOVXSKESA-N [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)N)C Chemical compound [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)N)C JEXZJCPBEOLNJL-MNOVXSKESA-N 0.000 description 1
- CTILQTLMYUYWJL-KGLIPLIRSA-N [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NC1COC1)C Chemical compound [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NC1COC1)C CTILQTLMYUYWJL-KGLIPLIRSA-N 0.000 description 1
- FRMCJULXBOFDJK-CVEARBPZSA-N [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NCC1=NC=CN=C1)C Chemical compound [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NCC1=NC=CN=C1)C FRMCJULXBOFDJK-CVEARBPZSA-N 0.000 description 1
- CPBAKBQBALURIJ-HIFRSBDPSA-N [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NCC=1OC=CN=1)C Chemical compound [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NCC=1OC=CN=1)C CPBAKBQBALURIJ-HIFRSBDPSA-N 0.000 description 1
- XLHOOALHPCENNY-KGLIPLIRSA-N [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NCCNS(=O)(=O)C)C Chemical compound [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NCCNS(=O)(=O)C)C XLHOOALHPCENNY-KGLIPLIRSA-N 0.000 description 1
- SNYDXDGADYNHSX-OLZOCXBDSA-N [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NCCNS(N)(=O)=O)C Chemical compound [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NCCNS(N)(=O)=O)C SNYDXDGADYNHSX-OLZOCXBDSA-N 0.000 description 1
- ICCFOSWIAHGKHE-NEPJUHHUSA-N [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NCO)C Chemical compound [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NCO)C ICCFOSWIAHGKHE-NEPJUHHUSA-N 0.000 description 1
- ORAIZMSEWBDOMY-MNOVXSKESA-N [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NNC(C(=O)N)=O)C Chemical compound [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NNC(C(=O)N)=O)C ORAIZMSEWBDOMY-MNOVXSKESA-N 0.000 description 1
- IYTASQZMGMMFFJ-OLZOCXBDSA-N [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NOCCS(N)(=O)=O)C Chemical compound [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C(=O)NOCCS(N)(=O)=O)C IYTASQZMGMMFFJ-OLZOCXBDSA-N 0.000 description 1
- RSHOBQPVIZASTK-MNOVXSKESA-N [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C1=NN=C(O1)C(=O)N)C Chemical compound [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)C1=NN=C(O1)C(=O)N)C RSHOBQPVIZASTK-MNOVXSKESA-N 0.000 description 1
- DCSCUBCLBDXUHM-HUUCEWRRSA-N [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)CNC(OC(C)(C)C)=O)C Chemical compound [Si](C)(C)(C(C)(C)C)ON1[C@@H]2C=C([C@H](N(C1=O)C2)CNC(OC(C)(C)C)=O)C DCSCUBCLBDXUHM-HUUCEWRRSA-N 0.000 description 1
- PAAZCQANMCYGAW-UHFFFAOYSA-N acetic acid;2,2,2-trifluoroacetic acid Chemical class CC(O)=O.OC(=O)C(F)(F)F PAAZCQANMCYGAW-UHFFFAOYSA-N 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazonic acid Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000010439 acute gonococcal cervicitis Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229920002892 amber Polymers 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000002051 biphasic Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- GCSVCUMDOQKEMT-UHFFFAOYSA-N butan-1-amine;hydrofluoride Chemical compound [H+].[F-].CCCCN GCSVCUMDOQKEMT-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 150000001733 carboxylic acid esters Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- 229940036735 ceftaroline Drugs 0.000 description 1
- RGFBRLNVZCCMSV-BIRGHMBHSA-N ceftaroline Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(N)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 RGFBRLNVZCCMSV-BIRGHMBHSA-N 0.000 description 1
- 229960004241 ceftobiprole medocaril Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- XQTIWNLDFPPCIU-UHFFFAOYSA-N cerium(3+) Chemical compound [Ce+3] XQTIWNLDFPPCIU-UHFFFAOYSA-N 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 201000011082 combat disease Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-M cyclohexylsulfamate Chemical compound [O-]S(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-M 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000007275 deallylation reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- PBWZKZYHONABLN-UHFFFAOYSA-M difluoroacetate Chemical compound [O-]C(=O)C(F)F PBWZKZYHONABLN-UHFFFAOYSA-M 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- GXBYFVGCMPJVJX-UHFFFAOYSA-N epoxybutene Chemical compound C=CC1CO1 GXBYFVGCMPJVJX-UHFFFAOYSA-N 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- CHPAJOSJONRYPT-YSKGHYERSA-N ethyl (2E)-2-[(R)-tert-butylsulfinyl]iminoacetate Chemical compound CCOC(=O)\C=N\[S@](=O)C(C)(C)C CHPAJOSJONRYPT-YSKGHYERSA-N 0.000 description 1
- DHFQUZNGDKBRMD-UHFFFAOYSA-N ethyl 2-(chloromethoxycarbonylamino)-3-methylbutanoate Chemical compound CCOC(=O)C(C(C)C)NC(=O)OCCl DHFQUZNGDKBRMD-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- DBPFRRFGLYGEJI-UHFFFAOYSA-N ethyl glyoxylate Chemical compound CCOC(=O)C=O DBPFRRFGLYGEJI-UHFFFAOYSA-N 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N ethylene glycol monomethyl ether Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 229960005394 flucloxacillin Drugs 0.000 description 1
- QWLICVXJMVMDDQ-UHFFFAOYSA-N fluoro acetate Chemical compound CC(=O)OF QWLICVXJMVMDDQ-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;N-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- XIQUJVRFXPBMHS-UHFFFAOYSA-N hydron;O-prop-2-enylhydroxylamine;chloride Chemical compound Cl.NOCC=C XIQUJVRFXPBMHS-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- PEHSSTUGJUBZBI-UHFFFAOYSA-N indan-5-ol Chemical compound OC1=CC=C2CCCC2=C1 PEHSSTUGJUBZBI-UHFFFAOYSA-N 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000003835 ketolide antibiotic agent Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 102000030974 metallo-beta-lactamase family Human genes 0.000 description 1
- 108060004734 metallo-beta-lactamase family Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- FBJOIJMLWUNGFB-RITPCOANSA-N methyl (2S,3R)-2-amino-3-methylpent-4-enoate Chemical compound COC(=O)[C@@H](N)[C@H](C)C=C FBJOIJMLWUNGFB-RITPCOANSA-N 0.000 description 1
- CNMFHDIDIMZHKY-UHFFFAOYSA-N methyl 2,2-dimethylpropanoate Chemical compound COC(=O)C(C)(C)C CNMFHDIDIMZHKY-UHFFFAOYSA-N 0.000 description 1
- JBQKOQBGTZEXRF-UHFFFAOYSA-N methyl(1,3-oxazol-2-yl)azanium;chloride Chemical compound Cl.CNC1=NC=CO1 JBQKOQBGTZEXRF-UHFFFAOYSA-N 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- UAVOCTDYPKOULU-UHFFFAOYSA-N methylchloranuidyl formate Chemical compound C[Cl-]OC=O UAVOCTDYPKOULU-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- 230000002906 microbiologic Effects 0.000 description 1
- JKLAGGHYICBLAT-UHFFFAOYSA-N molecular hydrogen;urea Chemical compound [H][H].NC(N)=O JKLAGGHYICBLAT-UHFFFAOYSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 150000004957 nitroimidazoles Chemical class 0.000 description 1
- CTNZOGJNVIFEBA-UPSUJEDGSA-N nocardicin A Chemical compound C1=CC(OCC[C@@H](N)C(O)=O)=CC=C1C(=N\O)\C(=O)N[C@@H]1C(=O)N([C@@H](C(O)=O)C=2C=CC(O)=CC=2)C1 CTNZOGJNVIFEBA-UPSUJEDGSA-N 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940005931 ophthalmologic Fluoroquinolone antiinfectives Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- TWLXDPFBEPBAQB-UHFFFAOYSA-N orthoperiodic acid Chemical compound OI(O)(O)(O)(O)=O TWLXDPFBEPBAQB-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- PYWFAPLYHPJXPW-UHFFFAOYSA-M palladium(2+);prop-1-ene;chloride Chemical class [Pd+]Cl.[CH2-]C=C PYWFAPLYHPJXPW-UHFFFAOYSA-M 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- WSHJJCPTKWSMRR-RXMQYKEDSA-N penam Chemical class S1CCN2C(=O)C[C@H]21 WSHJJCPTKWSMRR-RXMQYKEDSA-N 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- DWHGNUUWCJZQHO-ZVDZYBSKSA-M potassium;(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 DWHGNUUWCJZQHO-ZVDZYBSKSA-M 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000000063 preceeding Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-M pyrrolidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-M 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940041075 systemic Fluoroquinolone antibacterials Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003865 tazobactam Drugs 0.000 description 1
- 229960001114 temocillin Drugs 0.000 description 1
- BFFLLBPMZCIGRM-QMMMGPOBSA-N tert-butyl (2S)-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CO BFFLLBPMZCIGRM-QMMMGPOBSA-N 0.000 description 1
- NOEJBYQHQQUPEY-UHUGOGIASA-N tert-butyl (2S)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-methyl-5-trimethylsilyloxy-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound CC1C=C(O[Si](C)(C)C)CN(C(=O)OC(C)(C)C)[C@@H]1CO[Si](C)(C)C(C)(C)C NOEJBYQHQQUPEY-UHUGOGIASA-N 0.000 description 1
- ZSLXITIMMRZQBV-AWEZNQCLSA-N tert-butyl (2S)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-methyl-5-oxo-2,6-dihydropyridine-1-carboxylate Chemical compound CC1=C[C@@H](CO[Si](C)(C)C(C)(C)C)N(C(=O)OC(C)(C)C)CC1=O ZSLXITIMMRZQBV-AWEZNQCLSA-N 0.000 description 1
- KQLZXWXCBWPDAD-ZETCQYMHSA-N tert-butyl (2S)-4,4-difluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(F)(F)C[C@H]1CO KQLZXWXCBWPDAD-ZETCQYMHSA-N 0.000 description 1
- OLBWRIKUNCOAAZ-LSDHHAIUSA-N tert-butyl (3S,6S)-6-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-hydroxy-4-methyl-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound CC1=C[C@@H](CO[Si](C)(C)C(C)(C)C)N(C(=O)OC(C)(C)C)C[C@H]1O OLBWRIKUNCOAAZ-LSDHHAIUSA-N 0.000 description 1
- JNNVMRTXLPOSFY-SNVBAGLBSA-N tert-butyl (4R)-4-(cyclopropanecarbonyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate Chemical compound C1OC(C)(C)N(C(=O)OC(C)(C)C)[C@H]1C(=O)C1CC1 JNNVMRTXLPOSFY-SNVBAGLBSA-N 0.000 description 1
- MOWCOBFGXHCCSM-NFJWQWPMSA-N tert-butyl (4R)-4-[cyclopropyl(hydroxy)methyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate Chemical compound C1OC(C)(C)N(C(=O)OC(C)(C)C)[C@H]1C(O)C1CC1 MOWCOBFGXHCCSM-NFJWQWPMSA-N 0.000 description 1
- PNJXYVJNOCLJLJ-QMMMGPOBSA-N tert-butyl (4R)-4-formyl-2,2-dimethyl-1,3-oxazolidine-3-carboxylate Chemical compound CC(C)(C)OC(=O)N1[C@@H](C=O)COC1(C)C PNJXYVJNOCLJLJ-QMMMGPOBSA-N 0.000 description 1
- ZQGDTVLBDAEIJE-GFCCVEGCSA-N tert-butyl (4S)-4-(1-cyclopropylethenyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate Chemical compound C1OC(C)(C)N(C(=O)OC(C)(C)C)[C@H]1C(=C)C1CC1 ZQGDTVLBDAEIJE-GFCCVEGCSA-N 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl N-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- POMGWZNKBDMQQO-UHFFFAOYSA-N tert-butyl N-(isocyanatomethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCN=C=O POMGWZNKBDMQQO-UHFFFAOYSA-N 0.000 description 1
- KGZYTYBOSROIPX-OAHLLOKOSA-N tert-butyl N-[(2S)-1-[tert-butyl(dimethyl)silyl]oxy-3-cyclopropylbut-3-en-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](CO[Si](C)(C)C(C)(C)C)C(=C)C1CC1 KGZYTYBOSROIPX-OAHLLOKOSA-N 0.000 description 1
- UXWQXBSQQHAGMG-UHFFFAOYSA-N tert-butyl N-[(4-aminophenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(N)C=C1 UXWQXBSQQHAGMG-UHFFFAOYSA-N 0.000 description 1
- DYCUAXHBULVZRW-UHFFFAOYSA-N tert-butyl N-[2-(sulfamoylamino)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCNS(N)(=O)=O DYCUAXHBULVZRW-UHFFFAOYSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000002110 toxicologic Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- OJZNYUDKNVNEMV-UHFFFAOYSA-M trimethylstannanylium;hydroxide Chemical compound C[Sn](C)(C)O OJZNYUDKNVNEMV-UHFFFAOYSA-M 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Abstract
The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta- lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein. ncluding multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.
Description
WO 53215
Beta-Lactamase Inhibitor Compounds
Related Applications
This application claims priority to US. Provisional Application No. 62/395,464. filed
September 16, 2616 and US. Provisional Application No. 62/456,423, filed February 8,
2i)? '7, the contents of each of which are incorporated herein by reference.
Field of the ion
The present invention relates to novel oral beta—lactamase inhibitors, their pharmaceutical
compositions and methods of use. In addition, the present invention relates to therapeutic
methods for the treatment of ial infections, including overcoming bacterial otic
resistance.
Background of the Invention
The international microbiological and infectious disease community continues to express
serious concern that the continuing evolution of antibacterial resistance could result in
bacterial strains t which currently available antibacterial agents will be ineffective. The
outcome of such an occurrence could have considerable morbidity and mortality. In general,
bacterial pathogens may be classified as either Gram—positive or Gram—negative pathogens.
Antibiotic nds with effective activity against both Gram—positive and Gram—negative
pathogens are typically regarded as having a broad spectrum of activity.
In the fight against bacterial infection, beta—lactam antibiotics are essential. Beta—lactams are
a broad class of drugs which all have a actam in their core molecular structure, and
lly show effectiveness against a broad spectrum of Gram—positive and Gram—negative
bacteria by ting the cell wall synthesis of the bacterium. Because the drug target has no
eukaryotic analog, their toxicity is low and they are generally well—tolerated. They remain
among the most widely prescribed, safe and effective drugs ble to combat bacterial
infection. However, their effectiveness is limited by highly resistant infectious s such
as methicillin—resistant Staphylococcus aureus (MRSA) and multi—drug ant (MDR)
strains of Pseudomonas aeruginosa, Acinetobacter baumannii, ichia coli, Klebsiella
pneumoniae, and other Enterobacteriaceae. Such resistant bacteria are major causes of
patient morbidity and mortality. Helfand, ,B-lactams t Emerging bugs’:
Progress and Pitfalls, Expert Rev. Clin. Pharmacol. 1(4):559—571 (2008).
Beta—lactam antibiotics, alone and in combination with beta—lactamase inhibitors, continue to
ent an ial portion of the antibacterial agents used to combat disease. Beta—lactam
ance for Gram—negative infections is primarily driven by beta—lactamase activity; and
the significant dependence on beta—lactam antibiotics has lead to the diversification and
increased prevalence of beta—lactamases. These actamases are driving resistance to
even the newest beta—lactam otics. Llarrull, et al., The Future ofBeta-Lactams, Current
Opinion in Microbiology, 13 :55 1—557 (2010).
A major threat to the efficacy of these drugs is the increasing prevalence of extended—
spectrum beta—lactamases (ESBLs). actamases are enzymes that are produced by some
bacteria that ring open the beta—lactam portion of a beta—lactam antibiotic and thereby
deactivate it. There are currently, four classes of beta—lactamases, denoted as Class A, Class
B, Class C and Class D. Class A, Class C and Class D beta—lactamases are serine beta—
lactamases, while Class B actamases are metallo—beta—lactamases . Bush &
Jacoby, Updated Functional Classification of,B-Lactamases, Antimicrobial Agents and
Chemotherapy, 54(3):969—976 (Mar. 2010).
To help improve the effectiveness of beta—lactam antibiotics, some beta—lactamase inhibitors
have been developed. However, the currently available beta—lactamase inhibitors in many
instances are insufficient to counter the constantly increasing diversity of beta—lactamases.
The three most common serine beta—lactamase agents currently used — clavulanic acid,
tazobactam and tam — have activity only against certain Class A enzymes, which
severely limits their utility. Additionally, novel beta—lactamase inhibitors recently approved
or currently in clinical trials, such as tam and 5, are only available for
intravenous use and work primarily on Class A and C enzymes, with minimal effectiveness
against Class D beta—lactamases. Bebrone, et al., Current Challenges in Antimicrobial
Chemotherapy: Focus on ,B-Lactamase Inhibition, Drugs, 651—679 (2010). While these
agents represent a considerable ement over the currently ble beta—lactamase
inhibitors, agents which effectively hit all three classes of serine beta—lactamases, with the
added benefit of an orally effective dose form for use outside of the hospital setting are
desirable for combating the significant beta—lactam resistance seen today. Currently, there are
no approved beta—lactamase inhibitors which are administered orally and effective against
Class C or Class D beta—lactamases, yet resistance rates to conventional antibiotics are
continuing to rise.
Compounds similar to the ones disclosed herein, also with broad beta—lactamase inhibition
profiles (being effective t most Class A, Class C and Class D beta—lactamases), were
described in
following a:
R1 R3
2*!“\
o OSOgH
While the compounds of the
improvement in the spectrum of beta—lactamase inhibitors presently on the market or in the
clinic, the compounds described therein can only be administered intravenously (IV) e
they are not orally bioavailable. Moreover, the compounds disclosed therein could not be
made to be orally bioavailable by using a prodrug on the sulfate ting group on the
molecule. Therefore, these potent beta—lactamase inhibitors are limited to intravenous or
parenteral administration, which typically happens only in a al setting. ingly,
there are limited treatment options for patients with serious, resistant ions but who are
otherwise healthy and do not need to be admitted into the al, or patients who could be
discharged from a hospital but who would benefit from antibacterial treatment in an
outpatient setting (also known as “oral switch therapy”). The compounds of the W0
2013/150296 application have the potential to provide patients with more ive and
broader actamase inhibition than anything yet identified, but the compounds currently
require intravenous administration in a hospital setting.
There is a critical need for a new, broad spectrum, oral beta—lactamase inhibitor that would
provide a significant benefit for patients infected with resistant pathogens who may be able to
be treated outside of the hospital setting, or who are admitted to a hospital but may not have
reliable venous access. Such patients may have s, complicated infections from
pathogens which produce one or multiple beta—lactamases, but who may not require treatment
in a hospital setting, or those recovering from infections which were lly successfully
treated with an IV beta—lactam/beta—lactamase inhibitor combination in the hospital, but who
would benefit from continued beta—lactam/beta—lactamase inhibitor combination therapy
e of the hospital setting — which would be possible only with an orally active, broad—
spectrum beta—lactamase inhibitor such as described herein.
Furthermore, for patients with resistant bacterial infections which require hospital admission
for initial treatment, compounds according to the t invention, as described in Formulae
(Ia), (Ila), (Illa), (IVa) and (Va), can be administered enously in the hospital setting
until a patient is stable enough to be discharged into the community setting. Upon discharge,
the patient can continue therapy with the same medication by administration of a nd
according to one of Formulae (I), (II), (III), (IV), or (V), in a community g, while
maintaining a consistent treatment until the bacterial infection is resolved. There are
currently no Class A, C and D B—lactamase tors which can be stered initially by
IV with the additional benefit of oral administration once a patient is well enough to be
discharged from the hospital. The ability for a doctor to tailor the care to a t’ s needs
would allow for earlier discharge of patients who require hospitalization, and significantly
lessen the costs of treatment overall by avoiding prolonged hospital stays.
There is an urgent need for new, orally—active beta—lactamase inhibitors which are effective
against more than one of Class A, C and D beta—lactamases.
Summary of the ion
The present invention is directed to compounds which are orally available beta—lactamase
inhibitors. The compounds, and their pharmaceutically able salts, are useful in
combination with beta—lactam antibiotics for the treatment of bacterial infections, ing
infections caused by drug resistant organisms, including multi—drug resistant organisms.
More particularly, the invention relates to compounds of formula (1):
R1””, R3
0/ \
or a pharmaceutically acceptable salt thereof; wherein:
R1 is —C(O)NR7R8, —CN, phenyl, a 5—7 membered heteroaryl, —
C(O)NR’NR’C(O)R9, —C(O)NR’OR10, or a C1—C6 alkyl group, n the alkyl group is
substituted with one to three groups ting of halo, C1—C3 alkoxy, —OH, —CN, —NR7R8,
—NR7COR9, a 5—7 membered heteroaryl and a 5—7 membered heterocyclyl, and wherein the
phenyl and heteroaryl represented by R1 are optionally and independently substituted with l—
3 groups selected from halo, —OH, C1—C3 alkoxy, —CN, —NR7R8, and —CONR7R8;
R2 and R3 are independently selected from hydrogen, halo, C1—C3 alkyl, and C3—
C6 cycloalkyl;
R4 and R5 are ndently selected from hydrogen, halo, —CN, —COZR9, C1-C3
alkyl, and C1—C3 haloalkyl;
R6 is hydrogen, C1—C12 alkyl, C1—C4alkyl—C1—C3alkoxy—(NR’C1—C6alkyl)—C1—
C3alkoxy, C1—C4alkyl—C1—C3alkoxy—C1—C3alkoxy, C2—C12 alkenyl, C3—C10 cycloalkyl, a 5—7
membered heteroaryl and a 5—7 membered heterocyclyl, wherein the alkyl, alkenyl,
cycloalkyl, heteroaryl and heterocyclyl are optionally and independently tuted l—6
groups selected from a carboxyl, halo, C1—C6 alkoxy, C1—C6 alkyl and phenyl. Alternatively,
R6 is C1-C12 alkyl, C1-C4alkyl-C1-C3alkoxy-(NR’C1-C6alkyl)-C1-C3alkoxy, C1-C4alkyl-C1-
C3alkoxy—C1—C3alkoxy, C2—C12 alkenyl, C3—C10 cycloalkyl, a 5—7 ed heteroaryl and a
—7 membered heterocyclyl, wherein the alkyl, l, cycloalkyl, heteroaryl and
heterocyclyl are optionally and independently substituted l—6 groups ed from a
carboxyl, halo, C1—C6 alkoxy, C1—C6 alkyl and phenyl;
each R7 and R8 are ndently hydrogen, C1—C3 alkyl, C1—C3 alkoxy, ,
C3—C6 cycloalkyl, 4—7 ed heterocyclyl, or 5—7 membered heteroaryl, wherein the
alkyl, alkoxy, phenyl, cycloalkyl, heterocyclyl or aryl represented by R7 or R8 is
optionally and independently substituted with 1—6 groups selected from a 5—6 membered
heterocyclyl optionally substituted with one or two —F atoms, carboxyl or —CO(OC1—6 alkyl),
—6 membered aryl, —CN, —OH, C1—C3 alkyl ally substituted with —NH2 or —OH,
C1—C3 kyl, C1—C3 haloalkoxy, C1—C3 alkoxy —NHCO(C1—C3alkyl), —NHCO(C1—
C3alkoxy), —S(O)2NR’R”, -NHS(O)2NR’R”, -NHS(O)2(C1-C3alkyl), , and
—C(O)NR’R’ ’; each R9 is C1—C6 alkyl, C1—C6 kyl, C1—C6 haloalkoxy or C1—C6 ;
each R10 is a C1—C3 alkyl optionally substituted with 1—6 groups selected from a
—6 membered heterocyclyl optionally substituted with one or two —F atoms, carboxyl or
—CO(OC1—6 alkyl), a C3—C6 cycloalkyl, a 5—6 membered aryl, —CN, —OH, —NHCO(C1—
C3alkyl), C1—C3alkoxy), —S(O)2NR’R”, -NHS(O)2NR’R”, -NHS(O)2(C1-C3alkyl), -
NR’R”, or —C(O)NR’R”; and
each R’ and R” is independently hydrogen, , ethyl or propyl; or R’ and
R’’ are taken together with the nitrogen to which they are attached to form a 5—6 membered
heterocyclyl; provided that at least one of R2 and R3 is other than hydrogen.
Detailed Description of the Invention
In one aspect of the invention is an oral beta—lactamase inhibitor compound according to
formula (I); as described above.
In another aspect of the ion, R1 in formula (I) is —C(O)NR7R8, —CN, phenyl, a 5—6
membered heteroaryl, —C(O)NR’NR’C(O)R9, —C(O)NR’OR10, or a C1—C6 alkyl group,
wherein the alkyl group is substituted with one to three groups consisting of halo, C1—C3
alkoxy, —OH, —CN, —NR7R8, —NR7COR9, a 5—6 membered heteroaryl and a 5—7 membered
cyclyl, and n the phenyl and heteroaryl represented by R1 are optionally and
independently substituted with 1—3 groups selected from halo, —OH, C1—C3 alkoxy, —CN,
-NR7R8, and —CONR7R8;
R6 is hydrogen, C1-C12 alkyl, C1-C4alkyl-C1-C3alkoxy-(NR’C1-C6alkyl)-C1-C3alkoxy, C1-
C4alkyl—C1—C3alkoxy—C1—C3alkoxy, C2—C12 alkenyl, C3—C10 lkyl, a 5—6 membered
heteroaryl and a 5—7 membered heterocyclyl, wherein the alkyl, alkenyl, cycloalkyl,
heteroaryl and heterocyclyl are optionally and independently substituted l—6 groups selected
from a carboxyl, halo, C1—C6 alkoxy, C1—C6 alkyl and phenyl (alternatively, R6 is C1—C12 alkyl,
C1-C4alkyl-C1-C3alkoxy-(NR’C1-C6alkyl)-C1-C3alkoxy, C1-C4alkyl-C1-C3alkoxy-C1-
C3alkoxy, C2—C12 alkenyl, C3—C10 cycloalkyl, a 5—6 membered heteroaryl and a 5—7 membered
heterocyclyl, wherein the alkyl, alkenyl, cycloalkyl, heteroaryl and heterocyclyl are
optionally and independently substituted 1—6 groups selected from a carboxyl, halo, C1—C6
alkoxy, C1—C6 alkyl and phenyl); and each R7 and R8 are independently hydrogen, C1—C3
alkyl, C1—C3 alkoxy, phenyl, C3—C6 cycloalkyl, 4—7 membered heterocyclyl, or 5—6 membered
aryl, wherein the alkyl, alkoxy, phenyl, cycloalkyl, heterocyclyl or heteroaryl
ented by R7 or R8 is ally and independently substituted with 1—6 groups selected
from a 5—6 membered heterocyclyl ally substituted with one or two —F atoms, carboxyl
or —CO(OC1—6 alkyl), 5—6 membered heteroaryl, —CN, —OH, C1—C3 alkyl optionally substituted
with —NH2 or —OH, C1—C3 haloalkyl, C1—C3 haloalkoxy, C1—C3 alkoxy —NHCO(C1—C3alkyl),
—NHCO(C1—C3alkoxy), —S(O)2NR’R”, —NHS(O)2NR’R”, -NHS(O)2(C1-C3alkyl), -NR’R”,
and —C(O)NR’R’ ’; each R9 is C1—C6 alkyl, C1—C6 kyl, C1—C6 haloalkoxy or C1—C6
alkoxy;
In r aspect of the ion is a compound according to Formula (11):
R10,” \
2 “\
or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R4, R5 and R6 are
as defined for formula (I).
In one aspect of the invention is a compound according to Formula (111):
R30,” R3
(III)
or a pharmaceutically acceptable salt thereof, wherein the variables R1, R3, R4, R5 and R6 are
as defined for formula (I).
In a further aspect of the invention is a compound according to Formula (IV):
HZNJLIII'“ \
or a pharmaceutically acceptable salt thereof, wherein the variables R4, R5 and R6 are as
defined for formula (I).
In a further aspect of the invention is a compound according to a (V):
HgNJL/Illl" \
or a pharmaceutically acceptable salt thereof, n the variables R4, R5 and R6 are as
defined for formula (I).
In a further aspect of the invention is a compound according to Formula (Ia):
or a pharmaceutically acceptable salt thereof; wherein: R1 is —C(O)NR7R8, —CN, , a 5—7
ed heteroaryl, —C(O)NR’NR’C(O)R9, —C(O)NR’OR10, or a C1—C6 alkyl group,
wherein the alkyl group is substituted with one to three groups consisting of halo, C1—C3
alkoxy, —OH, —CN, —NR7R8, —NR7COR9, a 5—7 membered heteroaryl and a 5—7 membered
heterocyclyl, and wherein the phenyl and heteroaryl represented by R1 are optionally and
independently substituted with 1—3 groups selected from halo, —OH, C1—C3 alkoxy, —CN,
—NR7R8, and —CONR7R8; R2 and R3 are independently selected from en, halo, C1—C3
alkyl, and C3—C6 cycloalkyl; R4 and R5 are independently selected from hydrogen, halo, —CN,
—COZR9, C1—C3 alkyl, and C1—C3 haloalkyl; each R7 and R8 are independently en, C1—C3
alkyl, C1—C3 alkoxy, , C3—C6 cycloalkyl, 4—7 membered heterocyclyl, or 5—7 membered
heteroaryl, wherein the alkyl, alkoxy, phenyl, cycloalkyl, heterocyclyl or heteroaryl
ented by R7 or R8 is optionally and independently substituted with 1—6 groups selected
from a 5—6 membered heterocyclyl optionally substituted with one or two —F atoms, carboxyl
or —CO(OC1—6 alkyl), 5—6 membered heteroaryl, —CN, —OH, C1—C3 alkyl optionally substituted
with —NH2 or —OH, C1—C3 haloalkyl, C1—C3 haloalkoxy, C1—C3 alkoxy —NHCO(C1—C3alkyl),
—NHCO(C1—C3alkoxy), —S(O)2NR’R”, )2NR’R”, -NHS(O)2(C1-C3alkyl), -NR’R”,
and —C(O)NR’R’ ’; each R9 is C1—C6 alkyl, C1—C6 haloalkyl, C1—C6 koxy or C1—C6
alkoxy; each R10 is a C1—C3 alkyl optionally substituted with 1—6 groups selected from a 5—6
membered heterocyclyl optionally substituted with one or two —F atoms, carboxyl or —
CO(OC1—6 alkyl), a C3—C6 cycloalkyl, a 5—6 membered heteroaryl, —CN, —OH, —NHCO(C1—
C3alkyl), C1—C3alkoxy), —S(O)2NR’R”, -NHS(O)2NR’R”, -NHS(O)2(C1-C3alkyl), -
NR’R’ ’, or R’R’ ’; and each R’ and R’’ is independently hydrogen, methyl, ethyl or
propyl; or R’ and R’ ’ are taken together with the nitrogen to which they are attached to form
a 5—6 membered heterocyclyl; ed that at least one of R2 and R3 is other than hydrogen.
In a further aspect of the ion is a compound according to Formula (Ia):
or a pharmaceutically acceptable salt thereof; wherein: R1 is —C(O)NR7R8, —CN, phenyl, a 5—6
membered heteroaryl, —C(O)NR’NR’C(O)R9, —C(O)NR’OR10, or a C1—C6 alkyl group,
wherein the alkyl group is substituted with one to three groups consisting of halo, C1—C3
alkoxy, —OH, —CN, —NR7R8, —NR7COR9, a 5—6 membered aryl and a 5—7 membered
heterocyclyl, and wherein the phenyl and heteroaryl represented by R1 are optionally and
independently substituted with 1—3 groups selected from halo, —OH, C1—C3 alkoxy, —CN,
—NR7R8, and —CONR7R8; R2 and R3 are independently selected from hydrogen, halo, C1—C3
alkyl, and C3—C6 cycloalkyl; R4 and R5 are independently selected from hydrogen, halo, —CN,
—C02R9, C1—C3 alkyl, and C1—C3 haloalkyl; each R7 and R8 are independently hydrogen, C1—C3
alkyl, C1—C3 , phenyl, C3—C6 cycloalkyl, 4—7 ed heterocyclyl, or 5—6 membered
heteroaryl, wherein the alkyl, alkoxy, , cycloalkyl, heterocyclyl or heteroaryl
represented by R7 or R8 is optionally and ndently substituted with 1—6 groups ed
from a 5—6 membered heterocyclyl optionally substituted with one or two —F atoms, carboxyl
or —CO(OC1—6 alkyl), 5—6 membered heteroaryl, —CN, —OH, C1—C3 alkyl optionally substituted
with —NH2 or —OH, C1—C3 haloalkyl, C1—C3 haloalkoxy, C1—C3 alkoxy —NHCO(C1—C3alkyl),
—NHCO(C1—C3alkoxy), —S(O)2NR’R”, —NHS(O)2NR’R”, -NHS(O)2(C1-C3alkyl), -NR’R”,
and —C(O)NR’R’ ’; each R9 is C1—C6 alkyl, C1—C6 haloalkyl, C1—C6 haloalkoxy or C1—C6
; each R10 is a C1—C3 alkyl optionally substituted with 1—6 groups selected from a 5—6
membered cyclyl optionally substituted with one or two —F atoms, yl or —
CO(OC1—6 alkyl), a C3—C6 cycloalkyl, a 5—6 membered heteroaryl, —CN, —OH, —NHCO(C1—
C3alkyl), —NHCO(C1—C3alkoxy), —S(O)2NR’R”, —NHS(O)2NR’R”, —NHS(O)2(C1—C3alkyl), —
NR’R’ ’, or —C(O)NR’R’ ’; and each R’ and R’’ is independently hydrogen, methyl, ethyl or
propyl; or R’ and R’ ’ are taken together with the nitrogen to which they are attached to form
a 5—6 membered cyclyl; provided that at least one of R2 and R3 is other than en.
In another aspect of the invention is a compound according to Formula (Ila):
R1////, \
(Ila)
or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R4 and R5 are as
defined for formula (Ia).
In one aspect of the invention is a compound according to Formula (IIIa):
R1/0,], R3
0/1 N
(IIIa)
or a ceutically acceptable salt thereof, wherein the variables R1, R3, R4 and R5 are as
d for formula (Ia).
In a further aspect of the invention is a nd according to Formula (IVa):
Jill/Ill
H2N " \
2 N\
(IVa)
or a pharmaceutically acceptable salt thereof, wherein the variables R4 and R5 are as defined
for formula (Ia).
In a further aspect of the invention is a compound according to Formula (Va):
H2NJl”0"“ \
or a pharmaceutically acceptable salt thereof, wherein the variables R4 and R5 are as defined
for formula (Ia).
In one aspect of the inventions, for Formulae (I), (Ia), (II), or (IIa), R2 is C1—C3 alkyl. In
another aspect of the invention, for Formulae (I), (Ia), (II), or (IIa), R2 is methyl.
In one aspect of the invention, for a (I), (Ia), (III), and (IIIa), R3 is C1—C3 alkyl. In
another aspect of the invention, for a (I), (Ia), (III), and (IIIa), R3 is methyl.
In one aspect of the invention, for Formula (I), (Ia), (II), (IIa), (III), and (IIIa), R1 is selected
from an oxadiazole, —C(O)NHNHC(O)(C1—C3 alkyl), 2, —CH2NHCO(C1—C3 alkoxy),
—CH2NHCO(C1—C3 , or —CH2NHCO(C1—C3 haloalkyl), wherein the oxadiazole of R1 is
optionally substituted with —OH, C1—C3 alkoxy, —NR7R8, or —CONR7R8. In one aspect of the
invention, for Formula (I), (Ia), (II), (Ila), (III), and (Illa), R1 is selected from —CH2NH2,
Afi/T‘i, FsCiH/tfé" kio ”/tfxi
In a further aspect, for Formula (I), (la), (II), (IIa), (III), and (IIIa), R1 is —CN,
l. HZN/\/O\”)erfi’ Hamif KZ)‘; or
Yn\uifi
; wherein R11 is hydrogen or —C(O)NH2. In one aspect of the invention,
for a (I), (Ia), (II), (IIa), (III), and (IIIa), R1 is —CN or H2. In one aspect of
the invention, for Formula (I), (Ia), (II), (IIa), (III), and , R1 is —CN. In one aspect of
the invention, for Formula (I), (Ia), (II), (IIa), (III), and (IIIa), R1 is —C(O)NH2. In one aspect
of the ion, for Formula (I), (Ia), (II), (IIa), (III), and (IIIa), R1 is —C(O)NR7R8. In one
aspect of the invention, for Formula (I), (Ia), (II), (IIa), (III), and , when R1 is
—C(O)NR7R8, R7 is hydrogen and R8 is l) a phenyl optionally substituted with a C1—C3 alkyl
or C1—C3 alkyl—NHZ, 2) an C1—C3 alkyl or 3) C1—C3 alkoxy, wherein each alkyl or alkoxy of
represented by R8 is optionally and independently substituted with a C3—C6 cycloalkyl, —CN, —
OH, —NH2, 2, —NHSOzNH2, —C(O)NH2, -NHC(O)(C1-C3 alkyl), pyrazinyl, oxytanyl,
oxazolyl, or a pyrrolidinyl optionally substituted with one or more carboxyl, fluoro, or
—C(O)O(C1—C6 alkyl). In one aspect of the invention, for Formula (I), (Ia), (II), (IIa), (III), and
(IIIa), when R1 is —C(O)NR7R8, R7 is hydrogen and R8 is selected from the group consisting
’3’ F
/~ g 0
0 O 021;
HZN if\N HZN/ \/\O:1L9 NH
9 9 £9 9
O/\o}i
o o
\S/ 0\ /0\s/
HN/\N/\;Z¢, A2
H N/ig H2N/\N/\\H H and —CHZOH.
, , , —CH2CN,
In one aspect of the invention, for any one of Formulae (I), (II), (III), (IV) or (V), R6 is C1—C12
alkyl. In one aspect of the invention, for any one of Formulae (I), (II), (III), (IV) or (V), R6 is
ethyl, isopropyl, l or isopentyl. In one aspect of the invention, for any one of Formulae
(I), (II), (III), (IV) or (V), R6 is isopropyl. In one aspect of the invention, for any one of
ae (I), (II), (III), (IV) or (V), R6 is C1—C4alkyl—OC(O)—(NHC1—C6alkyl)—C(O)C1—
C3alkoxy, C1—C4alkyl—OC(O)—C1—C4alkyl or C1—C4alkyl—OC(O)—C1—C3alkoxy. In one aspect of
the invention, for any one of Formulae (I), (II), (III), (IV) or (V), R6 is selected from the
«TOY“YEA“ >6waO
group consisting of: O 0
, , ,
{VOEKCAO, 29:9,FD,f23%,
\ 5% 791A
éf\/\O/, \
é n—
9 , 33A, methyl, n—propyl, n—butyl, n—pentyl,
hexyl, n—septyl, n—octyl, or n—nonyl.
In one aspect of the invention, for any one of Formulae (I), (Ia), (II), (IIa), (III), , (IV),
(IVa), (V) or (Va), R4 and R5 are ndently H, methyl or fluoro. In another aspect of the
invention, for any one of Formulae (I), (Ia), (II), (IIa), (III), (IIIa), (IV), (IVa), (V) or (Va),
one of R4 and R5 is hydrogen and the other is fluoro. In another aspect of the invention, for
any one of Formulae (I), (Ia), (II), (IIa), (III), (IIIa), (IV), (IVa), (V) or (Va), R4 is fluoro and
R5 is hydrogen. In another aspect of the invention, for any one of Formulae (I), (la), (II),
(IIa), (III), (IIIa), (IV), (IVa), (V) or (Va), R4 is hydrogen and R5 is fluoro. In r aspect
of the invention, for any one of Formulae (I), (la), (II), (IIa), (III), (IIIa), (IV), (IVa), (V) or
(Va), both R4 and R5 are hydrogen.
WO 53215
In r aspect of the invention, for any one of Formulae (I), (Ia), (II), (Ila), (III), (IIIa),
(IV), (IVa), (V) or (Va), both R4 and R5 are fluoro.
Any embodiment described herein can be combined with any other suitable embodiment
described herein to provide additional embodiments. For example, Where one embodiment
individually or collectively describes possible groups for R1 and a separate embodiment
bes possible groups for R2, it is understood that these embodiments can be combined to
provide an additional embodiment utilizing any of the possible groups for R1 with any of the
possible groups for R2. Analogously, the invention asses any ments called out
individually for R1, R2, R3, R4, R5 and R6 in combination with any specific embodiments
called out for each of the remaining variables.
nds of ae (I), (II), (III), (IV) and (V), and pharmaceutically acceptable salts
thereof, possess beneficial beta—lactamase inhibition spectrum and are suitable for oral
administration. Compounds of ae (Ia), (Ila), (IIIa), (IVa) and (Va), and
pharmaceutically acceptable salts thereof, possess beneficial beta—lactamase inhibition
spectrum and are suitable for intravenous, intraperitoneal, intramuscular or subcutaneous
administration, e.g., intravenous administration. As such, compounds of Formulae (Ia), (IIa),
, (IVa) and (Va), and pharmaceutically acceptable salts thereof can be advantageously
used when a patient is unable to take otics orally, such as in a hospital setting, urgent
care setting or g home setting. Once the patient has improved sufficiently to take
antibiotics orally, the treatment can be switched such that a compound of Formulae (I), (II),
(III), (IV) and (V), or a pharmaceutically acceptable salt thereof can be administered orally to
the patient. Additionally, compounds of Formulae (Ia), (IIa), , (IVa), (Va), (I), (II), (III),
(IV) and (V), and pharmaceutically acceptable salts thereof, may possess beneficial
efficacious, metabolic, toxicological and/or pharmacodynamic properties.
One aspect of the invention includes a compound according to one of the examples, or a
pharmaceutically acceptable salt thereof, namely:
Structure
(R)-ethyl 2-((2S,5R)
carbamoyl—3—methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yloxy)—2—flu0r0acetate
(S)—ethyl 2—((2S,5R)—2—carbam0yl—
3—methyl—7-OXO- l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yloxy)—2—flu0r0acetate
(2S)—{ [(2S ,5R)—2—carbam0yl—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy } (flu0r0)ethan0ic acid
lithium salt
(2R)—{ [(2S,5R)—2—carbam0yl—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. 3—en—6—
yl]0xy } (flu0r0)ethan0ic acid
m salt
{[(2S,5R)—2—carbam0yl—3—methyl—
7-OXO- l ,6—diazabicyclo[3 .2. l]0ct—
3—en—6—yl]oxy } (flu0r0)acetic acid
m salt
ethyl {[(2S,5R)—2—carbam0yl—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy } (flu0r0)acetate
ethyl {[(2S,5R)—2—carbam0yl—3—
methyl—7—0X0— l ,6—
icyclo[3 .2. l]0ct—3—en—6—
yl]0xy } (diflu0r0)acetate
5R)—2—carbam0yl—3—methyl—
7-OXO- l ,6—diazabicyclo[3 .2. l]0ct—
3—en—6—yl]0xy } (diflu0r0)acetic
acid lithium salt
ethyl {[(2S,5R)—2—carbam0yl—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy } acetate
{[(2S,5R)—2—carbam0yl—3—methyl—
7-OXO- l ,6—diazabicyclo[3 .2. l]0ct—
—yl]0xy } acetic acid lithium
2—{ [(2S,5R)—2—carbam0yl—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy } —2—flu0r0pr0pan0ic acid
lithium salt
propan—2—yl (2R)—{ [(2S,5R)—2—
carbamoyl—3—methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy } (flu0r0)ethan0ate
propan—2—yl (2S)—{ [(2S ,5R)—2—
carbamoyl—3—methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy } (flu0r0)ethan0ate
methylpentan—3 —yl (2S)—
{[(2S,5R)—2—carbam0yl—3—methyl—
7-OXO- l ,6—diazabicyclo[3 .2. l]0ct—
3—en—6—yl]0xy } (flu0r0)ethan0ate
2,4—dimethylpentan—3—yl (2R)—
{[(2S,5R)—2—carbam0yl—3—methyl—
7-OXO- l ,6—diazabicyclo[3 .2. l]0ct—
3—en—6—yl]0xy } (flu0r0)ethan0ate
tetrahydr0—2H—pyran—4—yl
{ [(2S,5R)—2—carbam0y1—3—rnethy1—
7—0X0—1,6—diazabicyclo[3 .2. 1]oct—
3—en—6—yl]oxy } (flu0r0)acetate
2—meth0xyethy1 {[(2S,5R)—2—
carbamoyl—3—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl]0xy } (flu0r0)acetate
2—meth0xyethy1 (2R)—{ [(2S,5R)—
2—carbam0y1—3—rnethy1—7—0X0— 1,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl]0xy } (flu0r0)ethan0ate
2-methoxyethyl (2S)-{ [(2S,5R)
carbamoyl—3—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl]0xy } (flu0r0)ethan0ate
S)-sec-butyl 2-(((2S,5R)
carbamoyl—3—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl)0xy)—2—flu0r0acetate
S)-sec-butyl 2-(((2S,5R)
carbamoyl—3—methy1—7—0X0— 1 ,6—
icyclo[3.2.1]oct—3—en—6—
)—2—flu0r0acetate
(2R)-(R)-sec-butyl 2-(((2S,5R)
carbamoyl—3—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl)0xy)—2—flu0r0acetate
(2S)-(R)-sec-butyl 2-(((2S,5R)
carbamoyl—3—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl)0xy)—2—flu0r0acetate
(R)—pentan—3—yl 2—((2S,5R)—2—
carbamoyl—3—methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yloxy)—2—flu0r0acetate
(S)—pentan—3—yl ,5R)—2—
carbamoyl—3—methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yloxy)—2—flu0r0acetate
ethyl 2-(((2S,5R)(2-
hydrazinecarbonyl)—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl)0xy)—2—flu0r0acetate
2-(((2S,5R)(2-
acetylhydrazinecarbonyl)—3—
methyl—7—0X0—l,6—
icyclo[3 .2. l]0ct—3—en—6—
yl)0xy)—2—flu0r0acetic acid
lithium salt
(R)((2S,5R)(4-
(aminomethyl)phenylcarbamoyl)—
3—methyl—7—0X0—l,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yloxy)—2—flu0r0acetic acid TFA
ethyl 2—flu0r0—2—(((2S,5R)—3—
methyl—7—0X0—2—((pyrazin—2—
ylmethyl)carbam0yl)— l ,6—
icyclo[3 .2. l]0ct—3—en—6—
yl)0xy)acetate
2—flu0r0—2—(((2S,5R)—3—methyl—7—
0X0—2—((pyrazin—2—
ylmethyl)carbam0yl)— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl)0xy)acetic acid lithium salt
(2R)-ethy1 2-(((2S,5R)
carbam0y1—4—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl)0xy)—2—flu0r0acetate
thy1 2-(((2S,5R)
carbam0y1—4—methy1—7—0X0— 1 ,6—
icyclo[3.2.1]oct—3—en—6—
yl)0xy)—2—flu0r0acetate
(2R)—2—(((2S,5R)—2—carbam0y1—4—
methyl—7—0X0—1,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl)0xy)—2—flu0r0acetic acid
lithium salt
(2S)—2—(((2S,5R)—2—carbam0yl—4—
methyl—7—0X0—1,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl)0xy)—2—flu0r0acetic acid
lithium salt
(2R)—isopr0py1 2—(((2S,5R)—2—
carbam0y1—4—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl)0xy)—2—flu0r0acetate
sopr0py1 2—(((2S,5R)—2—
carbam0y1—4—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl)0xy)—2—flu0r0acetate
(2R)—isopr0py1 2—(((2S,5R)—2—
carbam0y1—3—cyclopr0py1—7—0X0—
1,6—diazabicyclo[3.2.1]oct—3—en—6—
yl)0xy)—2—flu0r0acetate
(2S)—isopr0pyl 2—(((2S,5R)—2—
carbamoyl—3—cyclopr0pyl—7—0X0—
l,6—diazabicyclo[3 .2. l]0ct—3—en—6—
yl)0xy)—2—flu0r0acetate
(2R)-ethyl S,5R)
carbamoyl—3—cyclopr0pyl—7—0X0—
l,6—diazabicyclo[3 .2. l]0ct—3—en—6—
yl)0xy)—2—flu0r0acetate
(2S)-ethyl 2-(((2S,5R)
carbamoyl—3—cyclopr0pyl—7—0X0—
l,6—diazabicyclo[3 .2. l]0ct—3—en—6—
)—2—flu0r0acetate
(2R)—2—(((2S,5R)—2—carbam0yl—3—
cyclopropyl—7—0X0—l,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl)0xy)—2—flu0r0acetic acid
lithium salt
(2R)—2—(((2S,5R)—2—carbam0yl—3—
cyclopropyl—7—0X0—l,6—
icyclo[3 .2. l]0ct—3—en—6—
yl)0xy)—2—flu0r0acetic acid
lithium salt
2—(((2S,5R)—2—carbam0yl—3—
cyclopropyl—7—0X0—l,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl)0xy)—2—flu0r0acetic acid
lithium salt
(l—isopropyl—2—methyl—pr0pyl) 2—
[[(2S ,5R)—2—carbam0yl—3—methyl—
7-OXO- l ,6—diazabicyclo[3 .2. l]0ct—
3—en—6—yl]0xy] —2,2—diflu0r0—
acetate
octyl -[[(2S,5R)
carbamoyl—3—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl] oxy] —2—flu0r0—acetate
methyl (2R)[[(2S,5R)
carbamoyl—3—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl] oxy] —2—flu0r0—acetate
allyl -[[(2S,5R)
carbamoyl—3—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl] oxy] —2—flu0r0—acetate
propyl (2R)—2—[[(2S,5R)—2—
carbamoyl—3—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl] oxy] —2—flu0r0—acetate
isobutyl (2R)[[(2S,5R)
carbamoyl—3—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl] oxy] —2—flu0r0—acetate
butyl (2R)[[(2S,5R)
carbamoyl—3—methy1—7—0X0— 1 ,6—
diazabicyclo[3.2.1]oct—3—en—6—
yl] oxy] —2—flu0r0—acetate
pentyl (2R)[[(2S,5R)
carbamoyl—3—methy1—7—0X0— 1 ,6—
icyclo[3.2.1]oct—3—en—6—
yl] oxy] —2—flu0r0—acetate
hexyl (2R)[[(2S,5R)
carbamoyl—3—methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl] oxy] —2—flu0r0—acetate
l—isopr0p0xycarbonyloxyethyl
(2R)—2—[[(2S ,5R)—2—carbam0yl—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl] oxy] —2—flu0r0—acetate
(2R)-benzyl 2-(((2S,5R)
carbamoyl—3—methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl)0xy)—2—flu0r0acetate
2—[[(2S,5R)—2—(5—carbam0yl—l,3,4—
oxadiazol—2—yl)—3—methyl—7—0X0—
azabicyclo[3.2.l]0ct—3—en—6—
yl]0xy] —2—flu0r0—acetic acid
lithium salt
(2S)fluoro[[(2S,5R)—3—
methyl—7—0X0—2—(2—
oylethoxycaIbamoyl)— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy] acetic acid lithium salt
(2S)fluoro[[(2S,5R)—3—
methyl—7—0X0—2—(2—
sulfamoylethylcarbamoyl)— 1,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy] acetic acid lithium salt
ethyl 2-[[(2R)[[(2S,5R)
oyl—3—methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
] —2—flu0r0—
acetyl]0xymeth0xycarbonylamino
]—3—methyl—butan0ate
tert-butyl -((((2S,5R)—6—
((S)—2—eth0xy— l —flu0r0—2—
oxoethoxy)—3—methyl—7—0X0— 1,6—
diazabicyclo[3 .2. l]oct—3—ene—2—
carboxamido)0xy)methyl)pyrrolid
ine— l —carb0xylate
ethyl -fluoro(((2S,5R)—3—
methyl—7—0X0—2—((((S)—pyrrolidin—
2—yl)meth0xy)carbam0yl)— 1,6—
diazabicyclo[3 .2. l]oct—3—en—6—
yl)0xy)acetate TFA salt
ethyl (2S)(((2S,5R)—2—((((S)—
4,4—diflu0r0pyrrolidin—2—
yl)rneth0xy)carbam0yl)—3—methyl—
7-OXO- l ,6—diazabicyclo[3 .2. l]oct—
3—en—6—yl)0xy)—2—flu0r0acetate
TFA salt
-fluoro[[(2S,5R)—3—
methyl—7—0X0—2—[[(2S)—pyrrolidin—
2—yl]meth0xycarbam0yl] — l ,6—
diazabicyclo[3 .2. l]oct—3—en—6—
yl]0xy] acetic acid TFA salt
(2S)(((2S,5R)((((S)-4,4-
difluoropyrrolidin—2—
yl)rneth0xy)carbam0yl)—3—methyl—
7-OXO- l ,6—diazabicyclo[3 .2. l]oct—
3—en—6—yl)0xy)—2—flu0r0acetic acid
TFA salt
[(2R)—2—[[(2S, 5R)—2—carbam0yl—
3—methyl—7—0X0—l,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy]—2—flu0r0—
acetyl]0xymethyl 2,2—
dimethylpropanoate
indan-S-yl (2R)[[(2S,5R)
oyl—3—methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl] oxy] —2—flu0r0—acetate
(2S)fluoro[[(2S,5R)—3—
methyl—2—(0xetan—3—ylcarbam0yl)—
7-OXO- l ,6—diazabicyclo[3 .2. l]0ct—
3—en—6—yl]oxy]acetic acid lithium
(2S)fluoro[[(2S,5R)[2-
(methanesulfonamid0)ethylcaIba
m0yl]—3—methyl—7—0X0—1,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy] acetic acid lithium salt
(2S)fluoro[[(2S,5R)—3—
methyl—2—(0xazol—2—
ylcarbamoyl)—7-OXO- 1,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy] acetic acid lithium salt
(2S)fluoro[[(2S,5R)—3—
methyl—7—0X0—2—(pyrazin—2—
ylmethylcarbamoyl)— l ,6—
diazabicyclo[3 .2. 3—en—6—
yl]0xy] acetic acid lithium salt
(2S)[[(2S,5R)
propylmethoxycarbamoyl)—
3—methyl—7—0X0—l,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
] —2—flu0r0—acetic acid
lithium salt
—[[(2S,5R)—2—[(3—amin0—3—
oxo—propyl)carbam0yl]—3—methyl—
7-OXO- l ,6—diazabicyclo[3 .2. l]0ct—
3—en—6—yl]oxy]—2—flu0r0—acetic
acid lithium salt
(2S)fluoro[[(2S,5R)—3—
methyl—7—0X0—2—[(5—
oxopyrrolidin—2—
yl)meth0xycarbam0yl] — l ,6—
icyclo[3 .2. l]0ct—3—en—6—
yl]0xy] acetic acid lithium salt
(2S)fluoro[[(2S,5R)—3—
methyl—7—0X0—2—[2—(5—
rolidin—2—
yl)ethylcarbam0yl]—l,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy] acetic acid lithium salt
(2S)fluoro[[(2S,5R)—3—
methyl—7—0X0—2—(3—
sulfamoylpropylcarbamoyl)— 1,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy] acetic acid lithium salt
(2S)fluoro[[(2S,5R)—3—
methyl—7—0X0—2—[2—
(sulfamoylamin0)ethylcarbamoyl]
— l ,6—diazabicyclo[3 .2. l]0ct—3—en—
xy] acetic acid lithium salt
(2S)[[(2S,5R)[(tert-
butoxycarbonylamin0)methyl]—3—
methyl—7—0X0—l,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy] —2—flu0r0—acetic acid
m salt
(2S)[[(2S,5R)
(aminomethyl)—3—methyl—7—0X0—
l,6—diazabicyclo[3 .2. l]0ct—3—en—6
yl]0xy] —2—flu0r0—acetic acid
(2S)[[(2S,5R)
(acetamidomethyl)—3—methyl—7—
0X0— 1 zabicyclo[3 .2. l]0ct—3—
en—6—yl]0xy]—2—flu0r0—acetic acid
lithium salt
(2S)fluoro[[(2S,5R)—3—
methyl—7—0X0—2—[[(2,2,2—
trifluoroacetyl)amin0]methyl]—
l,6—diazabicyclo[3.2.l]0ct—3—en—6—
yl]0xy] acetic acid lithium salt
ethyl (2S)fluoro[[(2S,5R)
(cyanomethylcarbamoyl)—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl] oxy] acetate
ethyl (2R)—2—flu0r0—2—[[(2S,5R)—2—
(cyanomethylcarbamoyl)—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl] oxy] acetate
(2S)fluoro[[(2S,5R)
(cyanomethylcarbamoyl)—3—
—7—0X0—l,6—
icyclo[3 .2. l]0ct—3—en—6—
yl]0xy] acetic acid lithium salt
ethyl (2S)fluoro[[(2S,5R)
(cyanomethylcarbamoyl)—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl] oxy] acetate
ethyl (2R)—2—flu0r0—2—[[(2S,5R)—2—
(cyanomethylcarbamoyl)—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. 3—en—6—
yl] oxy] acetate
ethyl -fluoro[[(2S,5R)
(hydroxymethylcarbamoyl)—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl] oxy] e
ethyl (2R)—2—flu0r0—2—[[(2S,5R)—2
(hydroxymethylcarbamoyl)—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl] oxy] acetate
(2S)fluoro[[(2S,5R)
(hydroxymethylcarbamoyl)—3—
methyl—7—0X0—l,6—
icyclo[3 .2. l]0ct—3—en—6—
yl]0xy] acetic acid lithium salt
(2S)fluoro[[(2S,5R)
(acetamidomethylcarbamoyl)—3—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl]0xy] acetic acid lithium salt
(2S)fluoro[[(2S,5R)—3—
methyl—7—0X0—2—
[(sulfamoylamin0)methylcarbamo
yl]—l,6—diazabicyclo[3.2.l]0ct—3—
en—6—yl]0xy] acetic acid lithium
ethyl 2—(((2S,5R)—2—carbam0yl—4—
methyl—7—0X0— l ,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl)0xy)—2,2—diflu0r0acetate
S,5R)—2—carbam0yl—4—
methyl—7—0X0—l,6—
diazabicyclo[3 .2. l]0ct—3—en—6—
yl)0xy)—2,2—diflu0r0acetic acid
lithium salt
ethyl 2—(((2S,5R)—2—carbamoyl—4—
methyl—7—oxo— l ,6—
diazabicyclo[3 .2. l]oct—3—en—6—
yl)oxy)acetate
S,5R)—2—carbamoyl—4—
methyl—7—oxo—l,6—
diazabicyclo[3 .2. l]oct—3—en—6—
yl)oxy)acetic acid lithium salt
ethyl (2R)—2—(((2S,5R)—2—cyano—4—
—7—oxo— l ,6—
diazabicyclo[3 .2. l]oct—3—en—6—
yl)oxy)—2—fluoroacetate
(2R)—2—(((2S,5R)—2—cyano—4—
methyl—7—oxo—l,6—
diazabicyclo[3 .2. l]oct—3—en—6—
yl)oxy)—2—fluoroacetic acid
lithium salt
isopropyl 2—(((2S,5R)—2—
carbamoyl—4—methyl—7—oxo— l ,6—
diazabicyclo[3 .2. l]oct—3—en—6—
yl)oxy)acetate
Compounds of the invention e those of formulae (I), (Ia), (II), (Ila), (III), (Illa), (IV),
(IVa), (V), (Va) in free base (uncharged) state, as well as pharmaceutically acceptable salts
thereof.
£104 — As used herein the term “alkyl” refers to both straight and branched chain saturated
arbon radicals having the specified number of carbon atoms. References to individual
alkyl groups such as “propyl” are specific for the straight chain n only and references to
individual branched chain alkyl groups such as ‘isopropyl’ and “3 —pentyl” are specific for the
branched chain version only. In one aspect, “alkyl” is methyl.
Halo — As used herein, the term “halo” is intended to include fluoro, chloro, bromo and iodo.
In one aspect, the “halo” may refer fluoro, chloro, and bromo. In r aspect, “halo” may
refer to fluoro or chloro. In still another aspect, “halo” may refer to fluoro. In yet another
, “halo” may refer to chloro.
Haloalkyl — As used herein is an ” moiety as d above substituted with one or
more halogen atoms. In one aspect, a “haloalkyl” may be —CHF2, —CH2F or —CF3.
Cycloalkyl — In one aspect, alkyl” refers to a saturated monocyclic carbon ring, of
which one or more —CH2— groups may be optionally replaced with a corresponding number of
—C(O)— groups. Illustrative es of alkyl” include cyclopropyl, cyclobutyl,
cyclopentyl, and cyclopentenyl. In one aspect, “3— to 5—membered carbocyclyl” may be
cyclopropyl.
—7 Membered Heterocyclyl — The term “5—7 membered heterocyclyl” refers to a saturated or
partially saturated, non—aromatic monocyclic ring containing 5 to 7 ring atoms, of which at
least one ring atom is selected from nitrogen, , and oxygen, and of which a —CH2— group
may be ally replaced by a —C(O)— group. Analogously, “5—6 membered cyclyl”
refers to a saturated or partially saturated, non—aromatic clic ring containing 5 to 6
ring atoms, of which at least one ring atom is selected from nitrogen, sulfur, and , and
of which a —CH2— group may be optionally replaced by a —C(O)— group. Unless otherwise
specified, “5—7 ed heterocyclyl” and “5—6 membered heterocyclyl” groups may be
carbon or nitrogen . Ring nitrogen atoms may be optionally oxidized to form an
N—oxide. Ring sulfur atoms may be optionally oxidized to form S—oxides or sulphones.
Illustrative examples of “5—7 membered heterocyclyl” and “5—6 membered heterocyclyl”
include, but are not limited to, azetidinyl, dioxidotetrahydrothiophenyl,
2,4—dioxoimidazolidinyl, 3,5—dioxopiperidinyl, furanyl, olyl, isothiazolyl, isoxazolyl,
morpholinyl, oxazolyl, oxetanyl, oxoimidazolidinyl, 3—oxo—l—piperazinyl, 2—oxopyrrolidinyl,
2—oxotetrahydrofuranyl, oxo—l,3—thiazolidinyl, piperazinyl, piperidyl, 2H—pyranyl, pyrazolyl,
pyridinyl, pyrrolyl, pyrrolidinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyridazinyl, 4—pyridonyl,
tetrahydrofuranyl, tetrahydropyranyl, lyl, l,3,4—thiadiazolyl, thiazolidinyl,
thiomorpholinyl, thiophenyl, 4H—l,2,4—triazolyl, pyridine—N—oxidyl, tetrazolyl, oxadiazolyl,
triazolyl, pyrazinyl, triazinyl, and homopiperidinyl. In one embodiment, the terms “5—7
membered heterocyclyl” and “5—6 membered heterocyclyl” includes siderophores of 5—7 or 5—
6 members which contain at least one heteroatom.
— or 6—Membered Heteroaryl —The term “5—6 membered heteroaryl” refers to a monocyclic,
aromatic heterocyclyl ring containing 5 or 6 ring atoms, of which at least one ring atom is
selected from nitrogen, sulfur, and oxygen. Unless otherwise specified, “5—6 membered
WO 53215
heteroaryl” groups may be carbon or nitrogen linked. Ring nitrogen atoms may be ally
oxidized to form an N—oxide. Ring sulfur atoms may be optionally oxidized to form
S—oxides. rative examples of “5—6 membered heteroaryl” include furanyl, imidazolyl,
isothiazolyl, isoxazole, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, dinyl, pyridinyl,
pyrrolyl, tetrazolyl, azolyl, thiazolyl, enyl, and triazolyl.
Optionally substituted — As used herein, the phrase "optionally substituted" indicates that
substitution is optional and therefore it is le for the designated group to be either
substituted or unsubstituted. In the event a substitution is desired, the appropriate number of
hydrogens on the designated group may be replaced with a selection from the indicated
tuents, provided that the normal valency of the atoms on a particular substituent is not
exceeded, and that the substitution results in a stable compound.
In one aspect, when a particular group is designated as being optionally tuted with one
or more substituents, the particular group may be unsubstituted. In another , the
particular group may bear one substituent. In another aspect, the particular substituent may
bear two substituents. In still another aspect, the ular group may bear three substituents.
In yet another aspect, the particular group may bear four substituents. In a further aspect, the
particular group may bear one or two substituents. In still a further aspect, the particular
group may be unsubstituted, or may bear one or two substituents.
Pharmaceutically Acceptable — As used herein, the phrase "pharmaceutically acceptable"
refers to those compounds, materials, compositions, and/or dosage forms which are, within
the scope of sound medical judgment, suitable for use in contact with the tissues of human
beings and animals without excessive toxicity, irritation, allergic response, or other problem
or complication, commensurate with a reasonable benefit/risk ratio.
Mg— As used herein, the term “prodrug” refers to a chemically modified version of a
cologically active agent that is transformed in vivo to e an active drug. (See
Rautio, J., et al., Prodrngs: Design and Clinical Applications, Nature Rev., vol. 7, page 255
(March 2008)). In the present invention, prodrugs are used to make active beta—lactamase
inhibitor compounds orally bioavailable following absorption from the gastrointestinal tract.
Effective Amount — As used , the phrase "effective amount" means an amount of a
compound or composition which is sufficient enough to significantly and positively modify
the symptoms and/or conditions to be treated (e.g., provide a positive clinical response). The
effective amount of an active ient for use in a pharmaceutical ition will vary
with the particular condition being treated, the severity of the condition, the duration of the
treatment, the nature of concurrent therapy, the particular active ingredient(s) being
employed, the particular pharmaceutically—acceptable excipient(s)/carrier(s) utilized, and like
factors within the knowledge and expertise of the ing physician.
Compounds of Formulae (I), (Ia), (II), (Ila), (III), (Illa), (IV), (IVa), (V), and (Va) may form
stable pharmaceutically acceptable acid or base salts, and in such cases administration of a
nd as a salt may be appropriate. Examples of acid addition salts include acetate,
adipate, ascorbate, benzoate, benzenesulfonate, bicarbonate, bisulfate, butyrate, camphorate,
camphorsulfonate, choline, citrate, cyclohexyl sulfamate, diethylenediamine, ethanesulfonate,
fumarate, glutamate, ate, lfate, 2—hydroxyethylsulfonate, oate, ate,
hloride, hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate,
methanesulfonate, meglumine, 2—naphthalenesulfonate, nitrate, oxalate, pamoate, persulfate,
phenylacetate, phosphate, diphosphate, picrate, pivalate, propionate, quinate, salicylate,
stearate, succinate, sulfamate, sulfanilate, e, tartrate, tosylate (p—toluenesulfonate),
trifluoroacetate, and undecanoate. Examples of base salts include ammonium salts; alkali
metal salts such as , lithium and potassium salts; alkaline earth metal salts such as
aluminum, calcium and magnesium salts; salts with organic bases such as dicyclohexylamine
salts and N—methyl—D—glucamine; and salts with amino acids such as ne, lysine,
omithine, and so forth. Also, basic nitrogen—containing groups may be quatemized with such
agents as: lower alkyl halides, such as methyl, ethyl, , and butyl halides; dialkyl
sulfates such as dimethyl, diethyl, dibutyl; diamyl sulfates; long chain halides such as decyl,
lauryl, myristyl and stearyl halides; arylalkyl halides such as benzyl bromide and others.
Non—toxic physiologically—acceptable salts are preferred, although other salts may be useful,
such as in isolating or ing the product.
The salts may be formed by conventional means, such as by reacting the free base form of the
product with one or more equivalents of the appropriate acid in a t or medium in which
the salt is insoluble, or in a solvent such as water, which is removed in vacuo or by freeze
drying or by exchanging the anions of an existing salt for another anion on a suitable
ion—exchange resin.
When a compound disclosed herein is depicted by name or structure and has one or more
chiral centers, and where the name or ure encompasses more than one stereoisomer,
e.g., does not indicate the chemistry at one or more chiral centers, it is to be understood
that the name or structure encompasses all such stereoisomers and mixtures thereof.
The synthesis of optically active forms may be carried out by standard techniques of organic
chemistry well known in the art, for example by synthesis from optically active starting
materials or by resolution of a racemic form. Racemates may be separated into individual
enantiomers using known ures (see, for example, Advanced c Chemistry: 3rd
Edition: author J March, plO4—lO7). A le procedure involves formation of
reomeric derivatives by reaction of the racemic material with a chiral auxiliary,
followed by separation, for example by chromatography, of the diastereomers and then
cleavage of the auxiliary species. Similarly, the above—mentioned activity may be evaluated
using the standard tory techniques referred to after.
Stereoisomers may be separated using conventional techniques, e.g. chromatography or
fractional crystallisation. The enantiomers may be isolated by tion of a racemate for
example by fractional crystallisation, resolution or HPLC. The diastereoisomers may be
isolated by separation by virtue of the different physical properties of the diastereoisomers,
for example, by fractional crystallisation, HPLC or flash chromatography. Alternatively
particular stereoisomers may be made by chiral synthesis from chiral starting materials under
conditions which will not cause racemisation or epimerisation, or by derivatisation, with a
chiral reagent.
When a specific isomer is designated, structurally or by name, it is favorably provided
or ntially isolated from other stereoisomers of the same compound. In one aspect, a
mixture containing a particular stereoisomer of a compound of Formulae (I), (Ia), (II), (Ila),
(III), (Illa), (IV), (IVa), (V), or (Va) may contain less than 30%, particularly less than 20%,
and more particularly less than 10% by weight of other stereoisomers of the same compound.
In another aspect, a e containing a particular stereoisomer of a compound of ae
(I), (la), (II), (IIa), (III), (IIIa), (IV), (IVa), (V), or (Va) may contain less than 6%, particularly
less than 3%, and more ularly less than 2% by weight of other stereoisomers of the
compound. In another aspect, a mixture containing a particular stereoisomer of a compound
of Formulae (I), (Ia), (II), (Ila), (III), , (IV), (IVa), (V), or (Va) may contain less than
1%, particularly less than 0.5%, and more particularly less than 0.3%, and still more
particularly less 0.1% by weight of other stereoisomers of the compound.
In one aspect, the terms “infection” and “bacterial infection” may refer to a gynecological
infection. In another aspect the terms “infection” and “bacterial infection” may refer to a
respiratory tract infection (RTI). In still another, the terms “infection” and “bacterial
infection” may refer to a sexually transmitted disease. In yet another aspect, the terms
“infection” and “bacterial ion” may refer to an uncomplicated urinary tract infection
(UTI). In yet another aspect, the terms tion” and “bacterial infection” may refer to a
complicated urinary tract infection (cUTI). In a further aspect, the terms “infection” and
“bacterial infection” may refer to acute exacerbation of chronic bronchitis (ACEB). In yet a
further aspect, the terms tion” and “bacterial infection” may refer to acute otitis media.
In one aspect, the terms “infection” and “bacterial infection” may refer to acute sinusitis. In
another aspect, the terms “infection” and “bacterial ion” may refer to an ion
caused by drug resistant bacteria. In still another aspect, the terms “infection” and “bacterial
infection” may refer to catheter—related sepsis. In yet another aspect, the terms “infection”
and “bacterial infection” may refer to chancroid. In a r aspect, the terms “infection”
and “bacterial infection” may refer to chlamydia. In still a further aspect, the terms
“infection” and “bacterial infection” may refer to community—acquired pneumonia (CAP). In
yet a further aspect, the terms “infection” and “bacterial ion” may refer to complicated
skin and skin ure infection. In one aspect, the terms “infection” and “bacterial
infection” may refer to uncomplicated skin and skin ure infection ($881). In another
aspect, the terms “infection” and “bacterial infection” may refer to endocarditis. In still
another aspect, the terms “infection” and “bacterial infection” may refer to e
neutropenia. In yet another aspect, the terms “infection” and “bacterial infection” may refer
to gonococcal cerVicitis. In a further aspect, the terms “infection” and “bacterial infection”
may refer to ccal urethritis. In still a further aspect, the terms tion” and
“bacterial infection” may refer to hospital—acquired pneumonia (HAP). In yet another ,
the terms “infection” and “bacterial infection” may refer to osteomyelitis. In a further aspect,
the terms “infection” and “bacterial infection” may refer to sepsis. In still a further aspect,
the terms “infection” and “bacterial infection” may refer to syphilis. In a further aspect, the
terms “infection” and “bacterial infection” may refer to an abdominal infection (IAI).
In one aspect of the invention, the terms “infection” and “bacterial infection” may refer to an
infection selected from the group ting of complicated y tract ion,
uncomplicated urinary tract infection, kidney infection, lower respiratory tract infection,
al—acquired bacterial pneumonia, pneumonia, acute bacterial prostatitis, acute bacterial
skin and soft tissue infection, sepsis, intra—abdominal infection, and diabetic foot infection.
In one embodiment of the invention, the terms “infection” and “bacterial infection” refer to
an infection caused by Gram—negative bacteria, also referred to as a “Gram—negative
infection”. In one aspect of this ment, the Gram—negative infection is an infection
resistant to one or more antibiotics. In one aspect of this embodiment, the Gram—negative
infection is a multi—drug resistant infection. In one aspect of this embodiment, the Gram—
negative ion is caused by one or more Enterobacteriaceae spp. pathogens. In one
aspect of this embodiment, the one or more Enterobacteriaceae spp. pathogens includes one
or more E. coli, K. pneumoniae, K. oxytoca, C. freundii, C. koseri, E. cloacae, P. mirabilis,
M. morganii and/or S. marcescens. In one aspect of this ment, the one or more
Enterobacteriaceae spp. ens includes one or more E. coli or K. pneumoniae en.
In another aspect of this embodiment, the Gram—negative ion is caused by one or more
biothreat pathogens. In one aspect of this embodiment, the one or more biothreat pathogens
is Burkholderia spp., Y. pestis, and/or F. nsis. In any of these aspects of the
embodiment, the one or more egative pathogens may express one or more serine beta—
lactamase enzymes. In one aspect of this embodiment, the one or more serine beta—lactamase
enzymes includes one or more Class A, Class C and/or Class D beta—lactamase.
All the above mentioned infections can be caused by a variety of bacteria that potentially
could be treatable with the claimed agents in combination with penicillin—binding protein
inhibitors, or by itself. In one embodiment of the invention is a method of treating one or
more of the infections listed above comprising administering to a subject suffering from a
bacterial infection an effective amount of a compound of Formulae (I), (Ia), (II), (IIa), (III),
(IIIa), (IV), (IVa), (V), or (Va) or a pharmaceutically acceptable salt thereof, in combination
with an additional antibiotic agent. In one aspect of this embodiment, the additional
antibiotic agent is a actam antibiotic. In one aspect of this embodiment, the additional
antibiotic agent is a penicillin—binding protein inhibitor.
In one , there is provided the use of a compound of Formulae (I), (la), (II), (Ila), (III),
, (IV), (IVa), (V), or (Va), or a pharmaceutically acceptable salt thereof, in the
manufacture of a medicament for the production of a bacterial peptidoglycan inhibitory
effect, either alone or in combination with a penicillin—binding protein inhibitor, in a
warm—blooded animal such as man.
In another aspect, there is provided the use of a compound of Formulae (I), (Ia), (II), (IIa),
(III), (IIIa), (IV), (IVa), (V), or (Va), or a pharmaceutically acceptable salt thereof, in the
manufacture of a medicament for the treatment of a bacterial infection in a warm—blooded
animal such as man. In one , the compound of Formulae (I), (Ia), (II), (IIa), (III), (IIIa),
(IV), (IVa), (V), or (Va), or a pharmaceutically acceptable salt thereof, is administered in
combination with an additional antibiotic agent, such as a beta—lactam antibiotic. In one
aspect of this embodiment, the additional antibiotic agent is a penicillin—binding protein
inhibitor. In one aspect of this embodiment, the additional antibiotic agent is a beta—lactam
antibiotic. In one aspect of this embodiment, the beta—lactam antibiotic is selected from
cefpodoxime, cefuroxime, tigemonam, loracarbef, cefixime, cephaleXin, cefadroxil,
cefetamet, cefprozil, ceftibuten, cefditoren, faropenem, tebipenem, amoxicillin, carbenicillin,
cefdinir, ampicillin, oren, or a prodrug thereof. In one aspect of this embodiment, the
beta—lactam antibiotic is cefpodoxime proxetil. In one aspect of this ment, the beta—
lactam antibiotic is cefuroxime axetil. In one aspect of this embodiment, the beta—lactam
antibiotic is cefpodoxime, or a prodrug thereof. In one aspect of this embodiment, the beta—
lactam antibiotic is cefuroxime, or a prodrug f.
In still r , there is provided the use of a compound of Formulae (I), (Ia), (II),
(IIa), (III), (IIIa), (IV), (IVa), (V), or (Va), or a pharmaceutically acceptable salt thereof, in
the cture of a medicament for the treatment of complicated urinary tract infection,
uncomplicated urinary tract infection, kidney infection, lower respiratory tract infection,
hospital—acquired bacterial pneumonia, pneumonia, acute bacterial prostatitis, acute bacterial
skin and soft tissue infection, sepsis, intra—abdominal infection, and diabetic foot infections,
in a looded animal such as man. In one aspect of the ion, is the use of a
compound of Formulae (I), (Ia), (II), (IIa), (III), (IIIa), (IV), (IVa), (V), or (Va), or a
pharmaceutically able salt f, in the manufacture of a medicament for the
treatment of complicated urinary tract infections. In one aspect of the preceding two
embodiments, the nd of Formulae (I), (Ia), (II), (IIa), (III), (IIIa), (IV), (IVa), (V), or
(Va) is stered in combination with an additional antibiotic agent. In one aspect of this
embodiment, the additional antibiotic agent is a penicillin—binding protein inhibitor. In one
aspect of this embodiment, the additional antibiotic agent is a beta—lactam antibiotic. In one
aspect of this embodiment, the beta—lactam antibiotic is selected from oxime,
cefuroxime, tigemonam, loracarbef, cefiXime, cephaleXin, cefadroxil, cefetamet, cefprozil,
uten, cefditoren, nem, tebipenem, amoxicillin, carbenicillin, cefdinir, ampicillin,
cefditoren and prodrugs f. In one aspect of this embodiment, the beta—lactam otic
is cefpodoxime proxetil. In one aspect of this embodiment, the beta—lactam antibiotic is
xime axetil. In one aspect of this embodiment, the beta—lactam otic is
cefpodoxime, or a prodrug thereof. In one aspect of this embodiment, the actam
antibiotic is cefuroxime, or a prodrug thereof.
In another aspect, there is provided a method for producing a bacterial peptidoglycan
inhibitory effect, either alone or in combination with a penicillin—binding protein inhibitor, in
a warm—blooded animal such as man, said method comprising administering to said animal an
effective amount of a compound of Formulae (I), (Ia), (II), (IIa), (III), (IIIa), (IV), (IVa), (V),
or (Va), or a pharmaceutically acceptable salt f.
In a further aspect, there is provided a method for treating a bacterial infection in a warm—
blooded animal such as man, said method comprising administering to said animal an
effective amount of a compound of Formulae (I), (Ia), (II), (IIa), (III), (IIIa), (IV), (IVa), (V),
or (Va), or a pharmaceutically acceptable salt thereof. In one aspect of this embodiment, the
compound is as described for Formulae (I), (II), (III), (IV) or (V), or a pharmaceutically
acceptable salt thereof. In one aspect of this embodiment, for a compound of Formulae (I),
(II), (III), (IV) or (V), the compound is administered orally. In another aspect of this
embodiment, the compound of Formulae (I), (II), (III), (IV) or (V), or a pharmaceutically
acceptable salt thereof, is administered in combination with an additional antibiotic agent. In
one aspect of this ment, the additional otic agent is a penicillin—binding protein
inhibitor. In one , the additional antibiotic agent is a beta—lactam antibiotic. In one
aspect of this embodiment, the beta—lactam antibiotic is selected from cefpodoxime,
cefuroxime, tigemonam, loracarbef, cefiXime, cephaleXin, cefadroxil, cefetamet, cefprozil,
ceftibuten, cefditoren, nem, tebipenem, amoxicillin, carbenicillin, ir, ampicillin,
cefditoren and prodrugs thereof. In one aspect of this embodiment, the beta—lactam antibiotic
is cefpodoxime proxetil. In one aspect of this embodiment, the beta—lactam antibiotic is
xime axetil. In one aspect of this ment, the beta—lactam antibiotic is
oxime, or a prodrug thereof. In one aspect of this embodiment, the beta—lactam
antibiotic is cefuroxime, or a prodrug thereof.
In a further embodiment, there is provided a method for treating a bacterial infection in a
subject in need f, comprising administering to the subject an ive amount of a
compound of Formulae (Ia), (IIa), (IIIa), (IVa) or (Va), or a pharmaceutically acceptable salt
thereof enously, intraperitoneally, intramuscularly or subcutaneously, preferably
intravenously. As such, a compound of Formulae (Ia), (IIa), (IIIa), (IVa) or (Va), or a
pharmaceutically acceptable salt thereof are advantageously used when a patient is not able to
take medication by mouth, e.g., in a hospital setting (e.g., in an intensive care unit, an
ncy room setting, on a cardiology floor and the like), in an urgent care setting and a
nursing home setting. In one aspect of this embodiment, the compound of Formulae (Ia),
(IIa), (IIIa), (IVa) or (Va), or a pharmaceutically acceptable salt thereof, is stered
intravenously (IV). In one apsect of this embodiment, the compound of Formulae (Ia), (IIa),
(IIIa), (IVa) or (Va), or a pharmaceutically acceptable salt thereof, is administered until the
patient is able to take medication orally, e.g.,for the duration of the al stay or urgent
care stay, until such time the subject is able to be discharged from a hospital setting or urgent
care setting or until such time until the t’s condition has improved so that the t
can take medication orally, e.g., until the patient is able to orally take medication in a nursing
home setting. In one aspect of this embodiment, the nd of Formulae (Ia), (IIa),
(IIIa), (IVa) or (Va), or a ceutically acceptable salt thereof, is administered with a
beta—lactam antibiotic. In one aspect of this embodiment, the beta—lactam antibiotic is
selected from oxime, cefuroxime, tigemonam, loracarbef, cefixime, cephaleXin,
cefadroxil, cefetamet, cefprozil, uten, cefditoren, faropenem, tebipenem, amoxicillin,
carbenicillin, cefdinir, ampicillin, cefditoren and prodrugs thereof. In one aspect of this
ment, the beta—lactam otic is cefpodoxime, or a prodrug thereof. In one aspect
of this embodiment, the beta—lactam antibiotic is cefuroxime, or a prodrug thereof. In another
aspect of this embodiment, the method further comprises administering an effective amount
of a compound of Formula (I), (II), (III), (IV) or (V), or a pharmaceutically acceptable salt
thereof, to the subject in a community setting, after discharge from the hospital setting or
urgent care setting or When the subject has improved sufficiently so that the subject is able to
take medication orally, e.g., in a nursing home setting. In one aspect of this embodiment, the
compound of Formula (I), (II), (III), (IV) or (V), or a pharmaceutically acceptable salt
thereof, is administered orally in a community setting. In one aspect of this embodiment, the
compound of Formula (I), (II), (III), (IV) or (V), or a pharmaceutically acceptable salt
thereof, is administered in combination with the same beta—lactam otic that the
compound of Formulae (Ia), (Ila), (Illa), (IVa) or (Va) is paired with in the hospital setting,
urgent care setting or nursing home g. In one aspect of this embodiment, the
administration of a compound of Formulae (Ia), (IIa), (IIIa), (IVa) or (Va) is followed by oral
administration of a compound of a (I), (II), (III), (IV) or (V), or a pharmaceutically
able salt thereof, once the t is able to take medication by mouth, e.g., once the
patient has been discharged from the hospital setting or urgent care setting and is in a
community setting or whose condition has sufficiently improved in a g home setting to
orally take medication. Preferably, the switch from intravenous, intraperitoneal,
intramuscular or subcutaneous (compound of Formulae (Ia), (IIa), (IIIa), (IVa) or (Va)) to
oral administeration (compound of Formulae (I), (II), (III), (IV) or (V)) occurs without any
gaps in the ent of the patient.
In still a further aspect, there is provided a method for treating complicated urinary tract
infection, uncomplicated urinary tract infection, kidney infection, lower respiratory tract
infection, hospital—acquired bacterial pneumonia (HAP), pneumonia, acute bacterial
prostatitis, acute ial skin and soft tissue infection, , intra—abdominal infection, and
diabetic foot infections, in a warm—blooded animal such as man, said method sing
administering to said animal an effective amount of a compound of Formulae (I), (Ia), (II),
(IIa), (III), (IIIa), (IV), (IVa), (V), or (Va), or a pharmaceutically acceptable salt thereof. In
still a further aspect, there is provided a method for treating complicated urinary tract
infections, in a warm—blooded animal such as man, said method comprising administering to
said animal an effective amount of a compound of Formulae (I), (Ia), (II), (IIa), (III), (IIIa),
(IV), (IVa), (V), or (Va), or a pharmaceutically acceptable salt thereof. In one aspect of
either of the preceeding embodiment, the compound of Formulae(I), (Ia), (II), (IIa), (III),
(IIIa), (IV), (IVa), (V), or (Va), or a pharmaceutically acceptable salt thereof, is administered
in combination with an additional antibiotic agent. In one aspect of this ment, the
additional antibiotic agent is a penicillin—binding protein inhibitor. In one , the
additional antibiotic agent is a beta—lactam antibiotic. In one aspect of this embodiment, the
beta—lactam antibiotic is selected from cefpodoxime, cefuroxime, tigemonam, loracarbef,
cefiXime, cephaleXin, cefadroxil, cefetamet, cefprozil, ceftibuten, cefditoren, faropenem,
nem, illin, carbenicillin, cefdinir, ampicillin, cefditoren and prodrugs thereof. In
one aspect of this embodiment, the actam antibiotic is oxime proxetil. In one
aspect of this embodiment, the beta—lactam otic is cefuroxime axetil. In one aspect of
this embodiment, the beta—lactam antibiotic is cefpodoxime, or a prodrug f. In one
aspect of this embodiment, the beta—lactam antibiotic is cefuroxime, or a prodrug thereof.
In yet a further aspect, there is provided a compound of Formulae (I), (la), (II), (Ila), (III),
(IIIa), (IV), (IVa), (V), or (Va), or a ceutically acceptable salt thereof, for use in
producing a bacterial peptidoglycan inhibitory effect, either alone or in combination with a
penicillin—binding protein inhibitor, in a warm—blooded animal such as man. In one aspect,
there is provided a nd of Formulae (I), (la), (II), (Ila), (III), (IIIa), (IV), (IVa), (V), or
(Va), or a pharmaceutically acceptable salt thereof, for use in treating egative
bacterial infections, either alone or in combination with a beta—lactam antibiotic. In one
aspect of this embodiment, the beta—lactam antibiotic is selected from cefpodoxime,
cefuroxime, nam, loracarbef, cefiXime, cephaleXin, cefadroxil, cefetamet, cefprozil,
ceftibuten, cefditoren, faropenem, tebipenem, amoxicillin, carbenicillin, cefdinir, ampicillin,
cefditoren and prodrugs thereof. In one aspect of this embodiment, the actam antibiotic
is cefpodoxime proxetil. In one aspect of this embodiment, the beta—lactam antibiotic is
cefuroxime axetil. In one aspect of this embodiment, the beta—lactam antibiotic is
cefpodoxime, or a prodrug thereof. In one aspect of this ment, the beta—lactam
antibiotic is cefuroxime, or a prodrug thereof.
In one aspect of the invention, there is provided a method of inhibiting one or more beta—
lactamase enzyme comprising administering a compound of Formulae (I), (la), (II), (Ila),
(III), (IIIa), (IV), (IVa), (V), or (Va), or a pharmaceutically acceptable salt thereof, to an
animal in need thereof. In a further aspect, the one or more beta—lactamase enzyme is a serine
beta—lactamase enzyme. In a further aspect, the one or more beta—lactamase enzyme is
selected from the group ting of Class A, Class C and Class D. In a further asepct, the
one or more beta—lactamase enzyme is a Class A enzyme. In a further aspect, the one or more
beta—lactamase enzyme is a Class C enzyme. In a further asepct, the one or more beta—
lactamase enzyme is a Class D enzyme. In a further aspect, the one or more beta—lactamase
enzyme is a Class D enzyme and one or more of Class A and C s. In a further aspect,
the one or more beta—lactamase enzyme is all three of Class A, C and D enzymes.
The beta—lactamase inhibitors of Formulae (I), (Ia), (II), (Ila), (III), (IIIa), (IV), (IVa), (V), or
(Va) can be administered in combination with any beta—lactam antibiotic belonging, but not
d to, the classes of clavams, carbapenems, monobactams, penems, penicillins, and or
cephalosporins, or with any other compound susceptible to serine beta—lactamases. In one
aspect of the invention, a nd of Formulae (I), (Ia), (II), (Ila), (III), (IIIa), (IV), (IVa),
(V), or (Va) is combined with one or more of: penicillin, methicillin, oxacillin, nafcillin,
cloxacillin, dicloxacillin, flucloxacillin, temocillin, amoxicillin, ampicillin, co—amoxiclav,
azlocillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, cephalexin, cephalothin, CXA—
lOl, cefazolin, cefaclor, cefuroxime, cefamandole, cefotetan, cefoxitin, ceftriaxone,
cefotaXime, oxime, cefiXime, ceftazidime, ceftobiprole medocaril, cefepime,
cefpirome, ceftaroline, imipenem, meropenem, ertapenem, faropenem, sulopenem,
nem, PZ—601 (Protez Pharmaceuticals), ME1036 (Forest Labs), BAL30072, MC—l,
tomopenem, tebipenemn, aztreonam, nam, nocardicin A, or tabtoxinine—beta—lactam.
In one aspect of the invention, a compound of Formulae (I), (Ia), (II), (IIa), (III), (IIIa), (IV),
(IVa), (V), or (Va) is combined with cefpodoxime, cefuroxime, nam, cefixime or
faropenem. In one aspect of the invention, a compound of Formulae (I), (Ia), (II), (IIa), (III),
(IIIa), (IV), (IVa), (V), or (Va) is combined with an antibacterial nd from the group
consisting of penicillin V, illin, dicloxacillin, nafcillin, oxacillin, amoxicillin,
ampicillin, bacampicillin, amoxicillin—clavulanate, carbenicillin, cefadroxil, cephaleXin,
cephradine, or, cefprozil, cefuroxime , ir, loracabef, cefiXime, cefpodoxime,
and ceftibuten, or a prodrug or salt thereof. In one aspect of the invention, a compound of
Formulae (I), (Ia), (II), (IIa), (III), (IIIa), (IV), (IVa), (V), or (Va) is combined with an
antibacterial compound from the group consisting of cefpodoxime, xime, tigemonam,
loracarbef, cefixime, cephalexin, cefadroxil, cefetamet, cefprozil, ceftibuten, cefditoren,
faropenem, tebipenem, amoxicillin, carbenicillin, cefdinir, ampicillin, oren and
prodrugs thereof. In one aspect of the invention, a nd of Formulae (I), (Ia), (II), (IIa),
(III), , (IV), (IVa), (V), or (Va) is combined with cefpodoxime, or a prodrug thereof,
such as cefpodoxime proxetil. In one aspect of the invention, a nd of Formulae (I),
(Ia), (II), (IIa), (III), , (IV), (IVa), (V), or (Va) is combined with cefuroxime or a
g thereof, such as cefuroxime axetil.
In another aspect of the invention, the compound of Formulae (I), (II), (III) or (IV) is
administered in combination with a beta—lactam antibiotic and an additional antibiotic and/or
an additional beta—lactamase inhibitor. In one aspect of the invention, the additional
antibiotic agent is selected from one of the classes of aminoglycosides, spectinomycins,
macrolides, ketolides, streptogramins, oxazolidinones, tetracyclines, fluoroquinolones,
quinolones, coumarin antibiotics, eptides, lipoglycopeptides, nitroimidazoles,
ansamycins, phenicols, mupirocyn, ycin, ycin, linezolid, daptomycin,
vancomycin, beta—lactams and the classes mentioned in ANTIMICROBIAL AGENTS (ASM
Press, Ed: A. Bryskier (2005)).
In one aspect of the invention, the compound of Formulae (I), (Ia), (II), (IIa), (III), (IIIa),
(IV), (IVa), (V), or (Va) is administered in combination with a beta—lactam antibiotic and a
second agent which is designed to address beta—lactam resistance. In one aspect of the
invention, the second agent ed to s beta—lactam resistance may be a o—beta—
lactamase (MBL) inhibitor, also known as a Class B inhibitor.
In one aspect, there is provided a compound of Formulae (I), (Ia), (II), (IIa), (III), (IIIa), (IV),
(IVa), (V), or (Va), or a pharmaceutically acceptable salt f, for use in treating a
bacterial infection in a warm—blooded animal, such as man.
In another aspect, there is provided a nd of Formulae (I), (Ia), (II), (IIa), (III), (IIIa),
(IV), (IVa), (V), or (Va), or a pharmaceutically able salt thereof, for use in treating
complicated urinary tract infection, uncomplicated y tract infection, kidney infection,
lower respiratory tract infection, hospital—acquired bacterial pneumonia, pneumonia, acute
bacterial prostatitis, acute bacterial skin and soft tissue infection, sepsis, abdominal
infection, and diabetic foot infections, in a warm—blooded animal such as man. In another
aspect, there is provided a compound of Formulae (I), (la), (II), (IIa), (III), (IIIa), (IV), (IVa),
(V), or (Va), or a pharmaceutically acceptable salt thereof, for use in treating cated
urinary tract infections in a warm—blooded animal such as man.
In still another , there is provided a pharmaceutical composition comprising a
compound of Formulae (I), (Ia), (II), (IIa), (III), (IIIa), (IV), (IVa), (V), or (Va), or a
pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier,
diluent, or excipient. In one aspect of this embodiment, the pharmaceutical composition
further comprises a beta—lactam antibiotic. In one apsect of this embodiment, the beta—lactam
antibiotic is selected from cefpodoxime, xime, tigemonam, loracarbef, cefiXime,
cephalexin, cefadroxil, cefetamet, cefprozil, ceftibuten, cefditoren , faropenem, tebipenem,
illin, carbenicillin, cefdinir, ampicillin, cefditoren and prodrugs thereof.
The compositions of the invention may be in a form suitable for oral use (for example as
tablets, lozenges, hard or soft capsules, s or oily suspensions, emulsions, dispersible
powders or granules, syrups or elixirs), for topical use (for example as creams, ointments,
gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for
e as a finely divided powder or a liquid aerosol), for administration by insufflation
(for example as a finely divided powder) or for parenteral administration (for example as a
sterile aqueous or oily solution for enous, subcutaneous, intramuscular or intramuscular
dosing or as a suppository for rectal dosing). In one aspect of the invention, the compound of
Formulae (Ia), (Ila), , (IVa), or (Va), or a pharmaceutically acceptable salt thereof, is
administered intravenously. In another aspect of the invention, the compound of Formulae
(Ia), (IIa), (IIIa), (IVa), or (Va), or a ceutically acceptable salt thereof, is administered
intravenously in combination with one or more other antibacterial agent. In one aspect of the
invention, the compound of Formulae (I), (II), (III), (IV), or (V), or a pharmaceutically
acceptable salt thereof, is administered orally. In another aspect of the ion, the
compound of Formulae (I), (II), (III), (IV), or (V), or a pharmaceutically acceptable salt
thereof, is stered orally in combination with one or more other antibacterial agent. In
one aspect of any of these embodiments, the compound of Formulae (I), (Ia), (II), (IIa), (III),
(IIIa), (IV), (IVa), (V), or (Va), or a pharmaceutically acceptable salt f, is administered
simultaneously with one or more other cterial agents. In another aspect of this
embodiment, the compound of Formulae (I), (Ia), (II), (IIa), (III), (IIIa), (IV), (IVa), (V), or
(Va), or a pharmaceutically acceptable salt thereof, is administered consecutively with one or
more other antibacterial agents, such as a beta—lactam antibiotic.
In one embodiment of the invention is a method of treating a bacterial infection in a person in
need thereof, comprising administering to said person an effective amount of a compound of
one of Formulae (Ia), (IIa), (IIIa), (IVa) or (Va) intravenously in combination with one or
more additional antibacterial agent in a hospital setting, urgent care setting or nursing home
setting ed by administering to said person an ive amount of a compound of one of
Formulae (I), (II), (III), (IV) or (V) orally in combination with one or more additional
antibacterial agent outside of, for example, a hospital setting, urgent care g or nursing
home setting once the patient is again able to take medication by mouth.
In one embodiment of the invention is a method of treating a bacterial infection in a person in
need thereof, comprising orally administering to said person an ive amount of a
compound of one of Formulae (I), (II), (III), (IV) or (V) in combination with one or more
additional antibacterial agent as an oral switch therapy following administering to said person
an effective amount of one or more intravenously, intraperitoneally, intramuscularly or
aneously —administered antibacterial agent, e.g., a compound of Formulae (Ia), (Ila),
(Illa), (IVa) or (Va) or a pharmaceutically acceptable salt thereof. The , dose and
duration of the antibiotic therapy and timing to switch from an intravenous, intraperitoneal,
intramuscular or subcutaneous to oral medication are usually chosen by physician and can
depend on the patient’ s health, his or her ability to receive an oral ent and the type of
infections from which said person suffers. The patient may be switched from intravenous,
intraperitoneal, intramuscular or subcutaneous to oral treatment when the patient becomes
asymptomatic, has no fever or reduced fever (e.g., below 100.5O F, 1000 F, 99.50 F and the
like), is removed from a ventilator or is no longer in need of intravenous fluids.
The compositions of the ion may be obtained by conventional procedures using
tional pharmaceutical excipients well known in the art. Suitable pharmaceutically
acceptable ents for a tablet formulation include, for example, inert ts such as
lactose, sodium carbonate, calcium ate or calcium carbonate; granulating and
disintegrating agents such as corn starch or algenic acid; binding agents such as starch;
lubricating agents such as magnesium stearate, stearic acid or talc; vative agents such
as ethyl or propyl p—hydroxybenzoate; and anti—oxidants, such as ic acid. Tablet
formulations may be ed or coated either to modify their disintegration and the
subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve
their stability and/or appearance, in either case, using conventional coating agents and
procedures well known in the art.
The amount of active ingredient that is combined with one or more excipients to produce a
single dosage form will necessarily vary depending upon the host treated and the particular
route of administration. For example, a formulation intended for oral administration to
humans will generally contain, for example, active agent compounded with an appropriate
and convenient amount of excipients which may vary from about 5 to about 98 percent by
weight of the total composition. Dosage unit forms will generally contain about 100 mg to
WO 53215 2017/051692
about 4000 mg of an active ingredient. For oral administration, e.g., of compound of
Formulae (I), (II), (III), (IV) or (V) or pharmaceutically acceptable salts thereof, 01 g to 10 g
equiv of active ingredient per day are suitable; and for intravenous administration, e.g., of
compound of Formulae (Ia), (Ila), (Illa), (IVa) or (Va) or pharmaceutically acceptable salts
thereof, 0.5 to 8 g equiv of active ingredient per day are suitable.
In addition to the compounds of the present invention, the pharmaceutical composition of this
invention may also n or be co—administered (simultaneously, sequentially or separately)
with one or more known drugs selected from other ally useful classes of antibacterial
agents (for example, macrolides, quinolones, beta—lactams or aminoglycosides) and/or other
anti—infective agents (for example, an antifungal triazole or amphotericin). These may
include carbapenems, for example meropenem or imipenem, to broaden the therapeutic
iveness. Compounds of this invention may also contain or be inistered with
bactericidal/permeability—increasing protein (BPI) products or efflux pump inhibitors to
improve activity against Gram—negative bacteria and bacteria resistant to antimicrobial
agents.
As stated above the size of the dose ed for the therapeutic or prophylactic treatment of a
particular disease state will arily be varied depending on the host treated, the route of
administration and the severity of the illness being treated. Accordingly, the optimum dosage
may be determined by the practitioner who is treating any particular patient.
nds of Formulae (I), (Ia), (II), (IIa), (III), (IIIa), (IV), (IVa), (V), or (Va) may be
prepared in a variety of ways. The processes shown below illustrates a method for
synthesizing compounds of Formula (I) (wherein R1, R2, and R3 unless otherwise defined, are
as defined above). The reactions are performed in solvents appropriate to the reagents
and materials employed and are suitable for the transformations being effected. Also, in the
description of the synthetic methods described below, it is to be understood that all proposed
reaction conditions, including choice of solvent, reaction atmosphere, on temperature,
duration of the experiment and workup procedures, are chosen to be the conditions standard
for that reaction, which should be readily recognized by one skilled in the art. It is
understood by one d in the art of c synthesis that the functionality present on
various ns of the molecule must be compatible with the reagents and reactions
proposed. Such restrictions to the substituents, which are compatible with the reaction
conditions, will be readily apparent to one skilled in the art and alternate methods must then
be used. The Schemes and Processes are not intended to present an exhaustive list of
methods for preparing the compounds of Formulae (I), (Ia), (II), (Ila), (III), (Illa), (IV), (IVa),
(V), or (Va); rather, additional techniques of which the skilled chemist is aware may be also
be used for the compounds’ synthesis. The claims are not intended to be limited to the
structures shown in the Schemes and Processes.
It will also be appreciated that in some of the reactions shown in the Schemes and ses
mentioned herein, it may be necessary/desirable to protect any sensitive groups in
nds. The instances where protection is necessary or desirable are known to those
skilled in the art, as are suitable methods for such protection. Conventional protecting groups
may be used in ance with standard practice (for illustration see T.W. Greene,
Protective Groups in Organic sis, published by John Wiley and Sons, ) and as
described hereinabove.
The skilled chemist will be able to use and adapt the information contained and referenced
within the above references, and accompanying Examples therein and also the Examples and
Scheme herein, to obtain necessary starting als and products.
If not cially available, the necessary starting materials for the procedures such as
those described herein may be made by procedures which are selected from standard organic
chemical techniques, techniques which are ous to the synthesis of known, structurally
similar compounds, or techniques which are analogous to the described procedure or the
procedures described in the Examples.
It is noted that many of the starting materials for synthetic methods as described herein are
commercially available and/or widely reported in the scientific literature, or could be made
from commercially available compounds using adaptations of ses reported in the
scientific literature. The reader is further referred to Advanced Organic Chemistry, 5th
Edition, by Jerry March and Michael Smith, published by John Wiley & Sons (2001), for
l guidance on reaction ions and reagents.
WO 53215
l Procedures and Schemes:
In one aspect, compounds of Formulae (I) and (la), or pharmaceutically acceptable salts
thereof, may be prepared by the s outlined in Scheme 1. From the Weinreb amide,
introduction of substituents at the R3 position of Formulae (I) and (la) may be done Via a
Grignard reaction. The ester moieties can be introduced by palladium—catalyzed deallylation
followed by alkylation with cetates. Hydrolysis of the esters yield the acids.
atively, other R1 groups could be obtained by modifying the primary alcohol.
SCHEME 1:
[C3H5PdCI]2 9M9
H IIgand (RR) HO/V\ TBSCI N
N \
O Oll‘hthallmlde TBSO/\i/\ h drazine B
imidazole y r —
N32C03 DCM O O N
O MeOH’ 65C—,TBSO/\/\
DCM O Boc’ ;\
NH2 Boc20, DMF o N’O'V'e
primary amine i
Weinreb amide
2\ M /n, R3 //. R3 /n, R3
MgBr TBSO \ a-Grubbs TBSO GE TBSO '- \ AllONH-Ns, TBSO \
' 2nd gen_ cat. CeCI3,NaBH4, PPh3,DIAD,
THF, 0 C ,N N /N
Boc’ -, /N ,OA“
Boc %% toluene 65C OMeOH,OC Boc ’OH toluene, RT Boo N
ii i o
HO/IIHCER3 R3 R3
HO \ R8R7N \ RsRvNJLu. R3
TBAF N ’OA” Cr03,H5|06 N [OAII HNR7R8,HATU N ,OA” ZnBr
—» Boc’ [y — Boc’ 'i‘ _> Boc’ Ii] —2- HN N,OAII
Ns Ns Ns NS
primary alcohol
0 i 3
Jl, 1.PdPPh 3
, R 13l_dim:]{i1._,MeOH ii R3 i
R3 R8R7N \ R8R7N , \ , R
" '- LiOH, R8R7N '- \
R8R7N " \ '
- - y-
PhSH trIphosgene N barbIturIc aCId N THFHO
I 2 N
HN OAII R4 R4
N! /J—N\ 2. base, DMF /J—N\ R5 /]—N\ R5
H o OAII RARS o 0 OR‘3 0 O OH
BrJ$rOR6 O O
An alternative means of synthesizing compounds with substitution at R3 is shown in Scheme
2, with the key steps being a Diels—Alder reaction and a nitroso ene reaction.
SCHEME 2
H2N\S"\E O
(5) || j/RB(3'4 5C1) 0 O
o EtOJk" /
k )L,, R3 HCI J'n, R3 THF,'H20
Eto ’ EtO —> EtO ,
I N \\
0 ~”-s TMSOTf l (Boc)2O l
OQS’N Boc’N
DielsAlder 4:\
)L, R3 CDI NH OAc j, R3 302%? JL R3 TBSCI imi HzNJL’“ \
HO 0/ ,_4_, H2N " _2—’ H2“ " \ —' '
N OTBS
/N Boc
/N nitroso ene ,N ,OH
Boo Boo Boo N,
I}! Boo
R3 ‘i
ZnBr2 HZNJI’“ \ triphosgene HZNJI'“ R3
HN N,OTBS N
H N\
O OTBS
The acetate and ester moieties can be introduced in one or two steps according to Scheme 3.
SCHEME 3
HF, Py O OH O O
COZRs
In another aspect, compounds with formulae (1) and (la) or pharmaceutically acceptable salts
f, may be prepared by the process ed in Scheme 4, where substitution at R2 can be
installed Via a Michael addition to enone 1, followed by oxidation to afford enone 2, from
which the chemistry is r to that bed in Scheme 1.
SCHEME 4
R2 R2
1. R2Li, Cul
T350 (1 W," W
2. TMSCI, DIEA TBSO Pd(0AC)2 TBSO \
/N N
Boo 0 Bee” OTMS Boc’N o
enone 1 enone 2
Alternatively, the R1 amide can be installed after urea cyclization according to Scheme 5.
SCHEME 5
R2 R2 R2 R2
/’h, ZnBrZ /’I., PhSH /’I., tnphosgene' /”I.
TBSO \ TBSO \ TBSO \ TBSO \
,N ,OAII HN ,OAII HN ,OAII N
Boc N N N
I N
Ns Ns 0/ ‘
R2 j R2 2
Crog, H5|05 HNR7R8v HATU’ )0 R
TBAF HO/I' \ MHO L»R8R7N \
N\ N N‘
0/ OAII 0/ OAII 0/ 0A”
Compounds with tution at R2 can also be synthesized from ’s aldehyde as shown
in Scheme 6. The route from the primary amine to compounds with formulae (1) or (la) is
similar to Scheme 1.
SCHEME 6
O OH
O/\—// O
RZ-MgBrfl Dess- Martin 0/\—‘/<(|:W2WiLa.“ >LN1)TSOH0V2 TBSOAR2 AJL
2 ZnBr2 TBSO . R2
N‘ N‘ R _
—> :
2) BOCZO NH
Boo Boo Boo NH2
3) TBSCI
Additionally, compounds with substitution at R2 can be synthesized according to Scheme 7
below, Where the key step is a nitroso ene on. The amide can also be installed earlier in
the synthesis from the carboxylic acid and carried through to the end.
SCHEME 7
0 0
HOJfi + ||
\‘ S‘NH2
H20 0
1 4A sueves, DCM rt
., =
OH MeOH rt ('35 CH30H NH2
carboxylic acid
0 R2 0 F32 0 F32 JOL '
AIIyI-Br,LiOH \O)l,,,‘/\/ (Boc)20 \OJIII.,(:\/ RCM catalyst \OJLH Boo—NHOHVCUCI \o “d
I—> /N ,Boc
DMF,r1 HN\/\ tBuOH,requx Boc’NA DCM, rt Boo/N Py,02,DCM,rt Boc [i]
nitroso ene OH
R2 0 R2
o o R2
\O) IndL \ )L.
ZnBrz sgene O
—> —’ N
Boo/N BOC
'i" DCM,rt \OJLh'dHN N,OTBS DIEA,ACN,rt
The alkyl bromoacetates for introduction of the carboxylic acid and ester moieties can be
prepared by transesterification according to Scheme 8.
SCHEME 8
R4 R5 4 5
RBOH R R
WW0“ —’ Brxir0R6 KOtBu
o o
Chiral bromofluoroacetates for introduction of the R and S fluorocarboxylic acid and ester
es can be prepared by recrystallization of bromofluoroacetic acid with a chiral
ethanamine followed by esterification according to Scheme 9.
SCHEME 9
F F F F
CHCI -
Br/SrOEt —>NaOH Br/KrfOH NH2 3 (R) o- (S) R OH, Meglel6
Br 3
—>Br (R)
O o Recrystallization o EH43 o
times in CHCI3
In any of the above—mentioned pharmaceutical compositions, processes, methods, uses,
medicaments, and manufacturing features of the instant invention, any of the alternate
embodiments of the compounds of the invention described herein also apply. For e,
further details and method of ming the nitroso ene reaction on a variety of substrates
are as described below in the example section. These details and methods include e.g., a first
process for forming a compound of the formula VI:
R1,," R3
N PG'
OH (VI);
or a salt thereof, n
R1 is —C(O)NR7R8, —C(O)OR7, —CHZOR7, —CN, phenyl, a 5—6 membered heteroaryl, —
C(O)NR’NR’C(O)R9, —C(O)NR’OR10, or a C1—C6 alkyl group, wherein the alkyl group is
tuted with one to three groups consisting of halo, C1—C3 alkoxy, —OH, —CN, —NR7R8,
—NR7COR9, a 5—6 membered heteroaryl and a 5—7 membered heterocyclyl, and wherein the
phenyl and heteroaryl represented by R1 are optionally and independently substituted with l—
3 groups selected from halo, —OH, C1—C3 alkoxy, —CN, —NR7R8, and R8;
R2 and R3 are each independently selected from hydrogen, halo, C1—C3 alkyl, and C3—
C6 cycloalkyl, ed that at least one of R2 and R3 is other than hydrogen;
each R7 and R8 are independently hydrogen, C1—C3 alkyl, C1—C3 alkoxy, phenyl, C3—C6
lkyl, 4—7 membered heterocyclyl, or 5—6 membered heteroaryl, wherein the alkyl,
alkoxy, , cycloalkyl, heterocyclyl or aryl represented by R7 or R8 is optionally
and independently substituted with 1—6 groups selected from a 5—6 membered heterocyclyl
optionally substituted with one or two —F atoms, carboxyl or —CO(OC1—6 alkyl), 5—6
ed heteroaryl, —CN, —OH, C1—C3 alkyl optionally tuted with —NH2 or —OH, C1—
C3 haloalkyl, C1-C3 haloalkoxy, C1-C3 alkoxy -NHCO(C1-C3alkyl), -NHCO(C1-C3alkoxy),
—S(O)2NR’R”, —NHS(O)2NR’R”, —NHS(O)2(C1-C3alkyl), -NR’R”, and -C(O)NR’R”;
each R9 is C1—C6 alkyl, C1—C6 haloalkyl, C1—C6 koxy or C1—C6 alkoxy;
each R’ and R’’ is independently hydrogen, methyl, ethyl or propyl; or R’ and R’ ’ are
taken together with the nitrogen to which they are attached to form a 5—6 membered
heterocyclyl; and
PG and PG’ are each independently an amine protecting group;
the process comprising
reacting a compound of the formula XI:
PG (X1);
or a salt thereof, with PG’NHOH in the presence of an oxidant to form the
compound of the Formula VI;
Also provided is a second s for forming a compound of the formula VI:
R1,,“ R3
N PG'
OH (VI);
or a salt thereof, wherein
R1 is —C(O)NR7R8, —C(O)OR7, —CHZOR7, —CN, phenyl, a 5—6 membered heteroaryl, —
C(O)NR’NR’C(O)R9, R’OR10, or a C1—C6 alkyl group, wherein the alkyl group is
substituted with one to three groups ting of halo, C1—C3 alkoxy, —OH, —CN, —NR7R8,
—NR7COR9, a 5—6 membered heteroaryl and a 5—7 membered heterocyclyl, and wherein the
phenyl and heteroaryl represented by R1 are optionally and independently tuted with l—
3 groups selected from halo, —OH, C1—C3 alkoxy, —CN, —NR7R8, and —CONR7R8;
R2 and R3 are each ndently ed from hydrogen, halo, C1—C3 alkyl, and C3—
C6 cycloalkyl, provided that at least one of R2 and R3 is other than hydrogen;
each R7 and R8 are independently hydrogen, C1—C3 alkyl, C1—C3 alkoxy, phenyl, C3—C6
cycloalkyl, 4—7 membered heterocyclyl, or 5—6 membered heteroaryl, wherein the alkyl,
alkoxy, phenyl, cycloalkyl, heterocyclyl or heteroaryl represented by R7 or R8 is optionally
and independently tuted with 1—6 groups selected from a 5—6 ed heterocyclyl
optionally substituted with one or two —F atoms, yl or —CO(OC1—6 alkyl), 5—6
membered heteroaryl, —CN, —OH, C1—C3 alkyl optionally substituted with —NH2 or —OH, C1—
C3 haloalkyl, C1—C3 haloalkoxy, C1—C3 alkoxy —NHCO(C1—C3alkyl), —NHCO(C1—C3alkoxy),
—S(O)2NR’R”, —NHS(O)2NR’R”, —NHS(O)2(C1-C3alkyl), -NR’R”, and -C(O)NR’R”;
each R9 is C1—C6 alkyl, C1—C6 haloalkyl, C1—C6 haloalkoxy or C1—C6 alkoxy;
each R’ and R’’ is independently hydrogen, methyl, ethyl or ; or R’ and R’ ’ are
taken together with the en to which they are attached to form a 5—6 membered
heterocyclyl; and
PG and PG’ are each independently an amine protecting group;
the process comprising
reacting a compound of the formula XI:
PG (X1);
or a salt thereof, with PG’NzO to form the compound of the Formula VI.
In a first aspect, the compound of formula XI in the first or second process is of the formula:
R1,, ‘ R3
PG/O/
or a salt thereof.
In a second aspect, the compound of the formula VI in the first or second process is of the
Formula VII:
or a salt thereof.
In a third aspect, R2 in the first or second process, or formula VII is C1—C3 alkyl, wherein the
remaining features are as described in the first or second process and the first or second
aspect. Alternatively, R2 in the first or second s, or formula VII is methyl, wherein the
remaining features are as described in the first or second process and the first or second
aspect.
In a fourth apsect, the compound of the formula VI in the first or second process is of the
Formula VIII:
0H (VIII);
or a salt thereof, wherein the remaining features are as described in the first or second process
and the first or second aspect.
In a fifth aspect, R3 in the first or second process, or formula VIII is C1—C3 alkyl, wherein the
remaining features are as described in the first or second process and the first or second
aspect. Alternatively, R3 in the first or second process, or a VIII is methyl, n the
remaining features are as described in the first or second process and the first or second
aspect.
In a sixth , R1 in the first or second process is selected from an oxadiazole, —
C(O)NHNHC(O)(C1—C3 alkyl), —CH2NH2, -CH2NHCO(C1—C3 alkoxy), -CH2NHCO(C1—C3
alkyl), or —CH2NHCO(C1—C3 haloalkyl), n the oxadiazole of R1 is ally substituted
with —OH, C1—C3 , —NR7R8, or —CONR7R8; and wherein the remaining features are as
described in the first or second process and the first, second, third, fourth, or fifth aspect.
In a seventh aspect, R1 in the first or second process is selected from —CH2NH2,
O o
iu/Fi, min/>1, Kim/t;; and wherein the
remaining es are as described in the first or second process and the first, second, third,
fourth, fifth, or sixth aspect.
In an eighth aspect, R1 in the first or second process is: —CN,
)1 HQ 0 HzN/V \MO )L Rflfi/Ol
£2) >7;—
H if N\N/ or
Y \NN gi
o .
wherein R11 is hydrogen or —C(O)NH2; and wherein the remaining features are as described
in the first or second process and the first, second, third, , fifth, sixth, or seventh aspect.
In a ninth aspect, R1 in the first or second process is R7R8, —C(O)OR7, or —CN; and
n the remaining features are as described in the first or second process and the first,
second, third, fourth, fifth, sixth, seventh, or eighth aspect. Alternatively, R1 in the first or
second process is —C(O)NH2, —C(O)OH, —CN, or —C(O)OC1—C6 alkyl; wherein the remaining
features are as described in the first or second process and the first, second, third, fourth,
fifth, sixth, seventh, or eighth aspect. In another alternative, R1 in the first or second process
is —CN or —C(O)NH2; wherein the remaining features are as described in the first or second
process and the first, second, third, fourth, fifth, sixth, seventh, or eighth aspect. In another
ative, R1 in the first or second process is —CN; n the remaining features are as
described in the first or second process and the first, second, third, fourth, fifth, sixth,
seventh, or eighth aspect. In another alternative, R1 in the first or second s is —
7R8; wherein the remaining features are as described in the first or second process
and the first, second, third, fourth, fifth, sixth, seventh, or eighth aspect.
In a tenth aspect, R7 and R8 in the first or second process are both hydrogen; wherein the
remaining features are as described in the first or second process and the first, second, third,
fourth, fifth, sixth, seventh, eighth, or ninth aspect. atively, R7 in the first or second
process is hydrogen and R8 is l) a phenyl optionally substituted with a C1—C3 alkyl or C1—C3
alkyl—NHZ, 2) an C1—C3 alkyl or 3) C1—C3 alkoxy, wherein each alkyl or alkoxy of ented
by R8 is optionally and independently substituted with a C3—C6 cycloalkyl, —CN, —OH, —NH2, —
SOzNHz, —NHSOzNH2, —C(O)NH2, —NHC(O)(C1—C3 alkyl), pyrazinyl, oxytanyl, oxazolyl, or a
pyrrolidinyl optionally substituted with one or more yl, fluoro, or —C(O)O(C1—C6
alkyl); wherein the remaining features are as described in the first or second process and the
first, , third, fourth, fifth, sixth, seventh, eighth, or ninth . In another alternative,
R7 in the first or second s is hydrogen and R8 is selected from the group consisting of:
’3’ F
if/~ g. 0
0 O 021;
HZN \N HZN/ \/\O:1L9 NH
9 £9 9 9
H2N NH O O 0
’ ’ ’ ’
O O); gA/i‘i
AV o 0
g, 0 NH NH \/
O\ Mgi’ S /
H N O HZN/N,
, ,
O O
O O
\5/ \/
H2N/ \NM H2N/ \N/\ \
H HN/\é£ H and —CH20H; wherein.
, , , —CH2CN,
the remaining features are as described in the first or second process and the first, second,
third, fourth, fifth, sixth, seventh, eighth, or ninth aspect.
In an eleventh aspect, the compound of the formula VI in the first or second process is of the
Formula IX:
jIII,"
H2N \
N PG'
PG/ [11/
OH (IX);
or a salt thereof.
In a twelfth aspect, the compound of the formula VI in the first or second process is of the
Formula X:
jIII!"
H2N \
N PG'
PG/ [\ll/
OH (X);
or a salt thereof.
In a thirteenth , PG and PG’ in the first or second process taken together with the
nitrogen atom of the amine which they are ting each independently form a carbamate,
an amide, or a yl or N—aryl; wherein the remaining features are as described in the first
or second process and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth,
eleventh, or twelfth aspect. Alternatively, PG and PG’ in the first or second process are each
independently selected from t-butyloxycarbonyl (Boc), ybenzyl
(Cbz),EilluorenylmethyloxycarbonyE (Fmoc), 2,2,2—trichloroethoxycarbonyl (Troc), CF3CO,
acetyl (Ac), p—toluenesulfonamide (Ts), and methanesulfonyl (Ms); wherein the remaining
features are as described in the first or second process and the first, , third, fourth,
fifth, sixth, seventh, eighth, ninth, tenth, eleventh, or twelfth aspect. In another ative,
PG and PG’ in the first or second process are each the same; wherein the remaining features
are as described in the first or second process and the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh, or twelfth aspect. In another alternative, PG and PG’ in
the first or second process are each a xycarbonyl; wherein the ing features are as
described in the first or second process and the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh, or h aspect.
In a fourteenth aspect, the first process futher comprises reacting the compound of formula
XI with PG’NHOH in the presence of a metal catalyst; wherein the remaining features are as
described in the first or second process and the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh, twelfth, or thirteenth aspect. Alternatively, the metal
catalyst is ed from CuCl, CuBr, CuI, CuCN, CuSCN, CuBr—Mezs, Cu(OAc)2, and
CuOTf; wherein the remaining features are as described in the first or second process and the
first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, or
thirteenth aspect. In another alternative, the metal catalyst comprises a copper salt; wherein
the ing features are as described in the first or second process and the first, second,
third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, th, twelfth, or enth aspect.
In another alternative, the metal catalyst comprises a copper halide salt; wherein the
remaining features are as bed in the first or second process and the first, second, third,
fourth, fifth, sixth, h, eighth, ninth, tenth, eleventh, twelfth, or thirteenth aspect. In
another alternative, the metal st is CuCl or CuBr—Mezs; n the remaining features
are as described in the first or second process and the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh, twelfth, or enth aspect.
In a fifteenth aspect, the first process futher comprises reacting the compound of formula XI
with PG’NHOH in the presence of an amine additive; wherein the remaining features are as
described in the first or second process and the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth . In one aspect,
the amine additive process is pyridine, (lR,2R)—cyclohexane—l,2—diamine, N,N’—
dimethylethane—l,2—diamine, 2,6—di—tert—butyl—4—methylpyridine, l,lO—phenanthroline, trans—
exane— l ,2—diamine, Nl—(2—(diethylamino)ethyl)—N2,N2—diethylethane— l ,2—diamine, cis—
cyclohexane—l,2—diamine, or Nl,Nl,N2,N2—tetramethylethane—l,2—diamine; wherein the
remaining features are as described in the first or second process and the first, second, third,
fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth
aspect. atively, the amine is selected from pyridine, tidine, 4—
dimethyiaminopyridine, picoiine, l,8—diazabicyclo[5.4.0]undec—7—ene, and N,N—
diisopropylethylamine; wherein the remaining features are as bed in the first or second
process and the first, , third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
h, thirteenth, or fourteenth aspect.In another alternative, the amine is pyridine; wherein
the remaining features are as described in the first or second process and the first, second,
third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or
fourteenth aspect.
In a nth apsect, the oxidant in the first or second process is 02, air, FCC13, MnO2, meta—
peroxybenzoic acid (mCPBA), NaIO4, 2—iodoxybenzoic acid (IBX), (2,2,6,6—
Tetramethylpiperidin—l—yl)oxyl (TEMPO), benzoyl peroxide (BPO), H103, urea—H202, I2, N—
chlorosuccinimide (NCS), Dess—Martin inane (DMP), H2O2, or N—methylmorpholine
N—oxide ; wherein the remaining features are as described in the first or second
process and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
twelfth, thirteenth, fourteenth, or fifteenth . Alternatively, the oxidant is urea—H202,
H2O2 or 02; wherein the remaining features are as described in the first or second process and
the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth,
thirteenth, fourteenth, or fifteenth aspect.
In a seventeenth aspect, the reaction in the first or second process is carried out in a polar
t; wherein the remaining features are as described in the first or second s and the
first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth,
thirteenth, fourteenth, nth, or sixteenth aspect. Alternatively, the reaction is carried out
in DCM, THF, MTBE, EtOAc, iPrOAc, MeCN, H2O, MeOH, EtOH, i-PrOH, , n-
BuOH, 2—methyl—2—butanol, DMF, DMSO, ethylene glycol, hyleneglycol, sulfolane,
sulfolane/H2O mixture, DMF/H2O, NMP/H2O, DCM/H2O, MeOH/H2O, EtOH/H2O,
iPrOH/H2O, or n—BuOH/H2O; wherein the remaining features are as described in the first or
second process and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth,
eleventh, twelfth, thirteenth, fourteenth, fifteenth, or sixteenth aspect. In another alternative,
the reaction is carried out in methylene de or sulfolane; n the remaining features
are as described in the first or second process and the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth, th, twelfth, thirteenth, fourteenth, fifteenth, or nth
aspect.
In an eighteenth aspect, the reaction in the first or second process r comprises the
addition of water; wherein the remaining features are as described in the first or second
WO 53215
process and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
twelfth, thirteenth, fourteenth, fifteenth, sixteenth, or seventeenth aspect.
Examples
The invention will now be further described with nce to the following illustrative
es in which, unless stated otherwise:
(i) temperatures are given in degrees Celsius (°C); operations are carried out at room
temperature or ambient temperature, that is, in a range of 18—25 0C;
(ii) organic ons were dried over anhydrous magnesium e; evaporation of
organic t was carried out using a rotary evaporator under reduced pressure
(4.5 — 30 mmHg) with a bath temperature of up to 60 0C;
(iii) chromatography means flash chromatography on silica gel; thin layer
tography (TLC) was carried out on silica gel plates;
(W) in general, the course of reactions was followed by TLC or liquid
chromatography/mass spectroscopy (LC/MS) and reaction times are given for
ration only;
(V) final products have satisfactory proton nuclear magnetic resonance (NMR) spectra
and/or mass spectra data;
(vi) yields are given for ration only and are not necessarily those which can be
obtained by diligent process development; preparations were repeated if more
material was required;
(vii) when given, NMR data is in the form of delta values for major diagnostic protons,
given in part per million (ppm) relative to tetramethylsilane (TMS) as an internal
standard, determined at 300 MHZ in DMSO—d6 unless otherwise stated;
(viii) chemical symbols have their usual meanings;
(iX) solvent ratio was given in volume : volume (v/v) terms;
(X) an ISCO Combiflash refers to flash chromatography on silica gel using Isco
Combiflash® separation : RediSep normal phase flash column, flow rate,
—40 ml/min;
(Ki) the following abbreviations may have been used:
ACN Acetonitrile
BINAP 2,2’ —bis(diphenylphosphino)— l , l ’ —binapthyl
BoczO tert-butyloxycarbonyl anhydride
CDI rbonyldiimidazole
DAST Diethylaminosulfur trifluoride
DCM dichloromethane
DIPEA/DIEA N, N—diisopropylethylamine
DMAc N,N—dimethylacetamide
DMF N,N—dimethylformamide
DMAP thylaminopyridine
DMSO dimethylsulfoxide
ee enantiomeric excess
EtOAc/EA ethyl acetate
EtzO diethyl ether
GC gas chromatography
HATU O—(7—Azabenzotriazol— l—yl)—N,N,N‘,N‘—tetramethyluronium
hexafluorophosphate
Hex hexanes
HPLC high—performance liquid chromatography
hr/h hours
KOtBu potassium utoxide
LCMS liquid chromatography mass spectrometry
LDA Lithium diisopropylamide
MeCN acetonitrile
MeOH methanol
mins/min minutes
MTBE methyl tert—butyl ether
o/n overnight
Pd2(dba)3 Tris(dibenzylideneacetone)dipalladium(0)
PE petroleum ether
iPrOH i—propanol
rac. racemic
TBAF n—butylammonium fluoride
TEA triethylamine
TFA trifluoroacetic acid
THF tetrahydrofuran
TMS trimethyl silyl
Tosyl, Ts para—toluenesulfonyl
UPLC—MS ultra performance liquid chromatography mass spectrometry
Nitroso ene conditions and trials
In certain aspects, a nitroso ene reaction is used to install the requisite allylic hydroxylamine
functionality. mar Adam and Oliver Krebs, Chem. Rev., 2003, 103, 4131—4146;
Charles P. Frazier, Jarred R. Engelking, and Javier Read de Alaniz, J. Am. Chem.
Soc, 2011, 133 (27), 10430—10433; Leoni I. Palmer, Charles P. Frazier, Javier Read de
Alaniz, Synthesis 2014, 46, 269—280). In the presence of an oxidant, hydroxylamines are
oxidized to give highly reactive nitroso species, which react with an allylic substrate, as
shown in Scheme 10. The oxidant can be an c oxidant or a combination of an oxidant, a
metal st and optionally an amine additive. The nitroso species can be formed in situ (as
in the reaction to form a nd of a VI) from the hydroxylamine or prepared
separately and then added to the substrate, e.g., a compound of formula XI. For the l, 2, 3, 6—
tetrahydropyridine scaffold with a N—carbamate functionality, it is believe that the A03) allylic
strain exerted by the N—Boc functionality causes the R1 substituent to adopt a pseudo—axial
orientation. It is ed to block the approach of the nitroso reactant from that face of the
double bond. ore, the nitroso reactant reacts regio— and diastereoselectively from the
opposite side of R1 to form the desired t in high diastereoselectivity and
regioselectivity. The enantioselectivity is measured and has been demonstrated to be
uniformly high, > 99% ee by chiral HPLC analysis.
SCHEME lO
Oxidant, Solvent
Catalyst, Addidive, Oxidant, t
P62 i
R2 PG
_ [ 2 \NZO] ‘N=o
R11, R3 PG1 \y R1’I. \ R3
H \N H
I —>
Nitroso r‘ /N ’OH
N PG1
PG /1 Reactant R2 Ill
H R3 PG2
Substrate R1 Product
Reaction parameters, such as the oxidant, catalyst, ligand, solvent, reagent iometry,
reaction temperature and on time can affect the reaction outcome and were screened and
optimized. Some of the results are summarized in the following tables (ND 2 not
determined).
Oxidant screen
ate Reagents and Oxidant Conversion (by HPLC
conditions area%)
02, 1 atm 5-9
FCClg, 1.2 eq. 43-2
MnO2, 1.2 eq. 10-28
Na104, 2.2 eq. 21-3
m—CPBA, 2.2 eq. 30-9
BPO, 1.0 eq.
TEMPO, 1.5 eq.
H103, 1.2 eq. 3-0
12, 1.2 eq. 24-6
BocNHOH (1.5 H202, 3.0 eq. 8-9
>—‘ PG1=PG2=BOC 6C1) MnO2, 1.2 eq.
R1=CONH2 CuCl (0.05 eq.)
H202, 1 drop
RZZMC, R3=H
>—‘>—‘ Pyridine (0.013 IBX, 1.2 eq ND
eq.) PhI(0Ac)2, 1.2 ND
>—‘ (10V),17~25 0C,
urea hydrogen 63.9 12.1
—60 h
peroxide, 1.2 eq.
r—‘r—‘r—‘H NCS, 1.0 eq. 59.9 12.5
DMP, 1.0 eq. ND
3% H202, 1.2 eq 70 3.1
1.5% H202, 1.2 64.4 4.1
[\)>—‘>—‘ 6% H202, 1.2 eq 73.6 5.5
NMMO, 1.0 eq. 37.8 38.6
PG1=PG2=BOC BocNHOH (1.5 36% isolated product
R1=CO2Me eq.)
R2=CH20PMB , CuCl (0.05 eq.)
R3=H Pyridine (0.013
17~25 0C,
—60 h
N BocNHOH (1.5 46.08 10.28
eq.) FeC13 (1.2 eq.) 1.33 71.43
CuCl (0.05 eq.) Mn02 (1.2 eq.) 40.79 16.85
Pyridine (0.013 Na104 (1.2 eq.) 15.2 35.58
6C1) m-CPBA (1.2 3.04 89.1
PG1=PG2=BOC DCM eq.)
[\DN R1=CONH2 (10V),20~30 0C, H104 (1.2 eq.) 0.52 46.47
RZZH, R3=MC 20 — 60 h 30% H202 (1.2 4.69 7.9
12 (1.2 eq.) 1.39 52.85
CaOz (1.2 eq.) 19.66 33.73
BOCNHOH (3.0 H202 (3%, 3 Cq.), 54.3 30.5
eq.), CuCl (0.05 16 h
eq.), Sulfolane (5
V), H20 (5 V), H202 (3%, 3 Cq.), 38.8 0.24
Py (0.13 eq.), 96 h
0~5 OC,
BOCNHOH (2.0 H202 (3%, 2 Cq.), 70.0 4.1
eq.), CuBr—Me2S 64 h
(0.05 eq.),
Sulfolane (5 V),
H20 (0.5V), Py
(0.13 eq.), 25~30
ts and Solvent, time sion (by
conditions HPLC area%)
Product SM
% THF in DCM 77.6 5.0
(10 V), 90 h
% THF in DCM 77.5 4.7
(10 V), 90 h
% THF in DCM 68.8 19.4
(10 V), 90 h
BOCNHOH (1.5
eq.) DCM (10 V), 68 h 65.8 20.4
CuCl (0.05 eq.)
Pyridine (0.013 THF (10 V), 20 h 81.9 7.8
eq.), 15 OC, air
EtOAc (10 V), 68 h 69.5 19.0
Acetone (10 V), 68 87.3 3.6
DCM (10 V) 35.2 20.6
DCM/H20 1:1 38.0 18.7
(10 V)
MeOH (10 V) 50.0 21.8
MeOH/HzO 1:1 45.7 28.3
(10 V)
EtOH (10 V) 47.5 15.9
i-PrOH (10 V) 43.3 10.0
PG1=PG2=BOC BOCNHOH (1.5 2—Methyl—2—butanol 48.0 16.6
eq.) (10 V)
CuCl (0.05 eq.) Ethylene glycol (10 14.1 76.4
Pyridine (0.013 V)
O’\ eq.), 20—30 0C, air, Polyethyleneglycol 9.3 96.9
60 h 2000/H20
(5 g/5 V)
Sulfolane/HZO 1:1 57.0 14.7
(10 V)
Sulfolane/HZO 9:1 55.58 17.5
(10 V)
Sulfolane/HZO 3:7 23.3% 66.7
(10 V)
Sulfolane/HZO 1:1 62.3 5.9
(5 V)
BOCNHOH (1.5 DMF/HZO 58.11 1.71
eq.) 5V/5V
CuCl (0.05 eq.) NMP/HZO 44.18 0.43
Pyridine (0.013 5V/5V
eq.), 15—30 0C, 02
(1 atm), 48 h
Catalyst screen
l--Entry Substrate Reagents and Catalyst Conversion (by
t SM
.2
BocNHOH (1.5 Cu(OAc)2, 0.05 33.0 28.5
6(1) eq
CuCl (005 69-) ane/HZO 58.49 1.30
Pyridine (0.013 5V/5V, 24 h
n 69.) Sulfolane/HZO 38.83 0.24
DCM (10V), 5V/5V, 96 h
-7 20~30 °C, 02 (1 HOAc/HZO 7.95 71.02
atm), 65 h 5V/5V, 96 h
n CuCl, 0.05 eq., 24 58.49 1.30
nPGI=PG2=BOC CuCl, 0.05 eq., 96 38.83 0.24
R1=CONH2 h
RFH’ R3=Me CuBr, 0.05 eq. 72 63.42 7.31
CuSCN 32.98 47.05
(0.05 eq.), 72 h
BocNHOH (1.5 )2 59.69 15.94
69-), Pyridine (0.05 eq.), 72 h
-14 (0.013 99.), CuBr—SMez 68.71 3.36
Sulfolane (5 V), (005 eq.), 72 h
-15 H20 (5 V), 02, CuCN 5.60 5.32
~30 °Ca (0.05 eq.), 84 h
(0.05 eq.), 84 h
Cu(OTf)-t01uene 66.24 9.31
(0.05 eq.), 84 h
CuCl (0.05 eq.) 59.03 15.20
2—ethy10xazoline
(0.05 eq.), 84 h
CuCl . 26.26
(0.05 eq.)
(0.05 eq.), 89 h
Additive screen
ate Reagents Conversion (by
and HPLC area%)
Pyridine (0.013 eq.)
Ethane—1,2—diamine
(0.013 eq.)
(1R,2R)—cyclohexane—1,2—diamine
(0.013 eq.)
N] N]—dimethylethane—1,2—diamine
(0.013 eq.)
2,6—di—tert—buty1—4—methy1pyridine 31.5 34.0
(0.013 eq.)
1,10—0—Phenanthroline ND
(0.013 eq.)
N0 ligand 24.8 47.4
H N2 «\NH2,0.013 37.73 27.4
eq, 72h 9
H2N\/\N/ 5.60 5.32
| 0.013 e., 72h
1,10—0—Phenanthroline (0.013 eq.), 72 h 64.45 5.14
BocNHO ”803- 0.013 eq. 96h
H(1-5 Pyridine 58.49 1.30
eq-x CuCl (0.013 eq.), 24 h
(005661), Pyridine 38.83 0.24
PG1=PG2=B Sulfolane (0,013 eq.), 96h
0C (5 V) P ' '
, 74.1 7.1
_ yridine
R1—CONH2 H20 (5 (0.065 eq.), 84 h
WO 53215
Pyridine
(0.13 eq.), 24 h
N) 64.43 9.24
PVNqN. 0.013 eq., 72 h
HN/—\N_/—NH2 66.21 7.52
\—/ 0.013 eq., 72 h
NH2 6.79
C'S'_ 0.013 eq., 72 h
DMAP, 0.03 eq., 60 h 70.88 5.91
I 71.56 4.93
\N/\/N\
| 0.013 eq., 60h
0.013 eq., 89 h
18-Crown-6 (0.001 eq.), KCl (0.05
eq.), 36 h
L—sodiurn ascorbate (0.1 eq.), 36 h
18-Crown-6 (0.001 eq.), KCl (0.05
eq.), Py (0.013 eq.), 86 h
0 O
M0013 eq, wn—6
(0.001 eq.), KC1(0.05 eq.), 86 h
O0.013 eq, 18—Crown—6 (0.001
eq.), KC1(0.05 eq.), 86 h
BOCNHO Py (0.013 eq)., 85 h
H (1.5
eq.), CuCl H H
(0.05 eq.), HZN/\/N\/\M/\/N\/\NH2
Sulfolane
0.013 eq., 85 h
(5 V),
H20 (5
V), air,
—30 0C
Pyridine (0.013 eq.), 72 h
DMAP (0.013 eq.), 86 h
\N/\/N\
| 0.013 eq., 86 g
Sulfolane NH2
(5 V),
H20 (5 NH2
V), 02, 20— trans- 0.013 eq., 86 h
OC
BocNHO NH2
H (3 eq.),
CuCl NHZ
(0.05 eq.), trans- 0.013 eq, 66 h
Sulfolane
(5 V),
H20 (5
V), H2O2
(3%, 3
After screening, the best ions for the ate with PG1=PG2=Boc, R1=CONH2,
R2=Me, R3=H were: BocNHOH (1.5 eq), CuCl (0.05 eq), Py (0.013 eq), DCM (10V), 02
, 15—25 0C. For the substrate with PG1=PG2=Boc, R1=CONH2, R2=H, R3=Me, the best
conditions were: BocNHOH (1.5 eq), CuCl (0.05 eq), Py (0.013 eq), Sulfolane (5 V), H20 (5
V), m), 15—25 0C or BocNHOH (2 eq), CuBr—Me2S (0.05 eq), Py (0.13 eq), Sulfolane
(5 V), H2O (0.5 V), H2O2 (3% in water, 2—3 eq), 15—25 0C.
The following experimental procedures are for ration purposes.
BocNHOH (2 eq),
CuBr-MeZS (0.05eq),
i? Py(0.13eq), sulfolane j
(5V), H2O (0.5V) H2N unfit
H2N “.0/
/N ,OH
Boo/N 800 I}!
H202 (3% in water, 800
2eq), 15~25 0C, 29h
To a mixture of starting material (1 eq), BocNHOH (2 eq), CuBr2—SMe2 (0.05 eq) was added
sulfolane (5V) and H20 (0.5V), Pyridine (0.13 eq). The mixture was stirred 30—40 min at 15—
°C. 3% H202 (2 eq) was added dropwise for 24—30 h. After the reaction is judged as
complete, a solution of EDTA—2Na (0.31—0.32 eq. by weight) in water (3—3.2 x by weight)
and MTBE (7.7 x by weight) were added. The resulting mixture was stirred for 20—30 min
and settled for 20—30 min. The two phases were separated. The aqueous phase was extracted
with MTBE (4x by weight) three times. The ed organic solution was dried with
NaZSO4 and filtered, concentrated and ed by assay. 47.5% yield, 74.12% purity by
HPLC % area.
o o
H (1.5 eq.) CuCl (0-05 eq-) HzN " \
H2N 0
Boc’N ,N ,Boc
Py (0.013 eq.). 02 (9) 30° N
DCM OH
To the crude solution of substrate from previous step in DCM was added CuCl (0.05 eq.),
BocNHOH (1.5 eq.) and Py (0.013 eq.). The e was stirred under 02 atmosphere at
20i5 °C until the starting material is 35% by HPLC %area. EDTA—2Na solution (5.0 vol)
was d and the resulting mixture was stirred for at least 4 hours at 25i5 OC. The two
phases were separated. The aqueous phase was extracted with DCM (3.0 vol) two times. The
organic phases were combined and washed with water (5.0 vol) one time, concentrate under
vacuum at <40 °C to ~ 3.0 vol. i—PrOAc (5.0 V) was charged to the reactor and the mixture
was concentrated under vacuum at<40 °C to ~ 4.0 vol. This process was repeated one more
time. n—Heptane (5.0 vol) was added to the reactor at 40i5 OC. The resulting mixture was
gradually cooled to 20i5 0C. Solid was obtained by centrifuge and washed with i—PrOAc/n—
Heptane (1:1, 2 vol) and dried under vacuum at 35i5 °C at least for 12 hours. 71.68% yield
for 2 steps, 99.7% purity by HPLC %area.
ediate 1: S 1-h drox buten l isoindoline-l 3-di0ne
A 2—L reaction flask containing a stir bar and sodium carbonate (1.981 g, 18.69 mmol) was
placed under high vacuum and dried with a heating gun for ten minutes. Upon g, the
flask was backfilled with en. To it was added allylpalladium chloride dimer (0.553 g,
1.53 mmol), (1R,2R)—(+)—1,2—diaminocyclohexane—N,N'—bis(2—diphenylphosphino—1—
naphthoyl) (CAS 174810—09—4)(3.36 g, 4.25 mmol), and phthalimide (50 g, 339.83 mmol).
The flask was then purged with nitrogen for ten minutes. 1.4 L methylene chloride,
previously degassed with a nitrogen line for ten minutes, was then added. This suspension
was placed under an atmosphere of nitrogen; it was ately stirred and sonicated over a
ten—minute period to facilitate solvation. At that time, it was a yellow or light orange solution
containing white solid. To this mixture was added 2—vinyloxirane (24.06 g, 343.23 mmol).
The resulting mixture was d under a nitrogen atmosphere at ambient temperature for
approximately 48 hours. is during that time by LCMS and TLC (1:1 hexanes:ethyl
acetate) suggested progression of the reaction, and final analyses by those s suggested
complete conversion of starting al to one major product. The reaction mixture was
filtered, and the filtrate was concentrated under reduced pressure. The yellow, viscous fluid
was injected onto a 330—g silica column: a minimal volume of ene chloride was used
to thin the crude material. Silica gel chromatography (15 —75% ethyl acetate in hexanes, 40
minutes, 330 g column) was used to isolate the desired product as a viscous yellow fluid that
became a pale yellowish white solid (69.6 g, 94%) over a period of hours under reduced
pressure.
Optical Rotation : (2.02 g / 100 mL, methylene chloride) literature value = —72.2, obtained
value = —71.
Intermediate 2: S 1- tert-but ldimeth lsil 10x buten l isoindoline-l 3-di0ne
To a d solution of (S)—2—(1—hydroxybut—3—en—2—yl)isoindoline—1,3—dione (Intermediate
1, 69.4 g, 319.49 mmol) and imidazole (26.1 g, 383.39 mmol) in methylene chloride (160
mL), at ambient temperature under an atmosphere of nitrogen, was added tert—
butyldimethylchlorosilane (55.4 g, 367.41 mmol) as a solid. This addition was performed
over imately ten minutes. Warming of the mixture was observed during this addition.
After two hours stirring, the solution was poured into a saturated on of aqueous sodium
bicarbonate (approximately 150 mL); this biphasic mixture was shaken, and the organic layer
was separated. The aqueous layer was back—extracted three times with 200 mL methylene
chloride each time. The organic layers were ed, dried over ium sulfate,
filtered, and concentrated in vacuo. The d product was obtained as a pale yellow solid
after drying overnight under high vacuum (107 g, 101%).
Intermediate 3: S tert-but ldimeth lsil 10x butenamine
TBSOM
To a stirred solution of (S)—2—(1—(tert—butyldimethylsilyloxy)but—3—en—2—yl)isoindoline—1,3—
dione (Intermediate 2, 108.28 g, 326.65 mmol) in methanol (1 L), at ambient temperature
under a nitrogen atmosphere, was added hydrazine (35.9 ml, ll43.29 mmol). The yellow
on was heated to 65 OC. Within 30 minutes of reaching reaction temperature, a white
precipitate was observed in the on mixture; this solid quickly became the bulk of the
mixture, and at that time water (about 150 mL) was added to the reaction mixture. The
reaction continued stirring without uption and within a few minutes the solid dissolved.
Upon complete conversion as indicated by LCMS analysis (both starting material and product
give strong UV signals and are easily identified by LCMS), the heat was d and more
water was added (a total water content of 600 mL). The mixture was allowed to come to
ambient temperature.
The methanol was removed in vacuo at 35 °C (moderately reduced pressure); vacuum was
d and the aqueous was warmed to about 50 °C and then extracted with 4 x 200 mL
ene de. The organic extracts were combined, washed with saturated sodium
bicarbonate (aq), washed with brine, dried over sodium sulfate, filtered, and concentrated in
vacuo at not more than 30°C. The desired product was obtained as a yellow liquid (58.5 g,
94%).
Intermediate 4: 0-N-meth0x -N-meth mide
A stirred solution of potassium carbonate (343 g, 2.48 mol) in water (about 800 mL) was
prepared and cooled in an ice bath for 15 minutes under nitrogen. To it was added O,N—
dimethylhydroxylamine hydrochloride (l 10 g, 1.13 mol) and diethyl ether (about 800 mL).
To this mixture was then added bromoacetyl bromide (273 g, 1.35 mol) by addition funnel
over twenty minutes. The ice bath was removed and the mixture was stirred under nitrogen
for two hours. The layers were separated and the aqueous layer was extracted with ether
(about 350 mL). The organic layers were combined, dried over magnesium sulfate, filtered,
and concentrated in vacuo. The desired product was obtained as a yellow liquid (143 g, 70%).
WO 53215
Intermediate 5: S -tert-but ll- tert-but h lsil 10x buten 12-
1 methoxyg methyl )amino 0ethyl )carbamate
TBso/\;/\
Olly’OMe
A suspension of (S)—1—(tert—butyldimethylsilyloxy)but—3—en—2—amine (Intermediate 3, 60.4 g,
300 mmol) and cesium carbonate (103 g, 315 mmol) in acetonitrile (about 700 mL) and water
(about 120 mL) was prepared and stirred in an ice bath under nitrogen for 5 minutes. The
mixture was biphasic and ed so for the duration of the reaction. To this e was
then added 2—bromo—N—methoxy—N—methylacetamide (Intermediate 4, 57.0 g, 285 mmol) by
addition funnel over 10 minutes. The mixture was stirred for two days, with the temperature
maintained near 0°C. The mixture was kept in the freezer overnight. Another 0.05 eq of the
electrophile was added. To the mixture was added di—tert—butyl dicarbonate (165 mL, 2M
solution in THF). The organic layer was separated from the aqueous (TLC ted that no
product remained in the aqueous), and the organic layer was concentrated in vacuo. Silica gel
chromatography (5—55% ethyl acetate in hexanes), split into 3 batches, afforded the desired
product as a pale yellow oil (80 g, 66%).
Intermediate 6: S -tert-but ll- tert-but ldimeth lsil 10x buten 12-0x0 ent
enyl )carbamate
To a solution of (S)—tert—butyl 1—(tert—butyldimethylsilyloxy)but—3—en—2—yl(2—(methoxy—
(methyl)amino)—2—oxoethyl)carbamate (Intermediate 5, 32.5 g, 80.73 mmol) in THF (400
mL) under nitrogen at 0 °C was added prop—1—enylmagnesium bromide (323 ml, 161.45
mmol) dropwise. The on mixture was stirred at 0 °C for 1 hour, then quenched with
400 mL 10% citric acid, diluted further with 100 mL water and extracted with ether. The
organics were trated and the resulting oil was dissolved in ether and washed with
water and brine. The organics were dried over magnesium sulfate, filtered and concentrated.
Silica gel chromatography (5%—20% ethyl acetate/hexanes) afforded the d product as a
colorless oil (27g, 87%).
M_S: 384 ES+ (C20H37NO4Si)
WO 53215
1H NMR1300 MHz, CDCl;) 8: 0.05 (2, 6H); 0.88 (s, 9H); 1.39-1.47 (m, 9H); 1.90 (m, 3H);
3.80 (m, 2H); 4.05-4.18 (m, 2H); 4.43-4.76 (m, 1H); 5.22 (m, 2H); 5.86 (m, 1H); 6.21 (m,
1H); 6.91 (m, 1H).
Intermediate 7: S -tert-but 12- tert-but ldimeth lsil 10x meth l0x0-5 6-
dih dr0 ridine-l 2H -carb0x late
TBSO/h’fiOYN 0
(S)—tert—buty1 1—(tert—butyldimethylsilyloxy)but—3—en—2—yl(2—oxopent—3—enyl)carbamate
(Intermediate 6, 27.0 g, 70.39 mmol) was dissolved in toluene (650 mL). The solution was
purged with en for 15 minutes before the addition of Hoveyda—Grubbs Catalyst 2nd
Generation (0.885 g, 1.41 mmol). The reaction mixture was heated under nitrogen at 65 °C.
The reaction mixture was concentrated under reduced pressure. Silica gel chromatography
(10%—35% ethyl acetate/hexanes) afforded the desired product as a solid (17.0g, 70%).
Optical Rotation: 0.1 g/dL, methylene chloride 2 —175
Intermediate 8: 6S -tert-but l6- tert-but ldimeth lsil 10x meth lmeth l
trimeth lsil 10x -5 6-dih dr0 ridine-l 2H -carb0x late
To a suspension of copper(I) iodide (22.31 g, 117.12 mmol) in diethyl ether (250 mL) at 0°C
was added lithium (1.6M in ether) (146 mL, 234.25 mmol) Via cannula. The
suspension was d for 45 minutes at 0 °C. A on of (S)—tert—buty1 2—(((tert—
butyldimethylsilyl)oxy)methy1)—5—oxo—5,6—dihydropyridine— 1 (2H)—carboxy1ate (Intermediate
7, 20 g, 58.56 mmol) in diethyl ether (50 mL) was added dropwise to the suspension at 0°C.
Once addition was complete, the reaction mixture was stirred for 45 minutes at 0°C. To the
reaction mixture was then added trimethylsilane (1M in THF) (117 mL, 117.12 mmol)
dropwise, followed by ylamine (16.28 mL, 117.12 mmol). The reaction mixture was
d to warm to room temperature and stir for 2 hours. The reaction e was then
diluted with ethyl acetate and washed with ice cold saturated sodium bicarbonate solution
(added very carefully) three times, ed by brine. The organics were dried over sodium
sulfate, filtered and concentrated to afford a brown oil.
Intermediate 9: S -tert-but 12- tert-but ldimeth lsil 10x meth lmeth l0x0-
6-dih dr0 ridine-l 2H -carb0x late
To a solution of (6S)—tert—butyl 6—(((tert—butyldimethylsilyl)oxy)methyl)—5—methyl—3—
((trimethylsilyl)oxy)—5,6—dihydropyridine—1(2H)—carboxylate (Intermediate 8, 24.1 g, 56.08
mmol) in acetonitrile (280 mL) at room temperature was added palladium (II) acetate (12.59
g, 56.08 mmol). The on mixture was stirred at room temperature for ~40 hours, then
diluted with ethyl acetate and filtered through celite. The filtrate was concentrated onto silica
gel. Silica gel chromatography (0%—20% ethyl e/hexanes) afforded (S)—tert—butyl 2—
(((tert—butyldimethylsilyl)oxy)methyl)—3—methyl—5—oxo—5,6—dihydropyridine—1(2H)—
carboxylate (12.95 g, 65%) as a yellow solid.
Intermediate 10: 2S 5S -tert-but 12- tert-but ldimeth lsil 10x meth l-S-h drox
meth l-5 6-dih dr0 ridine-l 2H -carb0x late
TBso/“éN 'I
Boc’ ’OH
To a sion of cerium(III) de (8.98 g, 36.42 mmol) and (S)—tert—butyl 2—(((tert—
butyldimethylsilyl)oxy)methyl)—3—methyl—5—oxo—5,6—dihydropyridine—1(2H)—carboxylate
(Intermediate 9, 12.95 g, 36.42 mmol) in methanol (200 mL) at 0 °C was added sodium
dride (1.378 g, 36.42 mmol), portionwise. After 15 minutes, the reaction mixture was
diluted with saturated ammonium chloride (100 mL) and water (100 mL), then extracted
twice with ether. The organic extracts were washed with brine, dried over magnesium
e, filtered and concentrated. Silica gel chromatography (0%—20% ethyl e/hexanes)
afforded (2S,5S)—tert—butyl 2—(((tert—butyldimethylsilyl)oxy)methyl)—5—hydroxy—3—methyl—5,6—
dihydropyridine—1(2H)—carboxylate (9.79 g, 75%) as a colorless oil.
Intermediate 11: 2S 5R -tert-but 15- N- all 10x nitr0 hen lsulfonamido tert-
but ldimeth lsil 10x meth lmeth l-5 6-dih dr0 ridine-1 2H x late
TBSO/dN’ ,OAII
Boc N
To a solution of (2S,5S)—tert—butyl 2—(((tert—butyldimethylsilyl)oxy)methyl)—5—hydroxy—3—
methyl—5,6—dihydropyridine—1(2H)—carboxylate (Intermediate 10, 9.79 g, 27.38 mmol) in
toluene (100 mL) at room temperature was added triphenylphosphine (8.58 g, 32.86 mmol),
N—(allyloxy)—2—nitrobenzenesulfonamide (7.07 g, 27.38 mmol) and diisopropyl
azodicarboxylate (6.47 mL, 32.86 mmol). The reaction mixture was stirred overnight, then
filtered and trated. The resulting oil was twice triturated with hexanes and filtered.
Silica gel chromatography (0%—20% ethyl acetate/hexanes) ed )—tert—butyl 5—(N—
(allyloxy)—2—nitrophenylsulfonamido)—2—(((tert—butyldimethylsilyl)oxy)methyl)—3—methyl—5,6—
dihydropyridine—1(2H)—carboxylate (10.75 g, 66%) as a light yellow foam.
Intermediate 12: 2S 5R -tert-but 15- N- all 10x nitr0 hen lsulfonamido
h drox meth lmeth l-5 6-dih dr0 ridine-l 2H x late
’ ,OAII
Boc N
To a solution of (2S,5R)—tert—butyl 5—(N—(allyloxy)—2—nitrophenylsulfonamido)—2—(((tert—
butyldimethylsilyl)oxy)methyl)—3 —methyl—5,6—dihydropyridine—1(2H)—carboxylate
(Intermediate 11, 10.75 g, 17.98 mmol) in THF (100 mL) at 0 °C was added
tetrabutylammonium fluoride (1M in THF) (23.38 mL, 23.38 mmol). The reaction mixture
turned from yellow to greenish brown. The reaction mixture was d for about 2 hours,
then concentrated onto silica gel. Silica gel chromatography (0%—70% ethyl acetate/hexanes)
afforded (2S,5R)—tert—butyl 5—(N—(allyloxy)—2—nitrophenylsulfonamido)—2—(hydroxymethyl)—3—
methyl—5,6—dihydropyridine—1(2H)—carboxylate (7.72 g, 89%) as a tan foam.
Intermediate 13: 2S 5R N- all 10x nitr0 hen lsulfonamido tert-
butox carbon lmeth l-1 2 5 6-tetrah dr0 ridinecarb0x lic acid
HOJHHd(1 N ,OAll
Boc/ N
To a solution of periodic acid (1.588 g, 8.27 mmol) in wet acetonitrile (20 mL) (0.75% water
by volume) at room ature was added chromium(VI) oxide (0.019 g, 0.19 mmol). The
mixture was stirred until complete dissolution was achieved. To a solution of )—tert—
butyl 5—(N—(a11yloxy)—2—nitropheny1su1fonamido)—2—(hydroxymethy1)—3—methy1—5 ,6—
dihydropyridine—1(2H)—carboxy1ate (Intermediate 12, 2 g, 4.14 mmol) in wet acetonitrile (20
mL) (0.75% by volume) at 0°C was added dropwise the usly formed ic
acid/chromium oxide solution (20 mL, 2 eq.), and stirred for 15 s. The reaction
mixture was diluted with DCM (100 mL) and washed with 10% citric acid (50 mL) and twice
with brine. The organics were dried over sodium sulfate, filtered and concentrated to afford a
tan foam (1.9 g, 92%).
Intermediate 14: 2S 5R -tert-but 15- N- all 10x nitr0 hen lsulfonamido
carbam0 lmeth l-5 6-dih dr0 ridine-l 2H -carb0x late
W610LBoc,N N,OA||
To a solution of (2S,5R)—5—(N—(a11yloxy)—2—nitrophenylsulfonamido)—1—(tert—butoxycarbony1)—
3—methy1—1,2,5,6—tetrahydropyridine—2—carboxylic acid (Intermediate 13, 1.9 g, 3.82 mmol)
in DMF (9.5 mL) at 0°C was added HATU (2.178 g, 5.73 mmol), ammonium chloride (0.613
g, 11.46 mmol) and DIEA (2.67 mL, 15.28 mmol) dropwise. The reaction mixture was
warmed to room temperature and stirred for 15 minutes. The reaction e was diluted
with ethyl acetate and washed with saturated sodium bicarbonate and 1:1 brinezwater. Silica
gel chromatography (0%—70% ethyl e/hexanes) afforded (2S,5R)—tert—buty1 5—(N—
(allyloxy)—2—nitrophenylsulfonamido)—2—carbamoy1—3—methy1—5,6—dihydropyridine—1(2H)—
carboxylate (1.270 g, 67%) as a light orange foam.
Intermediate 15: ZS 5R -tert-but lS- all 10x amino carbam0 lmeth l-5 6-
dih dr0 ridine-1 2H -carb0x late
HZNJI'“Cf \
, xOAII
Boc N
To a solution of (2S,5R)—tert—butyl 5—(N—(a11yloxy)—2—nitrophenylsulfonamido)—2—carbamoyl—
3—methy1—5,6—dihydropyridine—1(2H)—carboxy1ate (Intermediate 14, 3.63 g, 7.31 mmol) in
acetonitrile (100 mL) at room temperature was added potassium carbonate (5.05 g, 36.55
mmol) and thiophenol (3.75 mL, 36.55 mmol). The on mixture was d overnight at
room temperature. The reaction mixture was concentrated and the resulting e was
triturated with DCM and filtered to remove solids. The filtrate was concentrated onto silica
and purified. Silica gel chromatography (0%—90% ethyl acetate/hexanes) afforded (2S,5R)—
tert—butyl 5—((allyloxy)amino)—2—carbamoy1—3—methy1—5,6—dihydropyridine— 1(2H)—carboxy1ate
(1.49 g, 65%) as a yellow oil.
Intermediate 16: ZS 5R but lS- N- all 10x -1H-imidazolecarb0xamid0
carbam0 lmeth l-5 6-dih dr0 ridine-1 2H -carb0x late
H2N “’6‘
Boc N,OA||
To a solution of (2S,5R)—tert—butyl 5—((a11yloxy)amino)—2—carbamoy1—3—methy1—5 ,6—
opyridine—1(2H)—carboxy1ate (Intermediate 15, 1.49 g, 4.79 mmol) in THF (30 mL) at
room temperature was added N,N—diisopropylethylamine (2.5 mL, 14.36 mmol) and N,N—
carbonyldiimidazole (2.328 g, 14.36 mmol). The on mixture was stirred for ~2 hours at
room temperature. Another equivalent of CD1 was added, and the reaction mixture stirred at
room temperature for 1 hour, then another equivalent of CD1 was added and the reaction
d for another hour. The reaction mixture was diluted with DCM, and washed four times
with 1:1 brinezwater, then dried over magnesium sulfate, ed and concentrated to afford
an off—white foam, 1.86 g.
ediate 17: 2S 5R all 10x meth l0x0-1 abic clo 3.2.1 0ctene
carboxamide
To a solution of (2S,5R)—tert—butyl 5—(N—(allyloxy)—1H—imidazole—1—carboxamido)—2—
carbamoyl—3—methyl—5,6—dihydropyridine—1(2H)—carboxylate (Intermediate 16, 1.86 g, 4.59
mmol) in DCM (20 mL) at 0 °C was added oroacetic acid (3.53 mL, 45.88 mmol). The
reaction mixture was allowed to warm to room temperature slowly and stir overnight. The
reaction mixture was concentrated. The oil was redissolved in DCM and washed with
saturated sodium onate. The aqueous was extracted once with ~10% MeOH/DCM.
The organics were dried over magnesium sulfate, filtered and concentrated. Silica gel
chromatography (0%—30% acetone/dichloromethane) afforded (2S,5R)—6—(allyloxy)—3—
methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (0.83 g, 76%) as a light
yellow oil.
Exam le 1: R -eth 12- 2S 5R bam0 lmeth l0x0-1 6-diazabic clo 3.2.1 oct-
3-en 10x flu0r0acetate
Exam le 2: S -eth 12- 2S 5R carbam0 lmeth l0x0-1 6-diazabic clo 3.2.1 oct-
3-en 10x flu0r0acetate
Exam le 3: ZS - ZS 5R -Z-carbam0 lmeth l0x0-1 6-diazabic clo 3.2.1 0cten-
6- 1 0x flu0r0 ethanoic acid lithium salt
O O’SI/OH
Exam le 4: ZR - ZS 5R -Z-carbam0 lmeth l0x0-1 6-diazabic clo 3.Z.1 0cten-
6- 1 0x flu0r0 ethanoic acid lithium salt
Hid/“6:? N
OJ—N‘O’SrOHF
Exam le 5: ZS 5R -Z-carbam0 lmeth l0x0-1 abic clo 3.Z.1 0cten
yl|0xyflflu0r02acetic acid lithium salt (mixture of diastereomers)
HZNJ’I'fi(i N
02—N,O,$rOHF
Examples 1-Z
To a solution of )—6—(allyloxy)—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—
carboxamide (Intermediate 17, 100 mg, 0.42 mmol) in methanol (3 mL) at room
temperature was added 1,3—dimethylbarbituric acid (132 mg, 0.84 mmol) and
tetrakis(triphenylphosphine)palladium(0) (48.7 mg, 0.04 mmol). The reaction was stirred at
room temperature for 2 hours. The reaction e was concentrated to afford an orange
film. The orange film was dissolved in DMF (3 mL) and potassium carbonate (175 mg, 1.26
mmol) and ethyl bromofluoroacetate (0.299 mL, 2.53 mmol) were added. The on
mixture was stirred overnight at room temperature and was then diluted with ethyl acetate
and filtered through a 0.45 n filter to remove solid potassium carbonate. The filtrate was
washed twice with 1:1 brinezwater. The organics were dried over magnesium sulfate, filtered
and concentrated. Silica gel chromatography % ethyl acetate/hexanes) afforded ethyl
2—(((2S ,5R)—2—carbamoyl—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—en—6—yl)oxy)—2—
fluoroacetate (97 mg, 76 %) as a mixture of diastereomers of Example 1 and Example 2 as
an orange foam.
M_S: 198 ES+ (C3H11N303)
Examples 3-5
To a solution of ethyl S,5R)—2—carbamoy1—3—methy1—7—oxo—1,6—diazabicyclo[3.2. 1]oct—3—
en—6—y1)oxy)—2—fluoroacetate (Examples 1-2, 97 mg, 0.32 mmol) in THF (3 mL) and water (1
mL) at —5°C was added lithium hydroxide (9.25 mg, 0.39 mmol) as a solution in water (0.5
mL). The mixture was stirred at 0 °C for 60 minutes, allowed to warm to room ature
and stirred for 15 minutes. The reaction mixture was adjusted to pH = 7 with 0.5M HCl. The
THF was evaporated and the remaining aqueous phase was frozen and 1yophi1ized.
Purification of Examples 1-5
The mixture resulting from the reaction described in Examples 3—5 was ed by reversed
phase HPLC (Synergi Polar RP 21.2 mm x 100 mm, 4 um d with YMC C30 20 mm x
150 mm, 5 um; 0% to 50% acetonitrile in water, 10 min; 20 mL/min) to obtain:
Example 1: ethyl {[(2S,5R)—2—carbamoy1—3—methy1—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—en—6—
y1]oxy}(f1uoro)acetate (first e1uting ester): 4.4 mg, 4.5%
M_S: 302 ES+ (C12H16FN305)
1H NMR 1300 MHz: DMSO-dg) 8: 1.21 (t, 3H); 1.62 (s, 3H); 3.05 (m, 1H); 3.75 (m, 1H);
4.03 (m, 1H); 4.20 (m, 3H); 6.01 (m, 1H); 6.13-6.31 (d, 1H); 7.36 (bs, 1H); 7.81 (bs, 1H).
Example 2: (S)—ethy1 2—((2S,5R)—2—carbamoy1—3—methy1—7—oxo—1,6—diazabicyclo[3.2. 1]oct—
3—en—6—yloxy)—2—f1uoroacetate (second e1uting ester): 4.2 mg, 4.3%
M_S: 302 ES+ (C12H16FN305)
1H NMR 1300 MHz: g) 8: 1.26 (t, 3H); 1.63 (s, 3H); 3.08 (m, 1H); 3.75 (m, 1H);
3.94 (m, 1H); 4.20 (m, 1H); 4.27 (q, 2H); 6.03 (m, 1H); .50 (d, 1H); 7.37 (bs, 1H); 7.83
(bs, 1H).
Example 3: (2S)—{ [(2S,5R)—2—carbamoy1—3—methy1—7—oxo—1,6—diazabicyclo[3.2. 1]oct—3—en—6—
y1]oxy}(fluoro)ethanoic acid (first e1uting acid): 7.7 mg, 8.8%.
M_S: 274 ES+ 2FN305)
1H NMR 1300 MHz, DMSO—dg) 5: 1.61 (s, 3H); 3.05 (m, 1H); 3.68 (m, 1H); 3.96 (m, 1H);
4.13 (m, 1H); 5.12-5.33 (d, 1H); 6.03 (m, 1H); 7.31 (bs, 1H); 7.80 (bs, 1H).
Example 4: (2R)—{ [(2S,5R)—2—carbamoyl—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—en—6—
yl]oxy}(fluoro)ethanoic acid (second eluting acid): 9.9 mg, 11%
M_S: 274 ES+ (C10H12FN305)
1H 0 MHz= g) 5: 1.61 (s, 3H); 3.05 (m, 1H); 3.70 (m, 1H); 4.00 (m, 1H);
4.13 (m, 1H); 5.15-5.37 (d, 1H); 6.01 (m, 1H); 7.31 (bs, 1H); 7.78 (bs, 1H).
e 5: {[(2S,5R)—2—carbamoyl—3—methyl—7—oxo—1,6—diazabicyclo[3.2. 1]oct—3—en—6—
yl]oxy}(fluoro)acetic acid (mixture of diastereomers): 20.4 mg, 23%
M_S: 274 ES+ (C10H12FN305)
1H NMR1300 MHz, DMSO-dg) 8: 1.62 (s, 6H); 3.06 (m, 2H); 3.70 (m, 2H); 4.01 (m, 2H);
4.14 (m, 2H); 5.14-5.35 (d, 1H); 5.18-5.40 (d, 1H); 6.03 (m, 2H); 7.32 (bs, 2H); 7.80 (bs,
The absolute stereochemistry for all compounds was determined by characterizing the co—
l structure of example 4 complexed with AmpC. The absolute stereochemistry of the
other diastereomer, example 3, was assigned as having the opposite stereochemistry at the
fluoroacetate carbon. The stereochemistry of each ester was assigned by hydrolysis of each
ester to its corresponding acid and comparison of the UPLC retention times to those of
examples 3 and 4.
Exam le 6: eth 1 2S 5R bam0 lmeth l0x0-1 6-diazabic clo 3.2.1 0cten-
6-yl|0xyflflu0r0)acetate (mixture of diastereomers)
According to the procedure given for examples 1 and 2, (2S,5R)—6—(allyloxy)—3—methyl—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 17, 0.506 g, 2.13 mmol)
was converted into 70 mg of Example 6 after HPLC gi Polar RP 21.2 mm x 100 mm,
4 um coupled with YMC C30 20 mm x 150 mm, 5 um; 20% to 60% acetonitrile in water, 10
min; 20 ) and lyophilization.
M_S: 302 ES+ (C12H16FN305)
1H NMR1300 MHz= DMSO-dg) 8: 1.22 (t, 3H); 1.27 (t, 3H); 1.63 (s, 6H); 3.07 (m, 2H); 3.76
(m, 2H); 3.94 (m, 1H); 4.05 (m, 1H); 4.20 (m, 2H); 4.26 (m, 4H); 6.03 (m, 2H); 6.06—6.24 (d,
1H); 6.14-6.32 (d, 1H); 7.37 (bs, 1H); 7.83 (bs, 1H).
Exam le 7: eth 1 2S 5R carbam0 lmeth l0x0-1 6-diazabic clo 3.2.1 0cten-
6- 1 0x difluoro acetate
(2S ,5R)—6—(allyloxy)—3 —methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide
(Intermediate 17, 204.2 mg, 0.86 mmol) was converted according to the procedure for
examples 1 and 2 using ethyl ifluoroacetate (0.441 mL, 3.44 mmol) to give 130 mg
(47%) of the title compound as an orange foam. e phase chromatography on 40 mg
(Synergi Polar RP 21.2 mm x 100 mm, 4 um coupled with YMC C30 20 mm x 150 mm, 5
um; 20% to 40% acetonitrile in water, 10 min; 20 mL/min) ed the title compound as a
white solid (21 mg).
M_S: 320 ES+ (C12H15F2N305)
1H NMR1300 MHz, DMSO-dg) 8: 1.30 (t, 3H); 1.65 (s, 3H); 3.19 (m, 1H); 3.84 (m, 1H);
4.06 (m, 1H); 4.26 (m, 1H); 4.39 (q, 2H); 6.05 (m, 1H); 7.42 (bs, 1H); 7.87 (bs, 1H).
Exam le 8: 2S 5R carbam0 lmeth l0x0-1 6-diazabic clo 3.2.1 0cten
1 0x difluoro acetic acid lithium salt
Ethyl 2—(((2S ,5R)—2—carbamoyl—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—en—6—yl)oxy)—
2,2—difluoroacetate (Example 7, 113.7 mg, 0.36 mmol) was converted according to the
procedure for Examples 3—5. A white solid was ed after HPLC (Synergi Polar RP 21.2
mm x 100 mm, 4 um coupled with YMC C30 20 mm x 150 mm, 5 um; 100% water, 10 min;
) and lyophilization, 36.7 mg.
M_S: 292 ES+ (C10H11F2N305)
WO 53215
1H NMR1300 MHz, g) 5: 1.63 (s, 3H); 3.13 (m, 1H); 3.75 (m, 1H); 3.95 (m, 1H);
4.18 (m, 1H); 6.04 (m, 1H); 7.34 (bs, 1H); 7.83 (bs, 1H).
Exam le 9: eth 1 2S 5R carbam0 lmeth l0x0-1 6-diazabic clo 3.2.1 0ct
enyl |0xy {acetate
HZNJII" \
o‘ N‘O’yo\/
(2S ,5R)—6—(allyloxy)—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide
(Intermediate 17, 0.198 g, 0.83 mmol) was converted according to the procedure for
Examples 1—2 using ethyl bromoacetate (0.592 mL) to give 147 mg (62%) as an orange solid.
Reverse phase chromatography on 41.5 mg (Synergi Polar RP 21.2 mm x 100 mm, 4 um
coupled with YMC C30 20 mm x 150 mm, 5 um; 10% to 50% acetonitrile in water, 10 min;
) afforded the title compound as a White solid (32 mg).
M_S: 284 ES+ (C12H17N305)
1H NMR1300 MHz, DMSO-dg) 8: 1.22 (t, 3H); 1.61 (s, 3H); 3.00 (m, 1H); 3.68 (m, 1H);
4.05 (m, 1H); 4.13 (m, 1H); 4.16 (q, 2H); 4.37—4.65 (m, 2H); 6.05 (m, 1H); 7.33 (bs, 1H);
7.77 (bs, 1H).
Exam le 10: 2S 5R carbam0 lmeth l0x0-1 6-diazabic clo 3.2.1 0cten
1 0x acetic acid lithium salt
Ethyl 2—(((2S ,5R)—2—carbamoyl—3—methyl—7—oxo— 1 ,6—diazabicyclo[3 .2. 1]oct—3—en—6—
yl)oxy)acetate (Example 9, 105.5 mg, 0.37 mmol) was hydrolyzed according to the
procedure for Examples 3—5 to give 34 mg (37%) of the title nd after HPLC (Synergi
Polar RP 21.2 mm x 100 mm, 4 um; 0% to 20% acetonitrile in water, 10 min; 20 )
and lyophilization.
M_S: 256 ES+ (C10H13N305)
1H NMR1300 MHz2 DMSO—dg) 5: 1.60 (s, 3H); 2.96 (m, 1H); 3.58 (m, 1H); 3.87 (m, 2H);
4.05 (m, 1H); 4.27 (m, 1H); 6.08 (m, 1H); 7.27 (bs, 1H); 7.74 (bs, 1H).
Exam le 11: 2- 2S 5R carbam0 lmeth l0x0-1 abic clo 3.2.1 0cten
1 0x flu0r0 r0 anoic acid lithium salt mixture of diastere0mers
(2S ,5R)—6—(allyloxy)—3 —methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide
(Intermediate 17, 0.101 g, 0.43 mmol) was converted according to the procedure for
Examples 1—2 using methyl 2—bromo—2—f1uoropropanoate (0.315 g, 1.70 mmol) to give methyl
2—(((2S ,5R)—2—carbamoy1—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—en—6—yl)oxy)—2—
fluoropropanoate (0.105 g, 82 %) as an orange foam. Reverse phase chromatography
(Synergi Polar RP 21.2 mm x 100 mm, 4 pm coupled with YMC C30 20 mm x 150 mm, 5
pm; 100% water, 10 min; 20 mL/min) afforded the title compound as a White solid (19.1 mg,
19%).
M_S: 302 ES+ (C12H16FN305)
1H NMR1300 MHz2 DMSO-dg) 8: 1.67 (m, 6H); 3.04 (m, 1H); 3.72 (m, 4H); 3.80 (m, 1H);
4.17 (m, 1H); 6.02 (m, 1H); 7.36 (bs, 1H); 7.81 (bs, 1H).
Hydrolysis according to the procedure for Example 3—5 ed 19.1 mg of e 11 as a
White solid after reverse phase purification (Synergi Polar RP 21.2 mm x 100 mm, 4 pm
coupled with YMC C30 20 mm x 150 mm, 5 pm; 100% water, 10 min; 20 mL/min).
M_S: 288 ES+ (C11H14FN305)
1H NMR 300 MHz g) 5: 1.45 (m, 3H); 1.61 (s, 3H); 3.02 (m, 1H); 3.65 (m, 1H);
3.92—4.09 (m, 1H); 4.11 (m, 1H); 6.04 (m, 1H); 7.32 (m, 1H); 7.80 (m, 1H).
Intermediate 18: is0 r0 12-br0m0flu0r0acetate
”)0? \/ iPrOH, tBuOK, hexane, O C
O 32* YO
O O
To a solution of ethyl 2—bromo—2—fluoroacetate (0.639 mL, 5.41 mmol) in hexanes (70 mL)
and panol (7 mL) at 0°C was added potassium t—butoxide (0.091 g, 0.81 mmol) in two
equal portions, 5 minutes apart. The reaction mixture was stirred for 1 hour at 0°C. The
reaction was quenched with concentrated HCl (7 mL) and the layers were separated. The
organics were washed twice with water, dried over magnesium sulfate, filtered and
concentrated at 0°C to afford a colorles oil (0.88 g, 4.42 mmol, 82%). NMR confirmed the
identity of the product, containing a trace of hexanes. The product was used as is in the next
step.
1H 0 MHz, CDCléfi) 8: 1.34 (m, 6H); 5.18 (m, 1H); 6.45-6.62 (d, 1H).
Reference: Tet. Lett. (2000) 791.
Exam le 12: 1'0 an 1 2R - 2S 5R carbam0 lmeth l0X0-1 6-
diazabic clo 3.2.1 0cten 1 0x flu0r0 ethanoate
Exam le 13: 1'0 an 1 2S - 2S 5R carbam0 lmeth l0X0-1 6-
diazabic clo 3.2.1 0cten 1 0x flu0r0 ethanoate
HZNJJ/I'fiO N F
O OJWO
o 7’
Example 12-13
(2S ,5R)—6—(allyloxy)—3 —methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide
(Intermediate 17, 0.103 g, 0.43 mmol) was converted according to the ure for
Examples 1—2 using isopropyl 2—bromo—2—fluoroacetate (Intermediate 18, 0.518 g, 2.60
mmol). 34 mg of each diastereomer was ed after HPLC (Synergi Polar RP 21.2 mm x
100 mm, 4 um coupled with YMC C30 20 mm x 150 mm, 5 um; 25% to 50% acetonitrile in
water, 10 min; 20 mL/min) and lyophilization. The chemistry of the ester was assigned
by hydrolysis of each ester to its ponding acid and comparison of the UPLC retention
time to those of examples 3 and 4.
Example 12: (first eluting ester) 33.4 mg, 24%
M_S: 316 ES+ (C13H13FN305)
1H NMR 1300 MHz, DMSO—dg) 5: 1.22 (m, 6H); 1.63 (s, 3H); 3.03 (m, 1H); 3.75 (m, 1H);
4.01 (m, 1H); 4.19 (m, 1H); 5.00 (m, 1H); 6.01 (m, 1H); 6.11—6.29 (d, 1H); 7.37 (bs, 1H);
7.81 (bs, 1H).
Example 13: (second eluting ester) 33.6 mg, 25%
M_S: 316 ES+ (C13H13FN305)
1H NMR 1300 MHz: DMSO-dg) 8: 1.27 (m, 6H); 1.63 (s, 3H); 3.07 (m, 1H); 3.75 (m, 1H);
3.94 (m, 1H); 4.20 (m, 1H); 5.05 (m, 1H); 6.03 (m, 1H); 6.02—6.21 (d, 1H); 7.37 (bs, 1H);
7.82 (bs, 1H).
Intermediate 19: 2 4-dimeth l entan 12-br0m0flu0r0acetate
ing the procedure for intermediate 18, using ethyl 2—bromo—2—fluoroacetate (0.639
mL, 5.41 mmol) and 2,4—dimethyl—3—pentanol (7.05 mL, 50.27 mmol) the title compound was
obtained as a colorles oil (0.988 g, 3.87 mmol, 71.6%).
1H NMR 1300 MHz, CDCléfi) 8: 0.94 (m, 12H); 2.01 (m, 2H); 4.73 (m, 1H); 6.52-6.69 (d,
Exam le 14: 24-dimeth l entan 1 2S - 2S 5R carbam0 lmeth 0-1 6-
diazabic clo 3.2.1 0cten 1 0x fluoro ethanoate
Exam le 15: 24-dimeth l entan 1 2R - 2S 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 1 0x flu0r0 ate
HZNJII'fi? N F
o N‘o ”J140
Examples 14-15
(2S ,5R)—6—(allyloxy)—3 —methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide
(Intermediate 17, 0.097 g, 0.41 mmol) was converted according to the procedure for
Examples 1—2 using 2,4—dimethylpentan—3—yl 2—bromo—2—fluoroacetate (0.626 g, 2.45 mmol)
to give 35 mg of each diastereomer (23% for each, 46% total) after HPLC gi Polar RP
21.2 mm x 100 mm, 4 um coupled with YMC C30 20 mm x 150 mm, 5 um; 40% to 70%
acetonitrile in water, 10 min; 20 mL/min) and lyophilization. The stereochemistry of the
esters was ed by hydrolysis of each ester to its corresponding acid and comparison of
the UPLC retention time to those of examples 3 and 4.
Example 14: d eluting peak) 34.5 mg, 23%
M_S: 372 ES+ (C17H26FN305)
1H NMR1300 MHz= DMSO-dg) 8: 0.86 (m, 12H); 1.63 (s, 3H); 1.94 (m, 2H); 3.07 (m, 1H);
3.78 (m, 1H); 3.98 (m, 1H); 4.23 (m, 1H); 4.62 (m, 1H); 6.04 (m, 1H); 6.15—6.34 (d, 1H);
7.38 (bs, 1H); 7.81 (bs, 1H).
Example 15: (first eluting peak) 35.2 mg, 23%
M_S: 372 ES+ (C17H26FN305)
1H NMR1300 MHz= DMSO-dg) 8: 0.84 (m, 12H); 1.63 (s, 3H); 1.93 (m, 2H); 3.03 (m, 1H);
3.78 (m, 1H); 4.07 (m, 1H); 4.21 (m, 1H); 4.60 (m, 1H); 5.99 (m, 1H); 6.27—6.45 (d, 1H);
7.37 (bs, 1H); 7.83 (bs, 1H).
Intermediate 20: tetrah dr0-2H- ran 12-br0m0flu0r0acetate
Following the ure for Intermediate 18, using ethyl 2—bromo—2—fluoroacetate (0.319
mL, 2.70 mmol) and tetrahydro—2H—pyran—4—ol (2.333 mL, 24.33 mmol), the title compound
was obtained as a colorless oil (0.15 g, 0.62 mmol, 29 %).
M_S: ES+ 241.2 for C7H10BrFO3
1H NMR 300 MHz CHLOROFORM-d 8 m: 1.47 - 1.81 (m, 2 H) 1.84 - 2.13 (m, 2 H)
3.39 — 3.68 (m, 2 H) 3.75 - 4.07 (m, 2 H) 4.37 (q, J=7.18 Hz, 1 H) 6.37 - 6.74 (m, 1 H)
Exam le 16: tetrah dr0-2H- ran 1 2S 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 1 0x flu0r0 acetate mixture of diastereomers
HzNJII.H\j? N
)—N\ F
O o#00
Following the procedure from Examples 1—2, using (2S,5R)—6—(allyloxy)—3—methyl—7—oxo—1,6—
icyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 17, 40 mg, 0.17 mmol) and
tetrahydro—2H—pyran—4—yl 2—bromo—2—fluoroacetate (Intermediate 20, 312 mg, 1.29 mmol),
the title compound was ed after purification by reverse phase ISCO (15.5 g C18 Gold,
0%—80% acetonitrile/water), light orange solid as a mixture of diastereomers. (5.5 mg, 9%)
M_S: ES+ 358.1 for C15H20FN306
1H NMR 300 MHz CHLOROFORM-d 8 m 1.15 - 1.42 (m, 2 H) 1.60 (br. s., 2 H) 1.92
(s, 3 H) 3.14 - 3.45 (m, 2 H) 3.56 (d, J=11.52 Hz, 1 H) 3.88 - 4.13 (m, 2 H) 4.20 - 4.50 (m, 2
H) 5.09 (br. s., 1 H) 5.35 - 5.58 (m, 1 H) 5.63 - 5.96 (m, 1 H) 6.09 (br. s., 1 H)
Intermediate 21: 2-meth0x eth m0flu0r0acetate
Brwowo/
ing to the procedure for Intermediate 18, using ethyl 2—bromo—2—fluoroacetate (1.278
mL, 10.81 mmol) and 2—methoxyethanol (13.94 mL, 183.79 mmol) the title compound was
obtained as a colorles oil (1.04 g, 4.84 mmol, 44.7%). NMR was tent with a 3:1
mixture of productzstarting material, which was used as is in the next step.
1H NMR1300 MHz, DMSO-dg) 8: 3.27 (s, 3H); 3.57 (m, 2H); 4.35 (m, 2H); 7.22-7.38 (d,
WO 53215 Z
Exam le 17: Z-meth0x eth 1 ZS 5R -Z-carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 1 0x fluoro acetate (mixture of diastereomers)
Exam le 18: Z-meth0x eth l ZR - ZS 5R -Z-carbam0 lmeth 0-1 6-
diazabic clo 3.2.1 0cten 1 0x fluoro ethan0ate
HZNJ’I'fi(i N
)—N\ F
0 0V0\/\
O 0/
Exam le 19: Z-meth0x eth 1 ZS - ZS 5R -Z-carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 1 0x fluoro ethan0ate
'fi(iL .
O N‘OJVo\/\/
o 0
Example 17-19
According to the procedure for es 1—2, (2S,5R)—6—(allyloxy)—3—methyl—7—oxo—1,6—
icyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 17, 0.101 g, 0.43 mmol) was
converted into the title compound using 2—methoxyethyl 2—bromo—2—fluoroacetate
(Intermediate 21, 0.549 g, 2.55 mmol). The following products were obtained after HPLC
(Synergi Polar RP 21.2 mm x 100 mm, 4 um coupled with YMC C30 20 mm x 150 mm, 5
um; 30% to 50% acetonitrile in water, 10 min; 20 mL/min) and lization (wherein the
stereochemistry of the esters was assigned by hydrolysis of each ester to its corresponding
acid and comparison of the UPLC retention time to those of Examples 3 & 4):
Example 17: mixture of diastereomers: 14.3 mg, 10.1%
M_SZ 332 ES+ (C13H18FN305)
1H NMR1300 MHz, DMSO-dg) 8: 1.63 (s, 6H); 3.07 (m, 2H); 3.26 (s, 3H); 3.27 (s, 3H);
3.54 (m, 2H); 3.59 (m, 2H); 3.73 (m, 1H); 3.77 (m, 1H); 3.98 (m, 1H); 4.03 (m, 1H); 4.19 (m,
1H); 4.32 (m, 4H); 6.02 (m, 2H); 6.11-6.30 (d, 1H); 6.17-6.35 (d, 1H); 7.37 (bs, 2H); 7.81
(bs, 2H).
Example 18: (first eluting : 22 mg, 15.6%,
M_S: 332 ES+ (C13H13FN305)
1H NMR1300 MHz= DMSO-dg) 5: 1.63 (s, 3H); 3.06 (m, 1H); 3.27 (s, 3H); 3.55 (m, 2H);
3.77 (m, 1H); 4.05 (m, 1H); 4.20 (m, 1H); 4.30 (m, 2H); 6.02 (m, 1H); 6.18—6.36 (d, 1H);
7.37 (bs, 1H); 7.82 (bs, 1H).
Example 19: (second eluting ester): 22.8 mg, 16.1%
M_S: 332 ES+ (C13H13FN305)
1H NMR 300 MHz DMSO-dg) 8: 1.62 (s, 3H); 3.07 (m, 1H); 3.27 (s, 3H); 3.59 (m, 2H);
3.75 (m, 1H); 3.99 (m, 1H); 4.20 (m, 1H); 4.34 (m, 2H); 6.03 (m, 1H); 6.11—6.30 (d, 1H);
7.37 (bs, 1H); 7.83 (bs, 1H).
ediate 22: S -sec-but lZ-bromo-Z-fluoroacetate
BrJYOf
To a solution of ethyl o—2—fluoroacetate (0.319 mL, 2.70 mmol) and (S)—butan—2—ol
(3.72 mL, 40.54 mmol) in hexane (35 mL) at 0°C was added potassium t—butoxide (0.061 g,
0.54 mmol) in two equal portions 5 minutes apart. The reaction mixture was stirred for 2
hours at 0°C, then overnight at room temperature. The reaction was quenched with saturated
ammonium chloride and the layers were separated. The organics were washed three times
with water, dried over ium sulfate, filtered and trated at 0°C to afford a
colorles oil, 0.550 g, 96%.
1H NMR1300 MHz, DMSO-dg) 8: 0.88 (m, 3H); 1.25 (m, 3H); 1.61 (m, 2H); 4.91 (m, 1H);
7.16-7.33 (m, 1H).
Intermediate 23: R -sec-but 12-br0m0flu0r0acetate
To a on of ethyl 2—bromo—2—fluoroacetate (0.319 mL, 2.70 mmol) and (R)—butan—2—ol
(3.72 mL, 40.54 mmol) in hexane (35 mL) at 0°C was added potassium t—butoxide (0.061 g,
0.54 mmol) in two equal portions 5 minutes apart. The reaction mixture was stirred for 2
hours at 0°C, then at room temperature for 2 hours. Then, more (R)—butan—2—ol (3.72 mL,
40.54 mmol) was added followed by another 0.1 eq of potassium xide. The reaction
mixture was stirred at room temperature overnight. 0.1 eq of potasium t—butoxide was added
every 2 hours for 6 hours. The reaction was quenched with ted ammonium chloride
and the layers were separated. The organics were washed four times with water, dried over
magnesium sulfate, filtered and concentrated at 0°C to afford a colorles oil, 422 mg, 73%.
1H NMR1300 MHz= DMSO-dg) 8: 0.88 (m, 3H); 1.25 (m, 3H); 1.61 (m, 2H); 4.91 (m, 1H);
7.16-7.33 (m, 1H).
Exam le 20: 2R - S -sec-but 12- 2S 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 10x flu0r0acetate
Exam le 21: 2S - S -sec-but 12- 2S 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 10x flu0r0acetate
Example 20-21
Prepared according to the procedure for Examples 1— 2. To a solution of )—6—
(allyloxy)—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate
17, 0.196 g, 0.83 mmol) in methanol (5 mL) at room temperature was added 1,3—
dimethylbarbituric acid (0.258 g, 1.65 mmol) and tetrakis(triphenylphosphine)palladium(0)
(0.095 g, 0.08 mmol). The reaction was stirred at room temperature for 2 hours then
concentrated to afford an orange film. The orange film was dissolved in DMF (5 mL), and
potassium carbonate (0.343 g, 2.48 mmol) and (S)—sec—butyl 2—bromo—2—fluoroacetate
(Intermediate 22, 0.528 g, 2.48 mmol) were added. The on mixture was stirred for ~5
hours at room temperature then d with ethyl acetate and filtered through a 0.45 um filter
to remove solid potassium carbonate. The filtrate was washed three times with 1:1
brine:water. The organics were dried over magnesium sulfate, ed and concentrated.
Silica gel chromatography (0%—65% ethyl acetate/hexanes) afforded (S)—sec—butyl 2—
(((2S ,5R)—2—carbamoyl—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—en—6—yl)oxy)—2—
fluoroacetate (0.218 g, 80 %) as a light yellow foam, ~1:1 mixture of diastereomers.
Separation of diastereomers was done on reverse phase HPLC (Atlantis T3 19 mm x 150 mm,
—50% itrile in water, 20 mL/min, 15 min). The stereochemistry of the esters was
ed by hydrolysis of each ester to its corresponding acid and comparison of the UPLC
retention time to those of examples 3 and 4.
Example 20: (first eluting peak) 84 mg, 31%
M_S: 330 ES+ (C14H20FN305)
1H NMR1300 MHz= DMSO-dg) 8: 0.84 (t, 3H); 1.22 (d, 3H); 1.55 (m, 2H); 1.63 (s, 3H);
3.03 (m, 1H); 3.76 (d, 1H); 4.04 (m, 1H); 4.19 (s, 1H); 4.86 (m, 1H); 6.01 (m, 1H); 6.13-6.31
(m, 1H); 7.37 (bs, 1H); 7.82 (bs, 1H).
Example 21: (second eluting peak) 85 mg, 31%.
M_S: 330 ES+ (C14H20FN305)
1H NMR1300 MHz= DMSO-dg) 8: 0.84 (t, 3H); 1.22 (d, 3H); 1.55 (m, 2H); 1.63 (s, 3H);
3.03 (m, 1H); 3.76 (d, 1H); 4.04 (m, 1H); 4.19 (s, 1H); 4.86 (m, 1H); 6.01 (m, 1H); 6.13-6.31
(m, 1H); 7.37 (bs, 1H); 7.82 (bs, 1H).
Exam le 22: 2R - R -sec-but 12- ZS 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 10x r0acetate
diazabic clo 3.2.1 0cten 10x r0acetate
‘i \
O \O/Sro
Example 22-23
Examples 22—23 were prepared according to the procedure for Examples 1—2. To a solution of
(2S ,5R)—6—(a11yloxy)—3 —methy1—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide
(Intermediate 17, 0.202 g, 0.85 mmol) in methanol (5 mL) at room temperature was added
1,3—dimethy1barbituric acid (0.266 g, 1.70 mmol) and tetrakis(tripheny1phosphine)—
palladium(0) (0.098 g, 0.09 mmol). The reaction was stirred at room temperature for 2 hours.
The reaction mixture was concentrated to afford an orange film. The orange film was
dissolved in DMF (5 mL), and potassium carbonate (0.353 g, 2.55 mmol) and (R)—sec—buty1
2—bromo—2—fluoroacetate (Intermediate 23, 0.421 g, 1.98 mmol) were added. The reaction
mixture was stirred for 3 hours at room ature then diluted with ethyl acetate and
ed through a 0.45 um filter to remove solid potassium carbonate. The filtrate was
washed three times with 1:1 brinezwater. The organics were dried over magnesium sulfate,
filtered and concentrated. Silica gel chromatography (0%—65% ethyl acetate/hexanes)
afforded (R)—sec—buty1 2—(((2S,5R)—2—carbamoy1—3—methy1—7—oxo—1,6—diazabicyclo[3.2.1]oct—
3—en—6—y1)oxy)—2—fluoroacetate (0.220 g, 78 %) as an orange foam, 1:1 e of
diastereomers. Separation of diastereomers was done on reverse phase HPLC (Atlantis T3 19
mm x 150 mm, 30—50% itrile in water, 20 mL/min, 15 min). The stereochemistry of the
WO 53215
esters was assigned by hydrolysis of each ester to its corresponding acid and comparison of
the UPLC retention time to those of examples 3 and 4.
Example 22: (first eluting peak) 90 mg, 32%
M_S: 330 ES+ (C14H20FN305)
1H NMR1300 MHz, DMSO-dg) 8: 0.87 (t, 3H); 1.17 (d, 3H); 1.59 (m, 2H); 1.63 (s, 3H);
3.03 (m, 1H); 3.76 (d, 1H); 4.02 (m, 1H); 4.19 (s, 1H); 4.86 (m, 1H); 6.02 (m, 1H); 6.16-6.34
(m, 1H); 7.37 (bs, 1H); 7.82 (bs, 1H).
Example 23: (second eluting peak) 87 mg, 31%
M_S: 330 ES+ (C14H20FN305)
1H 0 MHz= DMSO-dg) 8: 0.88 (t, 3H); 1.24 (d, 3H); 1.61 (m, 2H); 1.63 (s, 3H);
3.08 (m, 1H); 3.76 (d, 1H); 3.94 (m, 1H); 4.21 (s, 1H); 4.89 (m, 1H); 6.04 (m, 1H); 6.03-6.22
(m, 1H); 7.38 (bs, 1H); 7.82 (bs, 1H).
Intermediate 24: entan 12-br0m0flu0r0acetate
Br Ear-#0
HO —>
Ethyl 2—bromo—2—fluoroacetate (0.639 ml, 5.41 mmol) was added to a mixture of dry pentan—
3—ol (4.68 ml, 43.25 mmol) and hexane (20 ml). The ing mixture was cooled to 0°C.
KOtBu (0.091 g, 0.81 mmol) was added and the mixture was allowed to stir for 16 h at 25°C.
The reaction was then quenched with 1N HCl (30 mL), washed with water (50 mL) and brine
(50 mL), dried with NaZSO4, and concentrated. The crude material was purified by flash
chromatography (20 g silica gel, 0—100% EtzO in hexane, 25 min) to give pentan—3—yl 2—
bromo—2—fluoroacetate (0.754 g, 61.4 %) as a colorless oil.
1H NMR (300 MHz, FORM-d) 8 ppm 0.96 (td, J=7.46, 2.08 Hz, 6 H) 1.60 - 1.76
(m, 4 H) 4.93 (dt, J=12.28, 6.33 Hz, 1 H) 6.50 (s, 0.5 H) 6.67 (s, 0.5 H)
Exam le 24: R - entan 12- 2S 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 10x flu0r0acetate
HZNJI'“Cf \
Exam le 25: S - entan 12- 2S 5R carbam0 lmeth 0-1 6-
diazabic clo 3.2.1 0cten 10x flu0r0acetate
H2NJ01.H\:(i
o (Virob
Example 24-25
Examples 24—25 were prepared according to the procedure for Examples l—2. To a solution of
(2S ,5R)—6—(allyloxy)—3 —methyl—7 —oxo— l ,6—diazabicyclo[3 .2. l]oct—3—ene—2—carboxamide
(Intermediate 17, 272 mg, 1.15 mmol) in methanol (5 mL) at room temperature was added
l,3—dimethylbarbituric acid (358 mg, 2.29 mmol) and Pd(Ph3P)4 (132 mg, 0.11 mmol). The
reaction was stirred at room temperature for 2 hours. The mass of the desired product was
observed and no starting material was seen by LCMS. The reaction mixture was
trated to afford an orange film. The orange film was dissolved in DMF (5 mL), and
K2CO3 (475 mg, 3.44 mmol) and —3—yl 2—bromo—2—fluoroacetate (Intermediate 24, 75 1
mg, 3.31 mmol) were added. The reaction mixture was stirred overnight at room ature
then diluted with ethyl acetate and filtered through a 0.45 u filter to remove solid potassium
carbonate. The filtrate was washed twice with 1:1 brinezwater. The organics were dried over
magnesium sulfate, filtered and trated. Silica gel chromatography (0%—70% ethyl
acetate/hexanes) afforded —3—yl 2—(((2S,5R)—2—carbamoyl—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.l]oct—3—en—6—yl)oxy)—2—fluoroacetate (320 mg, 81 %) as a light yellow foam.
LCMS and NMR m it is a 1:1 mixture of diastereomers. The diastereomers were
separated on reverse phase HPLC (Atlantis T3 4.6mm x 50mm 5um column, from 30 to 50%
ACN in water in 5 min, flow rate 1 ml/min).
Example 24 : 125 mg, 32%
UPLC LCMS 2min_Acid_CV10 method acid condition retention time: 0.86 min, 344
(M+H)+
1H NMR1300 MHz, CHLOROFORM-d) 8 ppm 0.92 (td, J=7.46, 3.21 Hz, 6 H) 1.61 - 1.75
(m, 4 H) 1.93 (s, 3 H) 3.21 - 3.35 (m, 2 H) 4.07 (dd, J=4.91, 2.64Hz, 1 H) 4.36 (s, 1 H) 4.91
(quin, J=6.18 Hz, 1 H) 5.47 (br. s., 1 H) 5.77 (s, 0.5 H) 5.94 (s, 0.5 H) 6.07 - 6.12 (m, 1 H)
6.59 (br. s., 1 H)
Example 25: 125 mg, 32%
UPLC LCMS 2min_Acid_CV10 method acid ion retention time: 0.91 min, 344
(M+H)+
1H NMR (300 MHz, CHLOROFORM-d) 6 ppm 0.93 (t, J=7.46 Hz, 3 H) 0.95 (t, J=7.46 Hz, 3
H) 1.63 - 1.74 (m, 4 H) 1.93 (s, 3 H) 3.20 - 3.38 (m, 2 H) 4.02 (dd, J=5.00, 2.55 Hz, 1 H) 4.35
(s, 1 H) 4.92 (quin, J=6.18 Hz, 1 H) 5.56 (br. s., 1 H) 5.69 (s, 0.5 H) 5.89 (s, 0.5 H) 6.07 —
6.14 (m, 1 H) 6.64 (br. s., 1 H)
Into a 250—mL round—bottom flask purged and maintained with an inert atmosphere of
nitrogen, was placed a solution of tert—butyl (3R,6S)—6—[[(tert—butyldimethylsi1y1)—
oxy]methyl] —5—methy1—3— [N—(prop—2—en— 1—yloxy)(2—nitrobenzene)sulfonamido] — 1 ,2,3 ,6—
ydropyridine—1—carboxy1ate (Intermediate 11, 13.6 g, 22.75 mmol, 1 eq.) in
dichloromethane (100 mL). This was followed by the addition of ZnBrz (10.2 g, 45.29 mmol,
2 eq.) in several batches. The resulting solution was d ght at room temperature.
The resulting solution was diluted with 500 mL of dichloromethane. The resulting mixture
was washed with 2 x 200 mL of sodium bicarbonate (aq) and 2 x 200 mL of NH4C1 (aq). The
mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This
resulted in 12 g (crude product) of the title compound as yellow oil.
M_SZ 498 ES+ (C22H35N3O6881)
Intermediate 26: 3R 6S ut ldimeth lsil 10X meth l-S-meth l-N- r0
en 10X -1 2 3 6-tetrah dr0 ridinamine
Into a 250—mL round—bottom flask, purged and maintained with an inert atmosphere of
nitrogen, was placed a solution of N—[(3R,6S)—6—[[(tert—butyldimethylsilyl)oXy]methyl]—5—
methyl— 1,2,3 ,6—tetrahydropyridin—3 —yl] —2—nitro—N—(prop—2—en— 1 )benzene— 1—sulfonamide
(Intermediate 25, 12 g, 24.11 mmol, 1 eq.) in N,N—dimethylformamide (100 mL), 2—
ylacetic acid (4.4 g, 47.77 mmol, 2 eq.). This was followed by the addition of LiOH
(5.8 g, 242.17 mmol, 10 eq.), in portions. The resulting solution was stirred for 2 h at room
temperature, then d with 500 mL of water, and extracted with 5 X 200 mL of ethyl
acetate, and the organic layers combined. The organic mixture was washed with 3 X 200 mL
of brine and 2 X 200 mL of sodium bicarbonate (aq.). The miXture was dried over anhydrous
sodium sulfate and concentrated under vacuum. This resulted in 8.4 g (crude product) of the
title compound as yellow oil.
M_SZ 313 ES+ (C16H32N20281)
Into a 2 L 3—necked round—bottom flask, purged and maintained with an inert atmosphere of
nitrogen, was placed a solution of (3R,6S)—6—[[(tert—butyldimethylsilyl)0Xy]methyl]—5—methyl—
N—(prop—2—en—1—y10Xy)—1,2,3,6—tetrahydropyridin—3—amine (Intermediate 26, 8.4 g, 26.88
mmol, 1 eq.) in acetonitrile (1.6 L) and N,N—diisopropylethylamine (14.2 g, 109.87 mmol, 4
eq.). This was followed by the addition of a solution of hloromethyl ate (2.9 g,
9.77 mmol, 0.4 eq.) in acetonitrile (100 mL) dropwise with stirring at —15°C over 3 hr. The
ing solution was stirred overnight at room temperature. The resulting miXture was
trated under vacuum. The crude product was diluted with 500 mL of ethyl acetate. The
resulting miXture was washed with 2 X 400 mL of NH4Cl (aq.) and 2 X 400 mL of brine, then
concentrated under vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:10). This resulted in 3.9 g (43%) of the title compound as yellow
M_S: 339 ES+ (C17H30N203Sl)
Intermediate 28: 2S 5R h dr0x meth lmeth [ r0 en 10x -1 6-
diazabicyc10|3.2.1 |0cten0ne
HO/I'“ \
Into a 100 mL round—bottom flask was placed tetrahydrofuran (30 mL) and (2S,5R)—2—[[(tert—
butyldimethylsilyl)oxy] methyl] —3—methyl—6—(prop—2—en— l—yloxy)— 1 ,6—diazabicyclo[3 .2. 1]oct—
3—en—7—one mediate 27, 3.2 g, 9.45 mmol, 1 eq.) and the solution was cooled to 0°C,
then TBAF (14.2 mL 1N in THF, 1.5 eq.) was added dropwise. The reaction mixture was
d for 1 h at 0°C in a ice bath. The resulting mixture was concentrated under
. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether
(1:5—1:2). This resulted in 1.6 g (75%) of the title compound as a light yellow solid.
M_S: 225 ES+ (C11H16N203)
1H NMR1300 MHz, CDCl;) 8 1.63 (3H, d), 3.20 (2H, d), 3.62 - 3.84 (2H, m), 3.85 — 3.90
(2H, m), 4.35 - 4.48 (2H, m), 5.28 - 5.39 (2H, m), 5.95 - 6.08 (2H, m).
Intermediate 29: 2S 5R meth l0x0 r0 en 10x
diazabic clo 3.2.1 0ctenecarb0x lic acid
Ho)“-cf \
To a solution of H5IO6(12.93 g,56.71 mmol) in wet CH3CN(150 mL, 0.75% H20 v/v) at RT
was added 28 mg, 1.28 mmol). The mixture was stirred until it was completely
dissolved. Into a 100 mL round—bottom flask, was placed wet acetonitrile (35 mL) and
(2S ,5R)—2—(hydroxymethyl)—3—methyl—6—(prop—2—en— 1—yloxy)— 1 ,6—diazabicyclo[3 .2. 1]oct—3—en—
7—one (Intermediate 28, 740 mg, 3.30 mmol, 1 eq.) and it was cooled to 0°C. Then, the
above oxidation solution (35 mL, 3 eq.) was added dropwise over the course of 30 min at
0°C. The ing solution was stirred for 1 h at 0°C in a water/ice bath. The reaction
WO 53215
mixture was then diluted with 200 mL of chloroform and 50 mL of citric acid solution (25%).
The c layer was isolated and then washed by 3 x 50 mL of brine, dried over anhydrous
sodium sulfate and concentrated under vacuum. This resulted in 0.70 g crude of the title
compound as yellow oil.
M_S: 239 ES+ (C11H16N204)
Intermediate 30: 2S 5R -N'-acet [ all 10x meth 0-1 6-
ic clo 3.2.1 0ctenecarb0h drazide
JII,,H ‘i
O N
x/L—N,
To a solution of (2S,5R)—6—(allyloxy)—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—
carboxylic acid (Intermediate 29, 195.7 mg, 0.82 mmol) in DCM (10 mL) at room
temperature was added 1—(3—dimethylaminopropyl)—3—ethylcarbodiimide hydrochloride (236
mg, 1.23 mmol), 1—hydroxybenzotriazole hydrate (219 mg, 1.23 mmol) and monoacetyl
hydrazine (101 mg, 1.23 mmol). The mixture was cooled to 0°C and DIEA (0.715 mL, 4.11
mmol) was added. The reaction mixture was allowed to warm to rt and stirred at room
temperature overnight, then diluted with ethyl acetate and washed twice with 1:1 brine:water.
The aqueous washes contained some product and were back extracted twice with ethyl
acetate and once with ~5% methanol in dichloromethane. The combined organics were dried
over magnesium sulfate, filtered and concentrated. Silica gel tography (0%—5%
methanol/dichloromethane) afforded the title compound as a white foam (45.5 mg, 19%,
~50% purity).
M_S: 295 ES+ (C13H13N4O4)
1H NMR1300 MHz, DMSO—dg) 5: 1.62 (s, 3H); 1.86 (m, 3H); 2.88 (m, 1H); 3.40 (m, 1H);
3.81 (m, 1H); 3.95 (m, 1H); 4.38 (m, 2H); 5.32 (m, 2H); 5.94 (m, 1H); 6.11 (m, 1H); 9.86 (s,
1H); 10.24 (bs, 1H).
Exam le 26: eth 12- 2S 5R 2-acet lh drazinecarbon lmeth l0X0-1 6-
diazabic clo 3.2.1 0cten 10X flu0roacetate
W0“... \
O N
02—N.09;fo\/
To a solution of (2S,5R)—N'—acetyl—6—(allyloxy)—3—methyl—7—oxo—1,6—diazabicyclo[3.2. 1]oct—3—
ene—2—carbohydrazide (Intermediate 30, 22.75 mg, 0.08 mmol, ) in methanol (3 mL) at room
temperature was added 1,3—dimethylbarbituric acid (48.3 mg, 0.31 mmol) and
tetrakis(triphenylphosphine)palladium(0) (17.87 mg, 0.02 mmol). The reaction was stirred at
room temperature for 2 hours then concentrated to afford an orange film. The orange film
was dissolved in DMF (3 mL). Potassium carbonate (64.1 mg, 0.46 mmol) and ethyl 2—
bromo—2—fluoroacetate (0.055 mL, 0.46 mmol) were added. The reaction mixture was stirred
for ~5 hours at room temperature then diluted with ethyl acetate and filtered h a 0.45
um filter to remove solid potassium carbonate. The filtrate was washed three times with 1:1
brinezwater. The organics were dried over magnesium sulfate, filtered and trated.
Silica gel chromatography (0%—65% ethyl acetate/hexanes) afforded the title compound as an
orange foam (25.9 mg, 94 %). The two diastereomers were present in a 1:1 ratio. The
material was dissolved in ethyl acetate and washed three times with 1:1 brinezwater. The
cs were dried over ium sulfate, filtered and concetrated. Another silica gel
column was run (0%—30% e/dichloromethane) to afford pure title compound (16.6 mg,
60%).
M_S: 359 ES+ (C14H19FN4O6)
1H NMR1300 MHz= DMSO-dg) 5: 1.24 (m, 3H); 1.65 (s, 3H); 1.86 (m, 3H); 3.09 (m, 1H);
3.89 (d, 1H); 4.01 (m, 1H); 4.25 (m, 3H); 6.09 (m, 1H); 6.20 (m, 1H); 9.90 (s, 1H); 10.30 (d,
Exam le 27: 2- 2S 5R 2-acet lh drazinecarbon lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 1 0x flu0r0acetic acid lithium salt
To a solution of ethyl S,5R)—2—(2—acetylhydrazinecarbonyl)—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—en—6—yl)oxy)—2—fluoroacetate (Example 26, 16.6 mg, 0.05 mmol) in
THF (1 mL) and water (0.33 mL) at 0°C was added lithium hydroxide (1M) (0.05 mL, 0.05
mmol), and stirred for 10 minutes at 0°C. Another 0.2 eq of lithium hydroxide was added.
After 30 minutes another 0.2 equivalents of lithium hydroxide were added. The reaction
mixture was stirred for an additional 30 minutes. HCl (0.5M) (0.046 mL, 0.02 mmol) was
added to adjust the pH to ~4—5. The reaction e was extracted with ethyl acetate twice.
The aqueous layer was frozen and lyophilized. 15 mg of the title compound was obtained as
an orange solid. The 2 diastereomers were t in a 1:1 ratio.
M_S: 331 ES+ (C12H15FN4O6)
1H NMR 300 MHz DMSO—dg) 5: 1.65 (s, 3H); 1.87 (m, 3H); 3.08 (m, 1H); 3.84 (m, 1H);
4.03 (m, 1H); 4.23 (s, 1H); 5.23 (m, 1H); 6.10 (m, 1H); 9.88 (s, 1H); 10.26 (bs, 1H).
Intermediate 31: tert-but 14- 2S 5R all 10x meth l0x0-1 6-
diazabic clo 3.2.1 enecarb0xamid0 benz lcarbamate
k0 ”noN)”i \
To a solution of (2S,5R)—6—(allyloxy)—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—
carboxylic acid (Intermediate 29, 130.5 mg, 0.55 mmol) in DMF (5 mL) at room
temperature was added tert—butyl 4—aminobenzylcarbamate (146 mg, 0.66 mmol), s
Base (0.287 mL, 1.64 mmol) and 1—propanephosphonic acid cyclic ide (50 wt% in
DMF) (0.326 mL, 1.10 mmol). The mixture was stirred at room temperature for 1h. Water
(10 mL) and 10% MeOH in DCM (20 mL) were added. The organic layer was separated,
and concentrated to give the crude product. Purification by flash chromatography (20g silica
gel, 0%—10% MeOH in DCM, 20 min) afforded the title compound (178 mg, 73.4 % yield,
~50% purity) as a yellow oil.
M_S: 443 ES+ (C23H30N405)
1H NMR (300 MHz, CHLOROFORM-d) 5 ppm 1.47 (m, 12 H) 3.10 - 3.23 (m, 1 H) 3.25 -
3.39 (m, 1 H) 4.34 - 4.54 (m, 3 H) 4.36 - 4.49 (m, 3 H) 5.25 - 5.45 (m, 2 H) 6.03 (d, J=6.61
Hz, 1 H) 6.09 - 6.17 (m, 1 H) 7.24 - 7.29 (m, 2 H) 7.42 - 7.62 (m, 2 H) 8.64 (s, 1 H)
Intermediate 32: R -eth 12- 2S 5R 4- tert-butox carbon lamino meth l hen [-
carbamo th l0x0-1 6-diazabic clo 3.2.1 0cten 10x flu0roacetate
To a solution of tert—butyl 4—((2S,5R)—6—(allyloxy)—3—methyl—7—oxo—1,6—diazabicyclo—
[3.2.1]oct—3—ene—2—carboxamido)benzylcarbamate (Intermediate 31, 178 mg, 0.40 mmol) in
methanol (10 mL) at room temperature was added Pd(Ph3P)4 (465 mg, 0.40 mmol). The
reaction was d at room temperature for 16 hours. The reaction mixture was
concentrated to afford crude intermediate tert—butyl 4—((2S,5R)—6—hydroxy—3—methyl—7—oxo—
1,6—diazabicyclo[3.2.1]oct—3—enecarboxamido)benzylcarbamate as an orange film. The crude
material was dissolved in DMF (1 mL). K2CO3 (167 mg, 1.21 mmol) and ethyl 2—bromo—2—
fluoroacetate (0.052 mL, 0.44 mmol) were added. The reaction mixture was stirred ght
at room temperature. EtOAC (20 mL) was added, and the reaction mixture was washed with
water (10 mL). The c layer was concentrated to give the crude product which was
purified by flash chromatography (12 g silca gel, 0—100% EtOAc in Hexane, 20 min; then 5%
MeOH in DCM, 10 min) to afford the title compound (11 mg, 5.4% yield) as an orange solid.
M_S: 507 ES+ (C24H31FN4O7)
1H NMR1300 MHz= CHLOROFORM-d) 5 ppm 1.36 (t, 3 H) 1.48 (s, 9 H) 2.00 (s, 3 H) 3.21
- 3.27 (m, 1 H) 3.36 (d, J=1.70 Hz, 1 H) 4.08 (dd, J=5.00, 2.74 Hz, 1 H) 4.24 - 4.42 (m, 5 H)
4.47 (s, 1 H) 5.78 - 5.95 (m, 1 H) 6.12 - 6.17 (m, 1 H) 7.38 - 7.55 (m, 4 H) 8.47 (s, 1 H)
Intermediate 33: R 2S 5R 4- tert-butox carbon lamin0 meth l hen l-
carbam0 l meth l0x0-1 6-diazabic clo 3.2.1 0cten 10x flu0r0acetic acid
lithium salt
“in0 ifI,“
To a solution of (2R)—ethyl S,5R)—2—((4—(((tert—butoxycarbonyl)amino)methyl)phenyl)—
oyl)—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—en—6—yl)oxy)—2—fluoroacetate
(Intermediate 32, 11 mg, 0.02 mmol) in THF (1 mL) and water (0.5 mL) at 0°C was added
m hydroxide (1M) (0.02 mL, 0.02 mmol). The mixture was stirred for 5 minutes at 0°C
and DCM (10 mL) was added. Hydrochloric acid (0.5N) was carefully added to adjust the
pH to ~5—6. The organic layer was separated and concentrated to give the title compound (8
mg, 77%) as a yellow solid.
UPLC acid condition retention time: 0.80 min, 479 (M+H)+
1H NMR 300 MHz CHLOROFORM-d 5 m 1.47 (s, 9 H) 1.98 (s, 3 H) 3.19 - 3.44 (m, 1
H) 4.03 — 4.55 (m, 6 H) 5.68 - 6.05 (m, 1 H) 7.44 - 7.56 (m, 4 H) 8.49 (br. s., 1 H)
Exam le 28: R 2S 5R 4- amin0meth l hen m0 l meth l0X0-1 6-
To a solution of (2R)—2—(((2S,5R)—2—((4—(((tert—butoxycarbonyl)amino)methyl)phenyl)—
carbamoyl)—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—en—6—yl)oxy)—2—fluoroacetic acid
lithium salt (Intermediate 33, 8 mg, 0.02 mmol) in DCM (2 mL) at 0 °C was added TFA
(0.128 mL, 1.67 mmol). The reaction mixuture was stirred at 0 °C for 6 hours and solvent
was removed. Toluene (2 x 1 mL) was added and concentrated to remove excess TFA. EtzO
(2 mL) was added and the precipitation formed was filtered, washed with EtzO and dried to
give the title compound (8 mg, 97%) as a TFA salt.
WO 53215
M_S: 379 ES+ (C17H19FN405)
1H NMR {300 MHz: D20) 5 ppm 1.75 (s, 3 H) 3.23 — 3.61 (m, 2 H) 4.12 — 4.25 (m, 3 H) 4.51
- 4.60 (m, 1 H) 5.53 — 5.98 (m, 1 H) 6.29 (br. s., 1 H) 7.45 — 7.57 (m, 4 H)
ediate 34: 2S 5R all 10X meth 0-N- razin lmeth l-1 6-
diazabic clo 3.2.1 0ctenecarb0xamide
N Oil—NOV
To a solution of (2S,5R)—6—(allyloxy)—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—
carboxylic acid (Intermediate 29, 199 mg, 0.84 mmol) in DMF (5 mL) at 0°C was added
pyrazin—Z—ylmethanamine (91 mg, 0.84 mmol), O—(7—azabenzotriazol—1—yl)—N,N,N',N'—
tetramethyluronium hexafluorophosphate (635 mg, 1.67 mmol) and DIEA (0.582 mL, 3.34
mmol). The reaction mixture was stirred for 30 minutes at room temperature, then diluted
with ethyl acetate and washed with saturated sodium bicarbonate once and 1:1 brinezwater
three times. The organics were dried over magnesium sulfate, filtered and trated.
Silica gel chromatography (0%—2.5% methanol/dichloromethane) afforded the title compound
(147 mg, 53.5 %) as an orange oil.
M_S: 330 ES+ (C16H19N503)
1H NMR1300 MHz= DMSO-dg) 8: 1.60 (s, 3H); 3.14 (m, 2H); 3.64 (m, 1H); 3.94 (m, 1H);
4.35 (m, 2H); 4.46 (m, 2H); 5.29 (m, 2H); 5.96 (m, 1H); 6.07 (m, 1H); 8.56 (m, 3H); 9.05 (m,
Exam le 29: eth lZ-flu0r0 2S 5R meth l0X0 2-
lmeth l carbam0 l -1 6-diazabic clo 3.2.1 0cten 1 0X acetate
N\ NJ,“
E / \
N F
O O/Sz/OV
To a solution of (2S,5R)—6—(allyloxy)—3—methyl—7—oxo—N—(pyrazin—Z—ylmethyl)—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 34, 153.8 mg, 0.47 mmol) in
methanol (3 mL) at room temperature was added 1,3—dimethylbarbituric acid (146 mg, 0.93
mmol) and tetrakis(triphenylphosphine)palladium(0) (54.0 mg, 0.05 mmol). The reaction
was stirred at room temperature for 2 hours. More tetrakis(triphenylphosphine)palladium(0)
(54.0 mg, 0.05 mmol) was added as well as 2 mL of methanol, and the mixture was stirred at
room ature for another 2 hours. The reaction mixture was concentrated to afford an
orange oil. The oil was dissolved in DMF (3 mL) and ium carbonate (194 mg, 1.40
mmol) and ethyl o—2—fluoroacetate (0.166 mL, 1.40 mmol) were added. The on
mixture was stirred overnight at room temperature then diluted with ethyl acetate and filtered
through a 0.45 um filter to remove solid ium carbonate. The filtrate was washed three
times with 1:1 brine:water. The organics were dried over magnesium sulfate, filtered and
concentrated. Silica gel chromatography (0%—100% ethyl acetate/hexanes) afforded the title
compound (95 mg, 52%) as a light orange foam. The compound is a 1:1 mixture of
diastereomers.
M_S: 394 ES+ (C17H20FN505)
1H NMR1300 MHz, DMSO—dg) 5: 1.22 (m, 3H); 1.63 (s, 3H); 2.71 (m, 1H); 3.10 (m, 1H);
3.98 (d, 1H); 4.02 (m, 1H); 4.26 (m, 2H); 4.47 (m, 2H); 6.05 (m, 1H); 6.20 (m, 1H); 8.56 (m,
3H); 9.10 (m, 1H).
To a solution of ethyl 2—fluoro—2—(((2S,5R)—3—methyl—7—oxo—2—((pyrazin—2—ylmethyl)—
carbamoyl)—1,6—diazabicyclo[3.2.1]oct—3—en—6—yl)oxy)acetate (Example 29, 95.3 mg, 0.24
mmol) in THF (2 mL) and water (0.66 mL) at 0°C was added lithium hydroxide (1M) (0.254
mL, 0.25 mmol), and stirred for 25 minutes at 0°C. Another 0.1 eq of lithium hydroxide was
added. After 15 minutes hydrochloric acid (0.5N) (0.242 mL, 0.12 mmol) was added to
adjust the pH to ~5—6. The reaction mixture was frozen and lyophilized. 90 mg of a pale
yellow solid were purified by reverse phase HPLC (YMC noid C30, 21.2mm x 150
mm, 4 um coupled with Synergi Polar RP, 21.2mm x 100mm, 4 um, 0%—30% acetonitrile in
water, 20 mL/min, 15 min). 23.6 mg (27%) of the title compound was obtained as a white
solid. The compound is a 1:1 mixture of diastereomers.
M_S: 366 ES+ 6FN505)
1H NMR1300 MHZ, DMSO-dg) 5: 1.63 (s, 3H); 3.09 (m, 1H); 3.68 (m, 1H); 4.02 (m, 1H);
4.29 (s, 1H); 4.48 (d, 2H); 5.22 (m, 1H); 6.05 (m, 1H); 8.57 (m, 3H); 9.07 (m, 1H).
Intermediate 35: S -tert-but ll- tert-but ldimeth lsil 10x buten l3-meth l
0x0butenyl )carbamate
To a solution of (S)—tert—butyl 1—(tert—butyldimethylsilyloxy)but—3—en—2—yl(2—
(methoxy(methyl)amino)—2—oxoethyl)carbamate (Intermediate 5, 30.79 g, 76.48 mmol) in
THF (200 mL) at 0 °C was added prop—1—en—2—ylmagnesium bromide (0.5M in THF) (300
mL, 149.90 mmol), and stirred at 0 °C for 1 hour. The reaction mixture was quenched with
200 mL 10% citric acid, diluted r with 100 mL water and extracted with ether. The
organics were concentrated and the ing oil was dissolved in ether and washed with
water and brine. The organics were dried over magnesium sulfate, filtered and concentrated.
Silica gel chromatography (0%—20% ethyl acetate/hexanes) afforded the desired product
(26.2 g, 89 %) as a colorless oil.
M_S: 384 ES+ (C20H37NO4Si)
1H 0 MHz= DMSO-dg) 8: 0.02 (d, 6H); 0.83 (s, 9H); 1.27-1.38 (m, 9H); 1.80 (m,
3H); 3.71 (m, 2H); 4.34 (m, 2H); 4.61 (m, 1H); 5.17 (m, 2H); 5.77 (m, 1H); 5.85 (m, 1H);
6.03 (m, 1H).
Intermediate 36: S -tert-but 12- tert-but ldimeth lsil 10x meth lmeth l0x0-
6-dih dr0 ridine-l 2H -carb0x late
TBSO/I’I(:(boc’N O
A on of rt—butyl t—butyldimethylsilyloxy)but—3—en—2—yl(3 —methyl—2—oxobut—3—
enyl)carbamate (Intermediate 35, 26.18 g, 68.25 mmol) in toluene (600 mL) was purged
with nitrogen for 15 minutes. (1,3—Bis—(2,4,6—trimethylphenyl)—2—imidazolidinylidene)—
dichloro(0—isopropoxyphenylmethylene)ruthenium (0.987 g, 1.57 mmol) was then added.
The reaction mixture was heated at 65 °C for 1.5 hours. The reaction mixture was
concentrated onto silica gel. Silica gel chromatography (0%—15% ethyl acetate/hexanes)
afforded the desired product (21.18 g, 87 %) as a colorless oil.
M_S: 356 ES+ (C18H33NO4Si)
1H NMR1300 MHz= DMSO-dg) 8: 0.01 (d, 6H); 0.81 (s, 9H); 1.42 (s, 9H); 1.75 (m, 3H);
3.74-3.89 (m, 3H); 4.04-4.32 (m, 1H); 4.67 (m, 1H); 6.88 (m, 1H).
Intermediate 37: 2S 5S -tert-but 12- tert-but ldimeth lsil 10x meth l-S-h drox
meth l-5 6-dih dr0 ridine-l 2H -carb0x late
TBSO/",,(j/N 'I
boc’ ’OH
To a solution of (III) chloride (14.68 g, 59.57 mmol) and (S)—tert—butyl 2—((tert—
butyldimethylsilyloxy)methyl)—4—methyl—5—oxo—5,6—dihydropyridine—1(2H)—carboxylate
(Intermediate 36, 21.18 g, 59.57 mmol) in methanol (300 mL) at 0 °C was added sodium
dride (2.254 g, 59.57 mmol) portionwise. After 15 minutes, the reaction mixture was
diluted with saturated ammonium chloride (100 mL) and water (100 mL), then extracted
twice with diethyl ether. The organic extracts were washed with brine, dried over magnesium
sulfate, filtered and concentrated. Silica gel chromatography % ethyl acetate/hexanes)
afforded the desired t (19.45 g, 91 %) as a colorless oil.
M_S: 358 ES+ (C13H35NO4Si)
1H NMR1300 MHz, g) 5: 0.02 (s, 6H); 0.86 (s, 9H); 1.39 (s, 9H); 1.69 (m, 3H);
2.63—2.72 (m, 1H); 3.59 (m, 2H); 3.82 (m, 1H); 4.03 (m, 1H); 4.21 (m, 1H); 5.04 (d, 1H);
.38 (m, 1H).
Intermediate 38: N- all 10x nitrobenzenesulfonamide
N02 0
©/S\N’O\/\||/,OH
To a stirred solution of O—allylhydroxylamine hydrochloride 5 g, 1341.59 mmol) in
DCM (2.5 L) at 0 OC, pyridine (318 mL, 3948 mmol) was added followed by the addition of
2—nitrobenzene—1—sulfonyl de (250 g, 1128.05 mmol) portionwise as a solid. The
reaction mixture was then stirred at the same temperature for 1 h. Completion of the reaction
was monitored by TLC. The reaction mixture was quenched with 1.5 N HCl (1 L). The
organic layer was separated, washed with water (250 mL), brine (250 mL), dried over
anhydrous NaZSO4, filtered and concentrated under vacuum to yield the residue. The crude
was purified by crystallization using EtOAc:petroleum ether (1:3) (800 mL) and afforded 202
g of the title compound as a light brown solid. The mother liquor was concentrated and
purified by silica gel column chromatography (mesh 60—120) using petroleum ether:EtOAc
(7:3) to yield another 19.1 g of the title compound as a yellow solid. The total yield was 76%.
UPLC: 257 (M—l) for C9H10N205S
1HNMR1400 MHz, DMSO-dg): 5 4.36-4.38 (m, 2H), 5.22-5.32 (m, 2H), 5.84-5.91 (m, 1H),
7.92-7.96 (m, 2H), 8.02-8.05 (m, 2H), 11.07 (s, 1H).
Intermediate 39: 2S 5R -tert-but 15- N- all 10X nitr0 hen lsulfonamido tert-
but ldimeth lsil 10X meth lmeth l-S 6-dih dr0 ridine-l 2H -carb0X late
TBSO/Ill'fi,N N’OW
To a solution of (2S,5S)—tert—butyl 2—((tert—butyldimethylsilyloxy)methyl)—5—hydroxy—4—
methyl—5,6—dihydropyridine—1(2H)—carboxylate (Intermediate 37, 19.45 g, 54.40 mmol) in
toluene (300 mL) at room temperature was added triphenylphosphine (17.06 g, 65.28 mmol),
N—(allyloXy)—2—nitrobenzenesulfonamide (Intermediate 38, 14.05 g, 54.40 mmol) and
diisopropyl azodicarboxylate (12.85 mL, 65.28 mmol). After 2 hours, the reaction mixture
was trated onto silica gel and purified. Silica gel chromatography (0%—50% ethyl
e/hexanes) afforded the desired product (25.2 g, 78 %) as a yellow oil.
M_S: 598 ES+ (C27H43N308SSi)
1H NMR1300 MHz= g) 8: 0.00 (s, 6H); 0.83 (s, 9H); 1.31 (m, 9H); 1.34 (m, 3H);
.25 (m, 1H); 3.59 (m, 2H); 3.99-4.41 (m, 5H); 5.17 (m, 2H); 5.72 (m, 2H); 7.93-8.16
(m, 4H).
ediate 40: 2S 5R -tert-but 15- N- all 10X nitr0 hen lsulfonamido
h drox meth lmeth l-5 6-dih dr0 ridine-l 2H -carb0X late
To a solution of )—tert—butyl 5—(N—(allyloxy)—2—nitrophenylsulfonamido)—2—((tert—
butyldimethylsilyloxy)methyl)—4—methyl—5,6—dihydropyridine—1(2H)—carboxylate
(Intermediate 39, 1 g, 1.67 mmol) in THF (11 mL) at 0 °C was added tetrabutylammonium
fluoride (1M in THF) (2.175 mL, 2.17 mmol). After 90 minutes, the on mixture was
WO 53215 2017/051692
concentrated onto silica gel. Silica gel chromatography (0%—70% ethyl acetate/hexanes)
ed the desired product (0.732 g, 90 %) as a tan foam.
M_S: 484 ES+ (C21H29N3OSS)
1H NMR1300 MHz= DMSO-dg) 8: 1.31 (m, 9H); 1.35 (m, 3H); 3.20 (m, 1H); 3.41 (m, 2H);
3.96-4.37 (m, 5H); 4.76 (m, 1H); 5.19 (m, 2H); 5.66-5.84 (m, 2H); 7.94-8.18 (m, 4H).
Intermediate 41: 2S 5R N- all 10x nitr0 hen lsulfonamido tert-
butox carbon lmeth [-1 2 5 6-tetrah dr0 ridinecarb0x lic acid
HO [Cf
N ,O
boc’ N A
To a solution of periodic acid (6 g, 31.26 mmol) in wet itrile (60 mL) (0.75% water by
volume) at room temperature was added um(VI) oxide (10 mg, 0.10 mmol). The
mixture was stirred until complete dissolution was achieved. To a solution of (2S,5R)—tert—
butyl 5—(N—(allyloxy)—2—nitrophenylsulfonamido)—2—(hydroxymethyl)—4—methyl—5,6—
dihydropyridine—1(2H)—carboxylate (Intermediate 40, 5 g, 10.34 mmol) in wet acetonitrile
(60 mL) (0.75% by volume) at 0 °C was added dropwise the previously formed ic
acid/chromium oxide solution (60 mL, 3 eq). After 30 minutes, the reaction mixture was
diluted with ether and washed with 10% citric acid, sat. sodium bicarbonate and brine. The
organics were dried over magnesium sulfate, filtered and concentrated to afford an orange
foam (4.16 g, 81%).
M_S: 498 ES+ (C21H27N309S)
1H NMR1300 MHz, DMSO-dg) 8: 1.26 (m, 9H); 1.31 (m, 3H); 3.02-3.25 (m, 1H); 3.90 (m,
1H); 4.17 (m, 3H); 4.65—4.77 (m, 1H); 5.12—5.21 (m, 2H); 5.68 (m, 1H); 5.88 (m, 1H); 7.92—
8.17 (m, 4H).
Intermediate 42: 2S 5R -tert-but 15- N- all 10x nitr0 hen lsulfonamido
o lmeth l-S 6-dih dr0 ridine-l 2H -carb0X late
H2N IMCC
N ,O
boc’ N A
To a solution of (2S,5R)—5—(N—(allyloxy)—2—nitrophenylsulfonamido)—1—(tert—butoxycarbonyl)—
yl—1,2,5,6—tetrahydropyridine—2—carboxylic acid mediate 41, 4.16 g, 8.36 mmol)
in DMF (35 mL) at room temperature was added ammonium de (0.895 g, 16.72 mmol),
HATU (4.77 g, 12.54 mmol) and DIEA (5.84 mL, 33.45 mmol). After 15 minutes, the
reaction mixture was diluted with ethyl acetate, washed with saturated sodium bicarbonate
and twice with 1:1 brine:water. The cs were dried over magnesium sulfate, filtered and
concentrated. Silica gel chromatography (0%—80% ethyl acetate/hexanes) was run twice to
afforded the desired product (2.16 g, 52 %) as a yellow foam.
M_S: 497 ES+ 8N4OgS)
1H NMR1300 MHz, DMSO-dg) 8: 1.26 (m, 9H); 1.37 (m, 3H); 3.12-3.35 (m, 1H); 3.80 (m,
1H); 4.18 (m, 3H); 4.64-4.79 (m, 1H); 5.13-5.22 (m, 2H); 5.68 (m, 1H); 5.88 (m, 1H); 7.04
(m, 1H); 7.45 (bs, 1H);7.90—8.18(m, 4H).
Intermediate 43: 2S 5R N- all 10X nitr0 hen namido meth [-1 2 5 6-
To a solution of (2S,5R)—tert—butyl 5—(N—(allyloxy)—2—nitrophenylsulfonamido)—2—carbamoyl—
4—methyl—5,6—dihydropyridine—1(2H)—carboxylate (Intermediate 42, 2.16 g, 4.35 mmol) in
DCM (20 mL) at room temperature was added zinc bromide (0.700 mL, 13.05 mmol). After
stirring overnight at room temperature, the reaction mixture was diluted with
dichloromethane and washed with saturated sodium bicarbonate and brine. The organics
were dried over magnesium sulfate, filtered and concentrated to afford the desired product
(1.450 g, 84 %) as a yellow foam.
M_S: 397 ES+ (C16H20N4O6S)
1H NMR1300 MHz, DMSO-dg) 8: 1.65 (m, 3H); 2.71 (m, 3H); 3.76 (m, 1H); 3.95 (m, 1H);
4.18—4.42 (m, 2H); 5.23 (m, 2H); 5.82 (m, 1H); 6.02 (m, 1H); 7.05 (bs, 1H); 7.30 (bs, 1H);
7.93-8.18 (m, 4H).
Intermediate 44: 2S 5R all 10X amin0 meth [-1 2 5 6-tetrah dr0 ridine
carboxamide and 2R 5R all 10X amin0 meth [-1 2 5 6-tetrah dr0 ridine
carboxamide
To a solution of (2S,5R)—5—(N—(allyloxy)—2—nitrophenylsulfonamido)—4—methyl—1,2,5,6—
tetrahydropyridine—2—carboxamide (Intermediate 43, 1.4 g, 3.53 mmol) and cesium
carbonate (9.21 g, 28.25 mmol) in THF (100 mL) at room temperature was added PS—
thiophenol (3—(3—mercaptophenyl)propanamidomethylpolystyrene) (1.55 mmol/g) (9.12 g,
14.13 mmol). After stirring overnight at room temperature, the reaction mixture was filtered
through a fritted funnel and the resin was washed twice with DCM. The filtrate was
concentrated to afford a yellow oil. Silica gel chromatography (0%—5%
methanol/dichloromethane) afforded a 3 to 1 e of trans and cis isomers (0.473 g,
63.4%) as a light yellow oil. The mixture was taken d without separation.
M_S: 212 ES+ (C10H17N302)
1H NMR1300 MHz, g) 8: 1.73 (m, 3H); 2.63 (m, 1H); 2.97 (m, 1H); 3.01 (m, 1H);
3.60 (m, 1H); 4.12 (m, 2H); 5.11—5.26 (m, 2H); 5.92 (m, 1H); 6.45 (m, 1H); 7.00 (m, 1H);
7.33 (bs, 1H).
ediate 45: 2S 5R all 10x meth l0x0-1 6-diazabic clo 3.2.1 0ctene
carboxamide
HZN \
0 0V
To a solution of )—5—(allyloxyamino)—4—methyl—1,2,5,6—tetrahydropyridine—2—
carboxamide and (2R,5R)—5—(allyloxyamino)—4—methyl—1,2,5,6—tetrahydropyridine—2—
carboxamide (Intermediate 44, 0.429 g, 2.03 mmol) and DIEA (1.415 mL, 8.12 mmol) in
acetonitrile (170 mL) at 0 °C was added sgene (0.241 g, 0.81 mmol) as a solution in
acetonitrile (1.5 mL) at a rate of 0.1 mL/min. Once addition was complete, the reaction was
warmed to room temperature and d two days. The reaction mixture was diluted with
ethyl acetate, washed with saturated sodium bicarbonate and brine, dried over magnesium
sulfate, filtered and concentrated. Silica gel chromatography (0%—20% ethyl acetate/hexanes)
afforded the product (0.312 g, 64.8%) as a light yellow oil.
M_S: 238 ES+ (C11H15N303)
1H NMR1300 MHZ, DMSO—dg) 5: 1.79 (m, 3H); 3.19 (m, 2H); 3.81 (m, 1H); 4.12 (m, 1H);
4.36 (m, 2H); 5.24—5.45 (m, 3H); 5.89—6.00 (m, 1H); 7.28 (bs, 1H); 7.49 (bs, 1H).
Exam le 31: ZR -eth lZ- ZS 5R -Z-carbam0 lmeth l0x0-1 6-
ic clo 3.2.1 en 10x -Z-flu0r0acetate
Exam le 32: ZS -eth lZ- ZS 5R -Z-carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 10x -Z-flu0r0acetate
Examples 31-32
To a solution of (2S,5R)—6—(a11yloxy)—4—methy1—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—
carboxamide (Intermediate 45, 0.2972 g, 1.25 mmol) in methanol (6 mL) at room
temperature was added 1,3—dimethy1barbituric acid (0.391 g, 2.51 mmol) and
tetrakis(triphenylphosphine)pa11adium(0) (0.145 g, 0.13 mmol). The reaction was stirred at
room temperature for 2 hours, then concentrated to afford an orange film. The orange film
was dissolved in DMF (6 mL). Potassium carbonate (0.519 g, 3.76 mmol) and ethyl
bromofluoroacetate (0.592 mL, 5.01 mmol) were added. The reaction mixture was stirred
overnight at room temperature, then diluted with ethyl acetate and ed through a 0.45 um
filter to remove solid potassium carbonate. The filtrate was washed twice with 1:1
brinezwater. The organics were dried over magnesium sulfate, filtered and concentrated.
Silica gel tography (0%—65% ethyl acetate/hexanes) afforded a 1:1 mixture of
diastereomers, 372 mg, 99%. tion of diastereomers was done on reverse phase HPLC
tis T3, 19 mm x 150 mm, 5 um, 20%—40% acetonitrile in water, 20 mL/min, 15 min).
Both diastereomers were obtained as white solids after 1yophi1ization.
The following products were obtained :
Example 31: (first eluting diastereomer): 108.8 mg, 29%
M_S: 302 ES+ (C12H16FN305)
1H NMR1300 MHz= DMSO-dg) 8: 1.23 (t, 3H); 1.82 (m, 3H); 3.19 (m, 1H); 3.29 (m, 1H);
3.96 (m, 1H); 4.23 (m, 1H); 4.24 (q, 2H); 5.52 (m, 1H); 6.28 (m, 1H); 7.32 (br s, 1H); 7.56
(br s, 1H).
Example 32: d eluting diastereomer): 103.3 mg, 27%
M_S: 302 ES+ 6FN305)
1H NMR1300 MHz, DMSO-dg) 8: 1.27 (t, 3H); 1.81 (m, 3H); 3.21 (m, 1H); 3.31 (m, 1H);
3.82 (m, 1H); 4.24 (m, 1H); 4.28 (q, 2H); 5.52 (m, 1H); 6.17 (m, 1H); 7.32 (br s, 1H); 7.55
(br s, 1H).
The stereochemistry of the two diastereomers were assigned based on order of elution as well
as based on the inhibitory activity of the corresponding carboxylic acids (examples 33 and
34): the more active acid, coming from the first eluting diastereomer, was assigned as the R—
isomer.
Exam le 33: 2R 2S 5R carbam0 lmeth l0x0-1 6-diazabic clo 3.2.1 0ct
en 1 0x flu0r0acetic acid lithium salt
To a solution of (2R)—ethyl 2—(((2S,5R)—2—carbamoyl—4—methyl—7—oxo—1,6—diazabicyclo—
[3.2.1]oct—3—en—6—yl)oxy)—2—fluoroacetate (Example 31, 96.6 mg, 0.32 mmol) in THF (3 mL)
and water (1 mL) at 0 °C was added lithium ide (0.337 mL, 0.34 mmol). The reaction
mixture was kept in ice bath and stirred for 15 s. Another 0.2 eq of lithium hydroxide
was added. After 15 minutes, the reaction mixture was adjusted to pH = 7 with 0.5N HCl.
The THF was evaporated and the remaining aqueous was frozen and lyophilized to afford a
pale yellow solid. Reverse phase HPLC (YMC noid C30, 19 mm x 150 mm, 5 um
coupled with Synergi Polar RP 21.2 mm x 100 mm, 4 um, 0%—40% itrile in water, 20
mL/min, 15 min) afforded the title compound as a white solid after lyophilization, 34.8 mg,
M_S: 274 ES+ (C10H12FN305)
1H NMR1300 MHz, g) 5: 1.83 (m, 3H); 3.21 (m, 2H); 3.91 (m, 1H); 4.16 (m, 1H);
.33 (m, 1H); 5.44 (m, 1H); 7.27 (br s, 1H); 7.53 (br s, 1H).
Exam le 34: 2S 2S 5R carbam0 lmeth l0x0-1 6-diazabic clo 3.2.1 0ct
en 1 0x flu0r0acetic acid lithium salt
The title compound was prepared from (2S)—ethy1 2—(((2S,5R)—2—carbamoyl—4—methy1—7—oxo—
1,6—diazabicyclo[3.2.1]oct—3—en—6—y1)oxy)—2—fluoroacetate (Example 32, 91.8 mg, 0.30
mmol) according to the procedure for Example 33. Purification ions were the same to
afford an off—White solid after lyophilization, 11.7 mg, 14%.
M_S: 274 ES+ (C10H12FN305)
1H NMR1300 MHz= g) 5: 1.81 (m, 3H); 3.21 (m, 2H); 3.87 (m, 1H); 4.16 (m, 1H);
.25 (m, 1H); 5.45 (m, 1H); 7.28 (br s, 1H); 7.54 (br s, 1H).
Exam le 35: 2R -is0 1'0 12- 2S 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 10x flu0r0acetate
Exam le 36: 2S -is0 1'0 12- 2S 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 10x flu0r0acetate
To a solution of (2S,5R)—6—(allyloxy)—4—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—
carboxamide (Intermediate 45, 0.15 g, 0.63 mmol) in methanol (3 mL) at room temperature
was added 1,3—dimethylbarbituric acid (0.197 g, 1.26 mmol) and tetrakis(triphenyl—
phosphine)palladium(0) (0.073 g, 0.06 mmol). The reaction was stirred at room temperature
for 2 hours, then concentrated to afford an orange film. The orange film was dissolved in
DMF (4 mL). Potassium carbonate (0.175 g, 1.26 mmol) and pyl 2—bromo—2—
fluoroacetate (Intermediate 18, 0.377 g, 1.90 mmol) were added. The reaction e was
stirred at room temperature for 4.5 hours then diluted with ethyl acetate and filtered through a
0.45 um filter to remove solid potassium ate. The filtrate was washed twice with 1:1
brinezwater. The organics were dried over magnesium sulfate, filtered and concentrated.
Silica gel chromatography (0%—65% ethyl acetate/hexanes) afforded a 1:1 mixture of
diastereomers, 196 mg, 98%. Separation of diastereomers was done on reverse phase HPLC
(Atlantis T3, 19 mm x 150 mm, 5 um, 20%—40% acetonitrile in water, 20 mL/min, 15 min).
Both diastereomers were obtained as white solids after lyophilization.
e 35 : (first eluting diastereomer): 58.6 mg, 31%.
M_S: 316 ES+ (C13H13FN305)
1H NMR1300 MHz, DMSO—dg) 5: 1.22 (m, 6H); 1.81 (m, 3H); 3.17 (m, 1H); 3.34 (m, 1H);
3.93 (m, 1H); 4.22 (m, 1H); 5.01 (q, 2H); 5.51 (m, 1H); 6.23 (m, 1H); 7.31 (br s, 1H); 7.54
(br s, 1H).
Example 36: (2nd eluting diastereomer): 53.8 mg, 29%.
M_S: 316 ES+ (C13H18FN305)
1H 0 MHz, g) 5: 1.28 (m, 6H); 1.81 (m, 3H); 3.19 (m, 1H); 3.29 (m, 1H);
3.82 (m, 1H); 4.24 (m, 1H); 5.06 (m, 1H); 5.52 (m, 1H); 6.14 (m, 1H); 7.32 (br s, 1H); 7.55
(br s, 1H).
Intermediates 46-50 were intentionally omitted.
Intermediate 51: R -tert-but 14- e do r0 lh drox meth [-2 2-
dimethyloxazolidinecarb0xylate
To a solution of (R)—tert—butyl 4—formyl—2,2—dimethyloxazolidine—3—carboxylate (Aldrich,
12.44 g, 54.26 mmol) in THF (150 mL) at —78 °C was added cyclopropylmagnesium bromide
(217 mL, 108.52 mmol), dropwise. The reaction mixture was allowed to warm to room
temperature and stir overnight. The reaction was quenched with water and d with ethyl
acetate and brine. The resulting emulsion was filtered through celite and the layers ted.
The organics were dried over magnesium sulfate, ed and concentrated. Silica gel
chromatography (0%—20% ethyl acetate/hexanes) afforded the title compound as a light
yellow oil (12.47 g, 85%).
1H NMR1300 MHz= DMSO-dg) 5: 0.16 (m, 2H); 0.37 (m, 2H); 0.82 (m, 1H); 1.45 (m, 15H);
2.87 (m, 1H); 3.86 (m, 2H); 3.97 (m, 1H); 4.74 (m, 1H).
Intermediate 52: R -tert-but 14- c clo r0 anecarbon l-2 th loxazolidine
ylate
To a solution of (R)—tert—butyl 4—(cyclopropyl(hydroxy)methyl)—2,2—dimethyloxazolidine—3—
carboxylate mediate 51, 12.47 g, 45.95 mmol) in DCM (300 mL) at room temperature
was added Dess—Martin periodinane (29.2 g, 68.93 mmol). The reaction mixture was stirred
overnight then diluted with ethyl acetate and washed with saturated sodium bicarbonate. An
emulsion formed and was filtered through celite. The layers were separated and the organics
washed with brine. The organics were dried over magnesium sulfate, ed and
concentrated. Silica gel chromatography (0%—20% ethyl acetate/hexanes) afforded the title
compound as a colorless oil (11.15 g, 90%).
1H NMR1300 MHz, DMSO-dg) 8: 0.90 (m, 4H); 1.38 (m, 12H); 1.54 (m, 3H); 2.12 (m, 1H);
3.94 (m, 1H); 4.18 (m, 1H); 4.56 (m, 1H).
Intermediate 53: S -tert-but l4- l-c clo r0 lvin l-2 2-dimeth lidine
carboxylate
To a suspension of potassium tert—butoxide (9.29 g, 82.80 mmol) in ether (250 mL) at room
temperature was added methyltriphenylphosphonium bromide (29.6 g, 82.80 mmol). The
mixture turned bright yellow and was heated to 40 °C for 1 hour. The mixture was cooled to
room temperature and a solution of (R)—tert—butyl 4—(cyclopropanecarbonyl)—2,2—
dimethyloxazolidine—3—carboxylate (Intermediate 52, 11.15 g, 41.40 mmol) in ether (30 mL)
was added and the reaction mixture was stirred for 2 hours. The reaction was quenched with
water (10 mL) and the layers were separated. The aqueous was extracted once with ether.
The combined organic ts were dried over magnesium sulfate, filtered and trated.
Silica gel chromatography % ethyl acetate/hexanes) afforded the title nd as a
colorless oil (9.84 g, 89%).
1H 0 MHz= DMSO-dg) 5: 0.42 (m, 2H); 0.65 (m, 2H); 1.43 (m, 16H); 3.76 (m, 1H);
4.09 (m, 1H); 4.27 (m, 1H); 4.66 (m, 2H).
Intermediate 54: S -tert-but ll- tert-but ldimeth lsil 10x c clo r0 lbuten
ylcarbamate
To a solution of (S)—tert—butyl 4—(1—cyclopropylvinyl)—2,2—dimethyloxazolidine—3—carboxylate
mediate 53, 8.25 g, 30.86 mmol) in methanol (100 mL) at room temperature was
added enesulfonic acid monohydrate (1.174 g, 6.17 mmol). The reaction mixture was
heated to 80 °C overnight. Another 0.2 eq of p—toluenesulfonic acid monohydrate was added
and heated at 80 °C for another 2 hours. The reaction mixture was cooled to room
temperature. Triethylamine (4.29 mL, 30.86 mmol) and di—tert—butyl dicarbonate (3.37 g,
.43 mmol) were added. The reaction mixture was stirred two days then trated. The
residue was dissolved in ethyl acetate and washed once with saturated sodium onate.
The combined organic extracts were dried over magnesium sulfate, filtered and concentrated.
The resulting oil was dissolved in DCM (100 mL). Imidazole (2.73 g, 40.11 mmol), 4—
dimethylaminopyridine (0.754 g, 6.17 mmol) and tert—butyldimethylsilyl chloride (4.65 g,
.86 mmol) were added and the reaction mixture was stirred overnight at room temperature.
The reaction mixture was filtered to remove solids and washed with brine twice. The organic
layer was dried over magnesium sulfate, filtered and concentrated. Silica gel
chromatography (0%—10% ethyl acetate/hexanes) afforded the title compound as a colorless
oil (6.77 g, 64%).
M_S: 342 ES+ (C18H35N03Si)
1H 0 MHz, DMSO—dg) 5: 0.04 (s, 6H); 0.39 (m, 2H); 0.63 (m, 2H); 0.85 (s, 9H);
1.32 (m, 1H); 1.37 (m, 9H); 3.55 (m, 1H); 3.67 (m, 1H); 3.99 (m, 1H); 4.63 (s, 1H); 4.78 (s,
1H); 6.80 (m, 1H).
Intermediate 55: S tert-but ldimeth lsil 10X c clo r0 lbutenamine
TBSO/\\/fl\\;7
To a solution of (S)—tert—butyl 1—(tert—butyldimethylsilyloxy)—3—cyclopropylbut—3—en—2—
ylcarbamate (Intermediate 54, 6.77 g, 19.82 mmol) in DCM (100 mL) at room temperature
was added zinc bromide (17.86 g, 79.28 mmol). The reaction mixture was d overnight
at room temperature. r 1 eq of zinc e was added. After several hours the
reaction mixture was filtered and washed with saturated sodium bicarbonate. The resulting
emulsion was filtered through a nylon filter and the layers were separated. The organics were
dried over magnesium sulfate, filtered and concentrated to afford the title compound as a
yellow oil (4.61 g, 96%).
1H NMR1300 MHz2 DMSO—dg) 5: 0.04 (s, 6H); 0.39 (m, 2H); 0.63 (m, 2H); 0.87 (s, 9H);
1.35 (m, 1H); 1.81 (m, 2H); 3.33 (m, 1H); 3.45 (m, 1H); 3.67 (m, 1H); 4.59 (s, 1H); 4.83 (m,
Intermediate 56: S -tert-but ll- tert-but h lsil 10X c clo r0 lbuten
l 2- meth0X meth 1 amino 0X0eth l carbamate
TBso’“\{JL\§7
o ’O\~
The title compound was prepared from (S)—1—(tert—butyldimethylsilyloxy)—3—cyclopropylbut—
3—en—2—amine (Intermediate 55, 4.61 g, 19.09 mmol) and 2—bromo—N—methoxy—N—
acetamide (Intermediate 4, 3.16 g, 17.36 mmol) following the procedure described
for Intermediate 5. The desired product was obtained as a light yellow oil (4.94 g, 64%).
M_S: 443 ES+ (C22H42N205Si)
1H NMR1300 MHZ; DMSO-dg) 5: 0.03 (m, 6H); 0.35 (m, 1H); 0.48 (m, 1H); 0.61 (m, 2H);
0.83 (m, 9H); 1.35 (m, 9H); 3.07 (m, 3H); 3.65 (m, 3H); 3.84 (m, 2H); 4.02 (m, 2H); 4.54 (m,
1H); 4.83 (m, 2H).
A suspension of cerium (III) chloride (27.8 g, 112.95 mmol) in THF (100 mL) at room
temperature was stirred usly for 2 hours. The suspension was cooled to —78°C and (E)—
prop—1—enylmagnesium bromide (0.5 M in THF) (226 mL, 112.95 mmol) was added
dropwise. The mixture was stirred at —78°C for 1.5 hours. (S)—tert—butyl 1—(tert—
butyldimethylsilyloxy)—3—cyclopropylbut—3—en—2—yl(2—(methoxy(methyl)amino)—2—
oxoethyl)carbamate (Intermediate 56, 5 g, 11.30 mmol) in THF (20 mL) was then added
dropwise at —78°C. The reaction was stirred at —78 °C for 30 minutes and then warmed to 0°C
for 15 minutes. The reaction was quenched with 10% citric acid, diluted further with water
and extracted twice with ether. The organics were washed once with brine, dried over
magnesium sulfate, filtered and trated. Silica gel chromatography (0%—20% ethyl
e/hexanes) afforded the title compound as a light yellow oil (4.0 g, 84%).
M_S: 424 ES+ (C23H41NO4Si)
1H NMR1300 MHz, DMSO—dg) 5: 0.03 (m, 6H); 0.43 (m, 2H); 0.61 (m, 2H); 0.83 (m, 9H);
1.34 (m, 10H); 1.84 (m, 2H); 2.04 (m, 1H); 3.74 (m, 1H); 3.84 (m, 2H); 4.03 (m, 1H); 4.57
(m, 1H); 4.79 (m, 2H); 6.28 (m, 1H); 6.84 (m, 1H).
Intermediate 58: S -tert-but 12- ut ldimeth lsil 10x meth lc clo r0 [
0x0-5,6-dihydropyridine-112H2-carb0xylate
The title compound was prepared from (S)—tert—butyl t—butyldimethylsilyloxy)—3—
cyclopropylbut—3—en—2—yl(2—oxopent—3—enyl)carbamate (Intermediate 57, 4 g, 9.44 mmol)
following the procedure described for Intermediate 7, except the reaction e was
heated at 110°C overnight. The desired product was obtained as a light brown oil (2.97 g,
82%).
M_S: 382 ES+ (C20H35NO4Si)
1H NMR1300 MHz2 DMSO—dg) 5: 0.01 (m, 6H); 0.62 (m, 1H); 0.80 (s, 9H); 1.00 (m, 3H);
1.42 (s, 9H); 1.61 (m, 1H); 3.80 (m, 1H); 3.95 (m, 2H); 4.19 (m, 1H); 4.75 (m, 1H); 5.72 (s,
Intermediate 59: 2S SS but 12- tert-but ldimeth lsil l0X meth [
c clo r0 l-S-h dr0X -5 6-dih dr0 -l 2H -carb0X late
TBSO/II" \
N '1
boc’ ’OH
The title compound was prepared from (S)—tert—butyl 2—((tert—butyldimethylsilyloxy)methyl)—
opropyl—5—oxo—5,6—dihydropyridine—1(2H)—carboxylate (Intermediate 58, 2.97 g, 7.78
mmol) ing the procedure described for Intermediate 10. The desired product was
obtained as a tan oil (2.74 g, 92%).
M_S: 384 ES+ (C20H37NO4Si)
1H NMR1300 MHz2 DMSO-dg) 8: 0.02 (m, 6H); 0.34 (m, 1H); 0.47 (m, 1H); 0.64 (m, 2H);
0.85 (m, 9H); 1.26 (m, 1H); 1.39 (s, 9H); 2.65 (m, 1H); 3.89 (m, 3H); 4.05 (m, 1H); 4.95 (m,
1H); 5.34 (m, 1H).
Intermediate 60: 2S 5R -tert-but 15- N- all l0X nitr0 hen lsulfonamido tert-
The title compound was prepared from (2S,5S)—tert—butyl 2—((tert—butyldimethylsilyloxy)—
methyl)—3—cyclopropy1—5—hydroxy—5,6—dihydropyridine—1(2H)—carboxylate (Intermediate 59,
2.74 g, 7.14 mmol) and N—(allyloxy)—2—nitrobenzenesulfonamide (1.85 g, 7.14 mmol)
following the procedure described for Intermediate 11. The desired product was obtained as
a light yellow oil (3.19 g, 71%).
M_S: 624 ES+ (C29H45N308SSi)
1H NMR 300 MHz DMSO-dg) 5: 0.00 (m, 6H); 0.34 (m, 1H); 0.63 (m, 2H); 0.83 (m, 9H);
1.37 (m, 9H); 3.30 (m, 1H); 3.84 (m, 2H); 4.30 (m, 4H); 5.18 (m, 2H); 5.75 (m, 1H); 8.04 (m,
Intermediate 61: 28 SR -tert-but 15- N- all l0X nitr0 hen lsulfonamido
c clo r0 l h dr0X meth l-5 6-dih dr0 ridine-1 2H -carb0X late
The title compound was prepared from )—tert—buty1 5—(N—(a11yloxy)—2—
nitrophenylsulfonamido)—2—((tert—butyldimethylsilyloxy)methy1)—3—cyclopropy1—5,6—
dihydropyridine—1(2H)—carboxy1ate (Intermediate 60, 3.19 g, 5.11 mmol) following the
procedure bed for Intermediate 12. The desired product was obtained as a tan foam
(2.35 g, 90%).
M_S: 510 ES+ (C23H31N30gS)
1H NMR1300 MHz2 g) 5: 0.32 (m, 2H); 0.62 (m, 2H); 1.35 (m, 9H); 3.30 (m, 1H);
3.67 (m, 2H); 4.27 (m, 4H); 4.71 (m, 1H); 5.19 (m, 2H); 5.71 (m, 1H); 8.04 (m, 4H).
ediate 62: 28 SR N- all l0X nitr0 hen lsulfonamido tert-
but0X carbon lc clo r0 l-1 2 5 ah dr0 ridinecarb0X lic acid
HOJI'“CF \
, ,0
boc I}! A
The title compound was prepared from (2S,5R)—tert—buty1 5—(N—(a11yloxy)—2—
nitrophenylsulfonamido)—3—cyclopropy1—2—(hydroxymethy1)—5,6—dihydropyridine— 1(2H)—
carboxylate (Intermediate 61, 2.35 g, 4.61 mmol) following the procedure described for
Intermediate 13. The desired product was obtained as an orange foam (2.28 g, 94%).
M_S: 524 ES+ (C23H29N3098)
Intermediate 63: 28 SR -tert-but 15- N- all l0X nitr0 hen lsulfonamido
carbam0 lc clo r0 l-5 6-dih dr0 ridine-1 2H -carb0X late
HZNJCl) \
,N ,0
boc I}! A
The title compound was prepared from (2S,5R)—5—(N—(allyloxy)—2—nitrophenylsulfonamido)—
1—(tert—butoxycarbonyl)—3—cyclopropyl—1,2,5,6—tetrahydropyridine—2—carboxylic acid
mediate 62, 2.28 g, 4.35 mmol) following the procedure described for Intermediate
14. The desired product was obtained as an orange foam (1.07 g, 47%).
M_S: 523 ES+ (C23H30N40gS)
1H NMR1300 MHz2 DMSO—dg) 5: 0.23 (m, 2H); 0.59 (m, 2H); 1.35 (m, 9H); 3.58 (m, 1H);
4.23 (m, 3H); 4.72 (m, 1H); 5.19 (m, 2H); 5.71 (m, 1H); 7.18 (m, 1H); 7.59 (m, 1H); 8.04 (m,
Intermediate 64: 2S 5R N- all 10X nitr0 hen lsulfonamido c clo r0 [-
6-tetrahydropyridinecarb0xamide
HZN \
The title compound was prepared from (2S,5R)—tert—butyl 5—(N—(allyloxy)—2—
nitrophenylsulfonamido)—2—carbamoyl—3—cyclopropyl—5,6—dihydropyridine—1(2H)—carboxylate
(Intermediate 63, 0.932 g, 1.78 mmol) following the procedure described for Intermediate
. The desired product was obtained as an orange foam (0.518 g, 68%).
M_S: 423 ES+ 2N4O6S)
1H NMR 300 MHz DMSO-dg) 8: 0.18 (m, 2H); 0.53 (m, 2H); 1.29 (m, 1H); 2.30 (m, 1H);
2.58 (m, 1H); 2.95 (m, 1H); 3.72 (m, 1H); 4.22 (m, 1H); 4.36 (m, 2H); 4.96 (m, 1H); 5.24 (m,
2H); 5.80 (m, 1H); 7.07 (bs, 1H); 7.39 (bs, 1H); 8.04 (m, 4H).
Intermediate 65: R all 10X amino c clo r0 [-1 2 5 6-tetrah dr0 ridine
carboxamide
The title compound was prepared from (2S,5R)—5—(N—(allyloxy)—2—nitrophenylsulfonamido)—
opropyl—1,2,5,6—tetrahydropyridine—2—carboxamide (Intermediate 64, 0.518 g, 1.23
mmol) following the procedure described for Intermediate 26. The desired product was
ed as a light yellow oil (0.171 g, 59%). The product is a mixture of diastereomers.
M_S: 238 ES+ 9N302)
1H NMR1300 MHz2 DMSO—dg) 5: 0.28 (m, 2H); 0.41 (m, 2H); 0.54 (m, 2H); 1.33 (m, 1H);
2.49 (m, 1H); 2.64 (m, 1H); 2.93 (m, 1H); 3.23 (m, 1H); 3.65 (m, 1H); 4.07 (m, 2H); 5.19 (m,
3H); 5.89 (m, 1H); 6.26 (m, 1H); 6.97 (bs, 1H); 7.34 (bs, 1H).
ediate 66: 2S 5R all l0X c clo r0 l0X0-1 6-diazabic clo 3.2.1 0ct
enecarb0xamide
The title compound was prepared from (R)—5—(a11yloxyamino)—3—cyclopropy1—1,2,5,6—
tetrahydropyridine—2—carboxamide (Intermediate 65, 0.316 g, 1.33 mmol) following the
procedure described for Intermediate 27. The desired product was obtained as a colorless
oil (0.261 g, 74%).
M_S: 264 ES+ (C13H17N303)
1H NMR1300 MHz= DMSO-dg) 8: 0.37 (m, 2H); 0.60 (m, 2H); 1.20 (m, 1H); 2.98 (m, 1H);
3.79 (m, 1H); 3.92 (m, 1H); 4.20 (m, 1H); 4.33 (m, 2H); 5.28 (m, 2H); 5.93 (m, 2H); 7.30
(bs, 1H); 7.86 (bs, 1H).
Exam le 37: 2R -is0 r0 12- 2S 5R carbam0 lc clo r0 0
diazabic clo 3.2.1 0cten l0X flu0r0acetate
Exam le 38: 2S -is0 r0 12- 2S 5R carbam0 lc clo r0 l0x0-1 6-
diazabic clo 3.2.1 0cten 10x flu0r0acetate
H2N \
o 0&07/
To a solution of (2S,5R)—6—(allyloxy)—3—cyclopropyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—
oxamide (Intermediate 66, 0.15 g, 0.57 mmol) in methanol (3 mL) at room
temperature was added 1,3—dimethylbarbituric acid (0.178 g, 1.14 mmol) and
tetrakis(triphenylphosphine)palladium(0) (0.066 g, 0.06 mmol). The reaction was stirred at
room temperature for 2 hours, then concentrated to afford an orange film. The orange film
was dissolved in DMF (4 mL). Potassium carbonate (0.157 g, 1.14 mmol) and isopropyl 2—
bromo—2—fluoroacetate (Intermediate 18, 0.340 g, 1.71 mmol) were added. The reaction
e was stirred at room temperature ght then diluted with ethyl acetate and filtered
through a 0.45 um filter to remove solid ium carbonate. The filtrate was washed twice
with 1:1 brine:water. The organics were dried over ium sulfate, filtered and
concentrated. Silica gel chromatography (0%—65% ethyl acetate/hexanes) afforded a 1:1
mixture of diastereomers, 166.3 mg, 86%. Separation of diastereomers was done on reverse
phase HPLC (Atlantis T3, 19 mm x 150 mm, 5 um, 20%—40% itrile in water, 20
mL/min, 15 min). Both diastereomers were obtained as white solids after lyophilization.
Example 37: (first eluting diastereomer) : 47.3 mg, 24%.
M_S: 342 ES+ (C15H20FN305)
1H NMR1300 MHz, DMSO-dg) 8: 0.39 (m, 2H); 0.61 (m, 1H); 1.19 (d, 3H); 1.21 (m, 1H);
1.24 (d, 3H); 2.99 (m, 1H); 3.88 (m, 1H); 4.01 (m, 1H); 4.29 (m, 1H), 5.00 (m, 1H); 5.87 (m,
1H); 6.20 (m, 1H); 7.36 (br s, 1H); 7.90 (br s, 1H).
Example 38: d eluting diastereomer): 49.8 mg, 26%.
M_S: 342 ES+ (C15H20FN305)
1H NMR1300 MHz, DMSO-dg) 8: 0.41 (m, 2H); 0.62 (m, 1H); 1.22 (m, 1H); 1.27 (d, 3H);
1.29 (d, 3H); 3.03 (m, 1H); 3.91 (m, 1H); 3.94 (m, 1H); 4.31 (m, 1H), 5.05 (m, 1H); 5.91 (m,
1H); 6.12 (m, 1H); 7.37 (br s, 1H); 7.93 (br s, 1H).
Exam le 39: ZR -eth lZ- ZS 5R -Z-carbam0 lc clo r0 l0x0-1 6-
diazabic clo 3.2.1 0cten 10x -Z-flu0roacetate
Exam le 40: ZS -eth lZ- ZS 5R -Z-carbam0 lc clo r0 l0x0-1 6-
diazabic clo 3.Z.1 0cten 10x -Z-flu0roacetate
H2N \
0 (TWOV
To a solution of )—6—(allyloxy)—3—cyclopropyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—
oxamide (Intermediate 66, 0.2972 g, 1.13 mmol) in methanol (6 mL) at room
temperature was added 1,3—dimethylbarbituric acid (0.352 g, 2.26 mmol) and
tetrakis(triphenylphosphine)palladium(0) (0.130 g, 0.11 mmol). The reaction was stirred at
room temperature for 2 hours, then concentrated to afford an orange film. The orange film
was dissolved in DMF (6 mL). Potassium carbonate (0.468 g, 3.39 mmol) and ethyl
luoroacetate (0.534 mL, 4.52 mmol) were added. The reaction mixture was stirred
overnight at room temperature then diluted with ethyl acetate and ed through a 0.45 um
filter to remove solid potassium carbonate. The filtrate was washed twice with 1:1
brinezwater. The organics were dried over magnesium sulfate, filtered and concentrated.
Silica gel chromatography (0%—65% ethyl acetate/hexanes) afforded a 1:1 mixture of
diastereomers, 303.7 mg, 82%. Separation of diastereomers was done on reverse phase
HPLC (Atlantis T3, 19 mm x 150 mm, 5 um, % acetonitrile in water, 20 , 15
min). Both diastereomers were obtained as white solids after lyophilization.
Example 39: (first eluting diastereomer): 107 mg, 29%
M_S: 328 ES+ (C14H13FN305)
1H NMR1300 MHz, DMSO-dg) 8: 0.39 (m, 2H); 0.61 (m, 2H); 1.21 (m, 4H); 3.01 (m, 1H);
3.89 (m, 1H); 4.02 (m, 1H); 4.19 (m, 2H); 4.29 (s, 1H); 5.88 (m, 1H); 6.22 (m, 1H); 7.36 (br
s, 1H); 7.91 (br s, 1H).
Example 40: (second eluting diastereomer): 110.9 mg, 30%.
M_S: 328 ES+ (C14H18FN305)
1H NMR1300 MHz, DMSO-dg) 8: 0.40 (m, 2H); 0.61 (m, 2H); 1.26 (m, 4H); 3.04 (m, 1H);
3.90 (m, 1H); 3.94 (m, 1H); 4.26 (m, 3H); 5.90 (m, 1H); 6.24 (m, 1H); 7.36 (br s, 1H); 7.92
(br s, 1H).
Exam le 41: 2R 2S 5R carbam0 lc clo r0 l0x0-1 6-
ic clo 3.2.1 0cten 1 0x flu0r0acetic acid m salt
To a solution of (2R)—ethyl 2—(((2S,5R)—2—carbamoyl—3—cyclopropyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—en—6—yl)oxy)—2—fluoroacetate (Example 39, 96.6 mg, 0.30 mmol) in
THF (3 mL) and water (1 mL) at 0°C was added lithium ide (1M) (0.310 mL, 0.31
mmol). The reaction mixture was kept in an ice bath and stirred for 15 minutes. Another 0.2
eq of lithium hydroxide was added. After 15 minutes the reaction mixture was adjusted to
pH = 7 with 0.5N HCl. The mixture was frozen and lyophilized to afford a pale yellow solid,
90.4 mg. Reverse phase HPLC (YMC Carotenoid 30, 19 mm x 150 mm, 5 pm coupled with
Synergi Polar RP, 21.2 mm x 100 mm, 4 pm, 0%—25% acetonitrile in water, 20 , 5
min) afforded the title copound as awhite solid, 45.9 mg, 52%.
M_S: 300 ES+ (C12H14FN305)
1H NMR1300 MHz= DMSO-dg) 8: 0.38 (m, 2H); 0.59 (m, 2H); 1.20 (m, 1H); 3.02 (m, 1H);
3.83 (m, 1H); 4.00 (m, 1H); 4.25 (m, 1H); 5.24 (m, 1H); 5.89 (m, 1H); 7.30 (br s, 1H); 7.88
(br s, 1H).
Exam le 42: 2R ZS 5R carbam0 lc clo r0 l0x0-1 6-
diazabic clo 3.2.1 0cten 1 0x flu0r0acetic acid lithium salt
I F
O \O/SfOH
To a solution of —(((2S,5R)—2—carbamoyl—3—cyclopropyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—en—6—yl)oxy)—2—fluoroacetic acid (Example 40, 96.6 mg, 0.30 mmol)
in THF (3 mL) and water (1) at 0°C was added lithium hydroxide (1M) (0.310 mL, 0.31
mmol). The reaction mixture was kept in ice bath and stirred for 15 minutes. Another 0.2 eq
of lithium hydroxide was added. After 15 minutes the reaction mixture was adjusted to pH =
7 with 0.5N HCl. The mixture was frozen and lized to afford a pale yellow solid, 90.6
mg. Reverse phase HPLC (YMC Carotenoid 30, 19 mm x 150 mm, 5 pm coupled with
Synergi Polar RP, 21.2 mm x 100 mm, 4 pm, 0%—25% acetonitrile in water, 20 mL/min, 5
min) afforded the title copound as awhite solid, 41.2 mg, 45%.
M_S: 300 ES+ (C12H14FN305)
1H NMR1300 MHz= DMSO-dg) 8: 0.39 (m, 2H); 0.59 (m, 2H); 1.20 (m, 1H); 3.02 (m, 1H);
3.82 (m, 1H); 3.98 (m, 1H); 4.24 (m, 1H); 5.24 (m, 1H); 5.90 (m, 1H); 7.31 (br s, 1H); 7.90
(br s, 1H).
Exam le 43: 2- ZS 5R carbam0 lc clo r0 0-1 6-diazabic clo 3.2.1 0ct
en 1 0x flu0r0acetic acid lithium salt
(2R)—2—(((2S ,5R)—2—carbamoyl—3—cyclopropyl—7—oxo—1,6—diazabicyclo[3.2. 3—en—6—
)—2—fluoroacetic acid (Example 41, 8 mg, 0.03 mmol) and (2S)—2—(((2S,5R)—2—
carbamoyl—3—cyclopropyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—en—6—yl)oxy)—2—fluoroacetic
acid (Example 42, 8 mg, 0.03 mmol) were combined in an amber Vial. Water (1.5 mL) was
WO 53215
added. The mixture was frozen and lyophilized to afford a white solid, 16 mg.
M_S: 300 ES+ (C12H14FN305)
1H NMR 300 MHz DMSO-dg) 8: 0.39 (m, 2H); 0.58 (m, 2H); 1.19 (m, 1H); 3.00 (m, 1H);
3.81 (m, 1H); 3.98 (m, 1H); 4.24 (m, 1H); 5.19 (m, 1H); 5.89 (m, 1H); 7.29 (br s, 1H); 7.88
(br s, 1H).
Intermediate 67: 1-is0 r0 lmeth 1- r0 1 2-br0m0-2 2-diflu0r0-acetate
To a solution of 2,4—dimethylpentan—3—ol (0.72 mL, 5.17 mmol) and N,N—
diisopropylethylamine (1.81 mL, 10.34 mmol) in DCM (20 mL) at 0°C was added 2—bromo—
2,2—difluoro—acetyl de (0.49 mL, 5.17 mmol) se. The reaction mixture was
stirred at 35°C overnight. The reaction was quenched with 10 mL of 1N hydrochloric acid.
The layers were separated. The cs were washed twice with water, once with brine,
then dried over magnesium sulfate, filtered and concentrated to afford the title compound as a
dark orange oil, 1.95 g, quant. Crude used in next step.
1H NMR1300 MHZ, CDCl§fl 5: 0.95 (m, 12H); 2.06 (m, 2H); 4.74 (m, 1H).
To a solution of (2S,5R)—6—hydroxy—3—methyl—7—oxo—1,6—diazabicyclo[3.2. 1]oct—3—ene—2—
carboxamide (Intermediate 193, 150 mg, 0.76 mmol) in DMF (5 mL) at room temperature
was added potassium carbonate (210.27 mg, 1.52 mmol) and (1—isopropyl—2—methyl—propyl)
2—bromo—2,2—difluoro—acetate (Intermediate 67, 623.28 mg, 2.28 mmol). The reaction
mixture was d for 4 hours at room temperature. Another two equivalents of (1—
isopropyl—2—methyl—propyl) 2—bromo—2,2—difluoro—acetate were added, and the reaction
e was stirred overnight at room temperature. The reaction mixture was diluted with
ethyl acetate and filtered to remove the potassium carbonate. The filtrate was washed three
WO 53215
times with 1:1 brinezwater. The organics were dried over magnesium sulfate, filtered and
concentrated. Silica gel chromatography (0% — 15% acetone/dichloromethane) afforded the
title compound as a light orange sticky film after lyophilization, 44.6 mg, 13%.
M_S: 390 ES+ (C17H25FN305)
1H NMR1300 MHz, DMSO-dg) 8: 0.86 (m, 12H); 1.64 (s, 3H); 1.99 (m, 2H); 3.15 (m, 1H);
3.85 (m, 1H); 4.07 (m, 1H); 4.28 (s, 1H); 4.69 (m, 1H); 6.03 (m, 1H); 7.42 (s, 1H); 7.85 (s,
Intermediate 68: oct 1 2R m0flu0r0-acetate
Br/'\H/O\/\/\/\/
To a suspension of (2R)—2—bromo—2—fluoro—acetic acid; (1S)—1—phenylethanamine
(Intermediate 168, 642.8 mg, 2.31 mmol) and 1—octanol (554 mg, 5.78 mmol) in DCM (9
mL) at room temperature was added chlorotrimethylsilane (1.19 mL, 9.39 mmol) dropwise.
The suspension became a solution and was stirred overnight at room temperature. The
reaction mixture was washed with water three times. The organics were dried over
magnesium sulfate, filtered and concentrated. Silica gel chromatography (0%—10% ethyl
acetate/hexanes) afforded the title nd as a colorless liquid, 554.9 mg, 89%.
1H NMR 300 MHz CDCléfi) 8: 0.84 (m, 3H); 1.24 (m, 10H); 1.61 (m, 2H); 4.22 (m, 2H);
7.25 (d, 1H).
Exam le 45: oct 1 2R 2S 5R carbam0 lmeth l0X0-1 6-
diazabic clo 3.2.1 0cten 1 0x flu0r0-acetate
H2N \
To a solution of (2S,5R)—6—hydroxy—3—methyl—7—oxo—1,6—diazabicyclo[3.2. 1]oct—3—ene—2—
carboxamide (Intermediate 193, 150 mg, 0.76 mmol) in 1,4—dioxane (4 mL) and DMF (0.5
mL) was added octyl —bromo—2—fluoro—acetate mediate 68, 0.09 mL, 2.06
mmol). The reaction mixture was cooled to 0°C and DBU (0.11 mL, 0.76 mmol) was added
dropwise. The reaction e was stirred for 10 minutes, then diluted with ethyl acetate
and washed three times with 1:1 water. The organics were dried over magnesium
sulfate, filtered and concentrated to afford an orange oil. Silica gel chromatography (0%—
60% ethyl e/hexanes) afforded the title compound as a White solid, 247.9 mg, 84%.
M_S: 386 ES+ (ClgHZSFNSOS)
1H NMR1300 MHz, DMSO-dg) 8: 0.86 (m, 3H); 1.25 (m, 10H); 1.59 (m, 5H); 3.04 (m, 1H);
3.78 (m, 1H); 4.04 (m, 1H); 4.16 (m, 3H); 6.00 (m, 1H); 6.24 (d, 1H); 7.37 (s, 1H); 7.81 (s,
Intermediate 69: oct 1 2R br0m0flu0r0-acetate
Br)\n/O\
The title compound was prepared from (2R)—2—bromo—2—fluoro—acetic acid; (1S)—1—
phenylethanamine (Intermediate 168, 526.2 mg, 1.89 mmol) and methanol (260 mg, 5.68
mmol) according to the ure for Intermediate 68 to afford a White oily/solid, 260 mg,
1H NMR {300 MHz, CDCifl) 5: 3.84 (s, 3H); 6.52 (d, 1H).
Exam le 46: meth 1 2R 2S 5R carbam0 lmeth l0X0-1 6-
diazabic clo 3.2.1 0cten 10X flu0r0-acetate
I \
The title compound was prepared from (2S,5R)—6—hydroxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 193, 120 mg, 0.61 mmol) and
methyl (2R)—2—bromo—2—fluoro—acetate (Intermediate 69, 0.09 mL, 1.52 mmol) according to
the procedure for Example 45 to a White foam, 81.2 mg, 46%.
M_S: 288 ES+ (C11H14FN305)
1H NMR1300 MHz, DMSO-dg) 8: 1.63 (s, 3H); 3.07 (m, 1H); 3.75 (m, 1H); 3.78 (s, 3H);
4.05 (m, 1H); 4.19 (s, 1H); 6.02 (m, 1H); 6.24 (m, 1H); 7.37 (s, 1H); 7.81 (s, 1H).
ediate 70: all 1 2R br0m0flu0r0-acetate
BrJWrOW
The title compound was prepared from (2R)—2—bromo—2—fluoro—acetic acid; (1S)—1—
phenylethanamine (Intermediate 168, 510 mg, 1.83 mmol) and allyl alcohol (0.37 mL, 5.5
mmol) according to the procedure for Intermediate 68 to afford a colorless liquid, 100 mg,
1H NMR1300 MHZ, ) 5: 4.71 (m, 2H); 5.31 (m, 2H); 5.86 (m, 1H); 6.55 (d, 1H).
Exam le 47: all 1 2R 2S 5R carbam0 lmeth l0X0-1 6-
diazabic clo 3.2.1 0cten 10X flu0r0-acetate
HZNJl, \
The title compound was ed from )—6—hydroxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 193, 50 mg, 0.25 mmol) and
allyl (2R)—2—bromo—2—fluoro—acetate (Intermediate 70, 100 mg, 0.51 mmol) according to the
procedure for Example 45 to afford a white foam, 61.3 mg, 77%.
M_S: 314 ES+ (C13H16FN305)
1H NMR1300 MHz, DMSO-dg) 8: 1.63 (s, 3H); 3.55 (m, 1H); 3.76 (m, 1H); 4.05 (m, 1H);
4.19 (s, 1H); 4.70 (m, 2H); 5.36 (m, 2H); 5.90 (m, 1H); 6.01 (m, 1H); 6.28 (d, 1H); 7.37 (s,
1H); 7.82 (s, 1H).
Intermediate 71: r0 1 2R m0flu0r0-acetate
Brk{(O\/\
The title compound was prepared from (2R)—2—bromo—2—fluoro—acetic acid; (1S)—1—
phenylethanamine mediate 168, 444.9 mg, 1.6 mmol) and l—propanol (0.3 mL, 4
mmol) according to the procedure for Intermediate 68 to afford a colorless liquid, 318 mg,
100%.
1H NMR1300 MHZ, CDCléfi) 5: 0.92 (t, 3H); 1.67 (m, 2H); 4.19 (m, 2H); 6.51 (d, 1H).
Exam le 48: r0 1 2R 2S 5R bam0 lmeth l0X0-1 6-
diazabic clo 3.2.1 0cten 10X flu0r0-acetate
HZNJl, \
The title compound was prepared from (2S,5R)—6—hydroxy—3—methyl—7—oxo—l,6—
diazabicyclo[3.2.l]oct—3—ene—2—carboxamide (Intermediate 193, 150 mg, 0.76 mmol) and
propyl (2R)—2—bromo—2—fluoro—acetate (Intermediate 71, 302.78 mg, 1.52 mmol) according
to the procedure for Example 45 to afford a white sticky foam, 156 mg, 65%.
M_S: 316 ES+ (C13H18FN305)
1H NMR1300 MHz= DMSO-dg) 8: 0.89 (t, 3H); 1.61 (m, 5H); 3.05 (m, 1H); 3.76 (m, 1H);
4.04 (m, 1H); 4.13 (m, 2H); 4.19 (m, 1H); 6.01 (m, 1H); 6.25 (d, 1H); 7.37 (s, 1H); 7.82 (s,
Intermediate 72: isobut 1 2R br0m0flu0r0-acetate
The title compound was prepared from —bromo—2—fluoro—acetic acid; —
phenylethanamine (Intermediate 168, 487.5 mg, 1.75 mmol) and 2—methyl—l—propanol (0.4
mL, 4.38 mmol) according to the ure for Intermediate 68 to afford a colorless liquid,
373 mg, 100%.
1H NMR {300 MHZ, CDCifl) 5: 0.91 (d, 6H); 1.97 (m, 1H); 4.00 (m, 2H); 6.51 (d, 1H).
Exam le 49: isobut 1 2R 2S 5R carbam0 lmeth l0X0-1 6-
diazabic clo 3.2.1 0cten 10X flu0r0-acetate
HZNJl, \
N\ .:
O 0’07’0\/<
The title compound was prepared from (2S,5R)—6—hydroxy—3—methyl—7—oxo—l,6—
diazabicyclo[3.2.l]oct—3—ene—2—carboxamide (Intermediate 193, 150 mg, 0.76 mmol) and
WO 53215 2017/051692
isobutyl —bromo—2—fluoro—acetate (Intermediate 72, 372.73 mg, 1.75 mmol) according
to the procedure for Example 45 to afford a sticky White foam, 161 mg, 64%.
M_S: 330 ES+ (C14H20FN305)
1H NMR1300 MHz= DMSO-dg) 8: 0.90 (d, 6H); 1.63 (s, 3H); 1.90 (m, 1H); 3.05 (m, 1H);
3.76 (m, 1H); 3.97 (m, 2H); 4.04 (m, 1H); 4.20 (s, 1H); 6.00 (m, 1H); 6.27 (d, 1H); 7.37 (s,
1H); 7.82 (s, 1H).
Intermediate 73: but 1 2R br0m0flu0r0-acetate
Br/vwrow
The title compound was prepared from (2R)—2—bromo—2—fluoro—acetic acid; (1S)—1—
phenylethanamine (Intermediate 168, 400 mg, 1.44 mmol) and 1—butanol (0.33 mL, 3.6
mmol) according to the procedure for Intermediate 68 to afford a colorless liquid, 322 mg,
quant.
1H NMR1300 MHZ, ) 8: 0.88 (t, 3H); 1.33 (m, 2H); 1.65 (m, 2H); 4.23 (m, 2H);
6.50 (d, 1H).
Exam le 50: but 1 2R 2S 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 10x flu0r0-acetate
HZNJ’“? \
The title compound was prepared from (2S,5R)—6—hydroxy—3—methy1—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 193, 150 mg, 0.76 mmol) and
butyl (2R)—2—bromo—2—fluoro—acetate (Intermediate 73, 322.49 mg, 1.51 mmol) according to
the procedure for Example 45 to afford a sticky White foam, 198 mg, 79%.
M_S: 330 ES+ (C14H20FN305)
1H NMR1300 MHz, DMSO-dg) 8: 0.88 (t, 3H); 1.35 (m, 2H); 1.59 (m, 2H); 1.63 (s, 3H);
3.06 (m, 1H); 3.77 (m, 1H); 4.04 (m, 1H); 4.20 (m, 2H); 4.21 (s, 1H); 6.00 (m, 1H); 6.24 (d,
1H); 7.37 (s, 1H); 7.82 (s, 1H).
WO 53215
Intermediate 74: ent 1 2R m0flu0r0-acetate
Br/'\H/0\/\/\
The title compound was prepared from (2R)—2—bromo—2—fluoro—acetic acid; (1S)—1—
phenylethanamine (Intermediate 168, 474.2 mg, 1.71 mmol) and 1—pentanol (0.46 mL, 4.26
mmol) according to the procedure for Intermediate 68 to afford a colorless , 363 mg,
1H NMR 300 MHZ CDCléfil 5: 0.88 (m, 3H); 1.28 (m, 4H); 1.60 (m, 2H); 4.17 (m, 2H);
6.45 (d, 1H).
Exam le 51: ent 1 2R 2S 5R carbam0 lmeth l0X0-1 6-
diazabic clo 3.2.1 0cten 10X flu0r0-acetate
HZNJII"? \
The title compound was prepared from (2S,5R)—6—hydroxy—3—methyl—7—oxo—1,6—
icyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 193, 150 mg, 0.76 mmol) and
pentyl (2R)—2—bromo—2—fluoro—acetate (Intermediate 74, 362.73 mg, 1.6 mmol) according to
the procedure for Example 45 to afford a sticky white foam, 225 mg, 86%.
M_S: 344 ES+ (C15H22FN305)
1H NMR1300 MHz= g) 5: 0.87 (m, 3H); 1.30 (m, 4H); 1.58 (m, 2H); 1.63 (s, 3H);
3.04 (m, 1H); 3.77 (m, 1H); 4.04 (m, 1H); 4.20 (m, 2H); 4.21 (s, 1H); 6.00 (m, 1H); 6.24 (d,
1H); 7.37 (s, 1H); 7.82 (s, 1H).
Intermediate 75: heX 1 2R br0m0flu0r0-acetate
Br/'\n/OV\/\/
The title compound was prepared from (2R)—2—bromo—2—fluoro—acetic acid; (1S)—1—
phenylethanamine (Intermediate 168, 400 mg, 1.44 mmol) and hexyl alcohol (0.45 mL, 3.6
mmol) according to the procedure for Intermediate 68 to afford a colorless liquid, 313 mg,
1H NMR1300 MHz, CDCléfi) 5: 0.86 (m, 3H); 1.22 (m, 6H); 1.59 (m, 2H); 4.17 (m, 2H);
6.45 (d, 1H).
Exam le 52: hex 1 2R 2S 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 10x flu0r0-acetate
HZNJII“‘i \
The title compound was prepared from (2S,5R)—6—hydroxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 193, 150 mg, 0.76 mmol) and
hexyl (2R)—2—bromo—2—fluoro—acetate (Intermediate 75, 313.62 mg, 1.3 mmol) according to
the procedure for e 45 to afford a sticky white foam, 224 mg, 82%.
M_S: 358 ES+ (C16H24FN305)
1H NMR1300 MHz= DMSO-dg) 5: 0.87 (m, 3H); 1.30 (m, 6H); 1.57 (m, 2H); 1.62 (s, 3H);
3.04 (m, 1H); 3.77 (m, 1H); 4.04 (m, 1H); 4.19 (m, 2H); 4.20 (s, 1H); 6.00 (m, 1H); 6.24 (d,
1H); 7.37 (s, 1H); 7.82 (s, 1H).
Intermediate 76: l-chloroeth liso r0 [carbonate
CITOTOY
To a solution of 2—propanol (0.64 mL, 8.39 mmol) and pyridine (0.79 mL, 9.79 mmol) at —
78°C was added 1—chloroethyl formate (0.76 mL, 6.99 mmol) dropwise. The reaction
mixture was d to slowly warm to room temperature and stir overnight. The reaction
e became a solid white clump and was ted in dichloromethane. The resulting
suspension was concentrated and the white solid was dissolved in ethyl acetate and washed
with water and brine. The organics were dried over magnesium sulfate, filtered and
concentrated to afford the title compound as a colorless liquid, 1.29 g, 99%.
1H NMR {300 MHz, CDCifl) 5: 1.35 (m, 6H); 1.84 (d, 3H); 4.96 (m, 1H); 4.44 (m, 1H).
Exam le53:1-iso r0 0x carbon 10x eth 1 2R 2S 5R carbam0 lmeth l
0x0-1 6-diazabic clo 3.2.1 0cten 1 0x flu0r0-acetate
O 0’27/07/0 O
o 7/
To a solution of (2R)—2—[[(2S,5R)—2—carbamoyl—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—
en—6—yl]oxy]—2—fluoro—acetic acid le 4, 194.46 mg, 0.71 mmol), N,N—
ropylethylamine (0.12 mL, 0.71 mmol) and 1—chloroethyl pyl carbonate
(Intermediate 76, 237.15 mg, 1.42 mmol) in DMF (5 mL) at room temperature was added
tetrabutylammonium chloride (162.22 mg, 0.71 mmol). The reaction mixture was heated at
40°C for ~4 hours, then d with ethyl acetate and washed twice with 1:1 water.
The organics were dried over magnesium sulfate, filtered and concentrated to afford an
orange oil. Silica gel chromatography (0%—50% ethyl acetate/hexanes) afforded the title
compound as a 1:1 mixture of diastereomers, white foam, 33.2 mg, 11%.
M_S: 404 ES+ (C16H22FN308)
1H NMR1300 MHz, DMSO—dg) 5: 1.23 (m, 6H); 1.46 (m, 3H); 1.62 (m, 3H); 3.05 (m, 1H);
3.79 (m, 1H); 4.00 (m, 1H); 4.19 (s, 1H); 4.80 (m, 1H); 6.00 (m, 1H); 6.33 (dd, 1H); 7.37 (s,
1H); 7.80 (d, 1H).
Exam le 54: 2R -benz 12- 2S 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 en 10x flu0r0acetate
HZNJI'“OI \
DBU (8.83 mL, 58.57 mmol) in DMF (30 mL) was added dropwise to a solution of (2S,5R)—
6—hydroxy—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate
193, 10.5 g, 53.25 mmol) and (R)—benzyl 2—bromo—2—fluoroacetate (Intermediate 171, 14.47
g, 58.57 mmol) in DMF (100 mL) at —40°C over a period of 30 minutes under nitrogen. The
resulting on was stirred at —40°C for 30 minutes, then quenched with water (15 mL).
The reaction mixture was extracted with ethyl acetate (3 x 20 mL). The combined organics
were washed with brine (3 X 20 mL), dried over sodium sulfate, filtered and trated.
Silica chromatography (0% to 40% ethyl acetate/petroleum ether) afforded the title
compound as a white solid, 8.8 g, 45%.
M_S: 364 ES+ (C17H18FN305)
1H NMR1400 MHz, DMSO-dg) 8: 1.62 (s, 3H); 2.92 (d, 1H); 3.75 (d, 1H); 3.99 (m, 1H);
4.02 (s, 1H); 5.25 (s, 2H); 5.76 (s, 1H); 6.33 (d, 1H); 7.38 (m, 5H); 7.39 (s, 1H); 7.85 (s, 1H).
ediate 77: 2S 5R tert-but l dimeth 1 Si] 1 0X meth l0X0-1 6-
diazabic clo 3.2.1 0ctenecarb0X lic acid
Ho)“-3 \
0 \OTBS
To a solution of methyl (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—l,6—
diazabicyclo[3.2.l]oct—3—ene—2—carboxylate mediate 185, 538.5 mg, 1.65 mmol) in
DCE (3 mL) in a 20 mL microwave vial was added trimethyltin hydroxide (477.l7 mg, 2.64
mmol). The reaction was run in the microwave for 2 hours at 80°C. The solvent was
removed and the resulting residue was ved in ethyl acetate and washed three times with
0.01N potassium bisulfate and once with brine. The organics were dried over sodium sulfate,
filtered and concentrated to afford an orange foam, 649 mg, 100%.
M_S: 3l3 ES+ (C14H24N204Si)
1H NMR1300 MHZ, DMSO—dg) 5: 0.00 (s, 6H); 0.78 (s, 9H); 1.50 (s, 3H); 2.92 (m, 1H);
3.47 (m, 1H); 3.53 (m, 1H); 3.77 (m, 1H); 5.85 (m, 1H).
o \OTBS
To a solution of )—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—l,6—
diazabicyclo[3.2.l]oct—3—ene—2—carboxylic acid (Intermediate 77, 397.5 mg, 1.02 mmol) in
DMF (6 mL) at 0°C was added oxamic hydrazide (209.83 mg, 2.04 mmol), HATU (387 mg,
1.02 mmol) and N,N—diisopropylethylamine (0.57 mL, 3.26 mmol). The reaction mixture
was stirred for 1 hour, then diluted with ethyl acetate and washed once with saturated sodium
bicarbonate. The aqueous contained some product and was extracted once with ethyl
acetate. The combined organics were dried over magnesium sulfate, filtered and
concentrated to afford a yellow oil. Silica gel chromatography (0%—5% methanol) afforded
the title compound as a light yellow solid, 142 mg, 35%.
M_S: 398 ES+ (C16H27N505Si)
1H NMR1300 MHz, DMSO—dg) 5: 0.00 (s, 6H); 0.78 (s, 9H); 1.53 (s, 3H); 2.95 (m, 1H);
3.60 (m, 1H); 3.67 (m, 1H); 4.04 (s, 1H); 5.98 (m, 1H); 7.75 (s, 1H); 8.07 (s, 1H); 10.30 (s,
1H); 10.48 (s, 1H).
Intermediate 79: 5- 2S 5R tert-but l dimeth 1 Si] 1 0X meth l0X0-1 6-
diazabic clo 3.2.1 0cten l -1 3 4-oxadiazole-Z-carboxamide
o \OTBS
To a on of 2—[2—[(2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carbonyl]hydrazino]—2—oxo—acetamide (Intermediate 78, 142
mg, 0.36 mmol) in DCM (6 mL) at room ature was added 4—nitrobenzenesulfonyl
chloride (79.17 mg, 0.36 mmol) and N,N—diisopropylethylamine (0.19 mL, 1.07 mmol). The
reaction e became yellow and was stirred for 30 minutes, then was diluted with
dichloromethane and washed with brine. The organics were dried over magnesium sulfate,
filtered and concentrated to afford an orange oil. Silica gel tography (0%—5%
methanol/dichloromethane) afforded the title compound as an orange foam, 93.8 mg, 69%.
M_S: 380 ES+ (C16H25N504Si)
1H NMR 300 MHz DMSO-dg) 8: 0.00 (s, 6H); 0.77 (s, 9H); 1.53 (s, 3H); 3.02 (m, 2H);
3.70 (m, 1H); 5.01 (s, 1H); 6.14 (m, 1H); 8.13 (s, 1H); 8.53 (s, 1H).
Intermediate 80: 5- 2S 5R h dr0x meth l0x0-1 6-diazabic clo 3.2.1 0cten-
2- l -1 3 4-0xadiaz01ecarb0xamide
To a solution of 5—[(2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—en—2—yl]—1,3,4—oxadiazole—2—carboxamide (Intermediate 79, 267.6
mg, 0.71 mmol) in ethyl acetate (6 mL) was added HF—pyridine (0.04 mL, 1.41 mmol). The
reaction mixture was stirred for 2.5 hours, then r 2 eq of HF—pyridine was added and
the reaction stirred for another hour. The reaction e was concentrated to afford the title
nd as a tan solid, 245 mg, 99%.
M_S: 266 ES+ 1N504)
1H NMR1300 MHz= DMSO-dg) 5: 1.52 (s, 3H); 3.01 (m, 2H); 3.66 (m, 1H); 4.95 (s, 1H);
6.18 (m, 1H); 8.09 (s, 1H); 8.45 (m, 1H).
To a solution of 5—[(2S,5R)—6—hydroxy—3—methyl—7—oxo—1,6—diazabicyclo[3.2. 1]oct—3—en—2—yl]—
1,3,4—oxadiazole—2—carboxamide (Intermediate 80, 176.8 mg, 0.67 mmol) in DMF (5
mL) was added ethyl (2S)—2—bromo—2—fluoro—acetate (0.16 mL, 1.33 mmol) and potassium
carbonate (276.39 mg, 2 mmol). The reaction mixture was stirred for 2 hours, then diluted
with ethyl acetate, filtered and washed three times with 1:1 brinezwater. The organics were
dried over magnesium sulfate, filtered and concentrated to afford a yellow oil. Silica gel
chromatography (0%—70% ethyl acetate/hexanes) afforded the title compound as a light
yellow film, 66.8 mg, 27%. The compound is a 7:3 mixture of diastereomers.
M_S: 370 ES+ (C14H16FN506)
WO 53215
1H NMR1300 MHz, DMSO—dg) 5: 1.25 (m, 3H); 1.72 (s, 3H); 3.20 (m, 2H); 4.19 (m, 1H);
.30 (m, 1H); 6.25 (m, 1H); 6.26 (m, 1H); 8.26 (s, 1H); 8.65 (s, 1H).
Exam le 55: 2- 2S 5R S-carbamo l-1 3 4-0xadiazol l meth 0-1 6-
diazabic clo 3.2.1 0cten 1 0x flu0r0-acetic acid lithium salt
To a solution of ethyl —[[(2S,5R)—2—(5—carbamoyl—1,3,4—oxadiazol—2—yl)—3—methyl—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—en—6—yl]oxy]—2—fluoro—acetate (Intermediate 81, 66.8 mg,
0.18 mmol) in THF (1 mL) and water (0.5 mL) at 0 °C was added lithium hydroxide (0.18
mL, 0.18 mmol). The reaction mixture was stirred for 10 minutes. Another 0.5 lents
of lithium hydroxide added. After 10 minutes, the reaction mixture was treated with an
additional 0.5 equivalents of lithium hydroxide. The reaction mixture was stirred for 20
minutes, neutralized with 0.5N HCl, frozen and lyophilized to afford a yellow solid. Reverse
phase ISCO (50 g RediSep Gold C18, 100% water, 4 min; then 0%—50% acetonitrile/water)
ed the title compound as an off—white solid, 26 mg, 36%. The compound is a 7:3
mixture of diastereomers.
M_S: 342 ES+ (C12H12FN506)
1H NMR 300 MHz DMSO—dg) 5: 1.70 (s, 3H); 3.20 (m, 2H); 4.15 (m, 1H); 5.20 (s, 1H);
.28 (m, 1H); 6.27 (m, 1H); 8.25 (s, 1H); 8.65 (s, 1H).
Intermediate 82: 2- 1 3-di0x0is0indolin 1 0x ethanesulfonamide
To a suspension of 2—hydroxyethanesulfonamide (Enamine, 1.92 mL, 7.19 mmol), N—
hydroxyphthalimide (1.41 g, 8.63 mmol) and triphenylphosphine (2.26 g, 8.63 mmol) at 0 °C
was added diisopropylazodicarboxylate (1.7 mL, 8.63 mmol) dropwise. The reaction mixture
became dark orange then turned pale yellow. After ng for ~3 hours the reaction mixture
was concentrated to afford a sticky pale yellow oil, which was triturated with ethyl
acetate/hexanes. The white solid was collected by filtration and is the title compound, 1.8 g,
M_S: 271 ES+ (C10H10N205S)
1H NMR 300 MHz DMSO-dg) 8: 3.52 (m, 2H); 4.50 (m, 2H); 6.96 (s, 2H); 7.87 (s, 4H).
Intermediate 83: 2-aminooxyethanesulfonamide
H2 N\|lS/\/0 NH2\
To a solution of 2—(1,3—dioxoisoindolin—2—yl)oxyethanesulfonamide (Intermediate 82, 740
mg, 2.05 mmol) in DCM (20 mL) at room ature was added methylhydrazine (0.11 mL,
2.05 mmol). A precipitate immediately formed. The suspension was stirred at room
temperature for ~2 hours, then concentrated. The solid was triturated with DCM and
collected by tion. The solid was triturated with methanol and the resulting white solid
was filtered off. NMR of the solid indicates byproduct. The filtrate was concentrated to
afford the title compound as an off—white solid, 228.2 mg, 58%. NMR indicates 73% desired
product.
1H NMR1300 MHz= DMSO-dg) 8: 3.27 (m, 2H); 3.85 (m, 2H); 6.11 (bs, 2H); 6.79 (s, 2H).
H ifI,
O N
% N\
O OTBS
To a solution of (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—1,6—
icyclo[3.2.1]oct—3—ene—2—carboxylic acid (Intermediate 77, 465.74 mg, 1.19 mmol)
in DMF (8 mL) at 0°C was added 2—aminooxyethanesulfonamide (Intermediate 83, 228.96
mg, 1.19 mmol), HATU (453.43 mg, 1.19 mmol) and N,N—diisopropylethylamine (0.57 mL,
3.26 mmol). The reaction mixture was then stirred for 1 hour at 0 0C, then diluted with ethyl
e and washed twice with 1:1 brine:water. The organics were dried over magnesium
sulfate, filtered and concentrated to afford a yellow oil. Silica gel chromatography (0%—80%
ethyl acetate/hexanes) ed the title compound as a colorless oil, 343 mg, 66%.
M_S: 435 ES+ (C16H30N4O6SiS)
1H NMR1300 MHz= DMSO-dg) 8: 0.00 (s, 6H); 0.78 (s, 9H); 1.45 (s, 3H); 2.97 (m, 1H);
3.20 (m, 2H); 3.57 (m, 2H); 3.84 (m, 1H); 4.02 (m, 2H); 6.01 (m, 1H); 6.80 (s, 2H); 11.74 (s,
To a solution of (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—N—(2—
sulfamoylethoxy)—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 84, 343
mg, 0.79 mmol) in ethyl acetate (4 mL) was added HF—pyridine (0.04 mL, 1.58 mmol). The
reaction mixture was stirred for 30 minutes. Another 2 eq. of HF—pyridine were added and
the on stirred for another hour. After 6 hours, and a total of 7 eq of HF—pyridine, the
reaction was complete. The reaction e was filtered to collect an ite solid. The
solid became gummy and stuck in the filter. Ethyl acetate and a small amount of methanol
was used to rinse the filter and transfer the solid to a flask. The solvent was removed under
vacuum to afford the title compound as an off—white solid, 337 mg, 100%.
M_S: 321 ES+ (C10H16N4O6S)
H2N\§/\/O\HJO|| |
O N
I; N\
O O O
The title compound was prepared from (2S,5R)—6—hydroxy—3—methyl—7—oxo—N—(2—
oylethoxy)—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 85, 279.32
mg, 0.65 mmol) and ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174, 0.08 mL, 0.65
mmol) according to the procedure for Example 45 to afford a light yellow oil, 26.7 mg, 10%.
M_S: 425 ES+ (C14H21FN40gS)
1H NMR1300 MHz, DMSO—dg) 5: 1.25 (m, 3H); 1.60 (m, 3H); 3.15 (m, 1H); 3.36 (m, 1H);
3.78 (m, 1H); 4.02 (m, 3H); 4.07 (m, 2H); 4.28 (m, 2H); 6.13 (m, 1H); 6.16 (d, 1H); 6.95 (s,
2H); 11.91 (s, 1H).
WO 53215 Z
Exam le 56: ZS -Z-flu0r0-Z- ZS 5R meth l0x0-Z- Z-sulfam0 leth0x carbam0 l-
1 6-diazabic clo 3.2.1 0cten 1 0x acetic acid lithium salt
To a on of ethyl (2S)—2—fluoro—2—[[(2S,5R)—3—methyl—7—oxo—2—(2—sulfamoylethoxy—
carbamoyl)—1,6—diazabicyclo[3.2.1]oct—3—en—6—y1]oxy] acetate (Intermediate 86, 26.7 mg,
0.06 mmol) in THF (1 mL) and water (0.5 mL) at 0 °C was added LiOH (0.06 mL, 0.06
mmol). The reaction mixture was stirred for 15 minutes, and another 0.5 equivalents of
lithium hydroxide was added. After 15 minutes, another 0.5 eq of lithium hydroxide was
added. After 30 minutes, and warming the temperature slightly, the reaction was complete.
The reaction mixture was neutralized with 0.5N HCl, frozen and lyophilized to afford a
yellow oil. The compound was purified by reverse phase ISCO (5.5 g RediSep Gold C18,
100% water). The title compound was obtained as an ite solid, 11.3 mg, 29%.
M_S: 397 ES+ (C12H17FN4OgS)
1H NMR1300 MHz, DMSO—dg) 5: 1.56 (s, 3H); 3.02 (m, 1H); 3.26 (m, 1H); 3.98 (m, 5H);
.20 (d, 1H); 6.03 (m, 1H); 7.06 (s, 2H).
Intermediate 87: ZS 5R all 10x meth l0x0-N- amo leth l -1 6-
diazabicycloI 3.Z.1 |0ctene-Z-carb0xamide
O O
goo J,
HZN/ \/\H I,‘ \
é N\
The title nd was prepared from (2S,5R)—6—allyloxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carboxylic acid (Intermediate Z9, 208.5 mg, 0.88 mmol) and
o—ethanesulfonamide hydrochloride (281.1 mg, 1.75 mmol) according to the procedure
for Intermediate 84 to afford a pale yellow oil, 86.6, 29%.
M_S: 345 ES+ (C13H20N405S)
1H NMR1300 MHz, DMSO-dg) 8: 1.63 (s, 3H); 3.04 (m, 1H); 3.14 (m, 2H); 3.26 (m, 1H);
3.51 (m, 2H); 3.94 (m, 1H); 4.09 (m, 1H); 4.36 (m, 2H); 5.27 (m, 2H); 5.95 (m, 1H); 6.07 (m,
1H); 6.89 (s, 2H); 8.52 (m, 1H).
Intermediate 88: 2S 5R h dr0x meth 0-N- 2-sulfam0 leth l -1 6-
diazabicyc10|3.2.1 |0ctenecarb0xamide
O O
/S/ I
H2N WMJ/ \
To a solution of (2S,5R)—6—allyloxy—3—methyl—7—oxo—N—(2—sulfamoylethyl)—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 87, 86.6 mg, 0.25 mmol) in
ol (3 mL) at room temperature was added methylbarbituric acid (78.53 mg, 0.5
mmol) and tetrakis(triphenylphosphine)palladium(0) (58.12 mg, 0.05 mmol). The on
mixture was stirred for 1 hour at room temperature, then concentrated to afford a dark orange
oil, 76.5 mg, 100%.
M_S: 305 ES+ (C10H16N405S)
Intermediate 89: eth 1 2S flu0r0 2S 5R meth l0x0 2-
sulfamo leth lcarbamo l-1 6-diazabic clo 3.2.1 0cten 10x acetate
0 O
540 JL
HZN/ w” 1,, \
)—w F
0 00%)\/
To a solution of (2S,5R)—6—hydroxy—3—methyl—7—oxo—N—(2—sulfamoylethyl)—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 88, 76.5 mg, 0.25 mmol) in 1,4—
dioxane (2 mL) and DMF (0.25 mL) was added ethyl (2S)—2—bromo—2—fluoro—acetate
(Intermediate 174, 0.09 mL, 0.75 mmol). The reaction mixture was cooled to 0 °C and
DBU (0.04 mL, 0.25 mmol) was added se. More ethyl (2S)—2—bromo—2—fluoro—acetate
(0.09 mL, 0.75 mmol) was added. Then, more DBU (0.04 mL, 0.25 mmol) was added. After
another 15 minutes at 0 °C with occasional warming, another 0.5 eq. of DBU was added.
The on mixture was stirred for another 15 minutes at room temperature. The on
mixture was diluted with ethyl acetate and washed three times with 1:1 brinezwater. The
organics were dried over magnesium sulfate, filtered and concentrated to afford an orange
oil. Silica gel chromatography (0%—25% acetone/dichloromethane) afforded the title
compound and with some triphenylphosphine oxide as an orange film, 77.3 mg, 75%.
M_S: 409 ES+ (C14H21FN4O7S)
Exam le 57: 2S flu0r0 2S 5R meth l0x0 2-sulfam0 leth lcarbam0 l-
1 6-diazabic clo 3.2.1 0cten 1 0x acetic acid lithium salt
o 0
£40 JL
HZN’ \/\N ’ \
2— F
O O/SZ/OH
T a solution of ethyl (2S)—2—fluoro—2—[[(2S,5R)—3—methyl—7—oxo—2—(2—sulfamoylethyl—
carbamoyl)—1,6—diazabicyclo[3.2.1]oct—3—en—6—y1]oxy] e (Intermediate 89, 72.3 mg,
0.18 mmol) in THF (2 mL) and water (1 mL) at 0°C was added 1M lithium hydroxide (0.18
mL, 0.18 mmol). The reaction e was stirred for 10 minutes at 0 0C, then neutralized
with 0.5N hydrochloric acid, frozen and lyophilized to afford a yellow solid. Reverse phase
ISCO (100% water) ed the title compound as a pale yellow solid, 14.3 mg, 21%.
M_S: 381 ES+ (C12H17FN4O7S)
1H NMR1300 MHz= DMSO-dg) 5: 1.64 (s, 3H); 3.13 (m, 3H); 3.52 (m, 3H); 3.99 (m, 1H);
4.14 (m, 1H); 5.24 (d, 1H); 6.04 (m, 1H); 6.90 (m, 2H); 8.57 (m, 1H).
E - \O/2]’ vow/EffO
o 0/\
To a solution of (2R)—2—[[(2S,5R)—2—carbamoyl—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—
en—6—yl]oxy]—2—fluoro—acetic acid (Example 4, 100 mg, 0.37 mmol), Hunig's base (0.06 mL,
0.37 mmol) and ethyl 2—(chloromethoxycarbonylamino)—3—methyl—butanoate (0.05 mL, 0.73
mmol) in DMF (1.5 mL) at room temperature was added tetrabutylammonium chloride
(83.42 mg, 0.37 mmol). The reaction mixture was stirred at 40 °C for 2 hours. It was then
diluted with ethyl acetate and washed twice with brine/water (1:1). The organics were dried
over anhydrous magnesium sulfate, filtered and trated to afford an orange oil. Silica
gel chromatography (0%—80% ethyl acetate/hexanes) afforded the title compound (7 mg,
3.63%) as a white solid.
M_S: 475 ES+ (C19H27FN409)
1H NMR1300 MHz= DMSO-dgfi 0.90 (m, 6H); 1.21 (m, 3H); 1.61 (s, 3H); 2.15 (m, 1H);
3.78 (m, 1H); 3.95 (m, 1H); 4.01 (m, 1H); 4.15 (m, 2H); 4.22 (m, 1H); 5.80 (m, 2H); 5.95 (m,
1H); 6.30 (d, 1H); 7.40 (s, 1H); 7.80 (s, 1H); 8.10 (d, 1H).
Intermediate 90: tert-but 1 2S 1 3-di0X0is0indolin 10X meth l rrolidine-l-
carboxylate
To a solution of diethylazodicarboxylate (14.21mL, 12.48 mmol) in THF (10 mL) at —10°C
was added dropwise a solution of triphenylphosphine (3273.22 mg, 12.48 mmol) in THF (20
mL). The suspension was d at —10 0C. After 20 minutes the suspension became a solid
and another 40 mL of THF was added. After 1 hour, a solution of Boc—L—prolinol (448.18
mL, 5.94 mmol) in THF (10 mL) was added, followed by a solution of N—
Hydroxyphthalimide (969.41 mg, 5.94 mmol) in THF (10 mL). The on mixture was
allowed to warm to room temperature and stir overnight. It was concentrated and the
resulting oil was triturated with ethyl acetate/hexanes. The precipitate was d by
filtration and the filtrate was concentrated onto silica gel. Silica gel chromatography (0%—
40% EtOAc/Hexanes) afforded the title compound (2.37 g, quant.) as a pale yellow solid.
M_S: 347 ES+ (ClgszNzos)
Intermediate 91: ut 1 2S amin00X meth l rrolidine-l-carbox late
Q40-NH2
To a solution of utyl (2S)—2—[(1,3—dioXoisoindolin—2—yl)oxymethyl]pyrrolidine—1—
carboxylate (Intermediate 90, 2.06 g, 5.95 mmol) in DCM (20 mL) at room temperature was
added hydrazine monohydrate (2.14 mL, 17.84 mmol). A white precipitate immediately
formed. The suspension was stirred at room temperature for 1 hour, then filtered through
. The filtrate was washed twice with brine/water (1:1), dried over anhydrous
magnesium sulfate, filtered and concentrated to afford the title compound (1.35 g, quant.) as
a sticky oil.
1H NMR1300 MHz: CDCl;) 8: 1.50 (s, 9H); 1.85 (m, 4H); 3.32 (m, 2H); 3.63 (m, 1H); 4.25
(m, 2H).
ylate
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxylic acid (Intermediate 77, 1.85 g, 5 .92
mmol) and tert—butyl —(aminooxymethyl)pyrrolidine—1—carboxylate mediate 91,
1.28 g, 5.92 mmol) according to the ure for Intermediate 84 to afford (585 mg, 19%)
a white sticky foam.
M_SZ 511 ES+ (C24H42N4O6SI)
To a solution of tert—butyl (2S)—2—[[[(2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—
1,6—diazabicyclo[3.2. 1]oct—3—ene—2—carbonyl]amino]oxymethyl]pyrrolidine—1—carboxylate
(Intermediate 92, 401 mg, 0.79 mmol) in ethyl acetate (20 mL) at 0 °C under nitrogen
atmosphere was added HF‘Pyridine (24 uL, 0.94 mmol). The reaction mixture was stirred at
room temperature for 3 hours, then concentrated. The crude material was partitioned
between DCM (100 mL) and brine (50 mL). The organic layer was dried over anhydrous
sodium sulfate, and concentrated to give the title compound (309 mg, 84%) as a white sticky
solid.
M_S: 396 ES+ (C18H28N406)
carboxylate
To a suspension of tert—butyl (2S)—2—[[[(2S,5R)—6—hydroxy—3—methyl—7—oxo—1,6—
diazabicyclo [3 .2. 1]oct—3 —ene—2—carbonyl] amino]oxymethyl]pyrrolidine— 1 xylate
(Intermediate 93, 309 mg, 0.78 mmol) and cesium carbonate (304.75 mg, 0.94 mmol)
in THF (15 mL) at 0 °C was added ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174,
0.14 mL, 1.17 mmol). The reaction was stirred at 0 °C for 8 hours. Water (50 mL) and
EtOAc (100 mL) were added. The organic layer was dried over anhydrous sodium sulfate,
concentrated, and purified by flash chromatography (20 g silica gel, 0—100%
EtOAc/Hexanes) to afford the title compound (164 mg, 40%) as a sticky solid.
M_S: 501 ES+ 3FN408)
1H NMR 300 MHz CDCl;) 8: 1.38 (m, 3H); 1.45 (s, 9H); 1.80 (s, 3H); 1.95 (m, 4H); 3.35
(m, 3H); 3.60 (m, 2H); 3.95 (m 4.01 (m, 1H); 4.28 (m, 2H); 4.35 (m, 2H); 5.75 (d, 1H);
, 1H);
6.10 (s, 1H).
Exam le 60: eth 1 2S flu0r0 2S 5R meth l0X0 S - rrolidin-Z-
l meth0X carbamo l -1 6-diazabic clo 3.2.1 en 1 0X acetate TFA salt
O‘N 1.. \
L F N\
O 0#0V
To a soluiton of tert—butyl —((((2S,5R)—6—((S)—2—ethoxy—l—fluoro—2—oxoethoxy)—3—
methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamido)oxy)methyl)pyrrolidine—1—
carboxylate (Example 59, 76 mg, 0.15 mmol) in DCM (10 mL) at 0 °C was added TFA (0.58
WO 53215
mL, 7.59 mmol) dropwise. The reaction mixture was stirred at 0 °C for 2 hours then
concentrated. The residue was triturated with diethyl ether to afford the title compound (53
mg, 83%) as a TFA salt.
M_S: 401 ES+ 5FN4O6)
1H NMR1300 MHz: CDCl;) 5: 1.45 (m, 3H); 1.86 (m, 4H); 2.15 (m, 3H); 3.55(m, 4H); 4.01
(m, 2H); 4.32 (m, 5H); 5.85 (d, 1H); 6.13 (s, 1H).
Intermediate 94: tert-but l S 1 3-di0X0is0indolin 1 0X meth l -4 4-
difluoropyrrolidine-l-carboxylate
FWOAIWF
N O
The title nd was prepared from tert—butyl (S)—4,4—difluoro—2—(hydroxymethyl)—
pyrrolidine—l—carboxylate (2.8 g, 11.8 mmol) according to the procedure for Intermediate 90
to afford (4.3 g, 95%) a pale yellow sticky solid.
M_S: 383 ES+ (ClgHzonNzos)
Intermediate 95: tert-but l S aminoox meth l-4 4-diflu0r0 rrolidine-l-
carboxylate
The title nd was ed from tert—butyl (S)—2—(((1,3—dioxoisoindolin—2—
yl)oxy)methyl)—4,4—difluoropyrrolidine—1—carboxylate (Intermediate 94, 1.9 g, 4.97
mmol) according to the procedure for Intermediate 91 to afford (1.25 g, 99%) an orange
sticky oil.
1H NMR1300 MHz: CDCl;) 8: 1.51 (s, 9H); 2.42 (m, 2H); 3.63 (m, 2H); 3.85 (m, 2H); 4.97
(m, 1H).
Intermediate 96: tert-but 1 2S 2S 5R tert-but ldimeth lsil 10X meth [-
7-0X0-1 6-diazabic clo 3.2.1 0ctenecarb0xamid0 0X meth l -4 4-
difluoropyrrolidine-l-carboxylate
The title compound was prepared from (2S,5R)—6—[tert—buty1(dimethy1)si1y1]oxy—3—methy1—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxy1ic acid (Intermediate 77, 1.3 g, 4.16 mmol)
and tert—butyl (S)—2—((aminooxy)methy1)—4,4—difluoropyrrolidine—1—carboxy1ate
(Intermediate 95, 1.26 g, 4.99 mmol) according to the procedure for Intermediate 84 to
afford (489 mg, 18%) a sticky White foam.
M_SZ 547 ES+ (C24H40F2N4O6SI)
The title compound was prepared from tert—butyl —((((2S,5R)—6—((tert—
butyldimethylsi1y1)oxy)—3—methy1—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—
carboxamido)oxy)methy1)—4,4—difluoropyrrolidine—1—carboxy1ate mediate 96, 489 mg,
0.89 mmol) according to the procedure for Intermediate 93 to afford (330 mg, 72%) as a
White sticky solid.
MS: 433 ES+ (C18H26F2N4O6)
Intermediate 98: tert-but 1 2S 2S 5R S eth0X flu0r00X0eth0X
meth 0-1 6-diazabic clo 3.2.1 0ctenecarb0xamid0 0X meth l -4 4-
difluoropyrrolidine-l-carboxylate
(DJ—ijgro\/
To a sion of tert—butyl (2S)—4,4—difluoro—2—((((2S,5R)—6—hydroxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carboxamido)oxy)methyl)pyrrolidine—1—carboxylate
(Intermediate 97, 300 mg, 0.69 mmol) and cesium carbonate (339 mg, 1.04 mmol) in ethyl
e (15 mL) at 0°C was added ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174,
0.1 mL, 0.83 mmol). The reaction was stirred at 10 °C for 1 hour. Water (50 mL) and
EtOAc (100 mL) were added. The organic layer was separated, concentrated and purified by
silica gel flash chromatography (0—100%, EtOAc/Hexane) to afford the title compound (70
mg, 18%) as a sticky white foam.
MS: 537 ES+ (C22H31F3N40g)
H C?
O\” I]
L F N\
O 0#0V
The title compound was ed from tert—butyl (2S)—2—((((2S,5R)—6—((S)—2—ethoxy—1—fluoro—
2—oxoethoxy)—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamido)oxy)methyl)—
4,4—difluoropyrrolidine—1—carboxylate (Intermediate 98, 26 mg, 0.05 mmol) according to the
procedure for Example 60 to afford (20 mg, 85%) as a TFA salt.
M_S: 437 ES+ (C17H23F3N4O6)
1H NMR1300 MHz, CDCl;) 8: 1.42 (m, 3H); 1.80 (s, 3H); 2.65 (m, 2H); 3.45 (m, 2H); 3.82
(m, 2H); 4.10 (m, 1H); 4.38 (m, 6H); 5.80 (d, 1H); 6.18 (s, 1H).
To a solution of tert—butyl (2S)—2—((((2S,5R)—6—((S)—2—ethoxy—l—fluoro—2—oxoethoxy)—3—
methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamido)oxy)methyl)pyrrolidine—1—
carboxylate (Example 59, 81 mg, 0.16 mmol) in THF (1 mL) and water (0.50 mL) at 0 °C
was added lithium hydroxide (1N, 0.01 mL, 0.40 mmol). The reaction mixture was d
for 30 min. Dilute HCl solution (0.5N) was added to adjust the pH to 2. The reaction
mixture was extracted with EtOAc (20 mL). The organic layer was dried over anhydrous
sodium sulfate and concentrated to afford the title compound (50 mg, 65%) as a gum.
M_33 471 133- (C20H29FN408)
The title compound was prepared from (2S)—2—[[(2S,5R)—2—[[(2S)—1—tert—butoxycarbonyl—
pyrrolidin—2—yl]methoxycarbamoyl]—3—methyl—7—oxo—1,6—diazabicyclo[3.2. 1]oct—3—en—6—
]—2—fluoro—acetic acid (Intermediate 99, 65 mg, 0.14 mmol) according to the
procedure for Example 60 to afford (40 mg, 70%) as a TFA salt.
MS: 473 ES+ (C20H29FN4Og)
1H NMR1300 MHz, mg) 5: 1.65 (s, 3H); 1.82 (m, 1H); 2.23 (m, 2H); 2.35 (m, 1H); 3.40 (m,
3H); 3.58 (m, 1H); 3.82 (m, 1H); 4.02 (m, 1H); 4.18 (m, 1H); 4.33 (m, 2H); 5.70 (d, 1H);
6.28 (s, 1H).
- 1 0X flu0r0acetic acid
kN O
0&0 O‘N L’
2* F
0 O/S]/OH
The title compound was prepared from tert—butyl (2S)—2—((((2S,5R)—6—((S)—2—ethoxy—l—fluoro—
2—oxoethoxy)—3—methyl—7—oxo— l ,6—diazabicyclo[3 .2. l]oct—3—ene—2—carboxamido)oxy)methyl)—
4,4—difluoropyrrolidine—l—carboxylate mediate 98, 37 mg, 0.07 mmol) according to the
procedure for Intermediate 99 to afford (35 mg, 90%) as a gum.
M_S: 507 133- (C20H27F3N408)
The title compound was prepared from (2S)—2—(((2S,5R)—2—((((S)—l—(tert—butoxycarbonyl)—4,4—
difluoropyrrolidin—2—yl)methoxy)carbamoyl)—3—methyl—7—oxo— l ,6—diazabicyclo[3 .2. l]oct—3—
en—6—yl)oxy)—2—fluoroacetic acid (Intermediate 100, 35 mg, 0.07 mmol) according to the
ure for Example 60 to afford (22 mg, 70%) as a TFA salt.
M_S: 409 ES+ (C15H19F3N4O6)
1H NMR1300 MHz= D;@ 5: 1.78 (s, 3H); 2.62 (m, 1H); 2.95 (m, 1H); 3.13 (m, 1H); 3.42 (m,
1H); 3.58 (m, 1H); 3.96 (m, 2H); 4.61 (m, 1H); 4.40 (m, 3H); 5.82 (d, 1H); 6.33 (s, 1H).
WO 53215
Exam le 64: 2R 2S 5R carbam0 lmeth l0x0-1 6-diazabic clo 3.2.1 oct-
3-en 10x flu0r0-acet 10x meth meth 1 r0 anoate
HZNJ'Cl) \
The title nd was prepared from (2R)—2—[[(2S,5R)—2—carbamoyl—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—en—6—yl]oxy]—2—fluoro—acetic acid (Example 4, 47 mg, 0.17
mmol) and methyl pivalate (0.05 mL, 0.34 mmol) according to the procedure for
Example 53 to afford (33.2 mg, 49.8%) as a white solid.
M_S: 388 ES+ (C16H22FN3O7)
1H NMR1300 MHz, DMSO—dg) 5: 1.12 (s, 9H); 1.62 (s, 3H); 3.01 (m, 1H); 3.82 (m, 1H);
4.02 (m, 1H); 4.19 (m, 1H); 5.76 (m, 1H); 5.87 (m, 1H); 5.91 (m, 1H); 6.25—6.43 (d, 1H);
7.41 (bs,1 H); 7.86 (bs,1H).
Exam le 65: indan-S- 1 2R 2S 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 10x flu0r0-acetate
HZNJ”‘? \
To a solution of (2R)—2—[[(2S,5R)—2—carbamoyl—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—
en—6—yl]oxy]—2—fluoro—acetic acid (Example 4, 100 mg, 0.37 mmol) and 5—indanol (58.9 mg,
0.44 mmol) in DCM (3 mL) and THF (3 mL) at 0 °C was added N,N'—dicyclohexyl—
carbodiimide (113.3 mg, 0.55 mmol) and DMAP (5.0 mg). The reaction mixture was stirred
at RT for 1 hour. The reaction was concentrated, then dissolved in EtOAC. The white solid
formed was filtered off. The filtrate was concentrated. Silica gel chromatography (0—80%
ethyl acetate/hexanes) afforded the title compound (72 mg, 48%) as a white solid.
M_S: 390 ES+ (C19H20FN305)
1H NMR1300 MHz= DMSO-dg) 5: 1.64 (s, 3H); 2.05 (m, 2H); 2.85 (m, 4H); 3.10 (m, 1 H);
3.79 (m, 1H); 4.06 (m, 1H); 4.22 (m, 1H); 6.06 (m, 1H); 6.44—6.51 (d, 1H); 6.86 (m, 1H);
6.97 (m, 1H); 7.28 (m, 1H); 7.43 (bs, 1H); 7.87 (bs, 1H).
Intermediate 101: 2S 5R tert-but l dimeth l sil 1 0X meth l-N- oxetan l
0X0-1 6-diazabic clo 3.2.1 0ctenecarb0xamide
‘flNJL.O \
o ‘O,Si\
To a solution of (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carboxylic acid (Intermediate 77, 100 mg, 0.32 mmol) in
DMF (1.5 mL) at 0 °C was added HATU (35 mg, 0.48 mmol) and N,N'—
diisopropylethylamine (0.167 mL, 0.96 mmol). The reaction mixture was stirred for 30
minutes at room temperature, then diluted with ethyl acetate and washed with saturated
sodium bicarbonate once and 1:1 brinezwater three times. The organics were dried over
magnesium sulfate, filtered and concentrated. Silica gel tography %
methanol/dichloromethane) afforded the title compound (80 mg, 68%) as a yellow oil.
M_SZ 368 ES+ (C17H29N3O4Sl)
Intermediate 102: 2S 5R h dr0X meth l-N- oxetan l0X0-1 6-
diazabicyc10|3.2.1 |0ctenecarb0xamide
O\lNJh,
’6 N\
O OH
A 25 mL round bottom flask was charged with (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—
methyl—N—(oxetan—3—yl)—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide
(Intermediate 101, 0.10 g, 0.22 mmol) in ethyl acetate (0.5 mL) at room temperature under
nitrogen. HF.Pyridine (0.015 mL, 0.33 mmol) was added and the reaction e was
stirred at room temperature for 1 hour. The solvent was d.
M_33 254 133+ (C11H15N3O4)
Intermediate 103: eth 1 2S flu0r0 2S 5R meth l 0xetan lcarbamo l
0x0-1 6-diazabic clo 3.2.1 0cten 1 0x acetate
OQNJL.0 \
O 00%)\/
To a solution of (2S,5R)—6—hydroxy—3—methyl—N—(oxetan—3—yl)—7—oxo—l,6—
diazabicyclo[3.2. l]oct—3—ene—2—carboxamide (Intermediate 102, 50 mg, 0.20 mmol) in 1,4—
dioxane (2 mL) and DMF (0.25 mL) was added ethyl (2S)—2—bromo—2—fluoro—acetate
(Intermediate 174, 0.047 mL, 0.39 mmol). The reaction mixture was cooled to 0 °C and
DBU (0.089 mL, 0.59 mmol) was added dropwise. The reaction mixture was stirred at 0
°C for 15 minutes, then diluted with ethyl acetate and washed three times with 1:1
brinezwater. The organics were dried over magnesium sulfate, filtered and concentrated.
Silica gel chromatography (0—80% Hexane) afforded the title compound (58 mg,
82.2%) as colorless oil. The compound is a 2:8 mixture of diastereomers.
M_SI 358 ES+ (C15H20FN3O6)
Exam le 66: 2S flu0r0 2S 5R meth l 0xetan lcarbam0 l 0x0-1 6-
diazabic clo 3.2.1 0cten 1 0x acetic acid lithium salt
To a on of ethyl (2S)—2—fluoro—2—[[(2S,5R)—3—methyl—2—(oxetan—3—ylcarbamoyl)—7—oxo—
l,6—diazabicyclo[3.2.l]oct—3—en—6—yl]oxy]acetate (Intermediate 103, 56.3 mg, 0.16 mmol) in
THF (10 mL) and water (0.5 mL) at 0 °C was added lithium hydroxide (1M) (0.50 mL, 0.50
mmol). The reaction e was stirred for 1 hour. HCl (lN) solution was added to adjust
pH to ~5—6. The t was removed. A sepabead column (saturated with water first, then
ACN, then washed with water) eluting with water (0%—5% ACN/water) afforded the title
compound (10 mg, 17.3%) as a white solid after lyophilization.
M_SZ 330 ES+ (C13H16FN3O6)
1H NMR1300 MHz, mg) 5: 1.63 (s, 3H); 3.22 (m, 1H); 3.37 (m, 1H); 4.04 (m, 1H); 4.30 (s,
1H); 4.58 (m, 2H); 4.86 (m, 3H); 5.15-5.56 (d, 1H); 6.15 (m, 1H).
Intermediate 104: 2S 5R tert-but l dimeth 1 Si] 1 0X -N- 2-
methanesulfonamido eth l meth l0X0-1 6-diazabic clo 3.2.1 0ctene
carboxamide
Ofs’N\/\NJ”H |
H H
O N
7|— /
o N‘O’S'
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxylic acid (Intermediate 77, 300 mg, 0.96
mmol) in DMF (1.5 mL) and mino—ethyl)—methanesulfonamide hydrochloride salt
(251.5 mg, 1.44 mmol) according to the procedure for Intermediate 101 to afford (220 mg,
53%) as a White solid.
M_SZ 433 ES+ 2N4OsSlS)
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—N—[2—
(methanesulfonamido)ethyl]—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—
carboxamide (Intermediate 104, 0.12 g, 0.28 mmol) according to the procedure for
Intermediate 102 to afford a tan residue.
M_SZ 319 ES+ (C11H13N4053)
H Cl)
Ojs’NwN " \
H H
o N
)— F
o o#Ox/
The title compound was prepared from (2S,5R)—6—hydroxy—N—[2—(methanesulfonamido)—
ethyl]—3—methyl—7—oxo—1,6—diazabicyclo[3.2.l]oct—3—ene—2—carboxamide (Intermediate 105,
80 mg, 0.25 mmol) and ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174, 0.089 mL,
0.75 mmol) ing to the procedure for Intermediate 103 to afford (25 mg, 18.8%) as a
white solid. The compound is a 1:4 mixture of diastereomers.
M_S: 423 ES+ (C15H23FN4O7S)
0\ [N j
\/\N I]
)S \
H
! F
O O/SZ/OH
The title compound was prepared from ethyl —fluoro—2—[[(2S,5R)—3—methyl—2—(3—
methylsulfonylpropylcarbamoyl)—7—oxo— 1 ,6—diazabicyclo[3 .2. 1]oct—3—en—6—yl]oxy] acetate
(Intermediate 106, 25 mg, 0.06 mmol) ing to the procedure for Example 66 to afford
(4.0 mg, 15.4%) as a white solid after lyophilization.
M_S: 395 ES+ (C13H19FN4O7S)
1H NMR1300 MHz= D;@ 8: 1.63 (s, 3H); 2.95 (s, 3H); 3.18-3.38 (m, 6H); 4.02 (m, 1H);
4.27 (s, 1H); 5.56-5.74 (d, 1H); 6.13 (m, 1H).
Intermediate 107: 2S 5R tert-but l dimeth 1 Si] 1 0X h l-N- oxazol-Z-
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxylic acid (Intermediate 77, 400 mg, 1.28
mmol) and oxazol—2—yl—methylamine hydrochloride (258.4 mg, 1.92 mmol) according to the
procedure for Intermediate 101 to afford (120 mg, 23.9%) as a white solid.
M_S: 393 ES+ (C13H23N4O4Si)
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—N—
(oxazol—2—ylmethyl)—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate
107, 0.12 g, 0.31 mmol) according to the procedure for Intermediate 102 to afford a residue.
MS: 279 ES+ (C12H14N404)
N! F
o 0/87/0\/
The title nd was prepared from (2S,5R)—6—hydroxy—3—methyl—N—(oxazol—2—ylmethyl)—
7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 108, 80 mg, 0.29
mmol) and ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174, 0.10 mL, 0.86 mmol)
according to the procedure for ediate 103 to afford (15 mg, 13.6%) a colorless oil.
The compound is a 15:85 mixture of diastereomers.
M_SZ 383 ES+ (C16H19FN4O6)
@0N\ NJ’I, \
0%Nxo/SZ/OHF
The title compound was prepared from ethyl —fluoro—2—[[(2S,5R)—3—methyl—2—(oxazol—
2—ylmethylcarbamoyl)—7—oxo— 1 ,6—diazabicyclo[3 .2. 1]oct—3—en—6—yl]oxy] acetate mediate
109, 15 mg, 0.039 mmol) according to the procedure for Example 66 to afford (4.0 mg,
.9%) as a white solid after lization.
M_S: 355 ES+ (C14H15FN4O6)
1H 0 MHz= D;@ 5: 1.62 (s, 3H); 3.28 (m, 2H); 4.03 (m, 1H); 4.36 (s, 1H); 4.47 (m,
2H); 5.56-5.74 (d, 1H); 6.13 (m, 1H); 7.01 (d, 1H); 7.71 (d, 1H).
Intermediate 110: 28 SR tert-but l dimeth 1 Si] 1 0X meth l0X0-N- razin-
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxylic acid (Intermediate 77, 200 mg, 0.64
mmol) and pyrazin—2—yl—methylamine oxalate (191.2 mg, 0.96 mmol) according to the
procedure for Intermediate 101 to afforded (120 mg, 46.4%) a white solid.
M_S: 404 ES+ (C19H29N5038i)
Intermediate 111: 28 SR h dr0X meth l0X0-N- razin lmeth [-1 6-
diazabic clo 3.2.1 enecarb0xamide
rm /I,'Ci \
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—N—(pyrazin—2—ylmethyl)—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate
110, 0.10 g, 0.26 mmol) according to the procedure for Intermediate 102 to afford a residue.
MS: 290 ES+ (C13H15N503)
Intermediate 112: eth 1 2S flu0r0 28 SR h l0X0 razin
lmeth lcarbamo l -1 6-diazabic clo 3.2.1 0cten 1 0X acetate
N\ NJ,“
E/ \
N )—N\ F
o OJWOV
The title compound was prepared from (2S,5R)—6—hydroxy—3—methyl—7—oxo—N—(pyrazin—2—
ylmethyl)—l,6—diazabicyclo[3.2. 3—ene—2—carboxamide (Intermediate 111, 70 mg, 0.24
mmol) and ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174, 0.086 mL, 0.73 mmol)
according to the ure for Intermediate 103 to afford (50 mg, 52.5%) a colorless oil.
The compound is a 15:85 mixture of diastereomers.
M_S: 394 ES+ (C17H20FN505)
Exam le 69: 2S flu0r0 2S 5R meth l0x0 razin lmeth [-
carbam0 l -1 6-diazabic clo 3.2.1 0cten 1 0x acetic acid lithium salt
E /N\
NJI'“ \
N F
O \OJYO“
The title compound was prepared from ethyl (2S)—2—fluoro—2—[[(2S,5R)—3—methyl—7—oxo—2—
(pyrazin—2—ylmethylcarbamoyl)— l ,6—diazabicyclo[3 .2. l]oct—3—en—6—yl] oxy] acetate
(Intermediate 112, 50 mg, 0.13 mmol) ing to the procedure for Example 66 to afford
(4.0 mg, 8.2%) a White solid after lyophilization.
M_S: 366 ES+ (C15H16FN505)
1H NMR1300 MHz= D;@ 5: 1.62 (s, 3H); 3.28 (m, 2H); 4.03 (m, 1H); 4.36 (s, 1H); 4.53 (m,
2H); 5.56-5.75 (d, 1H); 6.13 (m, 1H); 8.49 (m, 3H).
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—l,6—diazabicyclo[3.2. l]oct—3—ene—2—carboxylic acid (Intermediate 77, 200 mg, 0.64
mmol) and lopropylmethyl) hydroxylamine (83.6 mg, 0.96 mmol) according to the
ure for Intermediate 101 to afford (100 mg, 40.9%) a colorless oil.
M_S: 382 ES+ (C18H31N304Si)
Intermediate 114: ZS 5R -N- e do r0 lmeth0X h dr0X meth l0X0-1 6-
diazabicyc10|3.Z.1 |0ctene-Z-carb0xamide
A/O\ JV“,‘i
N \
//'—N.
O OH
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—N—
(cyclopropylmethoxy)—3—methyl—7—oxo— l ,6—diazabicyclo[3 .2. l]oct—3—ene—2—carboxamide
(Intermediate 113, 0. lg, 0.26 mmol) ing to the procedure for Intermediate 102 to
afford a residue.
M_33 268 133+ (C12H17N3O4)
Intermediate 115: eth 1 ZS -Z- ZS 5R -Z- e do r0 lmeth0X carbam0 lmeth l
0X0-1 6-diazabic clo 3.Z.1 0cten 1 0X -Z-flu0r0-acetate
The title compound was prepared from (2S,5R)—N—(cyclopropylmethoxy)—6—hydroxy—3—
methyl—7—oxo—l,6—diazabicyclo[3.2. l]oct—3—ene—2—carboxamide (Intermediate 114, 60 mg,
0.22 mmol) and ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174, 0.08 mL, 0.67
mmol) ing to the procedure for Intermediate 103 to afford (15 mg, 18%) a colorless
oil. The nd is a 1:9 mixture of diastereomers.
M_SZ 372 ES+ (C16H22FN3O6)
Exam le 70: ZS -Z- ZS 5R -Z- e do r0 lmethox 0 lmeth l0X0-1 6-
diazabic clo 3.Z.1 0cten 1 0X -Z-flu0r0-acetic acid lithium salt
The title compound was prepared from ethyl (2S)—2—[[(2S,5R)—2—(cyclopropylmethoxy—
oyl)—3—methyl—7—oxo— l ,6—diazabicyclo[3 .2. l]oct—3—en—6—yl]oxy] —2—fluoro—acetate
(Intermediate 115, 15 mg, 0.04 mmol) according to the ure for Example 66 to afford
(4.5 mg, 32.5%) as a White solid after 1yophi1ization.
M_S: 344 ES+ (C14H18FN306)
1H NMR1300 MHz= D;@ 8: 0.00 (m, 2H); 0.28 (m, 2H); 0.81 (m, 1H); 1.38 (s, 3H); 3.02
(m, 1H); 3.35 (m, 1H); 3.42 (m, 2H); 3.82 (m, 1H); 3.92 (s, 1H); 5.37—5.55 (d, 1H); 5.95 (m,
The title compound was prepared from (2S,5R)—6—[tert—buty1(dimethy1)si1y1]oxy—3—methy1—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxy1ic acid (Intermediate 77, 200 mg, 0.64
mmol) and alaninamide hydrochloride (119.6 mg, 0.96 mmol) according to the procedure for
Intermediate 101 to afford (140 mg, 57.2%) as a White solid.
M_S: 383 ES+ (C17H30N4O4Si)
The title compound was prepared from (2S,5R)—N—(3—amino—3—oxo—propy1)—6—[tert—
dimethy1)si1y1]oxy—3—methy1—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide
(Intermediate 116, 140 mg, 0.37 mmol) according to the procedure for ediate 102 to
afford a residue.
M_S: 269 ES+ (C11H16N4O4)
The title compound was prepared from (2S,5R)—N—(3—amino—3—oxo—propyl)—6—hydroxy—3—
—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 117, 90 mg,
0.34 mmol), K2CO3 (139.1 mg, 1.01 mmol) and ethyl (2S)—2—bromo—2—fluoro—acetate
(Intermediate 174, 0.12 mL, 1.01 mmol) ing to the procedure for Intermediate
103 to afford (26.0 mg, 20.8%) as a White solid. The compound is a 1:9 mixture of
diastereomers.
M_S: 373 ES+ (C15H21FN4O6)
The title compound was prepared from ethyl (2S)—2—[[(2S,5R)—2—[(3—amino—3—oxo—
propyl)carbamoyl]—3—methyl—7—oxo—1,6—diazabicyclo[3.2. 1]oct—3—en—6—yl]oxy]—2—fluoro—
acetate (Intermediate 118, 25 mg, 0.07 mmol) according to the procedure for Example 66 to
afford (8 mg, 34.6%) a White solid after lization.
M_S: 345 ES+ (C13H17FN4O6).
1H NMR1300 MHz, D29 8: 1.62 (s, 3H); 2.49 (m, 2H); 3.29 (M, 1H); 3.42 (m, 1H); 3.50
(m, 2H); 4.10 (m, 1H); 4.30 (s, 1H); 5.65-5.82 (d, 1H); 6.22 (m, 1H).
Intermediate 119: 2- ZS 0X0 rr01idin l meth0X isoindoline-l 3-di0ne
To a solution of diethylazodicarboxylate (16.6 mL, 14.6 mmol, 40% wt) in THF (10 mL) at
—10°C was added dropwise a solution of triphenylphosphine (3.83 g, 14.6 mmol) in THF (20
mL). The suspension was stirred at —10 0C. After 1 hour, a solution of (S)—(+)—5—
(hydroxymethyl)—2—pyrrolidinone) (0.80 g, 6.95 mmol) in THF (10 mL) was added dropwise,
followed by a solution of N—hydroxyphthalimide (1.13 g, 6.95 mmol) in THF (10 mL). The
reaction mixture was allowed to warm to room temperature and stir for 2 days. The reaction
mixture was concentrated. Silica gel chromatography (0—100 % EtOAc/Hexane, then 10%
MeOH/DCM) afforded the title compound (1.5 g, 83% ) as a pale yelllow solid.
M_S: 261 ES+ 2N204)
Intermediate 120: SS aminoox meth l rrolidin-Z-one
p40_NH2N
To a solution of 2—[[(2S)—5—oxopyrrolidin—2—yl]methoxy]isoindoline—1,3—dione (Intermediate
119, 1.5 g, 5.76 mmol) in DCM (70 mL) at room temperature was added hydrazine
drate (0.84 mL, 17.3 mmol). The reaction mixture was stirred at room ature
for 1 hour, then washed with water (3 x 20 mL). The aqueous layer was concentrated. A
sepabead column afforded the title compound (0.60 g, 79.9%) as a white solid.
MS: 163 ES+ (C3H6N202)
The title nd was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
6—diazabicyclo[3.2.1]oct—3—ene—2—carboxylic acid (Intermediate 77, 250 mg, 0.80
mmol) and 5—(aminooxymethyl) pyrrolidin—2—one (Intermediate 120, 156.2 mg, 1.2 mmol)
ing to the procedure for Intermediate 101 to afford (55 mg, 16.2%) as a white solid.
M_S: 425 ES+ (C19H32N405Si)
Intermediate 122: 28 SR h dr0X meth l0X0-N- 5-0X0 in
l meth0X -1 6-diazabic clo 3.2.1 0ctenecarb0xamide
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—N—[[(2S)—5—oxopyrrolidin—2—yl]methoxy] — 1 ,6—diazabicyclo[3 .2. 1]oct—3—ene—2—
carboxamide (Intermediate 121, 55 mg, 0.13 mmol) according to the procedure for
Intermediate 102 to afford a light yellow gum.
MS: 311 ES+ 3N405)
Intermediate 123: eth 1 2S flu0r0 28 SR meth l0X0 5-0X0 rrolidin
l meth0X o l -1 6-diazabic clo 3.2.1 0cten 1 0X acetate
04%NH
o.NJL,,, \
)—N\ F
0 (TWO\/
The title compound was prepared from (2S,5R)—6—hydroxy—3—methyl—7—oxo—N—[(5—
oxopyrrolidin—2—yl)methoxy] — 1 ,6—diazabicyclo[3 .2. 1]oct—3—ene—2—carboxamide (Intermediate
122, 35 mg, 0.11 mmol) and ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174, 0.04
mL, 0.34 mmol) according to the ure for Intermediate 103 to afford (15 mg, 32.1%)
as a sticky solid. The compound is a 1:4 mixture of diastereomers.
M_SZ 415 ES+ (C17H23FN4O7)
The title compound was prepared from ethyl (2S)—2—fluoro—2—[[(2S,5R)—3—methyl—7—oxo—2—
[(5—oxopyrrolidin—2—yl)methoxycarbamoyl] — 1 zabicyclo[3 .2. 1]oct—3—en—6—yl]oxy] acetate
(Intermediate 123, 15 mg, 0.036 mmol) ing to the ure for Example 66 to
afford (7.0 mg, 40%) a white solid after lyophilization.
M_S: 387 ES+ 9FN4O7).
1H NMR1300 MHz= D;@ 8: 1.64 (s, 3H); 1.82 (m, 1H); 2.25 (m, 1H); 2.38 (m, 2H); 3.24
(m, 1H); 3.76 (m, 2H); 3.96 (m, 2H); 4.09 (m, 2H); 5.63—5.82 (d, 1H); 6.17 (m, 1H).
Intermediate 124: 2S 0x0 rr01idin lmeth l4-meth lbenzenesulfonate
O-fi@9
To a stirred solution of (S)—(+)—5—(hydroxymethyl)—2—pyrrolinone (2.0 g, 17.4 mmol) and P—
toluenesulfonyl chloride (4.17 g, 21.9 mmol) in CHzClz (50 mL) at 0 °C were added
dimethylaminopyridine (111.4 mg, 0.91 mmol) and triethylamine (3.05 mL, 21.9 mmol).
The resulting mixture was allowed to warm to RT and stir for 12 hours. The reaction was
then quenched with water, and the aqueous layer was extracted with CHzClz. The combined
organic extracts were washed with 1N HCl solution and dried over anhydrous NaZSO4.
Removal of solvent under reduced pressure followed by flash chromatography (2.5% MeOH
in DCM) afforded the title compound (4.58 g, 93.2%) as a white solid.
M_S: 270 ES+ (C12H15NO4S).
Intermediate 125: 2- 2S 0x0 in lacetonitrile
To a solution of [(2S)—5—oxopyrrolidin—2—yl]methyl 4—methylbenzenesulfonate (Intermediate
124, 4.5 g, 16.7 mmol) in acetonitrile (50 mL) was added KCN (2.76 g, 41.8 mmol). The
solution was heated at 85 °C for 18 hours. The solution was then diluted with itrile
(200 mL), filtered through celite, and concentrated in vacuo. The residue was purified by
silica gel flash chromatography (9:1 DCM/MeOH) to afford the title compound (1.8 g,
86.8%) as a white solid.
M_S: 125 ES+ ZO).
Intermediate 126: tert-but lN- 2- 2S 0X0 rrolidin-Z- l eth l carbamate
To a stirred solution of )—5—oxopyrrolidin—2—yl]acetonitrile (Intermediate 125, 300 mg,
2.42 mmol) in methanol (l5mL) at 0°C was added di—tert—butyl dicarbonate (1.05 g, 4.83
mmol) and NiClz‘6 H20 (57.4 mg, 0.24 mmol). Then NaBH4 (0.64 g, 16.9 mmol) was added
over 30 minutes. The reaction mixture was warmed up to RT and stirred for 1 hour. Hunig's
base (0.42 mL, 2.42 mmol) was added, then stirred for 30 minutes. The t was
removed. The residue was dissolved in EtOAc and washed with sat. NaHC03 solution, brine,
dried over MgSO4, filtered and concentrated to afford the title compound (0.50 g, 90.6%) as a
white solid.
M_S: 229 ES+ (C11H20N203)
Intermediate 127: SS 2-amin0eth l rrolidin-Z-one
To a solution of tert—butyl N—[2—[(2S)—5—oxopyrrolidin—2—yl]ethyl]carbamate (Intermediate
126, 500 mg, 2.19 mmol) in DCM (2.5 mL) was added trifluoroacetic acid (1.15 g, 10.9
mmol). The reaction was then d at RT for 2 hours. The solvent was removed to afford
the title compound as a TFA salt.
M_S: 129 ES+ (C6H12N20)
Intermediate 128: 28 SR tert-but l dimeth 1 Si] 1 0X meth l0X0-N- 2- 5-
The title compound was prepared from )—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—l,6—diazabicyclo[3.2. l]oct—3—ene—2—carboxylic acid (Intermediate 77, 300 mg, 0.96
mmol) and 5—(2—aminoethyl)pyrrolidin—2—one TFA salt (Intermediate 127, 0.35 g, 1.44
mmol) according to the procedure for Intermediate 101 to afford (120 mg, 29.6%) as a White
solid.
M_SZ 423 ES+ (C20H34N404Sl)
I2 0
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
[2—(5—oxopyrrolidin—2—yl)ethyl] — l ,6—diazabicyclo[3 .2. l]oct—3—ene—2—carboxamide
(Intermediate 128, 120 mg, 0.28 mmol) according to the procedure for Intermediate 102 to
afford a White gum.
M_33 309 133+ (C14H20N4O4)
I2 0
The title compound was prepared from (2S,5R)—6—hydroxy—3—methyl—7—oxo—N—[2—(5—
oxopyrrolidin—2—yl)ethyl]—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate
129, 80 mg, 0.26 mmol), K2CO3 (179.3 mg, 1.3 mmol) and ethyl (2S)—2—bromo—2—fluoro—
acetate (Intermediate 174, 0.12 mL, 0.78 mmol) according to the ure for
Intermediate 103 to afford (30 mg, 28%) as a White solid. The compound is a 1:4 mixture of
diastereomers.
M_S: 413 ES+ (C13H25FN4O6)
The title compound was prepared from ethyl (2S)—2—fluoro—2—[[(2S,5R)—3—methyl—7—oxo—2—[2—
pyrrolidin—2—yl)ethylcarbamoyl] — 1 ,6—diazabicyclo[3 .2. 1]oct—3—en—6—yl] oxy] acetate
(Intermediate 130, 30 mg, 0.07 mmol) according to the ure for Example 66 to afford
(8.0 mg, 25.8%) as a White solid after lyophilization.
M_S: 385 ES+ (C16H21FN4O6)
1H NMR1300 MHz, mg) 5: 1.69 (s, 3H); 1.77 (m, 3H); 2.36 (m, 2H); 3.30 (m, 3H); 3.44
(m, 1H); 3.76 (m, 2H); 4.11 (m, 1H); 4.31 (m, 1H); 5.63—5.82 (d, 1H); 6.23 (m, 1H).
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—l,6—diazabicyclo[3.2. l]oct—3—ene—2—carboxylic acid (Intermediate 174, 300 mg, 0.96
mmol) and 3—aminopropane—l—sulfonamide hloride (251 mg, 1.44 mmol) according to
the procedure for Intermediate 101 to afford (198 mg, 47.7%) as a White solid.
M_S: 433 ES+ (C17H32N4058iS)
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—N—(3—sulfamoylpropyl)— l ,6—diazabicyclo[3 .2. l]oct—3—ene—2—carboxamide (Intermediate
131, 200 mg, 0.46 mmol) according to the procedure for Intermediate 102 to afford a White
M_S: 319 ES+ (C11H13N4053)
Intermediate 133: eth 1 2S flu0r0 28 SR h l0X0 3-
sulfamo 1 r0 mo l-1 6-diazabic clo 3.2.1 0cten 10X acetate
H2N II H
O N! F
O O
The title compound was prepared from (2S,5R)—6—hydroxy—3—methyl—7—oxo—N—(3—
sulfamoylpropyl)—l,6—diazabicyclo[3.2.l]oct—3—ene—2—carboxamide (Intermediate 132, 100
mg, 0.31 mmol) and ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174, 0.11 mL, 0.94
mmol) according to the ure for Intermediate 103 to afford (22 mg, 16.7%) as a White
solid. The nd is a 1:4 mixture of diastereomers.
M_S: 423 ES+ (C15H23FN4O7S)
HEESMNJ’“L \
2 H
o N
SrOHF
The title compound was prepared from ethyl (2S)—2—fluoro—2—[[(2S,5R)—3—methyl—7—oxo—2—(3—
sulfamoylpropylcarbamoyl)— 1 ,6—diazabicyclo[3 .2. 1]oct—3—en—6—yl]oxy] acetate (Intermediate
133, 22 mg, 0.05 mmol) according to the procedure for Example 66 to afford (8.0 mg, 37%)
a white solid after lyophilization.
M_S: 395 ES+ 9FN4O7S)
1H NMR1300 MHz= D;@ 8: 1.69 (s, 3H); 2.04 (m, 2H); 3.35 (m, 6H); 4.11 (m, 1H); 4.34
(m, 1H); 5.65-5.83 (d, 1H); 6.22 (m, 1H).
Intermediate 134: tert-butyl N-|2-1sulfamoylamin02ethyl |carbamate
o,\S/ N\/\ A0)<
, N
HN||2 H
A solution of tert—butyl N—(2—aminoethyl) carbamate (2.0 g, 12.5 mmol) and sulfamide (2.0 g,
24.9 mmol) in dioxane (10 mL) was stirred at 90 °C for 5 hours. The mixture was then
ed to remove the insoluble material and the filtrate was concentrated under reduced
pressure. The residue was then dissolved in EtOAc, washed with dilute HCl solution three
times, then brine, dried over MgSO4, filtered and concentrated to afford the title compound
(1.2 g, 40.2%) as a yellow oil.
1H NMR1300 MHz= DMSO-dg) 5: 1.39 (s, 9H); 2.92 (m, 2H); 3.04 (m, 6H); 6.50 (m, 3H);
6.75 (m, 1H).
Intermediate 135: 1-amin0 sulfamo lamino ethane TFA salt
\ H
28’ H2
To a solution of tert—butyl N—[2—(sulfamoylamino)ethyl]carbamate (Intermediate 134, 1.2 g,
.01 mmol) in DCM (5 mL) was added trifluoroacetic acid (5.72 g, 50.1 mmol). The reaction
mixture was stirred at room temperature for 2 hours. The solvent was removed to afford the
title compound as a yellow TFA salt.
M_SZ 140 ES+ (C2H9N30zS)
Intermediate 136: ZS 5R ut l dimeth 1 Si] 1 0X meth l0X0-N- 2-
sulfamo lamino eth l -1 6-diazabic clo 3.2.1 enecarb0xamide
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxylic acid (Intermediate 77, 300 mg, 0.96
mmol) and 1—amino—2—(sulfamoylamino) ethane TFA salt (Intermediate 135, 365 mg, 1.44
mmol) according to the procedure for Intermediate 101 to afford (117 mg, 28.1%) a white
solid.
M_SI 434 ES+ 1N505818)
O\\ ,“\/\ l/I
Hm? M " \
o N
O OH
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—N—[2—(sulfamoylamino)ethyl]—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide
(Intermediate 136, 117 mg, 0.27 mmol) according to the procedure for Intermediate 102 to
afford the title compound as a white gum.
M_SZ 320 ES+ (C10H17N5058)
WO 53215
The title compound was prepared from (2S,5R)—6—hydroxy—3—methyl—7—oxo—N—[2—
(sulfamoylamino)ethyl]—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 137,
80 mg, 0.25 mmol) and ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174, 0.089 mL,
0.75 mmol) according to the procedure for Intermediate 103 to afford (22.0 mg, 16.5%) as a
White solid. The compound is a 3:7 mixture of diastereomers.
M_S: 424 ES+ (C14H22FN507)
The title compound was ed from ethyl (2S)—2—fluoro—2—[[(2S,5R)—3—methyl—7—oxo—2—[2—
(sulfamoylamino)ethylcarbamoyl] — 1 ,6—diazabicyclo[3 .2. 1]oct—3—en—6—yl]oxy] acetate
(Intermediate 138, 30 mg, 0.071 mmol) according to the procedure for Example 66 to
afford (13.0 mg, 44.1%) as a White solid.
M_S: 396 ES+ (ClelgFN507S)
1H NMR1300 MHz= D;@ 5: 1.71 (s, 3H); 3.21—3.47 (m, 6H); 4.11 (m, 1H); 4.35 (m, 1H);
.64-5.84 (d, 1H); 6.22 (m, 1H).
Intermediate 139: ZS 5R tert-but l dimeth 1 Si] 1 0X meth l0X0-1 6-
ic clo 3.2.1 0ctenecarb0nitrile
To a solution of (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.l]oct—3—ene—2—carboxamide (Intermediate 192, 3.0 g, 9.63 mmol) in DCM
(50 mL) at room temperature was added Burgess Reagent (3.44 g, 14.4 mmol) portionwise
over 2 hours. The on mixture was stirred for an additional 16 hours, then washed with
1:1 water twice. The organics were dried over magnesium e, filtered and
concentrated. Silica gel chromatography (0—25% ethyl acetate/hexanes) afforded the title
compound (2.3 g, 81.3%) as a white solid.
M_S: 294 ES+ 3N302Si)
Intermediate 140: tert-but lN- 2S tert-but ldimeth lsil 10X meth l0X0-
1 6-diazabic clo 3.2.1 0cten l meth l carbamate
k 0CAM/0,, \
O o»Sl\
To a stirred solution of (2S)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carbonitrile (Intermediate 139, 1.2 g, 4.09 mmol) in
methanol (100 mL) at 0 °C was added di—tert—butyl dicarbonate (1.78 g, 8.18
mmol) and NiClz‘6 H20 (97.2 mg, 0.41 mmol). Then NaBH4 (1.08 g, 28.6 mmol) was added
over 30 minutes. The reaction mixture was then warmed to RT and stirred for 1 hour.
s base (0.71 mL, 4.09 mmol) was added, then stirred for 30 minutes. The solvent was
removed. The residue was dissolved in EtOAc and washed with sat. NaHC03 solution, brine,
dried over MgSO4, filtered and concentrated. The e was purified with silica gel
chromatography (40 g, 0%—35% EtOAc/Hexane) to afford the title compound (0.58 g, 35.7%)
as a white solid.
M_S: 398 ES+ (C19H35N304Sl)
Intermediate 141: tert-but lN- 2S 5R h dr0X meth l0X0-1 6-
diazabic clo 3.2.1 0cten l meth l carbamate
)(OJLN/n.0 \
O OH
The title compound was prepared from tert—butyl N—[[(2S,5R)—6—[tert—butyl(dimethyl)—
silyl]oxy—3—methyl—7—oxo— 1 ,6—diazabicyclo[3 .2. 1]oct—3—en—2—yl]methyl]carbamate
(Intermediate 140, 80 mg, 0.20 mmol) according to the procedure for Intermediate 102 to
afford a White gum.
M_S: 284 ES+ 1N3O4)
ediate 142: eth 1 2S 28 SR tert-but0X carbon 1 amino meth l
meth l0X0-1 6-diazabic clo 3.2.1 0cten 1 0X flu0r0acetate
)(OJLM/h.O \
O O/Sfov
The title compound was prepared from tert—butyl N—[[(2S,5R)—6—hydroxy—3—methyl—7—oxo—
1,6—diazabicyclo[3.2.1]oct—3—en—2—yl]methyl]carbamate (Intermediate 141, 50 mg, 0.18
mmol) and ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174, 0.063 mL, 0.53 mmol)
according to the ure for Intermediate 103 to afford (50 mg, 73.1%) a White solid. The
compound is a 1:9 mixture of diastereomers.
M_S: 388 ES+ (C17H26FN3O6)
The title compound was prepared from ethyl (2S)—2—(((2S,5R)—2—(((tert—butoxycarbonyl)—
amino)methyl)—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—en—6—yl)oxy)—2—fluoroacetate
(Intermediate 142, 50 mg, 0.13 mmol) according to the procedure for Example 66 to afford
(35 mg, 67.9%) as a White solid after lyophilization.
M_S: 360 ES+ (C15H22FN306)
1H NMR1300 MHz= D;@ 5: 1.43 (s, 9H); 1.65 (s, 3H); 3.17—3.36 (m, 3H); 3.49 (m, 1H);
3.74 (m, 1H); 4.05 (m, 1H); 5.62-5.81 (d, 1H); 6.08 (m, 1H).
WO 53215
To a solution of (2S)—2—[[(2S,5R)—2—[(tert—butoxycarbonylamino)methyl]—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—en—6—yl]oxy]—2—fluoro—acetic acid (Example 76, 25 mg, 0.07
mmol) in DCM (1 mL) at 0 °C was added trifluoroacetic acid (0.79 g, 6.96 mmol). The
reaction mixture was stirred for 2 hours, then concentrated. The residue was ved in pH
7 buffer, then loaded on a sepabead column (saturated with water first, then ACN, then
washed with water) eluting with (0%—2.5% CAN/water) to afford the title compound (8 mg,
37.7%) as a white solid after lization.
M_S: 260 ES+ (C10H14FN304)
1H NMR1300 MHz= ngl 8: 1.64 (s, 3H); 3.19-3.30 (m, 3H); 3.44 (m, 1H); 3.96 (m, 1H);
4.09 (m, 1H); 5.64-5.84 (d, 1H); 6.16 (m, 1H).
Intermediate 143: ZS 5R aminometh l tert-but l dimeth 1 Si] 1 0x meth [-
1,6-diazabicyclo| 3.2.1 -en0ne
0%“! /
‘0»Si\
To a solution of tert—butyl N—[[(2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—en—2—yl]methyl]carbamate (Intermediate 140, 100 mg, 0.25 mmol)
in DCM (5 mL) at 0 °C was added ZnBrz (170 mg, 0.75 mmol). The reaction mixture was
stirred at RT for 16 hours, then concentrated and used in the next step without purification.
M_S: 298 ES+ (C14H27N3Ole)
To a solution of )—2—(aminomethyl)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—1,6—
diazabicyclo[3.2.1]oct—3—en—7—one (Intermediate 143, 74 mg, 0.25 mmol) in pyridine (1 mL)
at 0 °C was added AczO (168 mg, 0.75 mmol). The reaction mixture was stirred at RT for 30
minutes, then washed with water, sat. NaHCOg, brine, dried over MgSO4, filtered and
concentrated. The residue was purified by silica gel tography (0%— 100%
Hexane) to afford the title compound (70 mg, 78.7%) as a white solid.
M_S: 340 ES+ (C16H29N303Si).
The title compound was prepared from of N—[[(2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—
methyl—7—oxo—1,6—diazabicyclo[3.2.l]oct—3—en—2—yl]methyl]acetamide (Intermediate 144, 70
mg, 0.21 mmol) according to the procedure for Intermediate 102 to afford a white gum.
M_S: 226 ES+ (C10H15N303)
Intermediate 146: eth 1 2S 2S 5R acetamidometh l meth l0X0-1 6-
diazabic clo 3.2.1 0cten 10X flu0r0-acetate
A//I,‘
u \
L F N\
O O#0v
The title compound was prepared from of N—[[(2S,5R)—6—hydroxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2. l]oct—3—en—2—yl]methyl]acetamide (Intermediate 145, 40 mg, 0.18 mmol)
and ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174, 0.063 mL, 0.53 mmol)
WO 53215
according to the procedure for Intermediate 103 to afford (15 mg, 25.6%) as a white solid
after lyophilization. The compound is a 15:85 mixture of diastereomers.
M_S: 330 ES+ (C14H20FN305)
The title compound was prepared from ethyl —[[(2S,5R)—2—(acetamidomethyl)—3—
methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—en—6—yl]oxy]—2—fluoro—acetate (Intermediate 146,
mg, 0.05 mmol) according to the procedure for Example 66 to afford (10 mg, 65.6%) a
white solid after lyophilization.
M_S: 302 ES+ (C12H16FN305)
1H 0 MHz, mg) 5: 1.64 (s, 3H); 1.99 (s, 3H); 3.19 (m, 1H); 3.34 (m, 2H); 3.64 (m,
1H); 3.79 (m, 1H); 4.05 (m, 1H); 5.63-5.81 (d, 1H); 6.09 (m, 1H).
Intermediate 147: eth 1 ZS ZS 5R aminometh l meth l0x0-1 6-
diazabic clo 3.2.1 en 1 0x flu0r0-acetate TFA salt
% F N\
O O#0v
To a solution of ethyl (2S)—2—[[(2S,5R)—2—[(tert—butoxycarbonylamino)methyl]—3—methyl—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—en—6—yl]oxy]—2—fluoro—acetate (Intermediate 142, 97.4 mg,
0.25 mmol) in DCM (2 mL) at 0 °C was added trifluoroacetic acid (2.87 g, 25.2 mmol). The
reaction mixture was stirred at 0 °C for 2 hours, then concentrated to afford the title
compound as TFA salt.
MS: 288 ES+ (C12H13FN304)
Intermediate 148: tert-but lN-chlorosulfon lcarbamate
k 0 9
OJLWEEI
To a stirred solution of tert—butanol (1.9 mL, 20 mmol) in CHzClz (12 mL) at 0°C was added
chlorosulfonyl isocyanate (1.4 mL, 15 mmol) dropwise over the course of 10 s. After
ng at 0 °C for 5 minutes, the on mixture was warmed to RT and stirred for 20
minutes. The reaction mixture was trated in vacuo to one—third volume. The flask
was placed back into the 0 °C bath, and the product crystallized out of solution. After 50
minutes, the product was collected by tion and washed with hexanes to afford the title
compound (2.8 g, 80.7%) as a white solid.
To a solution of ethyl (2S)—2—[[(2S,5R)—2—(aminomethyl)—3—methyl—7—oxo—1,6—diazabicyclo—
[3.2. l]oct—3—en—6—yl]oxy]—2—fluoro—acetate TFA salt (Intermediate 147, 72 mg, 0.25 mmol)
in DCM (2 mL) at 0 °C was added tert—butyl N—chlorosulfonylcarbamate (Intermediate 148,
54.0 mg, 0.25 mmol) and triethylamine (63.4 mg, 0.63 mmol). The reaction mixture was
stirred at RT for 30 minutes, then diluted with DCM, washed with water, brine, dried over
MgSO4, filtered and concentrated. The residue was purified by flash chromatography (0%—
100% EtOAc/Hexane) to afford the title compound (38 mg, 39.6%) as a white solid.
M_S: 384 ES+ (C14H17F4N305)
The title compound was prepared from ethyl (2S)—2—fluoro—2—[[(2S,5R)—3—methyl—7—oxo—2—
[[(2,2,2—trifluoroacety1)amino]methyl] — 1 zabicyclo[3 .2. 3—en—6—y1]oxy] acetate
(Intermediate 149, 38 mg, 0.10 mmol) according to the procedure for Example 66 to afford
(25 mg, 60.3%) a White solid after lyophilization.
M_S: 356 ES+ (C12H13FN305)
1H NMR1300 MHz= D;@ 5: 1.66 (s, 3H); 3.22 (m, 1H); 3.36 (m, 1H); 3.59 (m, 1H); 3.73
(m, 1H); 3.86 (m, 1H); 4.08 (m, 1H); 5.62-5.83 (d, 1H); 6.11 (m, 1H).
Intermediate 150: 2S 5R tert-but l dimeth l sil 1 0X -N- c anometh l meth l
0X0-1 6-diazabic clo 3.2.1 0ctenecarb0xamide
N§/\NJl,I \
)—N /
0 ‘0’3'\
The title compound was prepared from (2S,5R)—6—[tert—buty1(dimethy1)si1y1]oxy—3—methy1—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxy1ic acid (Intermediate 77, 700 mg, 2.24
mmol) and aminoacetonitrile hydrochloride (207 mg, 2.24 mmol) according to the ure
for ediate 101 to afford (302 mg, 38.4%) a White solid.
M_S: 351 ES+ (C16H26N403Si)
Intermediate 151: 2S 5R -N- c anometh l h dr0X meth l0X0-1 6-
diazabicycloI 3.2.1 |0ctenecarb0xamide
Nj/\MJl,1., \
l; N\
O OH
The title compound was prepared from (2S,5R)—6—[tert—buty1(dimethy1)si1y1]oxy—N—
(cyanomethy1)—3 1—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide
(Intermediate 150, 300 mg, 0.86 mmol) according to the procedure for Intermediate 102 to
afford a residue.
M_S: 237 ES+ (C10H12N4O3)
Oil—Nb/FSWO\/
To a solution of )—N—(cyanomethyl)—6—hydroxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 151, 239 mg, 1.01 mmol) in THF
(3 mL) and DMF (0.3 mL) at —40 °C was added DBU (0.18 mL, 1.22 mmol) and ethyl (2S)—2—
bromo—2—fluoro—acetate (Intermediate 174, 0.18 mL, 1.52 mmol). The reaction mixture was
stirred at —40°C for 30 minutes, then d with ethyl acetate and washed three times with
1:1 brinezwater. The organics were dried over magnesium sulfate, filtered and concentrated.
The residue was purified by flash tography 0% EtOAc/Hexane) to give a 1:4
e of diastereomers. The diastereomers were separated by reverse phase HPLC (T3
column, 20%—50% ACN/water, 10 minutes) to afford Example 80 (64 mg, 18.2%) and
Example 81 (8 mg, 2.3%) as white solids.
M_S: 341 ES+ (C14H17FN405)
1H NMR1300 MHz= DMSO-dg) 5: 1.27 (m, 3H); 1.64 (s, 3H); 3.13 (m, 1H); 3.61 (m, 1H);
3.98 (m, 1H); 4.21 (m, 5H); 6.06-6.26 (m, 1H); 6.10 (m, 1H); 9.18 (m, 1H).
Exam le 81: eth 1 2R flu0r0 2S 5R c anometh lcarbamo lmeth l0x0-
1 6-diazabic clo 3.2.1 0cten 1 0x acetate
f”)|,1,, \
M_S: 341 ES+ (C14H17FN405)
1H NMR1300 MHz, DMSO—dg) 5: 1.21 (m, 3H); 1.65 (s, 3H); 3.12 (m, 1H); 3.60 (m, 1H);
4.07 (m, 1H); 4.22 (m, 5H); 6.08 (m, 1H); 6.15—6.33 (m, 1H); 9.16 (m, 1H).
WO 53215
Exam le 82: 2S flu0r0 2S 5R c anometh lcarbamo l meth l0x0-1 6-
diazabic clo 3.2.1 0cten 1 0x acetic acid lithium salt
The title compound was prepared from ethyl (2S)—2—fluoro—2—[[(2S,5R)—2—(cyanomethyl—
carbamoyl)—3—methyl—7—oxo—1,6—diazabicyclo[3.2. 1]oct—3—en—6—yl]oxy] acetate (Example 80,
50 mg, 0.15 mmol) according to the procedure for Example 66 to afford (32 mg, 66.3%) as a
White solid after lyophilization.
M_S: 313 ES+ 3FN405)
1H NMR1300 MHz, mg) 5: 1.74 (s, 3H); 3.35 (m, 2H); 4.12 (m, 1H); 4.25 (m, 2H); 4.42
(m, 1H); 5.63-5.83 (d, 1H); 6.23 (m, 1H).
Intermediate 138 (230 mg) was separated by reverse phase preparative HPLC (T3 column,
ACN/Water 20—50% for 10 mins) to afford Example 83 (104 mg) and Example 84 (7 mg) as
White solids.
M_S: 424 ES+ (C14H22FN507S)
1H 0 MHz= DMSO-dg) 8: 1.27 (m, 3H); 1.63 (s, 3H); 2.97 (m, 2H); 3.10 (m, 1H);
3.26 (m, 2H); 3.73 (m, 1H); 3.96 (m, 1H); 4.21 (m, 3H); 6.06—6.26 (m, 2H); 6.56 (m, 3H);
8.45 (m, 1H).
Exam le 84: eth l ZR -Z-flu0r0-Z- ZS 5R -Z- c h lcarbamo lmeth l0X0-
M_S: 424 ES+ (C14H22FN507S)
1H 0 MHz2 DMSO—dg) 5: 1.21 (m, 3H); 1.62 (s, 3H); 2.95 (m, 2H); 3.07 (m, 1H);
3.24 (m, 2H); 3.71 (m, 1H); 4.06 (m, 1H); 4.21 (m, 3H); 6.03 (m, 1H); 6.14—6.31 (m, 1H);
6.55 (m, 3H); 8.42 (m, 1H).
To a solution of (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—1,6—
diazabicyclo[3.2.1]oct—3—ene—2—carboxamide mediate 19Z,1.0 g, 3.21 mmol) was added
paraformaldehyde (1.45 g, 16.1 mmol) in 1,4—dioxane (10 mL). The reaction mixture was
heated to 90 °C for 16 hours under microwave. The solvent was removed. Silica gel
chromatography (0%—80% EtOAc/Hexane) afforded the title compound (0.62 g, 56.5%) as a
white solid.
M_S: 342 ES+ (C15H27N3O4Sl)
Intermediate 153: eth 1 ZS -Z-flu0r0-Z- ZS 5R -Z- h dr0X meth lcarbamo l
meth l0X0-1 abic clo 3.Z.1 0cten 1 0X acetate
/\ JI’I,
HO N ‘\
L . N\
O 0#0V
To a solution of (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—N—(hydroxymethyl)—3—methyl—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 152, 230 mg, 0.67
mmol) and cerium(III) chloride (166 mg, 0.67 mmol) in THF (3 mL) at —78 °C was added
TBAF (0.67 mL, 0.67 mmol) (1M in THF). The e was stirred for about 10
minutes. To the reaction mixture was added ethyl (2S)—2—bromo—2—fluoro—acetate
mediate 174, 24.4 mg, 0.67 mmol). After 5 minutes, the reaction mixture was
partitioned between water and EtOAc. The organic layer was collected, washed with water,
brine, dried over MgSO4, filtered and trated. Silica gel chromatography (0%—80%
EtOAc/Hexane) afforded a mixture of two diastereomers in a ratio of 1:3, 180 mg.
Exam le 85: eth 1 2S flu0r0 2S 5R h drox meth mo lmeth l
0x0-1 6-diazabic clo 3.2.1 0cten 1 0x acetate
Ho/\NJ|, \
3— F
O O#O\/
Intermediate 153 (180 mg) was separated by reverse phase preparative HPLC (T3 ,
ACN/water 20—50% for 10 mins) to afford Example 85 (43 mg) and Example 86 (2.6 mg) as
white solids.
MS: 332 ES+ (C13H13FN3O6)
1H NMR1300 MHz, DMSO—dg) 5: 1.28 (m, 3H); 1.61 (s, 3H); 3.09 (m, 1H); 3.79 (m, 1H);
3.96 (m, 1H); 4.25 (m, 3H); 4.54 (m, 2H); 5.68 (m, 1H); 6.06—6.24 (m, 2H); 8.99 (m, 1H).
Exam le 86: eth 1 2R flu0r0 2S 5R h drox meth lcarbamo lmeth l
0x0-1 6-diazabic clo 3.2.1 0cten 1 0x acetate
HOAN \
M_S: 332 ES+ (C13H18FN306)
1H NMR1300 MHz= DMSO-dg) 5: 1.24 (m, 3H); 1.61 (s, 3H); 2.97 (m, 1H); 3.35 (m, 1H);
4.06 (m, 1H); 4.26 (m, 3H); 4.59 (m, 2H); 5.52 (m, 1H); 6.03 (m, 1H); 6.06—6.24 (m, 1H);
8.99 (m, 1H).
The title compound was prepared from ethyl (2S)—2—fluoro—2—[[(2S,5R)—2—
(hydroxymethylcarbamoyl)—3—methyl—7—oxo— 1 ,6—diazabicyclo[3 .2. 1]oct—3—en—6—yl]oxy] acetate
(Example 85, 15 mg, 0.05 mmol) according to the procedure for Example 66 to afford (8
mg, 55.3%) a white solid after lyophilization.
M_S: 304 ES+ (C11H14FN306)
1H NMR1300 MHz, D29 8: 1.77 (s, 3H); 3.42 (m, 2H); 4.17 (m, 1H); 4.41 (m, 1H); 4.79
(m, 2H); 5.70-5.89 (d, 1H); 6.28 (m, 1H).
Intermediate 154: tert-but lN- isoc anatometh lcarbamate
kJOL /\
O N N
H \o
To a stirred solution of Y—OH (10 g, 57.08 mmol) in THF (200 mL) at 0°C was
added methyl chloroformate (5.29 mL, 68.5 mmol) dropwise, followed by triethylamine (9.55
mL, 68.5 mmol) dropwise. A white itate formed immediately. The mixture was stirred
for 45 minutes before the on of NaN3 (5.58 g, 85.6 mmol) in water (10 mL) at 0 OC.
The resulting mixture was stirred at 0 °C for 1 hour, then diluted with water. The acyl azide
was extracted four times with toluene (4 x 25 mL) and the combined organic extracts were
successively washed with saturated sodium bicarbonate (2 x 30 mL) and water (50 mL). The
organics were dried over MgSO4 at 0 OC, filtered and then heated slowly with stirring until
nitrogen gas evolution was observed, which ed at 59 °C for 20 minutes. The
temperature was increased and ined at 64 °C for 1.5 hours, then increased slowly to 70
°C for 20 minutes. The solution was concentrated under reduced pressure to afford the title
nd (8.6 g, 87.5%) as a colorless oil.
Intermediate 155: tert-but lN- benz 10x carbon lamin0meth lcarbamate
)(OJLNAMAOAQO O
To a solution of tert—butyl N—(isocyanatomethyl)carbamate (Intermediate 154, 8.3 g, 48.2
mmol) in DCE (5 mL) at 0 °C was added benzyl alcohol (7.48 mL, 72.3 mmol) and
triethylamine (0.67 mL, 4.82 mmol), se. The reaction mixture was warmed to RT and
d for 30 s. The white solid formed was collected by filtration and washed with
hexane to afford the title compound (5.2 g, 38.5%) as a white solid.
M_SZ 303 ES+Na (C14H20N204).
Intermediate 156: tert-but lN- amin0meth l ate
o N/\NH2
A solution of tert—butyl zyloxycarbonylaminomethyl)carbamate (Intermediate 155,
1.5 g, 5.35 mmol) in methanol (20 mL) was bubbled with nitrogen gas. Pd/C (10%) (150
mg) was added. The reaction mixture was degassed and then put under hydrogen balloon for
minutes. The reaction mixture was ed through . The filtrate was concentrated
to afford the title compound as colorless oil.
M_SI 147 ES+ (C6H14N202)
Intermediate 157: tert-but lN- 2S 5R tert-but l dimeth 1 Si] 1 0x meth l
0x0-1 6-diazabic clo 3.2.1 0ctenecarb0n 1 amino meth l carbamate
Kay”)...0 0
O//‘—N‘o>/Si/%
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—l,6—diazabicyclo[3.2. l]oct—3—ene—2—carboxylic acid (Intermediate 77, 350 mg, 1.12
mmol) and tert—butyl N—(aminomethyl)carbamate (Intermediate 156, 246 mg, 1.68 mmol)
according to the procedure for Intermediate 101 to afford (170 mg, 34.4%) a white solid.
MS: 441 ES+ (C20H36N405SI)
Intermediate 158: 2S 5R -N- amin0meth l tert-but l dimeth 1 Si] 1 0X h [-
oHg‘0'?
To a solution of utyl N—[[[(2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—l,6—
diazabicyclo[3.2. l]oct—3—ene—2—carbonyl]amino]methyl]carbamate (Intermediate 157, 170
mg, 0.39 mmol) in DCM (3 mL) at 0 °C was added ZnBrz (261 mg, 1.16 mmol). The
reaction mixture was stirred at RT for 16 hours, then concentrated to afford the title
compound.
M_S: 341 ES+ 8N403SI)
To a solution of (2S,5R)—N—(aminomethyl)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—
l,6—diazabicyclo[3.2.l]oct—3—ene—2—carboxamide (Intermediate 158, 131 mg, 0.39 mmol)
in pyridine (3 mL) at 0 °C was added acetic anhydride (394 mg, 3.86 mmol). The reaction
e was stirred at RT for 30 minutes, then partitioned between EtOAc and water. The
organic layer washed with water, sat. NaHCOg, brine, dried over MgSO4, filtered and
concentrated. Silica gel chromatography (0%—80% EtOAc/Hexane) afforded the title
compound (75 mg, 50.8%) as a white solid.
M_S: 383 ES+ 0N4O4Si)
Intermediate 160: 2S 5R -N- acetamid0meth l h dr0X meth l0X0-1 6-
diazabicyc10|3.2.1 |0ctenecarb0xamide
o o
)LNAN I/I \
H H
0’ N‘OH
The title compound was prepared from (2S,5R)—N—(acetamidomethyl)—6—[tert—
butyl(dimethyl)silyl]oxy—3—methyl—7—oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide
(Intermediate 159, 75 mg, 0.20 mmol) according to the ure for Intermediate 102 to
afford a White gum.
M_S: 269 ES+ (C11H16N4O4)
Intermediate 161: eth 1 2S flu0r0 28 SR acetamidometh lcarbamo l
meth l0X0-1 6-diazabic clo 3.2.1 0cten 1 0X e
O O
MAMJLII‘ \
04—”?ng\/
The title compound was prepared from (2S,5R)—N—(acetamidomethyl)—6—hydroxy—3—methyl—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 160, 50 mg, 0.19 mmol)
and ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174, 0.067 mL, 0.56 mmol)
according to the procedure for ediate 103 to afford a White solid after sepabead
column (saturated with water first, then ACN, then eluting with water) eluting with (0%—15%
ter) and lyophilization, 21 mg, 27%. The compound is a 1:4 mixture of
diastereomers.
M_S: 373 ES+ (C15H21FN4O6)
The title compound was prepared from ethyl (2S)—2—fluoro—2—[[(2S,5R)—2—(acetamido—
methylcarbamoyl)—3 —methyl—7—oxo— 1 ,6—diazabicyclo[3 .2. 1]oct—3—en—6—yl] oxy] acetate
(Intermediate 161, 21 mg, 0.056 mmol) in water (1 mL) according to the ure for
Example 66 to afford (6.0 mg, 29.3%) a White solid after lyophilization.
M_S: 345 ES+ (C13H17FN4O6)
1H NMR1300 MHz= D;@ 5: 1.75 (s, 3H); 2.02 (s, 3H); 3.42 (m, 2H); 4.15 (m, 1H); 4.37 (m,
1H); 4.64 (m, 2H); 5.70-5.89 (d, 1H); 6.27 (m, 1H).
Intermediate 162: tert-but lN- tert-but0X carbon lamin0 meth lsulfamo [-
carbamate
)OOL Q’Oik
o NAN’S‘N 0
To a solution of tert—butyl N—(aminomethyl)carbamate (Intermediate 156, 700 mg, 4.79
mmol) in DCM (20 mL) at 0°C was added ylamine (0.67 mL, 4.79 mmol). Then tert—
butyl N—chlorosulfonylcarbamate (Intermediate 148, 1.03 g, 4.79 mmol) in DCM (5 mL)
was added dropwise. The reaction mixture was stirred at 0 °C for 30 minutes, then diluted
with DCM, washed with water, brine, dried over MgSO4, filtered and concentrated. The
residue was triturated with DCM/Hexane to afford the title compound (650 mg, 41.7%) as a
white solid.
M_S: 324 ES- 3N3O6S)
Intermediate 163: amino- sulfamo lamin0 e TFA salt
To a solution of tert—butyl N—[(tert—butoxycarbonylamino)methylsulfamoyl]carbamate
(Intermediate 162, 650 mg, 2 mmol) in DCM (5 mL) at 0 °C was added trifluoroacetic acid
(2.28 g, 19.9 mmol). The reaction mixture was stirred at RT for 30 minutes, then
concentrated to afford the title compound as light yellow gum.
Intermediate 164: ZS 5R tert-but l dimeth l sil 1 0X meth l0X0-N-
sulfamo lamin0 meth l-1 6-diazabic clo 3.2.1 0ctenecarb0xamide
The title compound was ed from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
oxo—l,6—diazabicyclo[3.2. l]oct—3—ene—2—carboxylic acid (Intermediate 77, 350 mg, 1.12
mmol) according to the procedure for Intermediate 101 to afford (125 mg, 26.6%) a white
solid.
M_S: 420 ES+ (C15H29N5058iS)
Intermediate 165: ZS 5R h dr0X h l0X0-N- sulfamo lamin0 meth [-1 6-
diazabicyc10|3.Z.1 |0ctene-Z-carb0xamide
\\ ’/ |
/S\N/\ JIM,
H2N N \
H H
O OH
The title compound was prepared from (2S,5R)—6—[tert—butyl(dimethyl)silyl]oxy—3—methyl—7—
[(sulfamoylamino)methyl] — l ,6—diazabicyclo[3 .2. l]oct—3—ene—2—carboxamide
mediate 164, 125 mg, 0.30 mmol) according to the procedure for Intermediate 102 to
afford a light yellow gum.
M_SZ 306 ES+ (C9H15N5058)
Intermediate 166: eth 1 ZS -Z-flu0r0-Z- ZS 5R meth l0X0-Z-
sulfamo lamin0 meth lcarbam0 l -1 6-diazabic clo 3.Z.1 0cten 1 0X acetate
0‘0 0
/S\ I
H2N NAN) ' \
H H
L . N\
O O#O\/
The title nd was prepared from (2S,5R)—6—hydroxy—3—methyl—7—oxo—N—
[(sulfamoylamino)methyl] — l ,6—diazabicyclo[3 .2. l]oct—3—ene—2—carboxamide (Intermediate
165, 88 mg, 0.29 mmol) and ethyl (2S)—2—bromo—2—fluoro—acetate (Intermediate 174, 0.10
mL, 0.86 mmol) according to the procedure for Intermediate 103 to afford (18 mg, 12.2%) a
white solid. The compound is a 17:83 mixture of diastereomers.
M_S: 410 ES+ (C13H20FN507S)
Exam le 89: ZS -Z-flu0r0-Z- ZS 5R meth l0X0-Z- sulfamo lamin0 -
meth lcarbam0 l -1 6-diazabic clo 3.Z.1 0cten 1 0X acetic acid lithium salt
The title compound was prepared from ethyl (2S)—2—fluoro—2—[[(2S,5R)—3—methyl—7—oxo—2—
WO 53215
[(su1famoy1amino)methy1carbamoy1] — 1 ,6—diazabicyclo[3 .2. 1]oct—3—en—6—y1] oxy] acetate
(Intermediate 166, 18 mg, 0.040 mmol) according to the procedure for Example 66 to
afford (5.0 mg, 25.3%) a white solid after 1yophi1ization.
M_S: 382 ES+ (C11H16F54O7S)
1H NMR1300 MHz, mg) 5: 1.76 (s, 3H); 3.40 (m, 2H); 4.16 (m, 1H); 4.41 (m, 1H); 4.63
(m, 2H); 5.70-5.89 (d, 1H); 6.28 (m, 1H).
Intermediate 167: racemic 2-br0m0flu0r0acetic acid
Br/SfOH
To a 50 L reactor at 0—5 °C was d a solution of ethyl 2—bromo—2—fluoroacetate (3.5 kg)
in tetrahydrofuran (7L, 2V) and a on of sodium hydroxide (830 g) in water (7L, 2V)
dropwise over 1 hour. The resulting solution was stirred at 0—5 °C for 1 hour. HC1 (160 mL)
was added dropwise at 0—5 OC. Water and tetrahydrofuran were removed by concentration
under vacuum. The residue was suspended in tetrahydrofuran (35 L, 10V) and conc. HC1
(1.57 L, 1.0 eq.) was added dropwise. Anhydrous sodium sulfate was added and the resulting
mixture was stirred for 2 hours. The solid was filtered off, and washed with THF (1L x 2).
The filtrate was concentrated under vacuum to give 2—bromo—2—fluoroacetic acid (2.2 kg) as a
yellow oil, which was combined with a previous batch made by the same method (940 g,
: 72%) and distilled in vacuum (65—70°C 100 Pa) to give 2—bromo—2—fluoroacetic acid
(2.55 kg, total yield 67%) as a colorless oi1.
1H NMR {400 MHz,CDC1;L 5 11.15 (s, 1H), 6.66 (d, 1H, J = 68 Hz).
Intermediate 168: S hen lethan-l-amine R br0m0flu0r0acetate
To a 10 L reactor at 0—5 °C was charged a solution of 2—bromo—2—fluoroacetic acid
(Intermediate 167, 2.0 kg) in 1 L of form (1V), to which, a solution of (S)—1—
phenylethanamine (1.39 kg) in 1 L of chloroform (1V) was added se. The mixture was
stirred at room temperature overnight and the resulting white solid was collected by filtration
to give a salt of (S)—1—pheny1ethanamine 2—bromo—2—fluoroacetate (2.5 kg; ee: 6%), which
was charged into a 10 L reactor, followed by addition of chloroform (5L, 2V). The resulting
mixture was stirred for 2 hours at 50°C (solid was partially ved in chloroform), cooled
to 0 OC, and was allowed to stand for 2 hours. Solid was collected by filtration, and washed
with cooled chloroform (500 mL, 0.2V). The recrystallization procedure was repeated 4 times
to afford 1.09 kg (97 %ee) of the title compound as a white solid with an overall yield of 31%
(2 steps).
Intermediate 169: entan l R m0flu0r0acetate
Br/SfOY
To a 2 L reactor at room temperature was d (S)—1—phenylethanamine (R)—2—bromo—2—
fluoroacetate mediate 168, 450 g), dichloromethane (900 mL, 2V) and iPrOH (2.0 eq.).
trimethylsilane (1.12 L) was added slowly, and a white precipitate was formed. The
resulting mixture was stirred at room temperature overnight. White precipitate was filtered
off, and the filter cake was washed with hexane (450 mL, 1V). The combined filtrate was
washed with water (3x100 mL). Organic solution was dried with anhydrous sodium sulfate,
filtered, concentrated under vacuum. Residue was distilled (54—60°C, 100 Pa) to give the title
compound as a colorless oil (290 g, 79% yield, 95% purity).
1H NMR 1CDCl§= 400 MHz): 6 6.53 (d, J: 51.2 Hz, 1H), 5.17 (m, 1H), 1.32 (m, 6H).
Intermediate 170: eth l R br0m0flu0r0acetate
Br/vwl/OV
Into a 50 mL 3—necked round—bottom flask, purged and maintained with an inert atmosphere
of nitrogen, was placed (1R)—1—phenylethan—l—amine; (2S)—2—bromo—2—fluoroacetic acid
(Intermediate 168, 30 g, 107.9 mmol) and ethanol (34.7 g, 755.3 mmol). This was ed
by the addition of chlorotrimethylsilane (82 g, 755.3 mmol) dropwise with stirring at room
temperature. The resulting solution was stirred for 4 h at room temperature, then ed by
the addition of 10 mL of water/ice. The resulting solution was extracted with 3,x,20 mL of
petroleum ether (30—60 degree) and the organic layers combined. The resulting mixture was
washed with 2,x,20 mL of brine. The mixture was dried over ous sodium sulfate,
filtered and concentrated. The residue was applied onto a silica gel column with eum
ether (30—60 degree). This resulted in 10 g (50%) of the title compound as a colorless oil.
1H NMR1300 MHz= CDCl§L 5 6.58 (d, 1H, J = 51 Hz), 4.38 (q, 2H, J = 6 Hz), 1.38 (t, 3H, J
= 6 Hz).
Intermediate 171: R -benz 12-br0m0flu0r0acetate
81893
Chlorotrimethylsilane (60 mL, 719.12 mmol) was added portionwise to (S)—l—
phenylethanamine bromo—2—fluoroacetate (Intermediate 168, 20 g, 71.91 mmol) and
phenylmethanol (60 mL, 71.91 mmol) at 25 °C over a period of 3 minutes under nitrogen.
The resulting solution was stirred at 25 °C for 4 hours. The reaction e was diluted with
heptane (500 mL), then washed with water and brine. The organics were dried over sodium
sulfate, filtered and concentrated. Silica gel chromatography (0% to 10% ethyl
acetate/petroleum ether) afforded the title compound as a yellow oil, 17.5 g, 98%.
1H 0 MHZ, CDCli—d, 30 °C) 5: 5.30 (s, 2H); 6.60 (d, 1H); 7.40 (m, 5H).
Intermediate 172: IR hen lethan-l-amine' 2S br0m0flu0r0acetic acid
OH ©45NH2
Into a 100—mL round—bottom flask was placed a solution of —phenylethan—1—amine
(107.7 g, 0.89 mol) in methanol (325 mL). This was followed by the addition of a solution of
2—bromo—2—fluoroacetic acid (Intermediate 167, 140 g, 0.89 mol) in methanol (420 mL)
dropwise with stirring at 0 °C over 30 min. The resulting solution was stirred overnight at
room ature, then concentrated under vacuum. The residue was diluted with CHC13
(3V). The solids were collected by filtration. The solid was dried under , then
suspended in CHC13 and heated to 60 °C for 2 hours. The mixture was then was cooled to
0°C and the solid was filtered. The process was repeated 6 times. This resulted in 80 g (32%)
of title compound as a white solid.
1H NMR1300 MHZ, d6—DMSO): 5 8.56 (brs, 3H), 7.49—7.46 (m, 2H), 7.42—7.38 (m, 2H),
7.36—7.34 (m, 1H), 6.48 (d, 1H, J = 56 HZ), .34 (m, 1H), 1.48 (d, 3H, J = 6.8 HZ).
Intermediate 173: S -iso r0 12-br0m0flu0r0acetate
Br/Kg/OY
Into a 250—mL 3—necked round—bottom flask, purged and maintained with an inert atmosphere
of en, was placed (R)—1—phenylethanamine (S)—2—bromo—2—fluoroacetate (Intermediate
172, 32.0 g, 116 mmol), and isopropanol (13.9 g, 232 mmol) in DCM (64 mL). This was
followed by the dropwise addition of chlorotrimethylsilane (56.4 g, 519 mmol) with ng
at room temperature. The resulting on was d overnight at room temperature, then
quenched by the addition of 100 mL of ice. The resulting solution was ted with 3
x 100 mL of eum ether (30—60 degree), and the c layers combined. The resulting
mixture was washed with 3 x 70 mL of brine. The e was dried over anhydrous sodium
sulfate and concentrated. The residue was applied onto a silica gel column with petroleum
ether (30—60 degree). This resulted in 19 g (83%) of title compound as colorless oil.
1H NMR 1CDC15, 400 MHz): 8 6.53 (d, J: 50.8 Hz, 1H), 5.17 (m, 1H), 1.32 (m, 6H).
Intermediate 174: ethyl 12S 2br0m0flu0r0acetate
Br/\n/0v
Into a 50 mL 3—necked round—bottom flask, purged and maintained with an inert atmosphere
of nitrogen, was placed (1R)—l—phenylethan—l—amine (2S)—2—bromo—2—fluoroacetic acid
(Intermediate 172, 20 g, 72 mmol) and ethanol (23.2 g, 504 mmol). This was followed by
the dropwise addition of chlorotrimethylsilane (54.8 g, 504 mmol) with stirring at room
temperature. The resulting solution was stirred for 4 h at room temperature, then quenched by
the addition of 10 mL of water/ice. The resulting solution was ted with 3 x 20 mL of
petroleum ether (30—60 degree) and the organic layers combined. The resulting mixture was
washed with 2 x 20 mL of brine. The mixture was dried over anhydrous sodium sulfate,
filtered and concentrated. The residue was applied onto a silica gel column with petroleum
ether (30—60 degree). This resulted in 6 g (45%) of title compound as colorless oil.
1H NMR1300 MHz= d6-DMSO): 5 6.57 (d, 1H, J = 56 Hz), 4.37 (q, J = 7.2 Hz, 2H), 1.33 (t, 3H, J =
7.2 Hz).
Intermediate 175: E -buten lb0r0nic acid
\ZL [OH
To a solution of (E)—but—2—en—1—ol (59.5 g, 826 mmol) in MeOH (360 mL) at room
temperature was added HdeCl4 (2.06 g, 8.34 mmol), then to the mixture was added B2(OH)4
(81.8 g, 919 mmol) by n at 30—40 0C. The resulting solution was stirred at 30—40 °C for
minutes, then filtered through celite.
1H—NMR gDMSO—dg, 400 MHz): 5 5.39—5.49 (m, 1H), 5.16—5.26 (m, 1H), 3.38 (s, 2H), 1.38—
1.58 (m, 5H)
Intermediate 176: S E tert-but lsulfin limino acetic acid
HowN‘lsl"\‘<
To molecular sieves type 4104 (500 g) in DCM (600 mL) at room ature was added (S)—
2—methylpropane—2—sulfinamide (100 g, 819mmol) and 2—oxoacetic acid e (91.2 g, 991
mmol). The resulting solution was stirred at room temperature for overnight, then filtered
through celite.
1H-NMR {DMSO-dg, 400 MHz): 8 7.77 (s, 1H), 5.74 (s, 1H), 1.13 (s, 9H)
Intermediate 177: 2S 3R S -1 l-dimeth leth lsulfinamido meth l enten0ic
To a solution of the crude product (S,E)—2—(tert—butylsulfinylimino)acetic acid (Intermediate
176) in DCM (600 mL) at 0—15 °C was added dropwise a solution of the (E)—but—2—
enylboronic acid (Intermediate 175) in MeOH (360 mL). The resulting on was stirred
at 0—15 °C for 1 hour. The molecular sieves were removed through filtration, and washed
with DCM. The te was removed by distillation under vacuum to get crude product. To
the crude product was added H20 (600 mL), petroleum ether (240 mL) and methyl tert—butyl
ether (120 mL), stirred at room temperature for 1 hour, then filtered and collected the solid
and dried under vacuum at 25 °C to afford the product (110 g, 58%) as a white solid.
1H—NMR (DMSO—dg, 400 MHz): 6 5.71—5.80 (m, 1H), 5.01—5.07 (m, 2H), 4.94 (d, J: 8 Hz,
1H), 3.58—3.62 (m, 1H), 2.56—2.61 (m, 1H), 1.15 (s, 9H), 0.975 (d, J = 4 Hz, 3H)
Intermediate 178: 12S= thyl 2-amin0methylpenten0ate
\OJLII'N3
To a solution of )—2—((S)—1,1—dimethylethylsulfinamido)—3—methylpent—4—enoic acid
(Intermediate 177, 44 g, 189 mmol) in MeOH (200 mL) was added dropwised SOClz (68.6
mL, 944 mmol) at 0 OC. The reaction mixture was stirred at 0 °C for 1 hour, then warmed up
to 70 °C and stirred overnight. The t was removed and the residue diluted with water.
To the water phase was added NaHC03 to lize pH to ~8, and extracted with DCM,
dried over NaZSO4, ed and concentrated to give 23 g crude t as a yellow liquid.
1H—NMR gDMSO—dg, 400 MHz): 5 5.71—5.82 (m, 1H), 4.97—5.05 (m, 2H), 3.61 (s, 3H), 3.27
(d, J: 8 Hz, 1H), 2.33—2.45(m, 1H), 1.79 (s, 2H), 0.96 (d, J: 8 Hz, 3H)
LCMS: tR=0.682, [M+H]+ 144.2
Intermediate 179: 12S33R 2-methyl 2-1allylamino2methylpenten0ate
0 E
\OJ'I/(k/
HN\/\
To a solution of (2S, 3R)—methyl 2—amino—3—methylpent—4—enoate (Intermediate 178, 23 g,
161mmol) in DMF (90 mL) at 0 °C was added LiOH (4.248 g, 177 mmol). The mixture was
stirred at 0°C for 30 minutes. Then a solution of 4—bromobut—1—ene (17.5 g, 145 mmol) in
DMF (15 mL) was added dropwised. The reaction was stirred at —7 °C for 20 mins, then
warmed to room temperature slowly, and stirred overnight. The reaction was quenched with
water, extracted with EtOAc. The organic layer was washed with water, brine, dried over
NaZSO4, filtered and concentrated to give 28 g crude product as yellow liquid.
1H—NMR (DMSO—dg, 400 MHz): 5 5.65—5.83 (m, 2H), 4.93—5.16 (m, 4H), 3.60 (s, 3H), 3.14—
3.22011, 1H), 3.06 (d, J = 8 Hz, 1H), 2.93—3.01(m, 1H), 2.34—2.41 (m, 1H), 0.99 (d, J = 8 Hz,
LCMS: tR=0.461, m/z: 184[M+H]
Intermediate 180: 12S13R z-methyl 2-1allylg tert-butoxycarbonyl [amino 2methylpent
en0ate
0 E
\OJL.N
Boc/ A
To a solution of (2S,3R)—methyl ylamino)—3—methylpent—4—enoate mediate 179,
28g, 153 mmol) in t—BuOH (150 mL) was added (Boc)20 (33.4 g, 153 mmol). The reaction
was stirred at room temperature for 10 minutes, then warmed up to 90 °C and d
ght. The reaction mixture was concentrated. The crude product was purified by flash
silica chromatography, elution gradient 0 to 6% EtOAc in eum ether. Pure fractions
were evaporated to afford the product (24 g, 56 %) as a light yellow liquid.
1H—NMR gDMSO—dg, 400 MHz}: 6 5.71—5.84 (m, 2H), 5.00—5.11 (m, 4H), 3.66—4.43 (m, 3H),
3.58 (s, 3H), 2.81 (s, 1H), 1.39 (s, 9H), 0.93 (d, J = 8 Hz, 3H)
LCMS: tR=1.096, 184[M—Boc+H]
Intermediate 181: 2S 3R tert-but l2-meth l3-meth l-2 3-dih dr0 ridine-l 2 6H -
dicarboxylate
\OJL.,0
To a solution of )—methyl 2—(allyl(tert—butoxycarbonyl)amino)—3—methylpent—4—enoate
(Intermediate 180, 24 g, 84.8 mmol) in DCM (250 mL) was added Grubbs catalyst, 1St
generation (886 mg 1.06 mmol) at 0 °C in three batches and stirred for 4 hours. More Grubbs
catalyst, 1St generation was added (886 mg 1.06 mmol) at 0 °C in three batches, then warmed
up to 25 OC. The resulting solution was stirred at room temperature overnight.
LCMS: tR=0.987, 156.2 [M—Boc+H], 295[M+K]
Intermediate 182: 2S 5R tert-but l2-meth 15- tert-
but0X carbon lh dr0X amin0 meth l-5 6-dih dr0 ridine-l 2 2H -dicarb0X late
\OJL, \
To a solution of (2S,3R)—1—tert—butyl 2—methyl yl—2,3—dihydropyridine—1,2(6H)—
dicarboxylate (Intermediate 181, 21.6 g, 84.8 mmol) in DCM (250 mL) was added
BocNHOH (16.9 g, 127 mmol), CuCl (0.419 g, 4.24 mmol) and pyridine (87 mg, 1.1 mmol)
and degassed with oxygen. The resulting solution was stirred at room temperature for 44
hours under oxygen. The solid was removed by tion. The filtrate was washed with
water (3 X 200 mL) and brine, dried over NaZSO4, filtered and concentrated. The crude
t was purified by flash silica chromatography, eluting with 0 to 50% DCM in
petroleum ether to give the product (29 g, 88%) as brown oil.
1H—NMR 1CDC13, 400 MHz): 8 5.66 (d, J: 16 Hz, 1H), 5.31 (s, 1H), 4.90 (d, 1H), 4.51 (d,
1H), 4.11 (t, J: 20 Hz, 1H), 3.75 (s, 3H), 3.50-3.61 (m, 1H ), 1.90 (d, J: 8 Hz, 3H), 1.43-
1.51 (m, 18H )
LCMS: tR=0.713, 279 [M—Boc+Na]
Intermediate 183: 2S 5R tert-but lZ-meth 15- tert-butox carbon ltert-
but ldimeth lsil 10X amino meth l-S 6-dih dro -l 2 2H -dicarb0X late
To a solution of (2S,5R)—1—tert—butyl 2—methyl 5—(tert—butoxycarbonyl(hydroxy)amino)—3—
methyl—5,6—dihydropyridine—1,2(2H)—dicarboxylate (Intermediate 182, 23 g 59.5 mmol) in
DCM (180 mL) was added imidazole (8.09 g 119 mmol). The resulting solution was stirred
at room temperature for 10 s, then a solution of TBS—Cl (11.6 g, 77.4 mmol) in DCM
(20 mL) was added dropwise at 0—5 OC. The reaction was stirred at 0 °C for additional 18
hours. The c phase was washed with water and brine, dried over , filtered and
concentrated. The crude product was purified by flash silica chromatography, eluting with
petroleum ether and DCM to give product (20 g, 67%) as a brown oil.
1H—NMR(CDC1;, 400 MHz): 5 5.7(s, 1H), 4.45—4.85 (m, 2H), 4.09 (d, J = 20 Hz, 1H), 3.76 (s,
3H), 3.53—3.58 (m, 1H), 1.9 (s, 3H), 1.45—1.54 (m, 18H), 0.92 (d, J = 16 Hz, 9H), 0.10 (d, J =
Hz, 6H).
LCMS: tR=1.467, 523 .55[M+Na]
Intermediate 184: 2S 5R -meth 15- tert-but ldimeth lsil 10X amino h [-1 2 5 6-
tetrahydropyridine-Z-carboxylate
HN NO,TB8
To a solution of (2S, 5R)—l—tert—butyl 2—methyl 5—(tert—butoxycarbonyl(tert—
butyldimethylsilyloxy)amino)—3—methyl—5,6—dihydropyridine— l ,2(2H)—dicarboxylate
(Intermediate 183, 20 g, 40 mmol) in DCM (200 mL) was added ZnBrz (35.5 g 160 mmol)
at 0 OC. The resulting solution was stirred at room temperature overnight. The solid was
removed through filtration. The filtrate was washed with ted NaHC03 to neutralize pH
to ~8, ted with DCM, dried over NaZSO4, filtered and concentrated. The crude product
was purified by flash silica chromatography, eluting with 0 to l% MeOH in DCM to give
product (8.4 g, 70%) as a brown oil.
1H—NMR(CDC1;, 400 MHz): 5 5.59—5.62 (m, 1H), 3.82 (s, 1H), 3.75 (s, 3H), 3.14—3.23 (m,
2H), 2.92—2.97 (m, 1H), 1.79 (s, 3H), 0.90 (s, 9H), 0.10 (s, 6H).
LCMS: tR=l.O73, 301.2[M+H]
ediate 185: meth 1 2S 5R tert-but l dimeth 1 Si] 1 0X meth l0X0-1 6-
diazabic clo 3.2.1 0ctenecarb0X late
\o I. \
o \OTBS
To a solution of (2S,5R)—methyl 5—(tert—butyldimethylsilyloxyamino)—3—methyl—l,2,5,6—
tetrahydropyridine—2—carboxylate (Intermediate 184, 42 g, 140 mmol) in MeCN (840 mL)
was added DIEA (72.2 g 560 mmol) and degassed with nitrogen, then a solution of
triphosgene (16.408 g, 56 mmol) in MeCN (120 mL) was added dropwised at 0 i 5 °C under
nitrogen. The resulting solution was stirred at room ature under nitrogen overnight.
The reaction e was concentrated, then added EtOAc and washed with lN citric acid,
ted NaHC03 and brine, dried over NaZSO4, filtered and concentrated. The crude
product was purified by flash C—lS chromatography, eluting with 0 to 38% MeCN in H20 to
give product (22 g, 49%) as an orange solid.
(CDC1;, 400 MHz): 5 6.15 (t, J = 1.6 Hz, 1H), 4.412 (s, 1H), 3.807 (s, 3H), 3.610—
3.629 (m, 1H), 3.506 (d, J: lle, 1H), 3290-3322011, 1H), 1.722 (s, 3H), 0.962 (s, 9H),
0.195 (s, 3H) 0.172 (s, 3H)
LCMS: tR=l.585, 327.35[M+H]
ediate 186: 2S 3R amin0meth l entenamide h dr0ch10ride
HZNJI’“N
NHZHCI
To a solution of (Intermediate 177, 75.2 kg, 322.8 mol, 1.0 eq.) in THF (600 L) was added
CDI (61.9 kg, 382.1 mol, 1.2 eq.) in batches at 20i10 OC. The mixture was stirred for 2 h at
20i10 OC. The mixture was cooled to —40i5 OC. NH3‘HZO (43.55 kg, 640.4 mol, 2.0 eq., 25
wt.%) was added dropwise at —40i5 OC. The e was stirred for 10 min at —40i5 0C.
After completion of the reaction, it was warmed to —10~0 0C, then concentrated under
vacuum to ~ 3.0 vol. THF (2.0 vol) was added and concentrated under vacuum to ~ 3.0 vol.
THF was swapped with EtOAc (2.0 vol) two times. EtOAc (6.0 vol) was added to the
solution, and cooled to 5i5 OC. MCSO3H (148.3 kg, l543.0 mol, 2.4 eq.) was added dropwise
at <10 OC, and stirred for l h at 5i5 OC. The mixture was centrifuged, and the resultant solid
cake was washed with EtOAc (1.0 vol) two times. The mother liquor was collected to afford
the compound in EtOAc solution, which was used directly in the next step. HCl (gas) was
bubbled into the solution at 0i5 °C for 17 h (~4 kg/h). After completion of the reaction, the
mixture was centrifuged and the resultant solid cake was washed with EtOAc (1.0 vol) two
times. The cake was dried over under vacuum at 25i5 °C for at least 12 h to afford the title
nd as a light yellow solid (98 kg, 90% overall yield from 2 .
1H NMR1400 MHz= DMSO): 6 8.24 (s, 2H), 8.00 (s, 1H), 7.56 (s, 1H), 5.84-5.76 (m, 1H),
.17-5.09 (m, 2H), 3.70-3.68 (m, 1H), 2.77-2.72 (m, 1H), 1.04 (d, J: 6.8 Hz, 3H).
Intermediates 187 and 188: all 1 2S 3R amin0meth l0x0 enten l and
tert-but lall 1 2S 3R amin0meth l0x0 enten lcarbamate
O : O :
L, 3 4'“ E
HN\/\ BOO/NA
To a solution of LiOH (27.55 kg, ll47.9 mol, 2.0 eq.) in DMF (285 L) was added
Intermediate 186 (95 kg, 564.67 mol, l.0 eq.) in batches at 0i5 OC. The mixture was stirred
for 0.5 h. Allyl bromide (76.76 kg, 634.5 mol, l.l eq.) was added dropwise for 9 h at 0i5 0C.
The reaction mixture was warmed to 20i5 °C and stirred for at least 8 h. The reaction
mixture was cooled to 10i5 °C and soft water was added (3.0 vol). The mixture was
extracted with DCM (3.0 vol) three times. The combined organics were washed with brine
(2.0 vol). The brine layer was extracted with DCM (3.0 vol). The combined organic layers
were concentrated under atmospheric re at < 60 °C to ~ 5.0 vol. t—Butyl alcohol (2.0
vol) was added to the solution and concentrated under vacuum at < 60 °C to ~ 5.0 vol. The
concentration with t—butyl alcohol (2.0 vol) was repeated once more until the water content
.2% to afford Intermediate 187. t—Butyl l (8.0 vol) was added to the concentrated
solution. BoczO (138.07 kg, 633.3 mol, 1.1 eq.) was added at 20i5 OC. The mixture was
warmed to 70i5 °C and stirred for at least 15 h. After tion of the reaction, the mixture
was cooled to 40i5 0C, then concentrated under vacuum at < 60 °C to ~ 5 vol. The
concentrated mixture was cooled to 25i5 OC, and soft water (5.0 vol) was added. The e
was extracted with methyl t—butyl ether (4.0 vol) two times. The combined organics were
washed with 0.5 M HCl solution (2.0 vol) once, brine (1.0 vol) three times and concentrated
under vacuum at <50 °C to ~ 2.0 vol. ane (1.0 vol) was added to the reactor and
concentrate under vacuum at <50 °C to ~20 vol. This was repeated once more. n—Heptane
(1.0 vol) was added to the concentrated solution, cooled to —10i5 °C and stirred for at least 2
h. The mixture was centrifuged and the resultant solid cake washed with cooled n—heptane
(0.5 vol). The cake was dried at 25i5 °C under vacuum for at least 12 h to afford
Intermediate 188 as a white solid (84.2 kg, 100% purity, 54.4% overall yield from 2 steps).
1H NMR1400 MHz= DMSO): 6 7.42 (s, 1H), 6.95 (s, 1H), 5.78-5.70 (m, 2H), 5.11-4.98 (m,
4H), 4.33 (d, J = 10.8 Hz, 1H), 3.92-3.78 (m, 2H), 2.70 (br, 1H), 1.41 (s, 9H), 0.88 (d, J = 6.4
Hz, 3H). LC/MS (ES+) m/z 169.2 (M + H)
Intermediates 189: 2S 5R -tert-but 15- tert-butox carbon 1 h dr0x amino
carbamo lmeth l-5 6-dih dr0 ridine-l 2H -carb0x late
I N Md
N ,B
To a solution of ediate 188 (81.0 kg, 301.8 mol, 1.0 eq.) in DCM (810 L) was added
Grubb’s catalyst, 1St generation (1.215 kg, 1.5 mol, 0.005 eq.) in 3 batches at 0i5 OC. The
reaction e was stirred for 1 h at 0i5 0C, then warmed to 25i5 °C and d for 1 h.
The mixture was cooled to 0i5 °C and more catalyst (1.215 kg, 1.5 mol, 0.005 eq.) was
added in 3 batches at 0i5 OC. The mixture was warmed to 25i5 °C and stirred for at least 8 h.
After completion of the reaction, CuCl (1.46 kg, 14.8 mol, 0.05 eq.), BocNHOH (59.94 kg,
450.7 mol, 1.5 eq.) and pyridine (0.31 kg, 3.9 mol, 0.013 eq.) were added to the solution at
25i5 OC. The e was stirred for at least 43 h at 25i5 °C under oxygen atmosphere.
Once the reaction was complete, EDTAzNa solution (5.0 vol) was added to the reactor and
stirred for at least 4 h at 25i5 OC. The layers were separated and the aqueous extracted with
DCM (3.0 vol) two times. The organics were combined and concentrate under vacuum at <40
°C to ~30 vol. Methyl t—butyl ether (MTBE) (2.0 vol) was added to the reactor and
concentrated under vacuum at <40 °C to ~30 vol. This was repeated once more. MTBE (2.5
vol), n—heptane (2.5 vol) and soft water (5.0 vol) were added to the concentrated solution and
the mixture was slurried at 20i5 °C for at least 2 h. The mixture was centrifuged and the cake
was washed with MTBE/n—heptane (0.5 vol, 1:1). The cake was dried under vacuum at 35i5
°C for at least 12 h until the water content 31% to afford the title compound as a light—brown
solid (70.3 kg, 98% purity, 61.3% l yield from 2 steps).
1H NMR1400 MHz= DMSO): 6 8.93-8.78 (m, 1H), 7.49 (s, 1H), 7.07 (s, 1H), 5.57(s, 1H),
4.62-4.41 (m, 2H), .50 (m, 2H), 1.79 (s, 3H), 1.43 (s, 1H), 1.40 (s, 9H). LC/MS (ES+)
m/z 272.2 (M + H)
Intermediates 190 and 191: tert-but 1 3R 6S tert-butox carbon 1 tert-
but ldimeth lsil 10x amino carbam0 l-S-meth l-3 6-dih dr0 ridine-l 2H -
carbox late and 2S 5R tert-but ldimeth lsil 10x amino meth [-1 2 5 6-
tetrah dr0 ridinecarb0xamide
JlI, I
H2N ['6‘ \
and HzNJII"
/N ,B00 HN
800 N N,OTBS
OTBS H
To a solution of Intermediate 189 (50 kg, 134.6 mol, 1.0 eq.) and imidazole (18.5 kg, 268.1
mol, 2.0 eq.) in DCM (500 L) was added TBS—Cl (30.5 kg, 202.0 mol, 1.5 eq.) in DCM
on (1.5 vol) se at 0i5 °C over 4.5 h. The mixture was warmed to 20i5 °C and
stirred for at least 5 h. After completion of the on, soft water (250 L, 5.0 vol) was
added. The layers were separated and the aqueous extracted with DCM (3.0 vol). The
combined organic layers were washed with soft water (3.0 vol) two times, then concentrated
under atmospheric distillation at <50 °C to ~20 vol. DCM (200 L, 4.0 vol) was added to the
solution and concentrated under atmospheric distillation at <50 °C to ~20 vol, until the water
t was 31%, affording Intermediate 190. DCM (750 L, 15.0 vol) was added to the
solution with stirring at 20i5 0C under nitrogen atmosphere. ZnBrz (60.5 kg, 268.9 mol, 2.0
eq.) was added to the solution and stirred for 6 h at 20i5 0C. More ZnBrz (30.5 kg, 135.6
mol, 1.0 eq.) was added to the reaction mixture ever 6—8 hours until the reaction was
complete (~5 eq total of ZnBrz). The reaction was ed with NaHC03 (113.0 kg, 1345.2
mol, 10.0 eq.) solution (18.0 vol) by addition below 20 OC. The mixture was stirred for at
least 1 hour at 20i5 0C, then centrifuged, and the liquor collected. The ant solid cake
was slurried with dichloromethane (5.0 vol) at 20i5 °C for 1 h, then centrifuged. The liquor
was combined with the previous liquor and the layers ted. The aqueous was extracted
with DCM (3.0 vol) two times. The combined organics were washed with soft water (4.0 vol)
four times, then concentrated the under normal re at <50 °C to ~20 vol. CH3CN (2.0
vol) was added to the solution and concentrate under vacuum at <50 °C to ~40 vol to afford
Intermediate 191 in solution.
LC/MS: (ES+) m/z 282.2 (M + H)
Intermediate 192: 2S 5R tert-but ldimeth lsil 10x meth l0x0-1 6-diaza-
bicyc10|3.2.1 -enecarb0xamide
o \OTBS
To a solution of Intermediate 191 (38.43 kg in theory, 134.6 mol, 1.0 eq.) in CH3CN (1036
L, 27 vol) was added DIEA (69.56 kg, 539.2 mol, 4.0 eq.) at 20i5 OC. The e was
cooled to 0i5 OC, and triphosgene (13.07 kg, 44.0 mol, 0.33 eq.) in CH3CN (115.2 L, 3.0 vol)
was added dropwise. The mixture was warmed to 25i5 °C and stirred for at least 8 h, then
cooled to 10i5 OC, and quenched with soft water (24.19 kg, 1343.9 mol, 10.0 eq.). The
mixture was stirred for at least 1 h, then concentrated under vacuum at <40 °C to ~50 vol.
The solution was cooled to 10i5 °C and MTBE (3 84 L, 10 vol) and brine (4.0 vol) were
added. The layers were separated, and the organics washed with brine (4.0 vol), and
concentrated under vacuum at <40 °C to ~20 vol. The MTBE was swapped with n—heptane
(1.0 vol) and the solid slurried for 1 h at 20i5 OC. The mixture was centrifuged and the cake
washed with n—heptane (0.5 vol) two times. The cake was slurried in MTBE (67.5 L) for at
least 3 h at 20i5 0C, then n—heptane (336 L) was added with stirring for at least 1 h. The
mixture was centrifuged and the resultant solid cake washed with n—heptane (1.0 vol). The
cake was dried under vacuum at 30i5 °C for 12 h to afford the title compound as a light—
brown solid (21.1 kg, 99.6% purity, 49.6% l yield from 3 steps).
1H NMR {400 MHz, DMSO): 5 7.80 (s, 1H), 7.33 (s, 1H), 6.06 (t, J = 2 Hz, 1H), 4.10 (s, 1H),
3.71—3.69 (m, 1H), 3.65 (d, J: 10.8 Hz, 1H), 3.10 (dd, J: 10.8 Hz, 2.0 Hz, 1H),1.63 (s, 3H),
0.92 (s, 9H), 0.14 (d, J = 0.8 Hz, 1H). LC/MS (ES+) m/z 312.2 (M + H)
Intermediate 193: 2S 5R -tert-but 15- tert-but0x carbon 1 h dr0x amino
carbam0 l meth l-5 6-dih dr0 -1 2H -carb0x late
HZNJI, \
To a solution of Intermediate 192 (18.5 kg, 59.4 mol, 1.0 eq.) in EtOAc (92.5 L, 5 vol) was
added HF‘Py (2.04 kg, 71.4 mol, 1.2 eq., 70 wt.%) at 0i5 OC. The mixture was stirred for at
least 10 h at 20i5 0C, then cooled to 0i5 °C and additional HF‘Py (0.33 kg, 11.6 mol, 0.2 eq.,
70 wt.%) was added. The e was d for at least 3 h at 20i5 0C, then MTBE (27.8 L,
1.5 vol) was added and stirred for 3 h at 10i5 OC. The mixture was centrifuged and the cake
washed with EtOAc (0.5 vol). The cake was slurried with EtOAc (2.0 V) for at least 1 h at
20i5 0C, then centrifuged. The cake was slurried with EtOAc (0.5 vol), then dried under
vacuum at 25i5 °C for 12 h to afford the title compound as a yellow solid (11.0 kg, 99.5%
purity, 91% yield).
1H NMR1400 MHz, DMSO): 6 9.56 (s, 1H), 7.79 (s, 1H), 7.32 (s, 1H), 6.10 (d, J: 3.2 Hz,
1H), 4.06 (s, 1H), 3.68-3.62 (m, 2H), 3.07 (d, J: 8.4 Hz, 1H), 1.61 (s, 3H). LC/MS (ES+) m/z
198.1 (M + H)
Intermediate 194: eth l S E tert-but lsulfin l imin0 acetate
N \ “k
To a solution of ethyl 2—oxoacetate (66 mL, 321 mmol, 50% in toluene) in DCM (1 L) at 0°C
was added (S)—2—methylpropane—2—sulfinamide (30 g, 248 mmol) and molecular sieves (4,51,
500 g). The resulting solution was stirred at room temperature for 18 hours. Molecular sieves
were removed by filtration; filtrate was concentrated by distillation under vacuum to give a
crude t, which was purified by flash silica chromatography (0% to 5% EtOAc in
eum ether) to give a colorless oil, 45 g, 88%.
1HNMR1400MHZ,CDC13): 81.28 (s, 9H), 1.39 (t, J = 12 Hz, 3H), 4.38 (q, J = 12 Hz, 2H),
8.01 (s, 1H).
Intermediate 195: eth l S S -tert-but lsulfin l meth [-1 2 3 6-
tetrahydropyridine-Z-carboxylate
Eto/l’mg/CiO¢$,N
To a solution of (S,E)—ethyl 2—(tert—butylsulfinylimino)acetate (Intermediate 194, 50 g, 244
mmol) in DCM (600 mL), at —78°C was added isoprene (97.21 mL, 971.91 mmol), followed
by addition of TMSOTf (97.42 mL, 416.54 mmol). The resulting on was stirred at
—78°C for 3 hours and quenched slowly at —78°C with phosphate buffer solution (pH=7.4, 1
L). After warming to room temperature, the mixture was extracted with DCM (3 x 500 mL).
The combined organic extracts were washed with water (2 x 500 mL) and brine. The organic
layer was dried over Na2S04, filtered and evaporated to afford 60 g of crude product as a
brown oil. The product was used in the next step without further cation.
1HNMR z, d6-DMSO): 51.08(s, 9H), 1.18 (t, J = 12 Hz, 3H), 1.64 (q, J = 4 Hz, 3H),
3.59 (m, 2H), 4.11 (dq, J = 12, 4 Hz, 2H), 4.30 (dd, J: 8,4 Hz, 1H), 5.39 (ddd, J: 4,8 4 Hz,
LCMS: (ES+) [M+H]+ = 274; HPLC tR=1.78 min.
Intermediate 196: 1- ut l 2-eth l S meth l-3 6-dih dr0 ridine-1 2 2H -
dicarboxylate
Eto/l’“‘?
Boc/0/
To a on of the crude hyl 1—((S)—tert—butylsulfinyl)—4—methyl—1,2,3,6—
tetrahydropyridine—2—carboxylate (Intermediate 195, 100 g) in MeOH (1 L) at 0°C was
added hydrogen chloride (100 mL, 4M in dioxane). The resulting solution was stirred at room
temperature for 18 hours. MeOH and HCl/dioxane were d by distillation under
vacuum to give a crude product, which was dissolved in water (1 L) and extracted with
EtOAc (3 x 500 mL). The pH of the aqueous solution was adjusted to 7 with solid NaHCOg.
The aqueous was extracted with EtOAc until LCMS showed no product detected. The
c phases were combined and dried over NaZSO4, filtered and concentrated to afford
crude product (30 g, 177 mmol) as a light yellow oil. The oil was dissolved in THF (500 mL)
and cooled by ice—water bath. To the cooled solution was added a solution of sodium
bicarbonate (22.3 g, 265.5 mmol) in water (500 mL), followed by di—tert—butyl dicarbonate
(57.8 g, 265.5 mmol). The resulting solution was stirred at room ature for 18 hours.
The two layers were separated. The s layer was extracted with ethyl acetate. The
combined organic layers were dried over NaZSO4, filtered and evaporated. Crude product was
purified by flash silica chromatography (0%—30% EtOAc in PE) to afford the title compound
47.5 g, 43% yield from Intermediate 194.
1HNMR1400MHZ, CDCl3 ): 8 1.24 (t, 3H), 1.50 (m, 9H), 1.71 (s, 3H), 2.46 (m, 2H), 3.73 (m,
1H), 4.10 (m, 3H), 4.95 (m, 1H);
LC—MS: (ES+) [M+Na]+ = 292; HPLC tR=1.71 min.
ediate 197: tert-but l S carbam0 lmeth l-3 6-dih dr0 ridine-l 2H -
carboxylate
HO/l"‘?
To a solution of 1—(tert—butyl) l (S)—4—methyl—3,6—dihydropyridine—1,2(2H)—
dicarboxylate (Intermediate 196, 47.5 g, 176 mmol) in THF (1000 mL) and water (500 mL)
at 0°C was added dropwise lithium hydroxide (1 M, 440 mL, 440 mmol). The reaction
mixture was warmed to room temperature and d for 16 hours. Solvent was removed;
residue was diluted with water. The pH of the solution was adjusted to ~3 with HCl (1N)
solution. The mixture was extracted with EtOAc (3 x 300 mL). c layers were
combined, washed with water and brine, dried over MgSO4, filtered and concentrated to give
a colorless oil, 40.3 g.
1HNMR1300MHZ, d6-DMSO): 8 1.38 (m, 9H), 1.64 (s, 3H), 2.53(m, 2H), 3.68 (m, 3H), 4.73
(m, 1H), 5.35 (dd, J=3, 15Hz, 1H), 12.45(s, 1H);
LCMS: (ES+) [M+Na]+ =264; HPLC tR=1.01 min.
Intermediate 198: ut l S carbam0 lmeth l-3 6-dih dr0 -1 2H -
carboxylate
To a solution of (tert—butoxycarbonyl)—4—methyl—l,2,3,6—tetrahydropyridine—2—
carboxylic acid (Intermediate 197, 40.3 g, 167.2 mmol) in THF (500 mL) at 0°C was added
N,N’—carbonyldiimidazole (32.5 g, 200.6 mmol) in portions. The crude was stirred at 0°C for
hours. Then ammonium acetate (38.2 g, 502.9 mmol) was added. The reaction was stirred
at room temperature for an additional 18 hours, quenched with water and extracted with
EtOAc. The combined organic layers were washed with water and brine, dried over NaZSO4,
filtered and concentrated. Crude product was purified by flash silica chromatography (0%—
% EtOAc in PE) to give a white solid, 25 g, 62%.
1HNMR (400MHz, d6-DMSO): 5 1.41 (s, 9H), 1.66 (s, 3H), 2.35 (s, 2H), 3.84 (m, 2H), 4.66
(m, 1H), 5.35 (m, 1H) 6.96 (s, 1H), 7.19 (s, 1H);
LCMS: (ES+) [M+Na]+ = 263; HPLC tR=0.86 min.
ediate 199: tert-but 1 3R 6S tert-but0X carbon 1 h dr0X amino
carbam0 lmeth l-3 6-dih dr0 ridine-1 2H -carb0X late
HZNJI"‘1
BOC CCN/OH
To a solution of tert—butyl (S)—2—carbamoyl—4—methyl—3,6—dihydropyridine—l(2H)—carboxylate
(Intermediate 198, 25g, 104.1 mmol) in DCM (250 mL) was added BocNHOH (70.6 g,
530.9 mmol), CuCl (6.1 g, 62.5 mmol) and pyridine (106.9 mg, 1.3 mmol). The resulting
solution was stirred at room temperature for 44 hours under oxygen. The solids were
removed by filtration. The filtrate was washed with water (6 X 500 mL) and brine, dried over
, filtered and concentrated. The crude product was purified by flash silica
tography (0%—50% EtOAc in PE) to give the title compound as a white solid, 40%
yield. Starting material was recovered (10 g). The same procedure was ed three times to
afford 15 g of product in total.
LCMSZ (ES+) [M+Na]+ = 394 (C17H29N3O6)
Intermediate 200: tert-but 1 3R 6S tert-butox carbon 1 tert-
but ldimeth lsil 10x amino carbam0 lmeth 1-3 6-dih dr0 ridine-1 2H -
carboxylate
To a solution of tert—butyl (3R,6S)—3—((tert—butoxycarbonyl)(hydroxy)amino)—6—carbamoyl—4—
methyl—3,6—dihydropyridine—1(2H)—carboxylate (Intermediate 199, 12 g, 32.3 mmol) in
DCM (96 mL) at 0 iSOC was added imidazole (4.4 g 64.6 mmol). The resulting solution
was stirred at room temperature for 10 mins, then TBS—Cl (4.8 g, 32.3 mmol) in DCM (10
mL) was added dropwise. The reaction mixture was stirred at 0°C for an additional 18 hours,
washed with water and brine, dried over , filtered and concentrated. The crude
product was ed by flash silica tography (0%—20% EtOAc in PE) to afford the
title compound as a white solid, 10 g, 63%.
LCMSZ (ES+) 486 (C23H43N3O6SI)
To a solution of utyl (3R,6S)—3—[tert—butoxycarbonyl—[tert—butyl(dimethyl)silyl]oxy—
—6—carbamoyl—4—methyl—3,6—dihydro—2H—pyridine—1—carboxylate (Intermediate 200,
21.7 g, 44.68 mmol) in DCM (250 mL) at 0°C was added zinc bromide (40.24 g, 178.71
mmol). The ing suspension was allowed to warm to room temperature and stir ~ 66
hours. The reaction mixture was cooled by ice—water bath, to which a slurry of NaHC03
(38.23 g, 10 equivalent) in water (300 mL) was added. The resulting mixture was stirred for 1
hr. Solid was removed by filtration and washed 3—4 times with DCM until no product was
detected from the rinsing solution. The two layers from the filtrate were separated. The
aqueous layer was extracted with DCM three times (until no product was detected from
s layer). The combined DCM solution was concentrated to remove most of the
solvent. The residue was partially dissolved in 10% MeOH in DCM and was loaded onto a
short silica gel pad and eluted with 10% MeOH in DCM. The filtrate was evaporated and
dried under vacuum to give a yellow foam solid (crude 9.9 g, 77%).
M_SZ 286 ES+ (C13H27N3Ole)
Intermediate 202: 2S 5R tert-but ldimeth lsil 10x meth l0x0-1 6-
diazabic clo 3.2.1 0ctenecarb0xamide
0 OTBS
To a clear solution of (3R,6S)—3—[[tert—butyl(dimethyl)silyl]oxyamino]—4—methyl—1,2,3,6—
tetrahydropyridine—6—carboxamide (Intermediate 201, 7.66 g, 26.83 mmol) in MeCN (150
mL) and DCM (200 mL) at 0°C was added N,N’—diisopropylethylamine (19.11 mL, 107.34
mmol) followed by a solution of triphosgene (2.71 g, 9.12 mmol) in MeCN (50 mL)
dropwise (2 mL/hour by a syringe pump). After addition, the solution was allowed to warm
to room ature and stirred overnight. The reaction mixture was concentrated to dryness.
The resulting residue was diluted with EtOAc and washed with brine. The aqueous layer was
extracted with EtOAc. The combined c ts were dried over MgSO4, filtered and
concentrated. Crude product was purified by silica gel chromatography (0%—100% EtOAc/
) to give the title compound as a white solid 4.36 g, 52%.
M_SZ 312 ES+ (C14H25N303Sl)
Intermediate 203: 28 SR h dr0x meth l0x0-1 6-diazabic clo 3.2.1 0ctene
carboxamide
o N‘OH
To a solution of (ZS,5R)—5—(((tert—butyldimethylsilyl)oxy)amino)—4—methyl—1,2,5,6—
tetrahydropyridine—2—carboxamide (Intermediate 202, 165.mg, 0.53 mmol) in ethyl acetate
(4 mL) at 0 °C was added HF—pyridine (0.02 mL, 0.64 mmol). The on mixture was
warmed to room ature and stirred for 1 hr. Only a small amount of product was
observed. r equivalent of HF—pyridine was added and the reaction mixture was stirred
for 3 hrs. The reaction mixture was concentrated to afford an orange solid.
M_S: 198 ES+ (C8H11N3O3)
Exam le 35: 2R -iso r0 12- 2S 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 10x flu0r0acetate
To a solution of (2S,5R)—6—hydroxy—4—methyl—7—oxo—l,6—diazabicyclo[3.2. l]oct—3—ene—2—
carboxamide mediate 203, 582 mg, 2.95 mmol) in l,4—dioxane (16 mL) and DMF (2
mL) was added isopropyl (2R)—2—bromo—2—fluoro—acetate (Intermediate 169, 881.1 mg, 4.43
mmol). The reaction mixture was cooled to 0 °C and DBU (0.44 mL, 2.95 mmol) was added
dropwise. The reaction mixture was stirred for 10 minutes, then diluted with ethyl acetate
and washed with 1:1 brine water twice. The organics were dried over magnesium sulfate,
filtered and concentrated. Silica gel chromatography (0%—90% ethyl acetate/hexanes)
afforded a white foam. The foam was ved in 1:1 acetonitrilezwater, frozen and
lized to afford a white solid, 614 mg, 66%. There is 6% of the S—diastereomer present.
M_SZ 316 ES+ (C13H18FN305)
1H NMR1300 MHz, DMSO—dg) 5: 1.22 (m, 6H); 1.81 (m, 3H); 3.17 (m, 1H); 3.34 (m, 1H);
3.93 (m, 1H); 4.22 (m, 1H); 5.01 (m, 2H); 5.51 (m, 1H); 6.23 (m, 1H); 7.31 (s, 1H); 7.55 (s,
Exam le 90: eth 12- 2S 5R carbam0 lmeth l0x0-1 6-diazabic clo 3.2.1 0ct
enyl[oxyzdiflu0r0acetate
H2N "13/N F
}—N\ F
O V
To a solution of (2S,5R)—6—hydroxy—4—methyl—7—oxo—l,6—diazabicyclo[3.2. l]oct—3—ene—2—
carboxamide mediate 203, 64.5 mg, 0.33 mmol) and ethyl ifluoroacetate (0.13
mL, 0.98 mmol) in DMF (3 mL) at room temperature was added potassium carbonate
(135.62 mg, 0.98 mmol). The mixture was stirred for ~3 hours, then diluted with ethyl
acetate and filtered. The filtrate was combined with a previous small batch, washed twice
with 1:1 brinezwater, dried over magnesium sulfate, filtered and concentrated. Silica gel
chromatography (0%—80% ethyl acetate/hexanes) afforded the title nd (52.1 mg,
34%) as an orange solid after lyophilization.
M_S: 320 ES+ (C12H15F2N305)
1H NMR1300 MHz, DMSO—dg) 5: 1.29 (t, 3H); 1.82 (m, 3H); 3.36 (m, 2H); 3.94 (m, 1H);
4.31 (m, 1H); 4.39 (m, 2H); 5.57 (m, 1H); 7.36 (s, 1H); 7.59 (s, 1H).
Exam le 91: 2- 2S 5R carbam0 lmeth l0x0-1 6-diazabic clo 3.2.1 0cten
1 0x -2 2-diflu0r0acetic acid lithium salt
HZN \
O}— ,OJerHFN
To a solution of ethyl 2—(((2S,5R)—2—carbamoyl—4—methyl—7—oxo—1,6—diazabicyclo[3.2. 1]oct—3—
en—6—yl)oxy)—2,2—difluoroacetate (Example 90, 46 mg, 0.14 mmol) in THF (2 mL) and water
(0.50 mL) at 0 °C was added 1M m hydroxide (0.14 mL, 0.14 mmol). The reaction
e was stirred at 0 °C for 10 minutes. Another 0.2 eq. of lithium hydroxide was added,
and after 5 minutes the reaction mixture was neutralized with 0.5N hydrochloric acid, and the
THF evaporated. The resulting on was frozen and lyophilized. Gilson purification
(Synergi Polar RP 21.2 mm x 100 mm, 4 um coupled with YMC C30 20 mm x 150 mm, 5
um, 0%—16% acetonitrile/water, 6 min) afforded the title compound (27.2 mg, 64.8%) as an
off—white solid.
M_S: 292 ES+ (C10H11F2N305)
1H NMR 300 MHz DMSO-dg) 8: 1.81 (m, 3H); 3.30 (m, 2H); 3.84 (m, 1H); 4.20 (m, 1H);
.48 (m, 1H); 7.29 (s, 1H); 7.55 (s, 1H).
Exam le 92: eth 12- 2S 5R carbam0 lmeth l0x0-1 6-diazabic clo 3.2.1 0ct
enyl 20x! [acetate
Oko/W/OV
To a solution of (ZS,5R)—6—((tert—butyldimethylsilyl)oxy)—4—methyl—7—oxo—1,6—diazabicyclo—
]oct—3—ene—2—carboxamide (Intermediate 202, 152 mg, 0.49 mmol) in THF (4mL) at 0
°C was added TBAF (0.49mL, 0.49 mmol). The mixture was stirred for ~10 minutes. To the
reaction mixture was added ethyl bromoacetate (0.05 mL, 0.49 mmol) and stirred for 10
minutes. More ethyl bromoacetate (0.05 mL, 0.49 mmol) was added and stirred 30 s.
Additional ethyl cetate (0.05 mL, 0.49 mmol) was added, and the reaction mixture
was warmed to room temperature and stirred for 1 hour. The on mixture was
concentrated onto silica gel and purified (0%—90% ethyl acetate/hexanes) to afford a colorless
oil. The oil was dissolved in 1:1 acetonitrilezwater, frozen and lized to afford the title
compound as a white solid, 78.5 mg, 56%.
M_S: 284 ES+ (C12H17N305)
1H NMR1300 MHz= DMSO-dg) 8: 1.23 (t, 3H); 1.84 (m, 3H); 3.19 (m, 2H); 3.97 (m, 1H);
4.17 (m, 3H); 4.53 (m, 2H); 5.46 (m, 1H); 7.29 (s, 1H); 7.50 (s, 1H).
Exam le 93: 2- 2S 5R carbam0 lmeth l0x0-1 6-diazabic clo 3.2.1 0cten
1 0x acetic acid m salt
HZN \
O o/\n/OH
To a solution of ethyl 2—(((2S,5R)—2—carbamoyl—4—methyl—7—oxo—1,6—diazabicyclo[3.2. 1]oct—3—
en—6—yl)oxy)acetate (Example 92, 57.4 mg, 0.2 mmol) in THF (2 mL) and water (1 mL) at 0
0C was added 1M lithium hydroxide (0.66 mL, 0.66 mmol). The reaction mixture was stirred
at 0 0C for 10 minutes. Another 0.2 equivalents of lithium ide was added and after 10
minutes the reaction is complete. The on mixture was neutralized with 0.5N
hydrochloric acid and 1 eq of sodium bicarbonate in water was added at 0 OC. The resulting
solution was frozen and lyophilized. Gilson purification (0%—16%, 6 min) afforded the title
compound as a white solid, 18.3 mg, 35%.
M_S: 256 ES+ (C10H13N305)
1H NMR1300 MHZ, DMSO-dg) 5: 1.85 (m, 3H); 3.11 (m, 2H); 3.88 (m, 2H); 4.07 (m, 1H);
4.24 (m, 1H); 5.39 (m, 1H); 7.24 (s, 1H); 7.48 (s, 1H).
Intermediate 204: 2S 5R ut ldimeth lsil 10x h l0x0-1 6-
diazabic clo 3.2.1 0ctenecarb0nitrile
The title compound was prepared from (ZS,5R)—6—((tert—butyldimethylsilyl)oxy)—4—methyl—7—
oxo—1,6—diazabicyclo[3.2.1]oct—3—ene—2—carboxamide (Intermediate 202, 0.205 g, 0.66
mmol) according to the procedure for Intermediate 139 to afford the title compound (159
mg, 82%) as a white solid.
M_S: 294 ES+ (C14H23N302Si)
Exam le 94: eth 1 2R 2S 5R c an0meth l0x0-1 6-diazabic clo 3.2.1 oct-
3-en 10x flu0r0acetate
The title compound was ed from (2S,5R)—6—((tert—butyldimethylsilyl)oxy)—4—methyl—7—
6—diazabicyclo[3.2.1]oct—3—ene—2—carbonitrile (Intermediate 204, 152 mg, 0.49 mmol)
according to the alternate procedure for Example 35 to afford (26.9 mg, 19%) a colorless oil.
There was approximately 9% S—diastereomer present.
M_S: 284 ES+ (C12H14FN304)
1H NMR1300 MHZ, DMSO-dg) 5: 1.09 (t, 3H); 1.72 (m, 3H); 3.26 (m, 2H); 3.97 (m, 1H);
4.11 (m, 2H); 4.94 (m, 1H); 5.30 (m, 1H); 6.16 (m, 1H).
Exam le 95: 2R 2S 5R c an0meth l0x0-1 6-diazabic clo 3.2.1 0cten-
6- 1 0x flu0r0acetic acid lithium salt
,,Cf\
The title compound was prepared from ethyl (2R)—2—(((2S,5R)—2—cyano—4—methyl—7—oxo—1,6—
diazabicyclo[3.2. 1]oct—3—en—6—y1)oxy)—2—fluoroacetate (Example 94, 22 mg, 0.08 mmol)
ing to the procedure for Example 91 to afford (3.8 mg, 15%) a light yellow solid.
M_S: 256 ES+ (C10H10FN304)
1H NMR1300 MHz, DMSO-dg) 8: 1.81 (m, 3H); 3.30 (m, 2H); 4.00 (m, 1H); 4.92 (m, 1H);
.27 (m, 1H); 5.28 (m, 1H).
Exam le 96: is0 1'0 12- 2S 5R carbam0 lmeth l0x0-1 6-
diazabic clo 3.2.1 0cten 10x acetate
4—N\ o
o 0/731/ T
To a solution of (2S,5R)—6—hydroxy—4—methyl—7—oxo—1,6—diazabicyclo[3.2. 1]oct—3—ene—2—
carboxamide (Intermediate 203, 93.38 mg, 0.47 mmol) and isopropyl bromoacetate (0.18
mL, 1.42 mmol) in DMF (4 mL) at room ature was added potassium carbonate
(196.35 mg, 1.42 mmol). The reaction mixture was stirred for ~3 hours, then diluted with
ethyl acetate and filtered. The filtrate was washed twice with 1:1 water, dried over
ium sulfate, filtered and concentrated. Silica gel chromatography % ethyl
acetate/hexanes) afforded the title compound as an ite solid after lyophilization in
acetonitrile, 106.6 mg, 72%.
M_S: 298 ES+ (C13H19N305)
1H NMR1300 MHz= DMSO-dg) 5: 1.23 (m, 6H); 1.84 (m, 3H); 3.19 (m, 2H); 3.97 (m, 1H);
4.16 (m, 1H); 4.35 (m, 1H); 4.62 (m, 1H); 5.00 (m, 1H); 5.46 (m, 1H); 7.29 (s, 1H); 7.50 (s,
BIOLOGICAL EXAMPLES
Example 102: Inhibition of beta-lactamase Enzymes
A buffer consisting of 0.1 M sodium phosphate (pH 7.0), 10 mM NaHCOg, and 0.005%
Triton X— 100 was used for all enzymes. The chromogenic substrate nitrocefin (SynGene,
Bangalore, India) was used at 100 MM. Enzyme activity was monitored by the 490 nm
absorbance increase upon efin hydrolysis. Assays were performed in clear polystyrene
384—well plates (Greiner e, Monroe, NC). Absorbance was measured for 1 hour at 30—
s als using a Spectramax absorbance plate reader (Molecular Devices, Sunnyvale, CA).
Measurement of beta—lactamase inhibition by INHIBITOR employed serial 3—fold dilutions of
the inhibitor in assay buffer, ranging from 100 uM to 62.7 pM. A background absorbance
progress curve for a control lacking enzyme and inhibitor was subtracted from each progress
curve.
The te set of progress curves for one enzyme with all inhibitor concentrations was
ted to numerical integration with the program Kintek Global Kinetic Explorer (Kintek
Corp, oe PA) to obtain a best—fit to the ism shown in Scheme 10.
k k
E+S<;—1'ES<;—2’E+P
k k
-1 -2
E+I.—+_3>EI
Scheme 10
where E, S, ES, P, I, and EI are the concentrations of the enzyme, nitrocefin, the enzyme—
nitrocefin complex, the nitrocefin hydrolysis product, INHIBITOR, and the enzyme—
INHIBITOR complex respectively. The ed value of Km(nitrocefin) was used to define
the fixed values of k+1, k_1, and 19,2, where k+1 = k_1 = 1 and k+2 = Km—l. The values of 19,2, k+3,
and k_3 were fit. Concentration series s of the absorbance measurements were used to
correct for slight absorbance baseline differences between wells. The parameter k+3 is
equivalent to the second order rate constant kinact/Ki. In some cases, the inhibition was in
rapid equilibrium on the experimental time scale, so that only the ratio k_3/k+3 = K could be
determined. Although k_3 represents reversal of tor binding in Scheme 10, hydrolysis of
the enzyme—inhibitor complex could not be ed based on kinetic measurements.
Best—fit absorbance values from the above ure at each time point for each
compound concentration were exported to Excel. To calculate the 60—min IC50, the %
WO 53215
tion at each inhibitor concentration at 60 min was calculated based on the best—fit
absorbance values at that time, using the equation
% inhibition 2 100 x (1 — Ainhib/Amax)
where A is the best—fit ance without inhibitor and Ainhib is the best—fit absorbance in the
presence of the inhibitor. IC50 was calculated from the set of % inhibition values by nonlinear
least—squares regression using the equation
% inhibition = 100 [I]“/(IC50 + [1]“)
where [I] is the inhibitor concentration and n is the Hill coefficient. The Excel add—in XLfit
(ID Business Solutions) was used for nonlinear regression.
Table 1 lists IC50s of exemplar compounds (uM)
Table 1
Class A Class C Class D
Example TEM-l AmpC OXA-48
60 min IC50 (HM) 60 min IC50 (HM) 60 min IC50 (HM)
0.019 0.071 0.015
0.00135 0.011 0.015
0.0044 0.02 0.017
00 0.0015 0.012 0.014
>—‘>—‘ r—‘O 0.43 0% #N 0.051
0.23 l\)l\)
l\)\l 0.047 0.018
93030) #030 0.081 0.14
0.0032 0.077
0.026 0 DJ 0.019
4k4> [\)>—‘ 0.0035 0.0064
0.024 0.0052
0.024 0.0073
0.093 0.22
0.057 0.41
O’\O’\ UJN 0.21 0.87
0.11 0.23
O\ O\ 0.66 0.012
O’\O\ OO\] 0.064 0.34
0.31 0.078
\]\]O\ r—‘OO 0.18 0.11
0.026 0.087
0.11 0.075
\]\] DJN 0.077 0.11
0.73 0.53
\l 4; 0.28 0.59
\]\l O’\Ul 0.083 0.42
0.94 0.22
0.085
0.054
0.033
0.00047
0.035
okN‘ofirm_E
Comparator 98
Comparator 99
Exam le 103: Restoration of t of cef odoxime in resence of fixed concentration
of 4 umeL of BLI
The minimal inhibitory concentration (MIC) values against each organism and drug
combination were determined using the Clinical and Laboratory Standards Institute
guidelines (CLSI) broth microdilution methodology (CLSI M07—AlO). The ended
quality l (QC) bacterial strains E. coli ATCC 25922, E. coli ATCC 35218 and
Klebsiella pneumoniae ATCC 700603 were incorporated into each test according to the CLSI
guidelines to assure that there was no variation between test dates (CLSI MlOO—S25). The
MICs of these QC strains were within QC range on all test occasions. Drug containing plates
were made using the master plate method. A cefpodoxime solution was prepared to 20X
concentration and 2—fold serial dilutions were made in cation adjusted Mueller—Hinton Broth.
Equal volumes of 20X ar compounds at a fixed concentration were added to the
master plate. lOuL was stamped into daughter plates using a Tecan EVO robot. Organism
suspensions were ed to a 0.5 McFarland standard and further diluted to yield a final
inoculum between 3x105 and 7x105 colony—forming units (CFU)/mL. Bacterial inocula were
made in sterile, cation ed Mueller—Hinton Broth (Beckton son). An inoculum
volume of l.lX concentration of 90 uL was added to wells (using a Tecan EVO robot). All
inoculated microdilution plates were incubated in ambient air at 35 ° C for 18—24 hours.
Following incubation, the lowest concentration of the drug that prevented Visible growth as
read at OD600 nm was recorded as the MIC (Table 2, all MICs are in ug/mL and all beta—
lactamase inhibitors were tested at a fixed concentration of ).
Table 2
C. Klebsiella pneumoniae
frezmdii
SHV-18,
AmpC,
WT OXA-2,
OXA-l,
Beta-lactarnase content: (ATCC OKP-6
CTX-M-
25922) (ATCC
, TEM-l
700603)
Cefpodoxirne alone >64 1 >64 HNo >64
+ 3 51 50.5 ,_1 0 U1
+ 4 50.125 50.06 0.06 0.06
25
2 MN .PH
+ 27 <0.03125 <0.03125 <0.03125 25
4; >—* N
0-5 N p—A
+33 <0.03125 50.03125 <0.03125 50.0625 <0.03125
<0-03125 50.125 50.0625
000024 0.25 0.01117
2 p—A
00039 l—‘N 0.063
+55 >32 0.0625 2 N U.) N
<0-03125 0.125 0.0625
<0-0625 >—* 0.0625
<0-03125 50.0625 <0.03125
32 >32
+66 16 0.5 >32 #00 00
<0-03125
>32 #-l> OCH
+ 69 >32 0.25 16 4; 00
+71 0.25 0.5 N
4 #N-P
32 ND EGOH
+ 74 0.5 <0.03125 <0.03125 N 0.03125
<0-03125 0.125 <0.03125
>32 ._1 O\ >32
<0-03125 <0.03125 <0.03125
>32 >32
>32 p—A000 >32
<0-03125 <0.03125
<0-03125 25
<0-03125 <0.03125
<0-03125 <0.03125
+ 91 50.03 50.03 50.03 50.03
+ 93 50.03 50.03 50.03 50.03
+ 95 32 0.25 p—A N N
0 Nbfiw
Comparator 97
ator 99
Exam le 104: Restoration of activit of various oral beta-lactams in resence of fixed
concentration of 4 u mL of BL]
Following the procedure from Example 103, MICs were determined for several beta—lactams
in presence of a fixed concentration (4 ug/mL) of exemplar compounds (Table 3) against 3
Enterobacteriaceae strains.
Table 3
Compound C. frezmdii E. coli ella
pneumomae
AmpC, WT SHV— 18, OXA—2,
TEM— 1
, (ATCC OKP—6 (ATCC
CMY65 25922) 700603)
Cefpodoxime >64 16
Ex. 3 (4ug/ml) 0.5 0.125
Cefpodoxime +
Ex. 4 (4ug/ml) 30.125 £0.06
Cefpodoxime +
Ex. 33 (4ug/ml) <0.03125 30.03125
oxime +
Ex. 34 (4ug/ml) 25 30.03125
Cefpodoxime +
Ex. 93 (4ug/ml) £0.06 £0.06
Ex. 3 (4ug/ml) 1 0.02
Ex. 4 (4ug/ml) 0.02 0.02
Cefuroxime +
EX. 33 (4pg/ml) <0.03125 <0.03125
Cefuroxime +
EX. 34 (4pg/ml) <0.03125 <0.03125
Tigemonam + 0.125 1
EX. 3 (4pg/ml)
Tigemonam + £0.06 £0.06 .0 L11
EX. 4 (4pg/ml)
Tigemonam + £0.06 £0.06 .o L11
EX. 33 (4pg/ml)
Tigemonam + £0.06 £0.06 .0 LII
EX. 34 (4pg/ml)
Tigemonam + 0.125 0.125 >—‘
EX. 93 (4pg/ml)
Tebipenem 0. 125 £0.06
Tebipenem + £0.06 £0.06
EX. 3 (4pg/ml)
Tebipenem + £0.06 £0.06
EX. 4 (4pg/ml)
nem + £0.06 £0.06
EX. 33 (4pg/ml)
Tebipenem + £0.06 £0.06
EX. 34 l)
Tebipenem + £0.06 £0.06
EX. 93 (4pg/ml)
0 (J1
Faropenem + 0.25 0.2 N00
EX. 3 (4pg/ml)
Faropenem + £0.06 £0.06 *—‘
EX. 4 (4pg/ml)
Faropenem + £0.06 £0.06 .0 LII
EX. 33 (4pg/ml)
Faropenem + £0.06 £0.06 .0 LII
EX. 34 (4pg/ml)
Faropenem + £0.06 £0.06
EX. 93 (4pg/ml)
Cefixime >64 ll 0.5
Cefixime + EX. 3 1 0.125 .0 LII
Cefixime + £0.06 £0.06
EX. 4 (4pg/ml)
Cefixime + £0.06 £0.06
EX. 33 (4pg/ml)
Cefixime + £0.06 £0.06
EX. 34 (4pg/ml)
Cefixime + £0.06 £0.06
EX. 93 l)
Loracarbef >64 N 03 l\)
EX. 3 (4ug/ml)
rbef + £0.06 £0.06
EX. 4 (4ug/ml)
Loracarbef + £0.06 £0.06
EX. 33 (4ug/ml)
Loracarbef + £0.06 £0.06
EX. 34 (4ug/ml)
Loracarbef + £0.06 £0.06
EX. 93 (4ug/ml)
Example 105: Stability/conversion in the absence or presence of metabolizing enzymes
The human intestinal S9 with the absence of PMSF, human liver S9, rat intestinal S9, and rat
liver S9 preparations were obtained from Xenotech (Lenexa, ).
The 500—uL incubation solution contained 0.8 mg/mL of enzyme (or no enzyme for buffer
stability), 10uM of test compounds in 100mM of HEPES buffer, pH 7.4. The hydrolysis
reactions were conducted in a l—mL glass insert (Analytical Sales, Pompton Plains, New
Jersey) in a shake water bath at 37 0C. At 0, 2, 5, 10, 15, 30 and 60 min, the reaction was
terminated by pipetting 50uL incubate to a 96 DeepWell plate (Thermo Fisher Scientific,
Rochester, New York) containing 100uL of acetonitrile with mL of Carbutamide
(Sigma—Aldrich, St. Louis, ri) as the internal standard. The crashed solutions were
then vortexed well followed by centrifuge at 4000rpm for 15min at 4 OC. The extract was
transferred to a new 96 DeepWell plate for MS analysis.
LC—MS/MS analysis was done using an AB Sciex QTrap 6500 mass spectrometer under
positive ionization mode, coupled to a Schimadzu Nexera LC system.
A Waters Atlantis T3 (3pm, 3.0 X 50mm) column was used for separation. The mobile phase
consisted 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) with a flow
rate set at 1.2 mL/min. For the prodrug analysis, the Multiple Reaction Monitoring (MRM)
specific for each compound was set up so that both prodrug and its hydrolyzed active can be
monitored simultaneously.
Table 4 lists the first—order ives of the exemplar compounds (Tl/2 in minutes). Half—
lives listed are based on disappearance of starting ester. As can be seen from Table 4, there is
a good correlation between the rat and human s. The data in Table 4 tes that
there is generally more rapid conversion of ester into the active compound by rat and human
liver S9 enzymes, while the esters are inantly stable in the presence of buffer and
intestinal S9.
Table 4
pH 7.4 Rat Intestinal Rat Liver Human Human Liver
E”mp e1
Buffer s9 s9 Intestinal s9 s9
4-4 38 6-5
1-4 21 1-9
0-5 2-4 0-8
“——1-4 17 -8 2-9
14 132 16
ND 44 1
——m- 1-5 >100 12-4
7 15 9-2
6-1 40 5-1
9-2 43 4-6
ND 34 9
35 27
2-4 6-9 2-4
240 32 163 39
_—-i- 3 36 8-5
0-22 2 0-39
1-8 8-2 2-3
3 42 6-1
——m- 1-8 32 6-9
2-8 73 3-5
1-7 1-5 6-4
0-45 5-7 0-84
2 <1-0 1-7
0-9 5 1-9
“——10 22 9-9
<1-0 <1-0 <1-0
<1-0 <1-0 <1-0
3-8 20 3-5
“——23 36 24
“——0-7 1 0-7
160-9 11 193-1 24-8
1-3 10-6 0
“——10-3 1475-6 57
ND = not determined
Example 106: Rat PK
Intravenous rat cokinetics of exemplar compounds were ined in jugular vein
cannulated e—Dawley rats (n23) (Harlan Laboratories, Indianapolis, IN) at a dose of 10
mg/kg. Compounds were dissolved and administered intravenously in 0.9% saline, pH 6.5 at
a dose volume of 2 mL/kg. Blood samples (~100 uL) were obtained via the jugular vein
catheter prior to dosing and at 0.08, 0.17, 0.25, 0.5, 1, 2, 4, and 8 hpd and prepared for plasma
in KZEDTA microtainers. Oral pharmacokinetic studies were conducted with exemplar
compounds at 10 mg/kg equivalents of carboxylic acids. Doses were dissolved and
administered orally in 25:75 PEG400: water for injection, pH 4.5 at a dose volume of 10
mL/kg. Blood samples were ed via the jugular vein catheter prior to dosing and at
0.25, 0.5, l, 2, 4, 8, and 24 hpd and prepared for plasma in KZEDTA microtainers. Plasma
samples were stored at —80°C prior to bioanalysis.
Sample preparation for LC/MS/MS analysis
Plasma samples were thawed on ice prior to processing. Samples (30 uL) were diluted and
proteins precipitated with 180 uL of acetonitrile containing 0.1% formic acid and 250 ng/mL
of carbutamide (Nl—(butylcarbanoyl)—sulfanilamide, Sigma—Aldrich Catalog# $385433) as an
internal standard. Samples were vortexed for 30 seconds, centrifuged at 3400g for 10
minutes and the supernatant transferred to injection vials.
LC/MS/MS conditions
Rapid hydrolysis precluded satisfactory analysis of circulating concentrations of Examples
12 and 35. LC/MS/MS analysis was completed on an AB Sciex QTrap 6500 mass
ometer in positive tion mode, coupled to a dzu Nexera LC system.
A Waters Atlantis T3 (3um, 3.0 x 50mm) column was used for chromatographic separation.
Injection volume was 1 uL. The mobile phase consisted 0.1% formic acid in water (A) and
0.1% formic acid in acetonitrile (B), with a gradient of 2—98% B:A over two minutes.
Pharmacokinetic analysis
Plasma concentration vs. time es following intravenous (IV) stration and oral
(PO) administration of ar compounds were analyzed by non—compartment analysis
using WinNonLin 6.4. Mean AUC and F% are summarized in Table 5. Absolute oral
bioavailability (F%) of es following stration of their respective esters was
determined as:
F% = 100 * (AUCpO*DoseiV)/(AUCiV*Dosepo).
In general, the exemplar compounds exhibit increased AUC upon oral dosing as compared
with sulfate—derived beta—lactamase inhibitors, resulting in favorable F%.
TableS
Example admmlstered AUC uM*h —
—————
—-IV_—————
—-I_———
—-I_———
“-F—————
34 IV 34 16.1
36 P0 34 13.5 84
P0 33 25.8 98
32 P0 34 11.5 71
31 P0 33 19.8 75
53 PO 4 2.2 1 1
65 PO 4 2.8 15
H2N \
N PO ETX2514 0.44
o ‘osogH
ETX2514
N PO Relebactam 0.29
o ‘osogH
Relebactam
q PO WCK 4234 0.45
o ‘osogH
WCK 4234
Exam le 106: In Vivo oral efficac of cef odoxime roxetil in combination with
Example 35 vs. E. coli 1beta-lactamase content: AmpC= CTX-M-14)
The oral in viva cy of Example 35 was evaluated in combination with cefpodoxime
il in a mouse neutropenic thigh infection model versus a relevant clinical isolate. The
isolate, E. coli ARC2687, ses the beta—lactamases AmpC and CTX—M—14, both of
which can readily hydrolyze cefpodoxime resulting in non—susceptible MICs in excess of 512
ug/mL. In combination with Example 33 (4 ug/mL), the cefpodoxime MIC is reduced to
<0.03 ug/mL. Dose setting for the study was based upon targeting cefpodoxime exposure
above an MIC of 0.03 ug/mL for at least 50% of the dosing interval for all treatment arms
while titrating increasing doses of the nd from Example 35. CD—1 mice (Charles
River, Wilmington US) were housed in shoebox type cages with contact bedding and
ated to the facility for a minimum of 2 days prior to use. The animal room was
maintained at 700 F, with 50 +/— 10% relative humidity and a 12—hour light/dark cycle. The
study was conducted using an IACUC—approved protocol in accordance with Title 9 of the
Code of Federal Regulations. Animals were ed neutropenic with two intraperitoneal
doses of cyclophosphamide (150 mg/kg —4 days and 100 mg/kg —1 day prior to infection
(Gerber er al. (1983) JInfect Dis 147(5); 7)). s were infected via an
intramuscular challenge of ~1 x 106 CFU administered within 100 uL of 0.9% saline. The
um was prepared from a 25 mL overnight culture of E. coli ARC 2687 in tryptic soy
broth media. Following an OD600 determination, the inoculum was diluted in 0.9% saline to a
concentration of ~10 x 106 CFU/mL prior to inoculation into the left and right thigh. Oral
therapy with cefpodoxime proxetil alone and in combination with Example 35 was initiated
2 hours post bacterial challenge. Doses were suspended in 0.5%HPMC/0.l% Tween 80 and
stered by oral gavage at a dose volume of 10 mL/kg. A terminal endpoint was
ed at 24 hr to determine bacterial counts in thigh tissue (CFU/gm). Animals were
ethically ized, thighs were asceptically removed, weighed and homogenized in 1 mL of
saline. Bacterial burden ation of tissue homogenate was performed by serial on
on tryptic soy agar plates which were incubated overnight at 37 °C prior to colony (CFU)
counting. The lower limit of detection was ~2.6 log10 CFU/gm of tissue.
As summarized in Table 6, bacterial burden in the thighs of mice receiving cefpodoxime
proxetil alone at 50 mg/kg q6h or Example 35 at 10 mg/kg q6h demonstrated r than 3
logo CFU/gm of growth after 24 hours of therapy. In combination with cefpodoxime
proxetil, increasing dose of the nd from Example 35 resulted in dose dependent
reduction of bacterial burden with maximal kill of —0.75 log10 CFU/gm (relative to initiation
of therapy) achieved at 50 mg/kg oxime proxetil +100 mg/kg Example 35 q6h.
Meropenem used as a positive control achieved just over l—log10 ion in CFU relative to
initiation of therapy at 600 mg/kg q6h administered subcutaneously.
Table 6
Group Dose Route/Regimen logloCFU/gm . CFU
(mg/kg) thigh Change
from 26
26 hr Growth vehicle PO/q6h 10.86 ——
Cefpodoxime 50 PO/q6h 10.24 . —0.62
proxetil alone.-
---_Example 35 10 PO/q6h 9.56 0.29 +3 .29 — l .30
Example 35 + 10+50 PO/q6h . . —5.09
cefpodoxime .-
WO 53215
Example 35 + 25+50 PO/q6h . . —5 .27
cefpodoxime
proxetil
Example 35 + 100+50 PO/q6h . . -5 .34
cefpodoxime
proxetil
_mSC/q6h 5.17 0.27 —1.10 —5.69
WE
Claims (20)
1. A compound according to a (I): or a pharmaceutically acceptable salt thereof; wherein: R1 is –C(O)NR7R8, -CN, phenyl, a 5-6 membered heteroaryl, -C(O)NR’NR’C(O)R9, R’OR10, or a C1-C6 alkyl group, wherein the alkyl group is substituted with one to three groups selected from halo, C1-C3 alkoxy, -OH, -CN, – NR7R8, -NR7COR9, a 5-6 membered heteroaryl and a 5-7 membered heterocyclyl, and wherein the phenyl and heteroaryl represented by R1 are optionally and independently substituted with 1- 3 groups selected from halo, -OH, C1-C3 alkoxy, -CN, –NR7R8, and -CONR7R8; R2 and R3 are independently selected from hydrogen, halo, C1-C3 alkyl, and C3-C6 cycloalkyl; R4 and R5 are ndently selected from en, halo, -CN, -CO2R9, C1-C3 alkyl, and C1-C3 haloalkyl; R6 is hydrogen, C1-C12 alkyl, C1-C4 alkyl-C1-C3 alkoxy-(NR’C1-C6 alkyl)-C1-C3 alkoxy, C1-C4 alkyl-C1-C3 alkoxy-C1-C3 alkoxy, C2-C12 l, C3-C10 cycloalkyl, a 5-6 membered heteroaryl and a 5-7 membered heterocyclyl, wherein the alkyl, alkenyl, cycloalkyl, heteroaryl and heterocyclyl are optionally and independently tuted with 1-6 groups selected from a carboxyl, halo, C1-C6 alkoxy, C1-C6 alkyl and phenyl; each R7 and R8 are independently hydrogen, C1-C3 alkyl, C1-C3 alkoxy, , C3-C6 cycloalkyl, 4-7 membered heterocyclyl, or 5-6 membered heteroaryl, n the alkyl, alkoxy, phenyl, cycloalkyl, heterocyclyl or heteroaryl represented by R7 or R8 is optionally and ndently substituted with 1-6 groups selected from a 5-6 membered heterocyclyl optionally substituted with one or two –F atoms, carboxyl or –CO(OC1-6 alkyl), 5-6 membered heteroaryl, -CN, -OH, C1-C3 alkyl optionally substituted with –NH2 or –OH, C1-C3 haloalkyl, C1-C3 haloalkoxy, C1-C3 alkoxy -NHCO(C1-C3alkyl), -NHCO(C1- C3alkoxy), NR’R’’, -NHS(O)2NR’R’’, -NHS(O)2(C1-C3alkyl), -NR’R’’, and -C(O)NR’R’’; each R9 is C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy or C1-C6 alkoxy; each R10 is a C1-C3 alkyl ally tuted with 1-6 groups selected from a 5-6 membered heterocyclyl optionally substituted with one or two –F atoms, carboxyl or –CO(OC1-6 alkyl), a C3-C6 cycloalkyl, a 5-6 membered heteroaryl, -CN, -OH, -NHCO(C1-C3 alkyl), C1-C3 alkoxy), NR’R’’, -NHS(O)2NR’R’’, -NHS(O)2(C1-C3 alkyl), - NR’R’’, or -C(O)NR’R’’; and each R’ and R’’ is independently hydrogen, methyl, ethyl or propyl; or R’ and R’’ are taken together with the nitrogen to which they are attached to form a 5-6 membered heterocyclyl; provided that at least one of R2 and R3 is other than hydrogen.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R6 is C1- C12 alkyl, C1-C4 alkyl-C1-C3 alkoxy-(NR’C1-C6 alkyl)-C1-C3 alkoxy, C1-C4 alkyl-C1-C3 - C1-C3 , C2-C12 alkenyl, C3-C10 cycloalkyl, a 5-6 membered heteroaryl and a 5-7 membered heterocyclyl, wherein the alkyl, l, cycloalkyl, heteroaryl and heterocyclyl are optionally and independently substituted with 1-6 groups selected from a carboxyl, halo, C1-C6 alkoxy, C1- C6 alkyl and phenyl.
3. The compound of claim 1 or 2, according to formula (III): or a pharmaceutically acceptable salt thereof.
4. The compound according to any one of claims 1-3 or a pharmaceutically acceptable salt thereof, wherein R3 is C1-C3 alkyl.
5. The compound according to claim 4 or a pharmaceutically acceptable salt thereof, n R3 is methyl.
6. The compound of any one of claims 1-5 or a pharmaceutically acceptable salt thereof, wherein R1 is –C(O)NR7R8.
7. The compound of claim 6 or a pharmaceutically acceptable salt thereof, wherein R7 and R8 are both hydrogen.
8. The compound of claim 3, according to formula (V): or a pharmaceutically acceptable salt thereof.
9. The compound of any one of claims 1-8 or a pharmaceutically able salt f, wherein R6 is C1-C12 alkyl.
10. The compound according to any one of claims 1-9 or a pharmaceutically acceptable salt f, wherein R4 and R5 are independently H, methyl or .
11. The compound ing to claim 10 or a pharmaceutically acceptable salt thereof, wherein one of R4 and R5 is hydrogen, and the other is .
12. The compound according to claim 10 or a pharmaceutically acceptable salt thereof, wherein R4 is fluoro and R5 is hydrogen.
13. The compound of Claim 1, wherein the compound is of the formula: or a pharmaceutically acceptable salt thereof.
14. The compound of Claim 1, wherein the compound is of the formula: or a pharmaceutically acceptable salt thereof.
15. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-14, and at least one pharmaceutically acceptable carrier, t or excipient.
16. Use of the compound according to any one of Claims 1-14, or a pharmaceutically acceptable salt thereof, in combination with a beta-lactam antibiotic in the manufacture of a medicament in treating a bacterial ion.
17. The use of claim 16, wherein said beta-lactam antibiotic is cefpodoxime proxetil.
18. The use of claim 16 or 17, wherein the bacterial infection is selected from the group consisting of complicated urinary tract infection, uncomplicated urinary tract infection, kidney infection, lower respiratory tract infection, hospital-acquired bacterial pneumonia (HAP), pneumonia, acute bacterial prostatitis, acute bacterial skin and soft tissue infection, , intraabdominal infection, and ic foot infection.
19. A process for forming a compound of the formula VI: (VI); or a salt thereof, wherein R1 is –C(O)NR7R8, –C(O)OR7, –CH2OR7, -CN, phenyl, a 5-6 ed aryl, - C(O)NR’NR’C(O)R9, -C(O)NR’OR10, or a C1-C6 alkyl group, wherein the alkyl group is substituted with one to three groups selected from halo, C1-C3 alkoxy, -OH, -CN, – NR7R8, -NR7COR9, a 5-6 membered aryl and a 5-7 membered heterocyclyl, and wherein the phenyl and aryl represented by R1 are optionally and independently substituted with 1- 3 groups ed from halo, -OH, C1-C3 alkoxy, -CN, -NR7R8, and R8; R2 and R3 are each independently selected from hydrogen, halo, C1-C3 alkyl, and C3-C6 cycloalkyl, provided that at least one of R2 and R3 is other than hydrogen; each R7 and R8 are independently hydrogen, C1-C3 alkyl, C1-C3 alkoxy, phenyl, C3-C6 cycloalkyl, 4-7 membered heterocyclyl, or 5-6 ed heteroaryl, wherein the alkyl, alkoxy, phenyl, cycloalkyl, heterocyclyl or heteroaryl represented by R7 or R8 is optionally and independently substituted with 1-6 groups selected from a 5-6 membered heterocyclyl optionally substituted with one or two –F atoms, carboxyl or –CO(OC1-6 alkyl), 5-6 membered heteroaryl, -CN, -OH, C1-C3 alkyl optionally substituted with –NH2 or –OH, C1-C3 haloalkyl, C1-C3 haloalkoxy, C1-C3 alkoxy -NHCO(C1-C3alkyl), -NHCO(C1- C3alkoxy), -S(O)2NR’R’’, -NHS(O)2NR’R’’, -NHS(O)2(C1-C3alkyl), -NR’R’’, and -C(O)NR’R’’; each R9 is C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy or C1-C6 alkoxy; each R’ and R’’ is independently hydrogen, methyl, ethyl or propyl; or R’ and R’’ are taken er with the nitrogen to which they are attached to form a 5-6 membered heterocyclyl; PG and PG’ are each independently an amine protecting group; the process comprising reacting a compound of the formula XI: (XI); or a salt thereof, with PG’NHOH in the presence of an oxidant to form the nd of the Formula VI.
20. A process for forming a compound of the a VI: (VI); or a salt thereof, wherein R1 is –C(O)NR7R8, –C(O)OR7, –CH2OR7, -CN, phenyl, a 5-6 membered heteroaryl, - ’NR’C(O)R9, -C(O)NR’OR10, or a C1-C6 alkyl group, wherein the alkyl group is substituted with one to three groups selected from halo, C1-C3 alkoxy, -OH, -CN, – NR7R8, -NR7COR9, a 5-6 membered heteroaryl and a 5-7 membered heterocyclyl, and wherein the phenyl and aryl represented by R1 are ally and independently substituted with 1- 3 groups ed from halo, -OH, C1-C3 alkoxy, -CN, -NR7R8, and -CONR7R8; R2 and R3 are each ndently selected from hydrogen, halo, C1-C3 alkyl, and C3-C6 cycloalkyl, provided that at least one of R2 and R3 is other than hydrogen; each R7 and R8 are independently hydrogen, C1-C3 alkyl, C1-C3 alkoxy, phenyl, C3-C6 cycloalkyl, 4-7 membered heterocyclyl, or 5-6 membered heteroaryl, n the alkyl, alkoxy, phenyl, lkyl, heterocyclyl or heteroaryl represented by R7 or R8 is optionally and independently substituted with 1-6 groups selected from a 5-6 membered cyclyl optionally substituted with one or two –F atoms, carboxyl or –CO(OC1-6 alkyl), 5-6 membered heteroaryl, -CN, -OH, C1-C3 alkyl optionally substituted with –NH2 or –OH, C1-C3 haloalkyl, C1-C3 haloalkoxy, C1-C3 alkoxy -NHCO(C1-C3alkyl), -NHCO(C1- C3alkoxy), -S(O)2NR’R’’, -NHS(O)2NR’R’’, -NHS(O)2(C1-C3alkyl), -NR’R’’, and -C(O)NR’R’’; each R9 is C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy or C1-C6 alkoxy; each R’ and R’’ is independently hydrogen, methyl, ethyl or propyl; or R’ and R’’ are taken together with the nitrogen to which they are attached to form a 5-6 membered cyclyl; PG and PG’ are each independently an amine protecting group; the process comprising reacting a compound of the formula XI: (XI); or a salt thereof, with PG’N=O to form the compound of the Formula VI.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/395,464 | 2016-09-16 | ||
US62/456,423 | 2017-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ791470A true NZ791470A (en) | 2022-08-26 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3512851B1 (en) | Beta-lactamase inhibitor compounds | |
TWI597281B (en) | Beta-lactamase inhibitor compounds | |
CN110662746B (en) | Compounds as orally administered prodrugs of beta-lactamase inhibitors, pharmaceutical compositions thereof and use for treating bacterial infections | |
JPH05509089A (en) | Cephalosporins and congeners, manufacturing processes and pharmaceutical compositions | |
RU2741496C2 (en) | Heterocyclic compounds and use thereof in treating or preventing bacterial infections | |
TW201815390A (en) | Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections | |
US20210198316A9 (en) | Macrocyclic broad spectrum antibiotics | |
JPWO2019208797A1 (en) | Oxo-substituted compound | |
WO2004073709A1 (en) | Antimicrobial agents | |
NZ791470A (en) | Beta-lactamase inhibitor compounds | |
JP2021070691A (en) | Pharmaceutical comprising oxo-substituted compound | |
TW202007689A (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
KR0177844B1 (en) | Antibacterial penem compounds | |
US20230339973A1 (en) | Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria | |
WO2023224892A1 (en) | Inhibitors of msba as antibiotics, pharmaceutical compositions, and uses thereof | |
EA044428B1 (en) | BETA-LACTAMASE INHIBITOR COMPOUNDS | |
EA037916B1 (en) | Beta-lactamase inhibitor compounds | |
TW202421162A (en) | Oxygen substituted compounds |